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ABSTRACT
Breast cancer is the most common cause of cancer in women. Overexpression of 
ErbB2 (HER2) occurs in 25-30% of sporadic breast cancer and is associated with 
poor prognosis. New therapies targeting ErbB2 have been developed and shown to 
influence the activity of chemotherapeutic agents. The main aim of this investigation 
was to study the potential role of ErbB2 in the repair of drug-induced DNA damage. 
Synergistic effects of trastuzumab, a monoclonal anti-ErbB2 antibody, in 
combination with common chemotherapeutics were evaluated in cell lines expressing 
different level of ErbB2. In addition, effects of ErbB2 nuclear localisation on cisplatin 
sensitivity were also investigated. Using the comet assay, effects of ErbB2 expression 
and its nuclear translocation on the kinetic of damage and repair of DNA interstrand 
crosslinks and DNA strand breaks were examined. Effects of trastuzumab, alone and 
in combination with cisplatin, on the cell cycle and apoptosis were studied using 
FACS analysis. Trastuzumab was shown to enhance drug sensitivity in cell lines 
overexpressing ErbB2. ErbB2 overexpression caused increased resistance to cisplatin 
whereas deletion of its nuclear localisation signal sequence led to an increased 
sensitivity. Study of the repair of drug-induced DNA damage revealed that 
modulation of ErbB2 expression altered the kinetics of repair of cisplatin-induced 
DNA interstrand crosslinks but not DNA intrastrand crosslinks, and that ErbB2 
nuclear translocation was important for the repair of cisplatin DNA damage. BRCA1 
is another important protein, as germline mutations of this gene have been shown to 
substantially increase the risk of hereditary breast cancer. Sensitivity of BRCA1 
down-regulated cells to radiotherapy, chemotherapeutic agents alone and in 
combination with gefitinib, an EGFR tyrosine kinase inhibitor, was also evaluated. 
Study of BRCA1 down-regulation produced conflicting results with published data 
but a synergistic effect was obtained between cisplatin and gefitinib in cells with 
down-regulated BRCA1 expression. These results establish a link between nuclear 
ErbB2 and repair of drug-induced DNA damage. In addition, they suggest an 
interaction between BRCA1 and the EGFR signalling pathway in cisplatin-induced 
DNA damage repair.
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Chapter 1 
Introduction
1.1 Epidemiology of Breast cancer
1.1.1 Definition of cancer
Under normal conditions, the multiplication of cells is carefully regulated and 
responsive to specific needs of the body. Tumour development occurs through a 
multi-step process, in which a succession of genetic alterations, conferring growth 
advantages, leads to the progressive transformation of normal cells into cancer cells 
(Hanahan and Weinberg, 2000).
1.1.2 Importance of Breast cancer
Breast cancer is a disease affecting mainly women (especially women between 50 and 
60 years old), with only 1% of all breast cancer cases affecting men (Weiss et al., 
2005). However, it is the second most common cause of female cancer death, after 
lung cancer. Nevertheless, the rate of breast cancer has been shown to vary around the 
world. Although the mortality rate for breast cancer has been decreasing since the late 
1980s, statistics show that its incidence has increased by more than 50% in the same 
time period (www.cancerresearchuk.org).
1.1.3 Molecular epidemiology of breast cancer
Breast cancer is a multi-step disease of molecular and genetic changes affecting one 
or more regulatory genes. Several studies have established the existence of molecular 
markers for the prognosis of breast cancer. Dahiya and Deng (1998) reported many 
possible molecular prognostic markers in breast cancer: BRCA1 and BRCA2 (Breast 
Cancer genes), p53, ErbB oncogenes, loss of heterozygosity, chromosomal 
aberrations, microsatellite instability, transforming growth factor alpha and the 
multiple drug resistance gene. Nonetheless, two types of breast cancer have been 
identified, hereditary breast cancer and sporadic breast cancer (Kenemans et al., 
2004).
• Hereditary breast cancer is caused by an inherited susceptibility to breast cancer 
due to germline mutation of high risk susceptibility genes, such as BRCA1, 
BRCA2 or CHEK2. Indeed, several studies (Nkondjock and Ghadirian, 2004; 
Miki et al., 1994; Wooster et al., 1995) have shown the importance of BRCA1
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and BRCA2, showing that germline mutations accounted for 5-10% of all breast 
cancers and 65% of hereditary cases. Cell-cycle-check-point kinase 2 (CHK2), 
responsible for the phosphorylation of p53 and BRCA1 in response to DNA 
damage, was also shown to be a good predictive marker in hereditary breast 
cancer, since CHK2 germline mutations were shown to be associated with 
increased risk of breast cancer (Weiss et al., 2005; Vahteristo et al., 2002).
In addition to germline mutations of high risk susceptibility genes, mutations of 
modest risk susceptibility genes have been identified, such as PTEN.
• Sporadic breast cancer results from an accumulation of unrepaired mutations in 
somatic genes, with no germline mutations. Oncogenes are then activated through 
mutations and their activation often associated with inactivation of tumour 
suppressor genes. Several oncogenes have been shown to play a major role in 
sporadic breast cancer, such as ErbB2. Slamon et al. (1987) reported that ErbB2 
overexpression plays an important role in breast cancer development as it is 
overexpressed in 20-30% of breast cancer and causes oncogenesis. In addition, 
Harari and Yarden (2000) demonstrated that ErbB2 overexpression caused 
increased chemoresistance.
Nonetheless, many other factors have been described to have an impact on the 
increased risk of breast cancer (Okobia and Bunker, 2003; Kenemans et al., 2004). 
Thus, gene expression profiling cam be used as a tool to classify breast cancers.
1.1.4 Treatment of breast cancer
The development of a tumour being progressive, breast cancer growth has been 
divided in four stages. For the earliest stages (I -  III) breast cancer can be treated 
using surgery, chemotherapy/radiotherapy and in some cases hormonal therapy.
• Surgery is divided into two types of operations for breast cancer, lumpectomy and 
mastectomy. Radiotherapy is usually used after a lumpectomy in order to destroy 
cancer cells that may still be present.
• Chemotherapy is usually used as a combination of chemotherapeutic drugs to 
increase efficacy and avoid drug resistance. It is usually given before or after 
breast surgery.
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• Hormone therapy is used to modify the amount of estrogen in the blood, which is 
a major factor of growth in many breast cancers.
However, for advanced breast cancer, there are three type of treatments: hormonal 
therapies (tamoxifen is the most common but progestogens and aromatase inhibitors 
can also be used), chemotherapy using combinations of drugs in order to increase the 
efficacy, and monoclonal antibody therapy (trastuzumab or Herceptin®) targeting the 
epidermal growth factor receptor ErbB2. Trastuzumab being the only humanized 
monoclonal antibody which has been approved for the treatment of breast cancer.
1.2 Anti-cancer drugs and breast cancer
Anticancer drugs can be classified according to their mechanism of action, as 
described in Figure 1.1. The different classes of chemotherapeutic drugs have been 
briefly reviewed, with emphasis on the drugs used in the study of ErbB2 and BRCA1.
Anticancer drugs
Alkylating 
agents and 
cross linking 
agents
I
Transfer 
alkyl group 
to DNA
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melphalan
Anti­
metabolites
Inhibit DNA 
synthesis
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Topoisomerase
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DNA damage by 
inhibition of 
topoisomerase 
action
e.g. etoposide, 
doxorubicin
Anti­
microtubules
Induce 
metaphase 
arrest by 
disrupting 
microtubules 
and mitotic 
spindle
e.g. paclitaxel
Hormonal
agents
Regulate
hormonal
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tamoxifen 
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cancer)
Targeted
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Target 
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molecules 
responsible 
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Figure 1.1 -  Classification of anti-cancer drugs according to their mechanism of action.
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1.2.1 Cisplatin
Cisplatin (CDDP -  Figure 1.2), or c/5-diamminedichloroplatinum(II), is a covalent 
DNA-binding agent (bifunctional alkylating agent). The pharmacological activity of 
cisplatin was identified in the late 1960s (Jakupec et al., 2003). Alkylating agents 
form the largest class of anticancer drugs. These include nitrogen mustards, 
nitrosoureas, alkyl sulfonates and platinum compounds. Alkylating agents act non- 
specifically on the cell cycle by forming highly reactive electrophilic species which 
bind covalently with alkyl groups onto nucleophilic sites. These agents react with 
cellular macromolecules such as DNA bases (Adenine; Guanine; Cytosine and 
Thymine) and proteins. Cisplatin forms interstrand crosslinks and intrastrand adducts, 
chlorine atoms allow the group to bind to N7 guanine atoms. By forming crosslinks, 
cisplatin inhibits DNA replication and transcription. Thus, causing inhibition of cell 
proliferation and apoptosis.
Cisplatin has become a widely used chemotherapeutic agent for a large number of 
cancers (e.g. bladder, ovarian, liver, gastric, brain, head, neck and lung). Cisplatin is 
also used in combination with radiation and other chemotherapeutic agents, to avoid 
resistance caused by the decrease of drug uptake and the increase of DNA repair. So 
far, cisplatin has not been widely used in the treatment of metastatic breast cancer due 
to its toxicity. Nonetheless, there has been an increasing interest in this compound in 
the past few years, as in vitro and in vivo studies demonstrated that combining 
cisplatin with the monoclonal antibody trastuzumab resulted in a higher response rate 
than either agent alone in metastatic breast cancer (Pegram et al., 1998).
h3n ci
Figure 1.2 -  Structure of cisplatin. Cisplatin (c/s-diamminedichloroplatinum(II), CDDP) is 
an inorganic compound with a planar structure.
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1.2.2 Melphalan
Melphalan or L-phenylalanine mustard (Figure 1.3) is also a bifunctional alkylating 
agent, belonging to the nitrogen mustard group. Similar to mechlorethamine but less 
reactive due to a slower rate of the chlorides ionisation, it forms bulky adducts by
(\ 7reacting with O and N guanine atoms. Melphalan is able to form two types of 
crosslinks: interstrand, intrastrand or between a DNA strand and a protein. Crosslinks 
result in the disruption of DNA replication and transcription, leading to cell cycle 
arrest and cell death. Melphalan is primarily used in the treatment of multiple 
myeloma and ovarian cancer.
CIHoCHoC2
N
/
c i h 2c h 2c
Figure 1.3 — Structure of melphalan (L-phenylalanine mustard).
1.2.3 Doxorubicin
Doxorubicin (or Adriamycin -  Figure 1.4) is an anthracycline (produced by 
Streptomyces peucetius) and is classified as a non-covalent DNA binding drug that 
inhibits topoisomerase II activity. Doxorubicin is an intercalating agent with a planar 
region stacking between paired DNA bases, forming tight drug-DNA interactions. 
Doxorubicin also causes free radical damage of the DNA due to the metabolism of 
the quinone ring releasing active oxygen species. This results in partial unwinding of 
the DNA, impaired DNA and RNA synthesis and double strand breaks in DNA. 
Increase in resistance to treatment with doxorubicin was associated with an increase 
in glutathione peroxidase activity and a decrease in drug accumulation due to an 
increase in drug efflux, mediated by P-glycoprotein. Doxorubicin is used for the 
treatment of a wide range of cancers, including breast cancer.
CHo— C H — COOH
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Figure 1.4 -  Structure of doxorubicin.
1.2.4 Etoposide
Etoposide (VP-16 -  Figure 1.5) is an inhibitor of chromatin function, and more 
precisely a topoisomerase II inhibitor. It is a semisynthetic derivative of 
podophyllotoxin from the mandrake plant. Topoisomerases are responsible for the 
unwinding of DNA to allow transcription and replication. They are also responsible 
for temporary DNA breakage and reseal, necessary for topological changes. The first 
type of topoisomerases (I) is responsible for transient single strand breaks whereas 
topoisomerase II produces double strand breaks to relieve tortional stress on the 
unwound DNA (topoisomerase I being responsible for the re-annealing).
Thus, etoposide stabilises the topoisomerase II-DNA complex (Figure 1.6), 
preventing topological changes, leading to double strand breaks, cell cycle arrest at S 
and G2 phases and apoptosis (Bromberg et al., 2003). Etoposide is commonly used 
for the treatment of lung, testicular and ovarian cancers.
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Figure 1.5 — Structure of etoposide (VP-16).
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Double strand break
Figure 1.6 -  Inhibition of topoisomerase II by etoposide (www.ovc.uoguelph.ca).
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1.2.5 Paclitaxel
Paclitaxel (Taxol) is a tricyclic diterpene isolated from Taxus brevifolia, the Pacific 
yew. It is also an inhibitor of chromatin function but it also inhibits microtubules. 
Microtubules are proteins polymers involved in cellular movement and morphology 
occurring in equilibrium between polymerized and free tubulin dimers. Inhibitors, 
such as paclitaxel (Figure 1.7) disrupt this equilibrium. Paclitaxel binds to form 
microtubules and shifts the equilibrium towards assembly, causing stabilisation and 
formation of abnormal bundles of microtubules, resulting in the inhibition of cell 
proliferation (Mastropaolo et al., 1995). It is one of the most active anti-cancer drugs 
and is effective against breast, ovary, lung, head and neck carcinomas. Paclitaxel is 
also used in combination with cisplatin in ovarian and lung carcinomas. Resistance to 
paclitaxel has been shown to be associated with increased P-glycoprotein and mutated 
tubulin. Paclitaxel is used in the treatment of breast, ovarian and lung cancer. In 
addition, recent studies have shown that combination of paclitaxel with trastuzumab 
increased the activity of either agent alone in ErbB2 overexpressing advanced breast 
cancer (Fountzilas et al., 2001).
O
HO
H,C.
CH
HO
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Figure 1.7 -  Structure of paclitaxel.
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1.2.6 Other chemotherapeutic treatments
There are two other categories of chemotherapeutic agents, antimetabolites and drugs 
affecting the endocrine function.
• Antimetabolites are usually cell cycle dependent and interfere with the production 
of nucleic acids resulting in the decrease of RNA and DNA synthesis, cell growth 
and proliferation. For example, methotrexate prevents the formation of 
tetrahydrofolate essential for purine and pyrimidine synthesis.
• Drugs affecting the endocrine function modify the growth of tumours by affecting 
steroid hormones or their antagonists. They can be separated into two groups, the 
antagonists (competitive antagonists) of estrogen receptors (used in treatment of 
breast cancer) inhibit the progression of the cell cycle between G1 and S phase 
and resulting in cell death. The second group is the glucocorticoids inhibiting 
protein synthesis, they attach to corticosteroid-binding proteins leading to 
apoptosis.
Finally, chemotherapeutic drugs can also be used as combination of two or more 
drugs in order to achieve a greater effect than either drug alone (e.g. synergistic or 
additive effect) and avoid drug resistance. However, each individual drug must have 
some anti-tumour activity. Moreover, each drug must also act by different mechanism 
to the other and have a different dose limiting toxicity when compared to its 
combination drug. In addition, for combination treatments, several cycles of treatment 
are usually given.
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1.3 DNA damage and repair mechanisms
It has been previously established that tumours arise from genetic and molecular 
changes caused by DNA damage or mistakes of the DNA replication mechanism. The 
different type of damage can be classified in three main categories of DNA damage 
(Hoeijmakers, 2001a). The first is caused by environmental agents, such as ultraviolet 
(UV), ionizing radiation (IR) and genotoxic chemicals (e.g. cigarette smoke). 
Secondly, DNA damage can be caused by byproducts of normal cellular metabolism, 
such as reactive oxygen species and products of lipid peroxidation. Finally, DNA 
damage can be caused due to the intrinsic instability of chemical bonds in DNA, 
spontaneous hydrolysis will lead to disintegration of chemical bonds in DNA and 
chemical changes in DNA bases.
Therefore, these DNA lesions can result in different adverse effects summarised in 
Figure 1.8. Indeed, Although DNA lesions usually trigger cell cycle arrest, through 
specific cell cycle checkpoint, in order to allow DNA damage repair (the different 
repair pathways are detailed hereafter), improper repair of the lesions may occur, due 
to the large extent of the damage. This will cause permanent mutations and 
oncogenesis (Zhou and Elledge, 2000). In addition, if the extent of the damage is too 
large, cells usually trigger apoptosis. Furthermore, damage affecting both DNA 
strands such as double strand breaks may result in improper chromosome segregation 
and apoptosis. In addition, those double strand breaks can lead to chromosomes 
aberrations, such as deletions, leading to oncogenesis. Nevertheless, permanent 
changes of the DNA sequence and oncogenesis may also result from point mutations 
induced by lesions interfering with DNA replication.
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Figure 1.8 -  DNA damage and repair mechanisms. Different DNA damage will trigger 
different mechanisms within the cell according to the type of damage and the extent: DNA 
damage repair, cell death or development of a tumour (oncogenesis). Figure obtained from 
Hoeijmakers J.H., Nature, 2001a, 411: 366-374.
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1.4 Cellular response to DNA damage
Figure 1.8 describes the organisation of the DNA damage response: repair, cell arrest, 
apoptosis and angiogenesis. In the following sections, the DNA repair pathways, cell 
cycle arrest and cell death are discussed.
1.4.1 DNA repair pathways
Hoeijmakers (2001b) described four main DNA repair pathways: Nucleotide Excision 
Repair (NER), Base Excision Repair (BER), Homologous Recombination (HR) and 
Non Homologous End Joining (NHEJ). These pathways have been associated with 
the repair DNA lesions caused by the different factors described previously and 
chemotherapeutic agents, such as crosslinking agents (Figure 1.9). Therefore, 
inherited defects in these repair pathways will results in apoptosis or oncogenesis. 
Although each pathway will be described individually hereafter, repair of some DNA 
lesions will involve proteins involved in different pathways, such as cisplatin-induced 
DNA damage having been shown to involve proteins of the nucleotide excision repair 
and homologous recombination (De Silva et al., 2000 and 2002).
Monoadduct Interstrand crosslink
a ;  i , /
XAL
DNA protein Intrastrand crosslink
crosslink
Figure 1.9 -  Interaction of crosslinking drugs with DNA. McHugh P.J. et al., The Lancet, 
2001,2: 483-490.
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Nucleotide Excision Repair (NER)
NER pathway is mainly responsible for correcting lesions that arise spontaneously. It 
corrects inappropriate base pairing (mismatch and damaged bases), lesions causing 
transcription and replication inhibition, such as bulky adducts and helix-distorting 
DNA adducts (McHugh et al., 2001). This repair pathway is divided into two sub­
pathways (Figure 1.10): global genome NER (survey the entire genome of distorting 
injury) and transcription-coupled repair for damage that block elongating RNA 
polymerases (Hoeijmakers, 2001a; de Laat et al., 1999). Although the recognition 
steps (I and II) of the damage is different for the two sub-pathways, subsequent steps 
are identical (III to V). Studies have shown that up to 25 proteins, including TFIIH, 
XPA and RPA, are necessary for the completion of the NER process involving lesion 
recognition, excision of 24-32 nucleotides strand containing the lesion and repair 
through normal replication mechanism (de Laat et al., 1999; Lindahl and Wood,
1999). Finally, after repair the protein complex is disassembled. Defects in this repair 
pathway have shown to cause other symptoms beyond NER defect, revealing that 
proteins of the NER pathway have additional purposes, such as transcriptional 
functions (Hoeijmakers, 2001b; de Laat et al., 1999).
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374.
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Base Excision Repair (BER)
BER pathway is mainly involved in the repair of damage caused by cellular 
metabolism. This pathway recognises inappropriate bases (mismatched or damaged), 
sites of base loss and single strand breaks. The molecular mechanism for BER has 
been reported by Lindahl and Wood (1999) and is described in Figure 1.11.
In the case of the repair of altered bases, BER is initiated by DNA glycosylases that 
cleave the base-deoxyribose glycosyl bond of the damaged nucleotide residue. It is 
noted that the DNA glycosylase are different according to the type of altered base to 
be removed from the DNA. The BER reaction will then be initiated at the abasic site, 
by APE1 endonuclease recruiting the DNA polymerase, polp, necessary for the gap- 
filling reaction. Alternatively, if the terminal sugar-phosphate residue is resistant to 
cleavage of DNA polp, the reaction may involve DNA pol5/e together with PCNA 
protein and FEN1 endonuclease for the repair synthesis of 2-10 bases. When the BER 
pathway is used for the repair of single strand breaks, it is initiated by the poly(ADP- 
ribose) polymerase-1 or PARP1, recruited at the site of the single strand break to 
protect it from unwanted recombination events, and the polynucleotide kinase (PNK). 
The following events are similar to the one described for the removal of an altered 
base (Lindahl and Wood 1999; Whitehouse et al., 2001).
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Homologous recombination (HR) and non homologous end 
joining (NHEJ)
These two mechanisms are used during the replication of single strand break and in 
the repair of double strand breaks arising from IR, chemicals and free radicals. The 
molecular mechanisms involve a protein scaffold (Lisby and Rothstein, 2004b; 
Jackson, 2002) summarised in Figure 1.12. Lisby and Rothstein (2004a) described 
four different steps in the recombinational repair of DNA damage. After DNA double 
strand break DNA ends are recognised and bound by the MRE11/NBS1/RAD50 
complex and Ku70/80. Following this, end-processing and binding of single stranded 
DNA occurs via replication proteins recruiting checkpoint proteins. The third step is 
the recombinational DNA repair (HR or NHEJ), at S and G2 phase. After DNA 
repair, foci are disassembled and the cell cycle is resumed.
Homologous recombination is a major repair pathway, it provides an error-free 
removal of damage of replicated DNA (S and G2 phases). Several studies have 
reported the detailed molecular mechanism of HR (Thompson and Schild, 2001; 
Pastink et al., 2001; Dronkert and Kanaar, 2001). After DNA damage, ATM and 
ATR are recruited (according to the type of damage) for phosphorylation of the 
MRE11/NBS1/RAD50 complex which exposes both 3’ ends (due to its exonuclease 
activity). Then, a nucleoprotein filament is formed due to the presence of RPA, 
RAD51 and the related proteins. BRCA1 and BRCA2 also play a major role in this 
repair pathway by associating with RAD51 (Khanna and Jackson, 2001) and the 
proteins of the BASC super complex (Wang et al., 2000b), such as the 
MRE11/NBS1/RAD50 complex. This leads to the subsequent exchange of strands 
with the identical sister chromatid (homologous sequence). Finally, Holliday 
junctions are resolved by resolvases (Khanna and Jackson, 2001).
Figure 1.12 also describes the non homologous end-joining repair pathway (NHEJ 
repair or V(D)J recombination), mainly present in the G1 phase (only one copy of the 
gene present). This repair pathway is more error prone since a few nucleotides are 
lost (end joining without any template). End-joining is activated by ATM and DNA- 
PKcs proteins. DNA-PKcS consists of a heterodimeric DNA (signaling function) 
targeting Ku70/80 complex (ends protection and approximation). Furthermore, 
Khanna and Jackson (2001) reported that MRE11/NBS1/RAD50 complex was also
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involved in the NHEJ repair, suggesting a role for BRCA1. Finally, both ends are 
ligated by XRCC4-ligaseIV (Hoeijmakers, 2001a; Pastwa and Blasiak, 2003). 
Therefore, DNA double strand breaks repair is an important repair pathway and is 
more difficult than the other type of DNA damage and erroneous rejoining may lead 
to oncogenesis.
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Figure 1.12 -  Homologous Recombination (HR) and Non Homologous End Joining 
(NHEJ or V(D)J recombination) molecular mechanism. Hoeijmakers J.H., Nature, 2001a, 
411:366-374.
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1.4.2 Cell cycle alterations in cancer
Cell cycle checkpoints are key transitions during the cell cycle progression. 
Checkpoints are present at different stages in the cell cycle, in order to arrest the cells, 
to repair DNA damage, dissipate an exogenous cellular stress signal or to wait for 
available growth factors, hormones or nutrients (Pietenpol and Stewart, 2002). 
Therefore, cell cycle checkpoints contribute to genomic stability. Thus, in response to 
DNA damage, cell cycle checkpoints integrate cell cycle control with DNA repair. 
Cellular response to DNA damage has been shown to be mediated through two 
groups of protein kinases, ATM/ATR and CHK1/CHK2 checkpoint kinases groups, 
and downstream checkpoint can be put into two categories: Gl/S (Figure 1.13) and 
G2/M (Figure 1.14) checkpoints (Walworth, 2000), since cell cycle arrest occurs most 
frequently at these boundaries. Nonetheless, although signaling pathways can be 
distinguished, they have considerable overlap.
Gl/S cell cycle checkpoint
The Gl/S checkpoint (Figure 1.13) is ruled by cyclin/Cdk complexes. Progression of 
the cell cycle is facilitated by cyclin D kinases causing the Rb phosphorylation and 
sequestration of Cip/Kip proteins, p21Cipl (or p21WAF1), p57Kip2 and p27Kipl, called 
Cdks inhibitors (Shapiro and Harper, 1999). Non-phosphorylated Rb is responsible 
for relieving transcriptional repression by forming a complex with E2F, and allowing 
transcription of genes necessary for the entry in S phase. Sequestration of Cip/Kip 
proteins inhibits the activation of cyclin E-Cdk2 complex formation, responsible for 
Rb phosphorylation and inhibition of Rb-E2F complexes (Harbour et al., 1999; Sherr 
and Roberts, 1999). In addition, inhibitory activity of Cip/Kip proteins has been 
shown to be present during all phases of the cell cycle. Nevertheless, Gl/S phase 
transition is also regulated by INK4 inhibitors responsible for the inhibition of Cdk4 
and Cdk6 activity, responsible for cell cycle progression (Pietenpol and Stewart, 
2002).
Therefore, exposure to DNA damaging agents will cause induction of INK4 inhibitors 
and Cip/Kip proteins are activated causing inhibition of cyclin D and Cdk4 and 6 and 
formation of cyclin E-Cdk2 complexes, leading to Rb phosphorylation and cell cycle
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arrest. It is also noted that p21NVAF1 activation is p53-dependent, nonetheless, Liu et 
al. (1996) reported that it could be activated through the MAPK signaling pathway.
Replicative
Senescence
Smad3
Smad4
Ultra Violet 
Stress Response
Growth
Factor
Withdrawal
OSK-3|l
CDK4/6 CDK2
f t  Suv39H1 
Rb HDAC
E2F/DP TARGET GENES: 
cydin E/A, E2F-1/2/3, cdc2. 
cMyc. p107 RanGAP, TK, 
DHFR. PCNA, H2A, etc
U tx q jitin a tio n
Contact inhibition
DNA Damage 
/
/
Replicative 
Senescence
• • • >  Ubiquiti nation
Ubiquitination
^  Kinase {  )  Phosphatase ^  ]  k Transcription factor
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G2 cell cycle checkpoint
The G2 cell cycle arrest (Figure 1.14) is regulated through the inhibition of Cdc2 
activation. Cdc2 is negatively regulated by its phosphorylation, preventing the 
formation of cyclin B-Cdc2 complexes and entry into mitosis (Pietenpol and Stewart, 
2002; Walworth, 2000). DNA damage maintains the phosphorylated state of Cdc2, 
through the activation of the members of PI3K family, including DNA-PK, ATM and 
ATR. This leads to the activation of CHK2 and 1, promoting the formation of 
Cdc25C-14-3-3 complexes, sequestered in the cytoplasm, and inhibition of Cdc2 
activity (Weinert, 1997; Matsuoka et al., 1998; Sanchez et al., 1997; Fumari et al., 
1997; Lopez-Girona et al., 1999). CHK1 has also been reported to be involved in the 
S phase checkpoint, as well as the G2/M checkpoint, and is activated in response to a 
large spectrum of DNA damaging agents whereas CHK2 has its main role in IR- 
induced apoptosis, but has also been reported to affect the S and Gl/S checkpoints 
(Zhou and Bartek, 2004; Eastman, 2004). During G2 arrest, p53 also undergoes 
modification, as it activates p21WAF1 responsible for the formation of complexes with 
cyclin B. Thus, p53 reduces the formation of cyclin B-Cdc2 complexes, necessary for 
cell cycle progression (Innocente et al., 1999; Flatt et al., 2000; Chan et al., 1999). In 
addition, p53 also acts as transcriptional up-regulator of 14-3-3 proteins, responsible 
for Cdc2 cytoplasmic sequestration, and GADD45, causing G2 cell cycle arrest (Chan 
et al., 1999; Wang et al., 1999a).
Consequently, those cell cycle checkpoints are important for the proper repair of 
cellular damage and defects in those may result in oncogenesis, through gene 
mutations and chromosome aberrations. Nonetheless, these checkpoints may result in 
activation of apoptosis if the damage are too large or the cells are unable to trigger 
DNA damage repair.
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1.4.3 p53 and apoptosis
Apoptosis or cell death (Figure 1.15) is a gene-directed program (Lowe and Lin,
2000) leading to cell shrinkage, membrane blebbing and DNA fragmentation. 
Apoptosis can be divided into two pathways, the extrinsic, regulated by cell surface 
receptors, their inhibitors and associated proteins, and the intrinsic pathway, 
controlled by apoptogenic factors on the mitochondria. The intrinsic pathway is 
regulated by pro- and anti-apoptotic regulators, members of the Bcl-2 family 
(Tsujimoto, 2003).
Nevertheless, many studies have shown the influence of several genes on apoptosis, 
but the most important and extensively studied is the tumour suppressor, p53 
(Fridman and Lowe, 2003; Vousden K.H., 2002). p53 was shown to have a pro- 
apoptotic activity by activating the transcription of genes promoting apoptosis (El 
Deiry, 1998). Indeed, p53 is able to control the transcription of pro-apoptotic 
members of the Bcl-2 family, such as Bax (Miyashita et al., 1994), acting upstream of 
the mitochondria. In addition, p53 was shown to transactivate apoptotic effectors, 
such as Apafl, responsible for activation of caspase 9 and the caspase cascade, 
leading to apoptosis (Kannan et al., 2001; Moroni et al., 2001; MacLachlan and El 
Deiry, 2002). Caspases are the central regulators of apoptosis since they are 
responsible for the cleavage of cytoskeletal and nuclear proteins, leading to apoptosis, 
in response to pro-apoptotic activation (Budihardjo et al., 1999). Nonetheless, p53 
does not only regulate the intrinsic pathway but has also been shown to regulate the 
extrinsic pathway and activate other genes linked to apoptosis (Owen-Schaub et al., 
1995; Attardi et al., 2000). In addition, p53 was also shown to induce anti-apoptotic 
pathways, such as the PI3K pathway through activation of PTEN and subsequent 
activation of Akt (Vivanco and Sawyers, 2002).
Therefore, p53 is an important player of the apoptosis and mutations or loss-of- 
function mutations in p53 will be critical as they have been shown to modulate 
apoptosis and drug resistance (Fulda et al., 1998; Petak et al., 2000). Nonetheless, 
apoptosis is not the only form of programmed cell death, as senescence is a non- 
apoptotic cell death. It is described as being an irreversible program of cell cycle 
arrest (Lowe and Lin, 2000), with p53 being an important factor (Wynford-Thomas, 
1999).
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1.5 BReast-CAncer susceptibility gene 1 (BRCA1)
BRCA1 is the BReast-CAncer susceptibility gene 1 encoding for a multifunctional 
phosphoprotein (Figure 1.16) and is mainly found in the nucleus and mitochondria 
(Coene et al., 2005). BRCA1 is a tumour suppressor which plays an important role in 
nuclear DNA maintenance, and its mutations have been associated with the increased 
risk of breast cancer (Miki et al., 1994). This protein is composed of several 
functional regions (Figure 1.16) including one N-terminal RING domain, two nuclear 
localization signals (NLS) and two BRCA1 carboxyl terminus (BRCT) motifs at the 
carboxyl terminus (Koonin et al., 1996; Chen et al., 1996; Narod and Foulkes, 2004). 
BRCA1 has been shown to be involved in a multiple of cellular pathways (Figure 
1.17), through protein-protein interactions or DNA binding (Deng and Brodie, 2000). 
Nonetheless, for its function in cell cycle progression and DNA damage response, 
BRCA1 is regulated through specific phosphorylation events (Scully et al., 1997a; 
Venkitaraman, 2002). Its functions include cellular response to DNA damage (Zhong 
et al., 1999; Jasin, 2002), cell cycle regulation and checkpoint activation (Hakem et 
al., 1997; Xu et al., 1999), apoptosis induction (Yan et al., 2002), centrosomes 
regulation (Deng, 2002), DNA binding (Yamane et al., 2000), chromatin remodelling 
(Lou et al., 2005; Ye et al., 2001), ubiquitin ligation (Hashizume et al., 2001; Ruffher 
et al., 2001) and transcription regulation (Monteiro, 2000).
Therefore, BRCA1 is a key protein responsible for maintaining genome integrity, 
since carriers of a BRCAlgermline mutation have been shown to have a risk of up to 
85% of developing breast cancer (James et al., 2007).
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1.5.1 BRCA1 and DNA damage repair
The association of BRCA1 with DNA damage repair was reported due to its 
hyperphosphorylation and relocation at the replication forks (Scully et a l, 1997a). 
Nevertheless, several studies have shown that BRCA1 was associated with or induced 
proteins involved in DNA repair (Figure 1.18). BRCA1 was shown to have a role in 
homologous recombination. In response to DNA double strand breaks, BRCA1 is 
phosphorylated by ATM, ATR and CHK2 kinases (Cortez et a l, 1999; Gatei et al, 
2001; Chaturvedi, et a l, 1999). Scully et a l (1997b) described the subsequent 
association of BRCA1 with RAD51 while other studies have reported its association 
with proteins such as the MRE11/NBS1/RAD50 (MRN) protein complex (Zhong et 
a l, 1999), proteins of the BRCA1-associated genome surveillance complex (BASC -  
Wang et a l, 2000b). By its association with the BASC super complex, BRCA1 will 
influence the type of repair used according to the type of DNA damage. Nonetheless, 
BRCA1 has a specific role in the homologous recombination by its association with 
the MRN protein complex, thus exposing the 3’ ends on either side of the break 
(Hoeijmakers, 2001a). Subsequently, BRCA1 associates with BRCA2 and RAD51 
forming a protein complex with the proliferating cell nuclear antigen (PCNA) at the 
DNA replication fork (Scully et a l, 1997b). Following this, BRCA1 dissociates from 
CtIP in order to activate the transcription of genes involved in the DNA damage 
response (Li et a l, 1999; Harkin et a l, 1999). However, when damage affect key cell 
cycle checkpoint genes, cells cannot repair DNA damage and cells proliferate, 
causing oncogenesis (Figure 1.18).
Studies by Zhong et al (2002) and Baldeyron et al (2002) also reported that BRCA1 
was involved in non-homologous end joining repair in order to facilitate the 
alignment of short areas of base homology on either side of the DNA break before 
ligation. In addition, Le Page et a l (2000) suggested that BRCA1 was involved in 
both pathways of the nucleotide excision repair. Indeed, BRCA1 is thought to be 
involved in transcription coupled repair through BRCA1-mediated protein 
ubiquitination, thus conferring resistance to cisplatin-induced DNA damage (Lorick 
et a l, 1999; Cullinane et a l, 1999; Anderson et a l, 1998). In addition, the study by 
Hartman and Ford (2002) demonstrated that BRCA1 deficient cells were deficient in 
global genomic repair, suggesting its involvement in this repair pathway. Therefore, 
BRCA1 interacts with key proteins involved in DNA damage repair and its mutation
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or loss of function will result reduction of DNA repair efficiency and increased 
toxicity or oncogenesis.
Moreover, BRCA1 has been reported to be associated with the Fanconi Anemia (FA 
-  autosomal recessive disease) core complex through the formation of a complex with 
FANCA protein involved in the recognition of the DNA replication fork after 
chemotherapy and activation of the FANCAD2 protein (Folias et a l , 2002; Pichierri 
et al., 2004). In addition, monoubiquitinated FANCD2 has been shown to co-localise 
with BRCA1 after DNA damage (Garcia-Higuera et a l , 2001). BRCA1 has also been 
shown to be associated with FANCAD1, which has been identified as BRCA2 and 
those two proteins have been shown to be involved in drug-induced DNA double 
strand breaks repair through homologous recombination (Howlett et a l, 2002; Tutt et 
a l, 2001). Taniguchi et al (2003) also reported that reduction of Fanconi Anemia 
protein F led to an increase in cisplatin sensitivity and demonstrating that association 
of BRCA1 with FA proteins was important for the repair of drug-induced DNA 
damage. Furthermore, Yamamoto et al (2005) and Nakanishi et al (2005) reported 
that deficiency in some FA genes led to a defect in homologous recombination. 
Therefore, interaction of BRCA1 with Fanconi Anemia proteins needs to be 
considered when studying BRCA1 DNA repair machinery.
Hence, it is clear that BRCA1 plays a major role in DNA repair and that its mutation 
will have important implication on tumour development and response to drug- 
induced DNA damage.
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1.5.2 BRCA1 as transcriptional regulator
Several studies reported the transcriptional activity of BRCA1, such as its 
transcriptional function in response to ionizing radiation (Figure 1.19). Scully et al. 
(1997c) reported that C-terminus of BRCA1 interacts with RNA polymerase II 
through RNA helicase A, demonstrating the interaction BRCA1 with the basal 
transcriptional machinery. Studies by Somasundaram et al. (1997) and Ouchi et al. 
(1998) also reported that BRCA1 induced the transcription of the promoter of 
GADD45 and especially those genes regulated by p53 such as p21WAF1 and MDM2. 
Ouchi et al. (2000) reported the binding of BRCA1 to STAT1, associating mainly 
with Ser727-phosphorylated STAT1, responsible for the increase in recruitment of 
transcriptional coactivators such as the CBP/p300 histone acetyltranferases and the 
DNA replication factor, MCM5. In addition, BRCA1 was also shown to interact with 
several transcription factors such as CtIP, E2F and ZBRK1 (Yoshida and Miki, 2004; 
Zheng et al., 2000). Moreover, Ouchi et al. (1998) reported that mutant form of 
BRCA1 lacking the BRCT domain led to a reduction in p53-mediated transcriptional 
activation. And a recent study by MacLachlan et al. (2002) demonstrated that BRCA1 
overexpression caused a stabilisation of p53, showing that BRCA1 is able to 
stimulate the p53 pathways. Thus, BRCA1 status can modulate apoptosis. 
Furthermore, Atalay et al. (2002) demonstrated that BRCA1 induced 46 genes with 
different function such as the transcription regulation, DNA repair, chromatin 
assembly, receptor-mediated signaling.
Consequently, BRCA1 is a transcriptional regulator for many genes, suggesting a 
bridging role for BRCA1 between DNA damage and stress response, leading to cell 
cycle arrest and apoptosis.
58
CHK2
p 2 l |  G ADD45 f
loJV *  M
Figure 1.19 -  Transcription and BRCA1. Example of BRCA1 transcriptional function in 
response to ionising radiation. Yoshida K. and Miki Y., Cancer science, 2004, 95(11): 866- 
871.
1.5.3 BRCA1 and cell cycle regulation
As described previously, after DNA damage, cells rely on the cell cycle checkpoints 
to stop their progression before DNA repair. Many studies have reported the 
implication of BRCA1 in the regulation of cell cycle checkpoints. Indeed, Quinn et 
al. (2003) demonstrated that BRCA1 was essential for G2/M cell cycle checkpoint, as 
they reported that cells deficient in BRCA1 were defective in this checkpoint, 
following exposure to spindle poisons and DNA damaging agents. Nonetheless, 
transfection of BRCA1 wild type gene restored the function of this checkpoint.
The role of BRCA1 as a regulator of cell cycle checkpoints has been shown to be due 
to its phosphorylation by ATM, ATR and the cell cycle checkpoint kinase 2 (CHK2). 
Indeed, Cortez et al. (1999) reported that ATM, activated by ionizing radiation- 
induced DNA double strand breaks, caused the phosphorylation of BRCA1 in 
response to DNA damage, necessary for efficient G2/M and intra-S phase 
checkpoints (Xu et al., 2001 and 2002). In addition, ATR, activated by stalled DNA 
replication forks, and CHK2 were also shown to cause BRCA1 phosphorylation, 
upon DNA damage, necessary for cell cycle checkpoints activation (Lee et al., 2000a; 
Tibbetts et al., 2000).
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Furthermore, Williamson et al. (2002) and Somasundaram et al. (1997) demonstrated 
that BRCA1 was able to stimulate the transcription of p21WAF1 and p27Kipl, both 
involved in the regulation of Gl/S cell cycle checkpoint. In addition, Yarden et al.
(2002) also described the importance of BRCA1 in the G2/M phase checkpoint since 
BRCA1 was shown to activate CHK1 kinase. In this study, they also demonstrated 
that BRCA1 expression controlled the expression, phosphorylation and cellular 
localisation of Cdc25C and cyclin B-Cdc2 complexes, necessary for G2/M transition. 
Finally, they established that BRCA1 regulated the expression of the inhibitor of 
cyclin B-Cdc2 complexes, Weel kinase, and 14-3-3 proteins, key regulators of the 
G2/M checkpoint. Therefore, loss of BRCA1 will cause defective checkpoints and 
accumulation of DNA damage.
1.5.4 BRCA1 and topoisomerase II
So far, BRCA1 has been shown to be a key player in the maintenance of genome 
integrity, through its participation in the response to DNA damage and the regulation 
of cell cycle checkpoints. Furthermore, BRCA1 has recently been shown to maintain 
genomic stability through its interaction and colocalisation with topoisomerase Ila in 
the S phase. Indeed, Lou et al. (2005) established that BRCA1 played a direct role in 
DNA decatenation and that deficiency in BRCA1 resulted in chromosome 
aberrations. In addition, it is suggested that BRCA1 participate in a decatenation 
checkpoint in order to maintain chromosome integrity (Deming et al., 2001). Thus, 
this new function of BRCA1 provides a better understanding of the importance of 
BRCA1 for genomic stability.
1.5.5 BRCA1 and cancer therapy 
Response to chemotherapy
Studies investigating the role of BRCA1 in response to chemotherapeutic treatment 
have established that BRCA1 is a modulator of DNA damage response. Indeed, 
Bhattacharyya et al. (2000) and Quinn et al. (2003) demonstrated BRCA1 caused an 
increased resistance to alkylating agents such as cisplatin and mitomycin C. 
Furthermore, they showed that BRCA1 deficient cells were more sensitive to 
crosslinking agents. Fedier et al. (2003) also established that BRCA1 conferred 
resistance to topoisomerase I and II poisons, such as topotecan and etoposide, but did
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not alter the sensitivity to spindle poisons. Conversely, Tassone et al. (2003) reported 
that BRCA1 mutation caused an increase resistance to doxorubicin, acting similarly 
to etoposide. Thus more understanding on the effect of BRCA1 on doxorubicin- 
induced DNA damage is required. In addition, Tassone et al. (2003) and Quinn et al. 
(2003) also reported that wild type BRCA1 induced an increase in sensitivity to 
spindle poisons, such as paclitaxel and vinorelbine. Nevertheless, conflicting results 
still exist as a decrease in paclitaxel sensitivity was reported when BRCA1 function 
was restored in human ovarian cancer cells (Zhou et al., 2003). Therefore, results 
suggest that BRCA1 blocks apoptosis after treatment with DNA damaging agents and 
induces it after spindle poisons treatment. Nonetheless, further understanding on the 
mechanisms involved is required as conflicting results have been published.
Response to radiotherapy
BRCA1 has been shown to play a role in DNA repair following radiation-induced 
DNA strand breaks. Many studies have reported the sensitivity of BRCA1 mutants to 
radiotherapy (Abbott et al., 1999; Cortez et al., 1999). They all showed that BRCA1 
deficient cell lines failed to repair the damage caused by radiation resulting in 
radiation hypersensitivity. Furthermore, Bhattacharyya et al. (2000) demonstrated 
that BRCA1 contributed to increased resistance to radiation-induced DNA damage by 
promoting the assembly of RAD51. Thus, BRCA1 not only plays an important role in 
drug-induced DNA damage response is associated with radiation resistance. 
Nevertheless, Wang et al. (2001) did not show the role of BRCA1 in radiation- 
induced DNA damage and suggested that the increased radiosensitivity was 
independent of the BRCA1 status but was due to a defect in the repair pathway. 
Furthermore, studies on heterozygous BRCA1 mutations have shown that BRCA1 
did not play a major role in radiosensitivity (Nieuwenhuis et al., 2002; Baeyens et al., 
2004), as heterozygous BRCA1 mutation carriers did not have an increased 
radiosensitivity compared to non-carriers of the BRCA1 mutations. Therefore, further 
understanding is required to determine the role of BRCA1 in radiation-induced DNA 
damage.
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1.6 The epidermal growth factor receptors 
1.6.1 The EGF receptor family
The Epidermal Growth Factor Receptor (EGF receptor or ErbB) family is the 
subclass I of the receptor tyrosine kinase superfamily (Hynes and Lane, 2005). It 
consists of four members (Figure 1.20): EGFR (or ErbBl or HER1), ErbB2 (or neu or 
HER2), ErbB3 (or HER3) and ErbB4 (or HER4). All four receptors are 
transmembrane glycoproteins (185KDa) formed of an extracellular domain (ligand 
binding region), a single membrane spanning region and a cytoplasmic tyrosine 
kinase domain (intracellular). Activation of the tyrosine kinase occurs via homo and 
heterodimerisation and ligand binding.
Different ligands (Figures 1.20 and 1.21) have been identified for each receptor 
(Hynes and Lane, 2005). EGF, transforming growth factor-a and amphiregulin bind 
to EGFR, whereas betacellulin, heparin-binding EGF and epiregulin to EGFR and 
ErbB4. Another group of ligands composed of neuregulins binds either to both ErbB3 
and ErbB4 or only to ErbB4. Although, no ligand has been identified for ErbB2, 
Brennan et al. (2000) reported that it was activated through homo or 
heterodimerisation with other members of the ErbB family. Once activated, these 
receptors lead to the activation of a large number of intracellular signalling pathways 
(Figure 1.21). However, it is noted that ErbB3 is deficient in tyrosine kinase activity. 
Two main signalling pathways have been identified, the Mitogen-Activated Protein 
Kinase (MAPK) signalling pathway and the Phosphatidyllnositol 3-kinase 
(PI3K)/Akt pathway (Riese and Stem, 1998; Yarden and Sliwkowski, 2001; Olayioye 
et al., 2000). Thus, activation of EGFR tyrosine kinases affects a variety of signal 
transductions, leading to increase of proliferation and inhibition of apoptosis 
(Vlahovic and Crawford, 2003). Nevertheless, ErbB receptors have been implicated 
in the development of many cancers. EGFR and ErbB2 overexpression are the two 
main ErbB receptors which have been shown to play a major role cancer development 
(Ohgaki et al., 2004; Sunpaweravong and Sunpaweravong, 2005; Slamon et al., 
1987). In addition, EGFR amplification is often accompanied by a mutated form of 
EGFR, EGFRvIII variant, having a deletion in the extracellular domain of the 
receptor (Ekstrand et al., 1992). More recently, mutations of the receptor tyrosine 
kinase domain have also been identified in non-small-cell lung cancers (Pao et al.,
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2004). Stephens et al. (2004) also identified mutations in the kinase domain of 
ErbB2, in non-small-cell lung cancers. Therefore, these two receptors are important to 
consider in the development of tumours.
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1.6.2 Epidermal growth factor receptors and cancer
Members of the EGFR family have been identified as being involved in development 
and progression of cancer. EGFR was the first to be linked with cancer (Gschwind et 
al., 2004). However, ErbB2 was also described as being an important player in cell 
proliferation in cancer and particularly in breast cancer (Yarden, 2001a). These 
proteins have been shown to be largely overexpressed in tumours and cause 
uncontrolled cell proliferation due to their tyrosine kinase activity.
Oncogenic Tyrosine Kinases (OTKs)
Indeed, tyrosine kinases, acting to transfer phosphate from ATP to tyrosine residues 
on cellular proteins, are tightly controlled. However, three mechanisms have been 
described by which they become constitutively active and lead to the development of 
tumours, thus being oncogenic. The first one is the chromosomal translocation, 
generating fusion proteins allowing constitutive activation of the kinase activity, the 
second is by overexpression and finally by point mutations in the juxtamembrane 
region of a receptor causing constitutive dimerisation and activation of its kinase 
activity (Blume-Jensen and Hunter, 2001). These oncogenic tyrosine kinases have 
two complementary roles in cancer. One is to increase stimulation of signalling 
pathways enabling the cells to proliferate and protecting them from apoptosis 
independently of the presence of growth factors, thus causing metastasis (Porter and 
Vaillancourt, 1998; Sawyers, 1997). The second role is to cause resistance to chemo- 
and radiotherapy, thus accumulating DNA damage and genetic aberrations, such as 
mutations (Nishii et al., 1996; Slupianek et al., 2001). The latter is achieved through 
four possible mechanisms. One being the reduction of DNA damage accumulation, 
although unlikely, DNA damage may accelerate the process of repair, thus reducing 
the number of lesions (Michel et al., 2001). The second one being the increase in the 
rate of repair, Masumoto et al. (1999) demonstrated that Bcr-Abl-like OTK 
transformed cells repaired cisplatin-induced DNA ICLs faster than untransformed 
cells. Indeed, to this date, it is suggested that homologous recombination repair is up- 
regulated in cells transformed by the Bcr-Abl-related family of OTKs, through up- 
regulation of RAD51 (Raderschall et al., 2002), whereas Deutsch et al. (2001) 
showed that NHEJ repair is downregulated. However, it is not confirmed if this 
observation is general to all OTKs and if it can be applied to other repair pathways.
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The third mechanism is the activation of cell cycle checkpoints. Although the 
mechanism, by which OTK-transformed cells increase the G2/M cell cycle arrest, is 
not known, Slupianek et al. (2002) reported that OTKs of the Bcr-Abl-related family 
induced G2/M checkpoint in response to different chemotherapeutic. Nevertheless, in 
response to radiation results have been more controversial (Nishii et al., 1996; 
Salloukh et al., 2000). Finally, OTKs can cause resistance to genotoxic damage 
through activation of anti-apoptotic proteins, such as B c1 -X l and Bcl2 (Kumar et al., 
1996), and inhibit pro-apoptotic proteins, Bad and Bax (Salomoni et al., 2000; Wang 
etal., 1999b).
Therefore, oncogenic tyrosine kinases, such as EGFR or ErbB2 are important to 
consider in the progression and treatment of tumours, thus development of new 
targeted therapies is needed.
EGFR
EGFR activation and signalling -  The Epidermal Growth Factor Receptor (EGFR) 
is a transmembrane glycoprotein, of the ErbB family, with a ligand-dependent 
intracellular tyrosine kinase activity (Velu, 1990). It is composed of an N-terminus 
extracellular region, a hydrophobic transmembrane region and a C-terminus 
intracellular region containing the tyrosine kinase domain. The N-terminus region is a 
ligand-binding site. Indeed, several studies have established that EGFR was the only 
receptor for EGF and TGFa ligands, nevertheless other ligands have also been shown 
to bind EGFR, such as amphiregulin, betaceilulin (Kelloff et al., 1996; Davies and 
Chamberlin, 1996). Both, EGF and TGFa, have a mitogenic activity amongst others 
(Velu, 1990), and have been implicated in the induction of angiogenesis, since EGFR 
has been shown to have a direct role in tumour development (Davies and Chamberlin, 
1996). This activation of EGFR will result in the formation of homodimers and three 
functional heterodimers (Baselga and Arteaga, 2005). Nevertheless, the preferred 
partner of EGFR for heterodimerisation is ErbB2 which result in increased affinity for 
ligands and greater catalytic activity then EGFR homodimers. This causes receptor 
auto-phosphorylation or trans-phosphorylation, as tyrosine residues on one receptor 
are cross-phosphorylated by the other member of the receptor pair, will form a 
docking site for several Src homology 2 containing signal transducers. After ligand- 
induced activation, EGFR couple to different intracellular proteins involved in signal
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transduction cascades, including the Mitogen-activated protein kinase (MAPK), 
phosphatidylinositol-3’-kinase (PI3K), the anti-apoptotic kinase Akt and several 
transcriptional regulators, such as STAT5 (Citri and Yarden, 2006, Hemandez- 
Sotomayor and Carpenter, 1992; Kelloff et a l, 1996). Nonetheless, EGFR signalling 
is negatively regulated through ubiquitylation by Cbl (Citri and Yarden, 2006).
EGFR nuclear localisation -  Recent studies have demonstrated that EGFR was able 
to be internalised and induce endosomal signalling leading to cell proliferation and 
survival (Wang et al., 2002). Furthermore, different studies have also established that 
EGFR was able to physically interact with proteins in the nucleus, such as STAT3 
causing activation of transcription (Lo et al., 2005 and 2006). In addition, Dittmann et 
al. (2005) established that nuclear EGFR is not only used as a transcriptional 
activator but also to trigger DNA damage repair in response to ionising radiation. 
Furthermore, they demonstrated that EGFR translocation occurs via a ligand- 
independent pathway in which stress induces the movement of the receptor from a 
perinuclear compartment into the nucleus. In addition, Hsu and Hung (2007) 
established that EGFR nuclear translocation was due to a tripartite nuclear 
localisation signal (NLS) sequence. Thus, EGFR endosomal and nuclear signalling 
need to be further characterised and will be important to consider when designing 
targeted therapies, as they need to act on the cell surface as well as in the nucleus.
EGFR and cancer -  As described in Figure 1.21, activation of EGFR will cause 
increased cell proliferation as well as cell motility, adhesion, invasion and survival. 
Therefore, when overexpressed, EGFR contributes to angiogenesis (Woodbum,
1999). In addition, EGFR activation has an anti-apoptotic activity, since inhibitors of 
its tyrosine kinase activity have been shown to promote apoptosis (Kulik et a l, 1997; 
Bruns et al., 2000). Consequently, deregulated expression of EGFR will result in 
increased EGFR signalling and angiogenesis.
Different mechanisms have been identified explaining the deregulated EGFR activity. 
The first one is the overexpression of EGFR, resulting from transcriptional or post- 
transcriptional mechanisms. EGFR overexpression has been observed in several 
cancers and was associated with invasiveness (Velu, 1990). The second mechanism is 
the activation of normal receptors, through autocrine overproduction of ligands. This 
will result in constant activation of EGFR and angiogenesis. Another mechanism is
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also the loss of the negative feedback, responsible for the negative regulation of 
EGFR cell signalling (Amit et a l , 2007). Finally, is the mutation of EGFR, forming 
mutants which are constitutively actives without ligands. The best characterised is the 
EGFR variant III (EGFRvIII), lacking the dimerisation arm and an essential part of 
the ligand binding domain. Nonetheless, this mutation results in ligand-independent 
tyrosine kinase activation (Kelloff et al., 1996). This mutation has been associated 
with increased resistance to chemotherapy and resistance to tyrosine kinase inhibitors 
(Learn et al., 2004; Camp et a l , 2005). In addition, other kinase domain missense 
mutations, deletions and insertions have been observed, causing enhanced 
autophosphorylation and cell survival (Lynch et a l , 2004; Paez et a l , 2004). 
Therefore, further understanding of signal transduction pathways will help designing 
new targeted therapies and improve the therapeutic outcome.
ErbB2
ErbB2 activation and signalling -  ErbB2 (human epidermal growth factor receptor 
2) is the only receptor of the ErbB family to be ligand-less (Brennan et a l , 2000) 
whereas other members of the ErbB family are activated by large family of ligands. 
Upon activation, growth factor receptors dimerise and transduce their signals by auto­
phosphorylation catalysed by the tyrosine kinase activity (Hunter, 2000). 
Nevertheless, ErbB2 having no known ligand, has been shown to be the preferred 
dimer partner of other ErbB receptors (Tzahar et a l , 1996; Graus-Porta et a l, 1997). 
In addition, Yarden and Sliwkowski (2001) reported that formation of ErbB2 
heterodimers led to a stronger intracellular signal than the one originating from other 
complexes. Therefore, ErbB ligands activate ErbB2 together with the appropriate 
high affinity co-receptor (Harari et a l, 1999; Karunagaran et a l, 1996).
Similarly to EGFR, activated ErbB2 induces PI3K/Akt signalling pathway as well as 
the MAPK pathway, causing cell proliferation. ErbB receptor activation of the PI3K 
pathway (Figure 1.22) occurs through the Src-homology 2 (SH2)-mediated 
recruitment of the p85 regulatory subunit of PI3K. Once recruited, the pi 10 catalytic 
subunit of PI3K phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) to form 
PIP3. PIP3 recruits phospholipid-binding domain containing proteins to the plasma 
membrane (Blume-Jensen and Hunter, 2001). Akt is one of the key effectors of the 
PI3K pathway and is recruited to the membrane through its PH domain, and
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phosphorylated (at threonine 308) through activation of PDK1 (Meier and 
Hemmings, 1999). Akt phosphorylation at serine 473 occurs via PDK2 but the 
identity of PDK2 remains controversial. Nonetheless, it was suggested that 
phosphorylation at serine 473 could be caused by integrin-linked kinase (ILK), 
mammalian target of rapamycin (mTOR)-rictor complex, protein kinase C (PKC) and 
Akt itself (Delcommenne et a l, 1998; Toker and Newton, 2000; Kawakami et al., 
2004; Sarbassov et al., 2005; Hay, 2005). Akt subsequently undergoes nuclear 
translocation and phosphorylates a number of downstream proteins. Indeed, Akt has 
been shown to phosphorylate Bad, blocking its pro-apoptotic activity (Danielsen and 
Maihle, 2002). In addition, Akt was shown to negatively regulate Raf and GSK-3 
kinases and FKHR, a cell cycle regulatory transcription factor. Akt was also reported 
to promote protein translation through mTOR, initiation factor 4E and ribosomal p70- 
S6  (Li et al., 2004). Finally, Akt was shown to promote cell cycle progression 
through downregulation of p21WAF1 and p27Kipl (Zhou et al., 2001b). Therefore, PI3K 
modulates cell proliferation and survival. Nonetheless, this pathway can be inhibited 
through the action of phosphatase and tensin homolog (PTEN) that the 3’ phosphate 
from PIP3, forming PIP2. Thus, inhibiting Akt phosphorylation and downstream 
signaling, PTEN is then used as a balance for controlled cell growth (Cantley and 
Neel, 1999). Moreover, Hay (2005) also reported that Akt activation was negatively 
regulated by mTOR-raptor complex, thus playing an important role in cell 
progression regulation.
In addition to the PI3K pathway, ErbB2 also activates the Ras-MAPK pathway (or 
MAPK -  Figure 1.22). This occurs either directly through the SH2 domain-mediated 
recruitment of Grb-2 or indirectly through the PTB domain-mediated binding of the 
She adaptor. By exchange of GDP for GTP, Gbr-2 activates Ras, which in turns binds 
and activates the Raf kinase (Schlessinger, 2000). This subsequently initiates the 
kinase cascade which involves phosphorylation of MEK1/2 and Erkl/2. Erk is 
responsible for the phosphorylation of cytoplasmic and cytoskeletal proteins such as 
MAPK-activated protein kinases and ribosomal p70-S6 kinase. In addition, Erk is 
translocated to the nucleus where it activates a number of transcription factors, such 
as E2F and API. Moreover, the MAPK pathway has also been implicated in 
chromatin remodeling through phosphorylation of histone H3 (Dunn et al., 2005). 
Therefore, activation of the MAPK cascade results in gene expression and cell
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proliferation. In addition, under stress, such as UV radiation, p38 MAPK stress 
pathway is activated causing cell proliferation, growth and survival. This pathway 
also modifies transcription factors, histones and chromatin remodeling factors (Dunn 
et al., 2005).
Nonetheless, other signalling pathways are also activated in response to ErbB 
activation (Figure 1.22). Indeed, studies have shown that ErbB receptors induced 
activation of the phospholipase Cy, causing increased intracellular calcium 
concentrations and phosphorylation of a number of substrates. In addition, STAT1, 
STAT3 and STAT5 have been shown to be phosphorylated and activate 
transcriptional gene involved in cell proliferation (Marmor et al., 2004).
Figure 1.22 -  ErbB downstream signalling pathways. Marmor M.D. et al., International 
Journal of Radiation Oncology Biology Physics, 2004, 58(3): 903-913.
ErbB2 nuclear localisation -  For growth factor receptors, nuclear translocation is 
more complex as they are integral membrane proteins, nuclear translocation requires 
a release from the lipid layer. So far, five mechanisms have been proposed, one is the 
internalisation of active receptors through dissociation from the endosomal 
compartment and direct entry into the nucleus (Myers et al., 2003; Stachowiak et al., 
1996; Marti and Wells, 2000). Another mechanism is that the active receptor is
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internalised into an endosomal compartment and then fuse with the nuclear envelope 
or transfer the receptor from an early-endosomal compartment into the nucleus (Giri 
et al., 2005). Growth factor receptors may also be translocated to the nucleus by 
direct escape from the membrane at the cell surface and enter the nucleus using 
importin (Myers et a l, 2003). Proteolytic cleavage may also occur to release the 
cytoplasmic tail of the receptor which then associates with importin for nuclear entry 
(Ni et al., 2001). Finally, receptors can use a ligand-independent pathway in which 
stress induces the movement of the receptor from a perinuclear compartment into the 
nucleus (Dittmann et a l, 2005; Offterdinger et al., 2003). Nevertheless, Giri et al. 
(2005) established that ErbB2 was internalised through endocytosis, involving 
importinpl for nuclear entry. Furthermore, Hsu and Hung (2007) identified a nuclear 
localisation signal sequence, common to all ErbB family members, and responsible 
for nuclear translocation. Although ErbB2 nuclear function has not yet been 
extensively studied, nuclear ErbB2 was also shown to associate with a specific DNA 
sequence, HER-2 associated sequence (HAS) in the cyclooxygenase enzyme COX-2 
promoter (Wang et al., 2004), a protein associated with tumour progression (Turini 
and Dubois, 2002). Therefore, further investigation is required in the exact role and 
function of nuclear ErbB2.
ErbB2 and cancer -  In normal cells this activation is carefully controlled by several 
mechanisms, such as dissociation of ligand-receptor complexes, dephosphorylation of 
the activated receptor, rapid internalisation and degradation of active receptors. 
However, overexpression of ErbB2 occurs in 20-30% of breast cancers and has been 
associated with enhancement of signalling pathways and angiogenesis (Di Fiore et 
al, 1987; Hudziak et al., 1987). It was suggested that overexpression of ErbB2 led to 
the formation of homodimers and auto-phosphorylation activity. Furthermore, 
overexpression of ErbB2 increases the formation of heterodimers, thus potentiating 
and prolonging the activation of downstream signalling pathways (Weiner et al., 
1989; Lonardo et al., 1990). Nevertheless, different mechanisms of action of ErbB2 
in the potentiation of cancer have been described. Several studies have reported that 
ErbB2 overexpression deccelerates the dissociation rates of ligands such as EGF 
(Wada et al., 1990) and neuregulins (Peles et al., 1993). Furthermore, Sorkin et al. 
(1993) demonstrated that ErbB2 could reduce the rate of internalization of EGFR, 
impairing the downregulation and degradation of the receptor, causing a longer
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activation of intracellular signalling. Finally, ErbB2 overexpression was shown to 
enhance the rate of recycling of EGFR to the cell surface, such that the heterodimers 
will have a slow degradation rate (Lenferink et al., 1998). Therefore, ErbB2 
overexpression causes the potentiation of signalling by evading inactivation processes 
and prolonging the intracellular signalling.
ErbB2 overexpression has also been shown to affect the cell cycle regulation. Indeed, 
Lee et al. (2000b) demonstrated that ErbB2 overexpression was associated with an 
up-regulation of cyclin D1 protein expression, causing progression through the Gl/S 
cell cycle checkpoint. It was also suggested that cyclin D was up regulated by ErbB2 
signalling, through Akt activation (Lane et a l, 2000; Neve et al., 2000). Thus, ErbB2 
amplification can cause progression through Gl/S cell cycle checkpoint and play a 
role in oncogenesis (Bartkova et al., 1997). Concomitantly to the enhancement of the 
cyclin D activity, ErbB2 overexpression was associated with increased degradation 
and sequestration of p27KipI (Lane et a l , 2000; Lenferink et al., 2001). This effect is 
thought to be the result of up-regulation of MAPK and PI3K signalling pathways, 
causing its phosphorylation and subsequent degradation (Sheaff et a l, 1997; Busse et 
al, 2000).
In addition to angiogenesis, ErbB2 overexpression causes resistance to 
chemotherapeutic agents and radiotherapy (Yu et al., 1996 and 1998a; Tsai et al., 
1993. It is thought that ErbB2 causes increased resistance through the anti-apoptotic 
machinery involving the Cdk inhibitor p21WAF1. Indeed, Yu et al. (1998b) 
demonstrated that ErbB2 transfected cells progressed less efficiently through the 
G2/M phase compared to untransfected cells. In addition, they reported that ErbB2 
overexpressing cells wild type for p21WAF1 conferred resistance to taxol-induced 
apoptosis and that this effect was abolished in ErbB2 overexpressing p21WAF1 null 
cells. Thus, these data suggest that resistance to chemotherapy is driven by ErbB2- 
induced activation of p21WAF1 through p53-dependent and independent mechanisms 
(Deng et al., 1995; Pietras et al., 1999).
Therefore, ErbB2 overexpression is an important factor in the development of 
tumours. Nevertheless, molecular mechanisms involved in ErbB2-induced 
chemoresistance are still unclear.
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ErbB2 mutations -  Mutations of ErbB2 have only recently been identified in non- 
small-cell-lung cancer (NSCLC) adenocarcinomas. These mutations involve somatic 
in-frame insertions within the exon 20 that correspond to the identical nine codon 
region in exon 20 of the EGFR gene where Stephens et al. (2004) reported insertions. 
The study by Wang et al. (2006) reported that cells carrying the ErbB2 in-frame 
YVMA insertion at residue 776 (ErbB2YVMA), which is the most common mutations 
reported in a study by Shigematsu et al. (2005), activate cell proliferation and anti- 
apoptotic pathways more potently than ErbB2 wild type and remain sensitive ErbB2 
targeted therapies, such as trastuzumab, but insensitive to EGFR tyrosine kinase 
inhibitors. Resistance to EGFR tyrosine kinase inhibitors was explained by the ability 
of ErbB2YVMA to increase association with and activate EGFR in the absence of 
ligands and kinase activity (Wang et al., 2006). In addition, this mutation caused 
auto-phosphorylation of ErbB2. Another mutation, the VC insertion at G776 in exon 
20 (ErbB2 ) also found in NSCLC, causing increased anti-apoptotic signalling, as 
well as having highly phosphorylated wild-type EGFR, was shown to confer 
resistance to tyrosine kinase inhibitors, such as gefitinib and erlotinib (Wang et al., 
2006). Nevertheless, cells carrying this mutation were shown to be sensitive to HKI- 
272, an irreversible dual-specific kinase inhibitor targeting EGFR and ErbB2, 
trastuzumab and lapatinib.
Therefore, mutations of ErbB2 will need to be studied further in order to develop 
targeted therapies and improve patient prognosis, as mutations have been shown to 
alter the response to ErbB targeted therapies and no clinical data are available for 
ErbB2 targeted therapies in NSCLC.
1.6.3 EGFR and ErbB2 targeted therapies
Overexpression of ErbB receptors, causing increased cell proliferation and 
angiogenesis is a strong rationale for designing ErbB targeted therapies. Indeed, 
several agents have been designed to modulate ErbB receptors signalling (Figure 
1.23). Nevertheless, they can be classified into two categories, small molecules 
inhibitors of the tyrosine kinase activity and monoclonal antibodies targeting the 
extracellular domain of the receptor (Baselga and Arteaga, 2005). Small inhibitors of 
the tyrosine kinase (TK) activity compete with ATP binding to the TK domain, thus 
inhibiting its activation and the ErbB signalling pathways. Different class of agents
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are being developed against members of the ErbB family. Those agents differ by their 
potency but also by their capacity to inhibit a single receptor or more than one ErbB 
receptor. Monoclonal antibodies, so far developed, have been classified according to 
their mode of action, since they can prevent the ligand binding and ligand-dependent 
receptor activation (EGFR), interfere with ligand-independent receptor activation 
(ErbB2) or can also prevent receptor heterodimerisation. Nevertheless, a third class of 
agents has also been investigated: ligand/antibody-toxin conjugates, causing 
inhibition of receptor activation.
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Figure 1.23 -  ErbB targeted therapies: modulation of ErbB receptors activity. Raymond 
E. et al., Drugs, 2000, 60(supll.l): 15-23.
Tyrosine kinase inhibitors
Tyrosine kinase inhibitors interfere with the ErbB receptors tyrosine kinases activity 
by inhibiting the phosphorylation of the tyrosine kinase, causing inhibition of ErbB 
signalling pathways. They are usually small molecules competing with the ATP 
binding site (number 6 in Figure 1.23). Those agents are mainly reversible inhibitors 
(Baselga and Averbuch, 2000) but irreversible inhibitors have recently been 
developed (Bridges, 1999; Fry, 1999). Nevertheless, other molecules inhibiting the 
tyrosine kinase have also been synthesised. Some act by mimicking the tyrosine 
moiety and substituting non-phosphorilable peptides at the binding region, and other
73
inhibit downstream signals by interrupting intracellular protein recognition (Raymond 
et a l, 2000). In addition, those agents differ by their potency against members of the 
ErbB family or by their capacity to inhibit a single receptor or on the contrary inhibit 
more than one receptor.
Gefitinib (Iressa™, ZD1839) -  One of the most studied tyrosine kinase inhibitors is 
gefitinib. It is a low molecular weight anilinoquinazoline (Figure 1.24), acting as a 
potent, selective and reversible ATP-competitive inhibitor of EGFR tyrosine kinase. 
In vitro and in vivo studies have demonstrated its ability to inhibit the 
autophosphorylation of the EGFR tyrosine kinase activity (Baselga and Averbuch, 
2000). In addition, gefitinib was shown to delay the cell cycle progression by 
disrupting the regulation of Cdk2. Di Gennaro et al. (2003) also described that growth 
inhibition caused by this agent was also associated with up-regulation of the Cdk 
inhibitor, p27k,pl. Anti-tumour activity of gefitinib, as a single agent, has not only 
been shown in vitro (Ciardiello et al., 2000), but also in vivo (Baselga and Arteaga, 
2005; Mellinghoff et al., 2005). Indeed, in addition to being approved in the treatment 
of non-small-cell-lung cancer, gefitinib was shown to improve survival of patients 
with advanced pancreatic cancer, head-and-neck cancer and glioblastoma. Moreover, 
combination studies with chemotherapeutic drugs have proven successful in vitro, as 
synergistic effects were demonstrated in several studies (Ciardiello et al., 2000; 
Friedmann et al., 2004), but the mechanism of action remains unclear. Nevertheless, 
two clinical trials (in advanced non-small-cell lung cancer) of gefitinib in 
combination with gemcitabine and cisplatin (Giaccone et al., 2004), and in 
combination with paclitaxel and carboplatin (Herbst et al., 2004) have proved 
unsuccessful. Results did not show the additive effects observed in vitro and 
treatments did not improve patient survival.
Nevertheless, new studies have shown that patients with NSCLC for whom first and 
second line chemotherapy failed, had an improved response rate, when treated with 
gefitinib alone, but did not have an improvement of the survival (Thatcher et a l,
2005). In addition, discovery of somatic mutations of EGFR in a subset of NCLCs 
was shown to increase the response rate to gefitinib (Lynch et al., 2004). 
Furthermore, Baselga (2006) reported that other markers of sensitivity and resistance 
have been identified, such as EGFR amplification, expression of ErbB3 and 
mutations in the Ras and ErbB2 genes. Additionally, although gefitinib is selective of
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the EGFR tyrosine kinase activity, Cappuzzo et al. (2005) demonstrated that EGFR 
positive NSCLC patients with an increased ErbB2 gene amplification had a better 
response to gefitinib single agent therapy. This may be explained by the ability of 
ErbB2 to form heterodimers with EGFR and increase its kinase activity.
Figure 1.24 -  Structure of gefitinib.
Erlotinib (Tarceva™, OSI-774) -  Similarly to gefitinib, erlotinib is a selective, low 
molecular weight inhibitor that binds competitively to the ATP binding site of the 
EGFR kinase domain. Furthermore, Schaefer et al. (2007) demonstrated that erlotinib 
inhibits ErbB2 kinase activity in the absence of EGFR, at sub-micromolar levels, 
causing inhibition of the Akt and MAPK signalling pathways. In addition, they 
showed that erlotinib was able to inhibit ErbB2/ErbB3 heterodimers signalling and 
cell proliferation activity, in the absence of EGFR.
Single agent activity has been demonstrated in vitro and in vivo in NSCLC and 
metastatic pancreatic cancer (Akita and Sliwkowski, 2003; Grunwald and Hidalgo, 
2003; Johnson et al., 2005). Erlotinib was also studied in combination with 
conventional chemotherapeutics but clinical trials failed to shown an improved 
prognosis, compared to the single agent. Nevertheless, similarly to gefitinib, patients 
with NSCLC for whom first and second line chemotherapy failed, had an improved 
response rate and survival after treatment with erlotinib single agent. Moreover, 
mutations of EGFR have been shown to lead to an increase in sensitivity to erlotinib
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(Hidalgo et al., 2001). Several studies have shown that expression of other members 
of the ErbB family could modulate the response to erlotinib. Although in vitro assays 
have shown that erlotinib was not effective against ErbB2 kinase, studies showed that 
ErbB2 phosphorylation decreased after erlotinib treatment. In addition, ErbB2 
overexpression was shown to render human tumour xenograft sensitive to erlotinib 
(Schaefer et al., 2007).
Lapatinib (GW572016) -  Lapatinib is a potent dual inhibitor of EGFR and ErbB2 
tyrosine kinase activity. This compound has been shown to be active in normal cells 
and tumour cells, causing inhibition of EGFR and ErbB2 phosphorylation, phospho- 
Erkl/2, phospho-Akt and cyclin D (Rusnak et al., 2001). In addition, its activity has 
been demonstrated in vitro and in breast xenografts (Xia et al., 2003). Furthermore, 
clinical studies have shown its activity in advanced and metastatic cancers (Burris et 
al., 2005). Phase II and III clinical trials have investigated the activity of lapatinib, in 
advanced breast cancer, as a single agent or in combination with capecitabine, a 
taxane or hormonal therapy in previously treated patients and untreated patients. 
Results indicated that lapatinib induced apoptosis and was associated with a higher 
clinical response (Burris, 2004). Xia et al. (2005) also demonstrated that combining 
lapatinib with trastuzumab, an anti-ErbB2 antibody, caused an enhancement of 
tumour apoptosis.
Other reversible tyrosine kinase inhibitors -  In addition to lapatinib, other dual 
reversible inhibitors of EGFR and ErbB2 tyrosine kinase activity are being 
developed, such as BMS-599626 and AEE788 (also targets vascular endothelial 
growth factor receptor -  VEGFR). Both of these compounds are being developed 
clinically, BMS-599626 has been shown to be a highly potent inhibitor of EGFR and 
ErbB2 kinases and inhibits cell proliferation through modulation of signalling 
pathways. Indeed, the preclinical study carried out by Wong et al. (2006) showed that 
BMS-599626 inhibits EGFR/ErbB2 heterodimerisation and provides an additional 
mechanism of inhibiting tumours in which receptor co-expression and 
heterodimerisation play a major role in inducing tumour growth.
Finally, other tyrosine kinase inhibitors have been developed, targeting tyrosine 
kinases other than the ErbB family members. Imatinib (Gleevec™, STI-571), is a 
competitive inhibitor of tyrosine kinase activity of additional tyrosine kinases,
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including c-Kit receptor and the platelet derived growth factor receptor (PDGFR). 
Imatinib has been shown to be particularly efficient against gastrointestinal stromal 
tumours (GISTs) with mutations in the c-Kit gene, expressing its activated form 
permanently (Heinrich et al., 2003). In addition, Imatinib has also been shown to be 
active against cancers associated with PDGFR alterations (Baselga and Arribas, 
2004). Dasatinib (Sprycel™, BMS-354825) is a dual inhibitor of Src-Abl that binds 
Abl with less stringent conformational requirements than imatinib (Shah et al., 2004). 
It has been shown to be active in patients with imatinib-resistant chronic 
myelogenous leukaemia (Talpaz et a l, 2005). In addition, mutations in GISTs 
causing resistance to imatinib have shown to be sensitive to sunitinib (Sutent™, SU- 
11248) a multitarget tyrosine kinase inhibitor blocking VEGFR, PDGFR and c-Kit 
activation (Demetri et al., 2006).
Irreversible tyrosine kinase inhibitors -  Compared to reversible inhibitors, 
irreversible kinase inhibitors have several advantages and potential. Indeed, 
irreversible inhibitors have been shown to have an enhanced potency. In addition, 
biological effect can be achieved at much lower doses since once the covalent bond 
has been formed, the biological effect persists (Denny, 2002; Bridges et al., 2001). 
Moreover, some irreversible inhibitors have been shown to be active against the 
function of mutated kinases that are resistant to reversible inhibitors. Kwak et al. 
(2005) demonstrated the EKB-569 and HKI-272, 4-anilinoquinoline-3-carbonitrile- 
based irreversible inhibitors, covalently bind to a conserved cysteine residue present 
in some ErbB receptors and are active in erlotinib and gefitinib resistant cell lines. 
The clinical study by Yoshimura et al. (2006) confirmed that patients with NSCLC 
with acquired resistance to gefitinib were sensitive to EKB-569. Furthermore, several 
studies have also reported a similar effect with CI-1033 and EKI-785 other 
irreversible EGFR kinase inhibitor (Carter et al., 2005; Kobayashi et al., 2005; 
Greulich et al., 2005). Therefore, designing new irreversible inhibitors may help 
overcoming acquired resistance.
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Antibodies blocking the extracellular binding region o f the 
receptor
These antibodies (numbers 1 and 2 in Figure 1.23) interfere with the activation of the 
receptor and modulate the intracellular cascade (Raymond et al., 2000). There are 
four categories of antibodies: monoclonal antibodies that are directed against EGFR 
(cetuximab) or ErbB2 (trastuzumab and pertuzumab), bispecific anti-EGFR (MDX- 
447) or anti-ErbB2 (MDX-210) monoclonal antibodies linked to an anti-CD64 
antibody.
Trastuzumab (Herceptin®) -  This monoclonal antibody is the only humanized 
mouse monoclonal antibody that binds to the extracellular domain of ErbB2 and 
inhibit the growth of ErbB2 overexpressing cells (Leonard et al., 2002). Currently, it 
is the only approved ErbB2 targeted therapy for the treatment of metastatic breast 
cancer. Trastuzumab has been shown to induce regression of ErbB2 overexpressing 
tumours. Nevertheless, mechanisms involved are not completely defined. Indeed, 
several molecular and cellular effects have been identified. The first one is the ability 
of trastuzumab to reduce cellular signalling from PI3K and MAPK cascades. 
Trastuzumab disrupts receptor dimerisation and mediates its internalisation and 
degradation, as shown in Figure 1.25 (Yarden, 2001b; Baselga et al., 2001; 
Sliwkowski et al., 1999). This process involves the recruitment of ubiquitin ligase (or 
Cbl) targeting the endosomes for lysosomal degradation by promoting receptor 
ubiquitination (Yarden, 2001b). Thus, trastuzumab down regulates ErbB2. 
Nonetheless, Lane et al. (2000) showed reduction of downstream signalling but no 
down regulation of ErbB2. Nagata et al. (2004) also suggested that trastuzumab 
disrupts the interaction between ErbB2 and Src tyrosine kinase, leading to the 
activation of PTEN, a PI3K inhibitor. It was also shown that reduction of downstream 
signalling pathways induced the Cdk inhibitor, p27kipl, thus promoting cell cycle 
arrest during the G1 phase and apoptosis (Sliwkowski et al., 1999; Lane et al., 2000; 
Neve et al., 2000; Baselga et al., 2001). Trastuzumab was also shown to promote 
apoptosis through induction of an immune response or antibody-dependent cellular 
cytotoxicity (ADCC), but further investigation is required to fully understand the 
importance of ADCC in the response to trastuzumab (Cooley et al., 1999; Clynes et 
al., 2000; Gennari et al., 2004). Furthermore, trastuzumab was shown to inhibit
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angiogenesis through reduction of microvessel density, endothelial cell migration, 
reduction of VEGF expression and transforming growth factor-a (Izumi et al., 2002; 
Klos et al., 2003). In addition, angiogenesis inhibition was also improved when 
trastuzumab was combined with paclitaxel. Moreover, trastuzumab inhibits the 
proteolytic cleavage of ErbB2 extracellular domain, or ECD, mediated by 
metalloproteases. Indeed, a 95kDa N-terminal truncated membrane-associated ErbB2 
fragment with increased kinase activity can be found on the cell surface, and an 
11 OkDa ECD is released and can be detected in the culture media (Christianson et al., 
1998; Zabrecky et al., 1991; Pupa et al., 1993). Molina et al. (2001) reported that 
trastuzumab blocks this cleavage in vitro and high serum levels of ErbB2 ECD 
correlated with poor prognosis and a decreased response to chemotherapy in patients 
with advanced breast cancer (Molina et al., 2002; Leitzel et a l, 1995; Yamauchi et 
al., 1997; Hayes et al., 2001). Finally, Pietras et al. (1994 and 1998) demonstrated 
that trastuzumab was able to inhibit DNA damage repair induced by cisplatin and 
unscheduled DNA synthesis after radiation. They reported that trastuzumab blocked 
DNA damage repair through inhibition of p21WAF1. Thus, allowing cell cycle 
progression and accumulation of unrepaired DNA damage, causing increased 
apoptosis.
Trastuzumab was first studied as a single agent and was proved to be efficient in 
metastatic breast cancer, overexpressing ErbB2 (Cobleigh et al., 1999). Nevertheless 
several studies have investigated the effect of trastuzumab in combination with 
common chemotherapeutic drugs, such as cisplatin, etoposide and paclitaxel, 
demonstrating the ability of trastuzumab to synergise with those drugs, in vitro and in 
vivo (Pegram et a l, 1999; Pegram et al., 2004a; Naruse et al., 2002). Pegram et al. 
(2004b) also demonstrated that a 3-way drug combination including trastuzumab, 
docetaxel and a platinum salt resulted in a higher response rate and a slower 
progression of the disease, in patients with advanced breast cancer overexpressing 
ErbB2. Robert et al. (2006) also reported, in a phase III randomised trial that patients 
treated with trastuzumab, paclitaxel and carboplatin had a slower disease progression 
than the patients treated with trastuzumab and paclitaxel. Similarly, Slamon et al. 
(2001) showed that combining trastuzumab with doxorubicin plus cyclophosphamide 
or single agent paclitaxel resulted in an improved survival rate compared to 
chemotherapy alone. Nevertheless, efficiency of trastuzumab treatment will depend
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on the ErbB2 status, drug scheduling and side effects, since administration of 
trastuzumab with anthracyclines resulted in severe cardiac dysfunction (Seidman et 
a l , 2002).
Nonetheless, tumours have been shown to develop trastuzumab resistance. Indeed, 
resistance to trastuzumab has been shown to be associated with mutation of the 
ErbB2 gene, found in lung cancers (Stephens et al., 2004 -  ErbB2 mutations detailed 
previously). However, no data are available on the mutation status and the response to 
trastuzumab in breast cancer. Resistance may also be achieved through an increased 
cell signalling. Since trastuzumab only affects ErbB2-mediated signalling, other 
dimers are not affected and can function in presence of trastuzumab. Nevertheless, 
Nagata et al. (2004) reported that PTEN plays a major role in the development of 
trastuzumab resistance as its loss of function result in Akt activation. Down 
regulation of PTEN was shown to block trastuzumab-mediated inhibition of 
proliferation and induce a poor response to trastuzumab therapy. Finally, resistance to 
trastuzumab therapy was also shown to be induced by the modulation of p27kipl as 
growth inhibitory properties of trastuzumab depend on this Cdk inhibitor (Le et al., 
2003). In addition, increased insulin growth factor-I receptor signalling can also cause 
the inhibition of trastuzumab-mediated growth arrest (Lu et al., 2001).
Therefore, future investigations will involve the study of novel drug combinations to 
overcome acquired resistance.
Figure 1.25 -  Internalisation of the ErbB2 receptor by trastuzumab. Yarden Y., 
European Journal of Cancer, 2001b, 37: S3-S8.
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Cetuximab (Erbitux®, IMC-C225) -  It is a chimeric mouse anti-EGFR antibody, 
approved for the treatment of irinotecan-refractory colorectal cancer. Cetuximab 
blocks EGFR tyrosine kinase activation by interfering with ligand receptor binding. 
In addition, six mechanisms have been identified, by which cetuximab inhibits 
tumour progression: inhibition of cell cycle progression, induction of apoptosis, 
inhibition of angiogenesis, inhibition of metastasis, synergise with chemotherapeutic 
agents and induction of immune response similarly to trastuzumab (Mendelsohn,
2000). Single agent treatment has been shown to be efficient in variety of solid 
tumours including colon, head and neck, NSCLC and renal cell carcinoma. Similarly 
to other ErbB targeted therapies, cetuximab was also used in combination with 
chemotherapeutic agents and was shown to be able to reverse resistance to irinotecan 
in colorectal cancer (Prewett et al., 2002). Furthermore, a randomised study 
(Cunningham et a l, 2004) confirmed the significant activity of cetuximab in 
combination of irinotecan in irinotecan-refractory disease.
Pertuzumab (Omnitarg™, 2C4) -  This is the first monoclonal antibody that 
prevents receptor heterodimerisation. Pertuzumab binds to ErbB2 and sterically 
hinders ligand-associated heterodimerisation of ErbB2 with other ErbB receptors. 
Thus, inhibiting intracellular signalling, including PI3K and MAPK cascades 
(Franklin et al., 2004). Pertuzumab has been shown to be active in vitro and in vivo, 
in breast and prostate cancer, independently of ErbB2 expression, through inhibition 
of the ErbB2-ErbB3 heterodimer formation (Agus et al., 2002 and 2005; Baselga,
2002). Furthermore, pertuzumab was shown to synergise with trastuzumab, blocking 
signalling through Akt but did not affect the MAPK cascade (Baselga, 2002).
Other antibody therapies -  Panitumumab (Vectibis™, ABX-EGF) is another 
monoclonal antibody targeting EGFR. This antibody has been shown to be active in 
prostate cancer and colorectal cancer (Harari et al., 2007). Furthermore, it was shown 
to be active in chemotherapy-refractory metastatic colorectal cancer (Van Cutsem et 
al., 2006). Similarly, EMD72000, a humanised anti-EGFR antibody, has been shown 
to have anti-tumour activity against colon cancer (Vanhoefer et al., 2004). h-R3 is 
another humanised monoclonal antibody targeting EGFR (Mateo et al., 1997). 
Preclinical studies have shown that h-R3 has anti-proliferative, pro-apoptotic and 
anti-angiogenic effects (Crombet-Ramos et al., 2002). This antibody was also shown
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to be active in combination with radiotherapy in head and neck cancer (Crombet et 
al., 2004).
Bispecific anti-EGFR (MDX-447) or anti-ErbB2 (MDX-210) monoclonal antibodies 
linked to an anti-CD64 antibody have also been developed. These antibodies have 
potential anti-neoplastic activity since they enhance cellular immune response against 
EGFR or ErbB2 positive cells, resulting in increased tumour cell death. MDX-210 
has been shown to be active in patients with advanced breast or ovarian cancer 
overexpressing ErbB2 (Valone et al., 1995). MDX-447 was also shown to be active 
clinically in advanced solid tumours (Fury et a l, 2007). Many other monoclonal and 
bi-specific antibodies have been developed and shown to be active in vitro and in 
vivo, those have been reviewed by Booy et al. (2006). Although antibody therapy 
may have disadvantages due the specificity of antibodies, this review also 
demonstrates that antibody therapy is becoming an important therapeutic tool.
Ligand/antibody-toxin conjugates acting on the extracellular 
ligand binding region
Normal ligands such as TGFa and EGF can fuse with truncated forms of 
immunogenic cellular toxins (e.g. ETA) or genistein fusion protein in order to block 
the activation of EGFR (Raymond et a l, 2000 -  Figure 1.23, numbers 3 and 5). In 
addition, scFv (side chain variable region-containing fragment) antibody-toxin 
conjugates have also been developed to target EGFR. Binding of such 
ligand/antibody-toxin conjugates (Figure 1.22, number 4), to EGFR, leads to the 
inhibition of downstream signalling pathways. Nevertheless, no agent has yet been 
shown to be active in vivo.
Combination therapies
ErbB targeted therapies have not only been used as single agents but also in 
combination with conventional chemotherapeutic agents, hormone therapy or other 
molecules-targeted therapies.
Combination with chemotherapeutic agents -  Indeed, as described previously 
ErbB targeted therapies have been used in combination with common
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chemotherapeutics, such as gefitinib with cisplatin (Friedmann et al., 2004) or 
trastuzumab with cisplatin or etoposide (Pegram et al., 1999; Pegram et al., 2004a; 
Naruse et al., 2002). Combination of trastuzumab with chemotherapeutic agents has 
also been used in a clinical study by Slamon et al. (2001). In addition, synergistic 
effects of trastuzumab with platinum salts and vinka alkaloids, described in the pre- 
clinical study by Pegram et al. (2004a), was also demonstrated clinically (Burstein et 
al., 2003; Pegram et al., 2004b). Similarly, efficacy of chemotherapeutic agents, such 
as cisplatin and paclitaxel, was shown to be enhanced when combined with gefitinib, 
in pre-clinical studies (Sirotnak et al., 2000; Friedmann et al., 2004). Nevertheless, 
phase III clinical trials, using gefitinib or erlotinib combined with gemcitabine and 
cisplatin or carboplatin and paclitaxel have proved unsuccessful (Giaccone et al., 
2004; Herbst et al., 2004; Gatzemeier et al., 2007). The failure of these trials can be 
explained by an antagonistic effect of the combination, as antagonism was 
demonstrated between cytostatic and cytotoxic agents such as tamoxifen and 
chemotherapeutic agents (Baselga, 2004; Albain et al., 2002). In addition, failure of 
these trials could be explained by the mutations of the ErbB receptors causing the 
tumour to be insensitive to anti-EGFR therapy (as discussed later in the resistance to 
targeted therapies). Nonetheless, in order to obtain positive clinical results, it is 
important to consider if ErbB inhibitors can reverse the acquired and primary 
resistance to common chemotherapy. Indeed, Saltz et al. (2007) and Cunningham et 
al. (2004) demonstrated that combination of cetuximab with irinotecan was active in 
patients resistant to irinotecan treatment.
Therefore, the lack of concordance between pre-clinical and clinical outcome points 
the way to further studies to investigate combinations of anti-ErbB therapies and 
chemotherapeutic agents.
Combination with hormone therapy -  Anti-ErbB therapies have also been 
combined with anti-estrogens in breast cancer and prostate cancer. Although EGFR 
tyrosine kinase inhibitors have shown limited activity in breast cancer patient, 
Baselga and Arteaga (2005) reported that, in vitro, combining gefitinib with 
tamoxifen caused an increased growth inhibition and anti-hormone resistance was 
overcome. Although the molecular basis of the cross-talk between ErbB receptors and 
estrogen receptors (ER) is unclear, it is suggested that EGFR and ErbB2 signalling 
phosphorylates and activates (ER) and its co-activator amplified in breast cancer-1
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(AIB-1), thus causing tamoxifen to act as an ER agonist (Osborne et a l, 2003). 
Nevertheless, further clinical investigations are required to determine the potential 
benefit of such combinations
Combination with other targeted therapies -  Such combination has recently 
become the focus of a number of studies. This is due to the fact that tumours are not 
dependent on just one receptor signalling pathway and that there is compensatory 
cross-talk among receptors signalling network (Gschwind et a l, 2004). Thus, three 
types of combinations have been identified.
The first one is the combination of ErbB targeted therapies with anti-receptor 
therapies. Indeed, ErbB2 was shown to potentiate EGFR signalling and its 
overexpression to counteract the activity of EGFR tyrosine kinase inhibitors 
(Karunagaran et al., 1996; Christensen et al., 2001). In addition, EGFR 
overexpression causing inhibition of trastuzumab activity was reversed in presence of 
TKIs (Motoyama et al., 2002). Furthermore, Nahta et al. (2004) demonstrated, in 
vitro, that trastuzumab was able to synergise with pertuzumab in breast cancer cells. 
Therefore, these data are the rationale for the combination of anti-EGFR and anti- 
ErbB2. Nevertheless, clinical trial results combining gefitinib with trastuzumab have 
proved unsuccessful (Moulder and Arteaga, 2003). Thus, suggesting the need of 
alternative approaches. Nonetheless, another type of combination can be considered, 
anti-insulin like growth factor I (IGF-I) with anti-ErbB therapies. Indeed, Chakravarti 
et al. (2002) and Lu et al. (2001) demonstrated that inhibition of EGFR TKIs and 
trastuzumab by IGF-I overexpression could be reversed by IGF-I receptor inhibitors 
(Garcia-Echeverria et al., 2004; Camirand et a l, 2005).
ErbB targeted therapies can also be combined with molecules targeting downstream 
signalling molecules. Indeed, abnormal activation of downstream molecules, due to 
mutations, can cause the tumours to be insensitive to ErbB targeted therapies (Bianco 
et al., 2003). Mutations in PTEN, an inhibitor of Akt, have been shown to cause 
resistance to trastuzumab (Nahta et a l, 2006). Furthermore, in vitro combination of 
EGFR TKI, gefitinib, with mTOR inhibitor has produced promising results. 
Therefore, this points the way to further investigations and new combinations.
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Finally, ErbB targeted therapies have been combined with agents interfering with 
essential components required for tumour growth. Hanahan and Weinberg (2000) 
identified six essential alterations for tumour growth: self-sufficiency in growth 
signals, insensitivity to growth inhibitory signals, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis and metastasis. Although anti-ErbB 
therapies interfere with the self-sufficiency in growth signals, they also have been 
shown to induce apoptosis, reduce VEGF, and inhibit angiogenesis and metastasis 
(Mendelsohn et al., 2003; Petit et al., 1997; Ciardiello et al., 2001). Nevertheless, 
studies have shown that enhanced angiogenesis caused resistance to EGFR inhibition 
(Viloria-Petit et al., 2001). Thus, Herbst et al. (2005) demonstrated that combining 
erlotinib with angiogenesis inhibitor, bevacizumab, increased the response rate. 
Nevertheless, tyrosine kinase inhibitors blocking EGFR and ErbB2 tyrosine kinase 
activity and the VEGF receptor tyrosine kinase have become available (Wedge et al., 
2002).
Therefore, future research is required to developed new drugs and drug targets, 
pointing the way to the development of new targeted therapies.
Resistance to targeted therapies
Over the past few years, several ErbB targeted therapies have been developed. 
Nevertheless, patients have been shown to become refractory to those therapies. 
Indeed, several mechanisms, responsible for the development of resistance, have been 
identified and lead to the improvement of targeted ErbB therapies.
Redundant tyrosine kinase receptors -  Firstly, the presence of redundant tyrosine 
kinase receptors can also influence the activation of signalling pathways. Herynk et 
al. (2003) demonstrated that c-Met activation led to an increased cell proliferation 
and angiogenesis, thus countering the effect of ErbB inhibitors. In addition, Kulik et 
al. (1997) and Lu et al. (2001) also demonstrated that activation of the tyrosine kinase 
receptor IGF-1R was associated with resistance to tyrosine kinase inhibitors and 
trastuzumab. Therefore, activation of alternative tyrosine kinase receptor will 
override the effect of ErbB inhibitors.
Angiogenesis -  Secondly, up-regulation of tumour angiogenesis promoting growth 
factors is another mechanism by which tumour cells overcome ErbB inhibition.
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Indeed, Viloria-Petit et al. (2001) demonstrated that tumours resistant to ErbB 
therapy increased angiogenesis and they showed that this was associated with an 
increased VEGF expression. This finding was further confirmed by Ciardiello et al.
(2003), showing that targeting EGFR could lead to increase angiogenesis and 
resistance to EGFR inhibitors but targeting EGFR together with VEGFR-2 did not 
result in resistant tumours. Therefore, targeting more than one survival pathway can 
cause greater tumour inhibition and the reduction of angiogenesis (Jung et al., 2002).
Constitutive activation of downstream signalling pathways -  This is the result of 
the alteration of signalling mediators, such as PTEN. Indeed, PTEN loss causes 
constitutive activation of PI3K, resulting in Akt activation and its anti-apoptotic 
functions. PTEN loss has been reported to cause resistance to gefitinib (Bianco et al.,
2003) and trastuzumab, as described previously. Nevertheless, other signalling 
mediators have been shown to cause resistance to targeted therapy, such as Src family 
kinases (Wiener et al., 2003; Dehm and Bonham, 2002) and STAT family members 
(Ni et al., 2000; Garcia et al., 2001)
Ligand-independent activation -  As demonstrated by Liu et al. (2002) and Moro et 
al. (2002), EGFR and several signalling mediators could be activated through 
interactions with integrins and their ligands in the cellular matrix, leading to the 
bypass of anti-EGFR antibody inhibitory effects and the activation of the tyrosine 
kinase activity.
Mutations -  As previously described, specific mutations of EGFR or ErbB2 
receptors have been shown confer resistance to targeted therapies. Mutations that 
cause resistance are usually mutations affecting amino acids within the kinase 
catalytic domain, preventing or weakening the interaction between this domain and 
the drug (Baselga, 2006). Furthermore, several studies reported untreated patients as 
well as patients responding to erlotinib or gefitinib can acquire secondary mutations, 
T790M mutation, localised within the ATP-binding site and rendering them resistant 
to those agents (Pao and Miller, 2005; Kobayashi et al., 2005; Greulich et al., 2005). 
Nevertheless, irreversible tyrosine kinase inhibitors have been shown to overcome 
this problem (Carter et al., 2005).
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Moreover, other mutations may play a role in the sensitivity or resistance to ErbB 
targeted therapies. Indeed, Pao et al (2005) reported that K-ras mutations led to 
signalling in the absence of EGFR input, leading to a lower response rate to EGFR 
tyrosine kinase inhibitors. Thus, suggesting that K-ras can be used as a marker of 
resistance to EGFR inhibitors, such as gefitinib and erlotinib. In addition, several 
studies have identified mutations in PI3K gene in glioblastoma, colorectal, ovarian 
and breast cancers, demonstrating that these tumours were PI3K-signalling dependent 
and that these mutations were responsible for angiogenesis. Thus, these tumours are 
highly sensitive to PI3K-Akt-mTOR pathway (Campbell et al., 2004; Bachman et a l ,
2004).
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1.7 Aims and objectives
ErbB2 and BRCA1 have been identified as playing a major role in the development 
of breast cancer. The aim of this investigation is to study the potential role of these 
proteins in the repair of drug-induced DNA damage. To this end, the following 
questions will be addressed:
• Does trastuzumab affect the chemosensitivity and the repair of drug-induced 
DNA damage of ErbB2 overexpressing breast cancer cells (Chapter 3)?
• Does ErbB2 inhibition by trastuzumab alter cell cycle regulation (Chapter 4)?
• How does ErbB2 expression affect the repair of cisplatin-induced DNA 
damage (Chapter 5)?
• Does nuclear ErbB2 play a role in the repair of cisplatin-induced DNA 
damage (Chapter 6)?
• How does BRCA1 expression affect chemotherapeutic response in breast 
cancer cells (Chapter 7)?
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Chapter 2 
Materials and Methods
MATERIALS
2.1 Cell lines and culture conditions
For the BRCA1 study, MCF-7 wild type, MCF-7 scrambled and MCF-7 3.23 
(BRCA1 expression down-regulated by plasmids encoding specific human BRCA1 
siRNA, based on the pSUPER plasmid) cell lines (plasmids detailed in Table 2.1) 
were kindly provided by Prof. A. Ashworth from the Institute of Cancer Research 
(Breakthrough Breast Cancer Research). MCF-7 wild type cells were grown in RPMI 
1640 (Autogen Bioclear, UK) supplemented with 10% heat inactivated (at 56°C for 
30 minutes) foetal calf serum, 1% of 200mM L-glutamine (Autogen Bioclear, UK), 
1% of 10,000 units Penicillin -  lOmg/ml Streptomycin (Sigma-Aldrich, UK) and 
500pl insulin at lOmg/ml (Sigma-Aldrich, UK) incubated at 37°C in 5% CO2. The 
MCF-7 scrambled and MCF-7 3.23 cell lines were grown in complete RPMI 1640 
media, supplemented with 250pl of lOmg/ml of selection marker blasticidin 
(Invivogen, UK).
For the ErbB2 study, MCF-7 cells (obtained from CR-UK London Research Institute) 
were grown as described above. SK-BR-3 cells (obtained from CR-UK London 
Research Institute) were cultured in McCoy’s 5A Modified Medium (Sigma-Aldrich, 
UK) supplemented with 10% foetal calf serum, 1% of 200mM L-glutamine (Autogen 
Bioclear, UK) and 1% of 10,000 units Penicillin -  lOmg/ml Streptomycin (Sigma- 
Aldrich, UK) incubated at 37°C in 5% CO2. MDA-MB-453 cells (obtained from CR- 
UK London Research Institute) were grown in Dulbecco’s Minimal Essential 
Medium (DMEM) (Autogen Bioclear, UK) supplemented with 10% foetal calf serum, 
1% of 200mM L-glutamine (Autogen Bioclear, UK) and 1% of 10,000 units 
Penicillin -  lOmg/ml Streptomycin (Sigma-Aldrich, UK) incubated at 37°C in 5% 
CO2. Human breast cancer cell line, MDA-MB-468, was grown in Dulbecco’s 
Minimal Essential Medium (DMEM) (Autogen Bioclear, UK) supplemented with 
10% foetal calf serum, 1% of 200mM L-glutamine (Autogen Bioclear, UK) and 1% 
of 10,000 units Penicillin -  lOmg/ml Streptomycin (Sigma-Aldrich, UK) incubated at 
37°C in 5% CO2. Transfected MDA-MB-468 cells (list of plasmids detailed in Table 
2.1) were grown in the same complete media containing G418 (Sigma-Aldrich, UK) 
selective agent at a concentration of 750pg/ml. All the cell lines used are summarised 
in Table 2.2.
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Transfected 
cell line Plasmid Vector Insert
Plasmid
Supplier
MCF-7
scrambled
pSUPER vector 
control pSUPER None
Dr. C. Lord 
Institute of 
Cancer 
Research 
(provided us 
with the 
transfected cell 
line)
MCF-7 3.23 pSUPERBRCAlsiRNA pSUPER
BRCA1
siRNA
sequence
Dr. Lord 
Institute of 
Cancer 
Research 
(provided us 
with the 
transfected cell 
line)
MDA-MB-468
pcDNA3
pcDNA3 vector 
control pcDNA3 None
Dr. Segatto 
(Regina Elena 
Cancer 
Institute, Italy)
MDA-MB-468
pcDNA3-ErbB2
pcDNA3 
ErbB2 wild 
type
pcDNA3 ErbB 2
Dr. Segatto 
(Regina Elena 
Cancer 
Institute, Italy)
MDA-MB-468 
pEGFP-N 1
pEGFP-N 1 
vector control pEGFP-N 1 None
Prof. Hung 
(MD Anderson 
cancer center, 
USA)
MDA-MB-468 
pEGFP-N 1 
ErbB2
pEGFP-N 1 
ErbB2 wild 
type
pEGFP-N 1 ErbB2
Prof. Hung 
(MD Anderson 
cancer center, 
USA)
MDA-MB-468 
pEGFP-N 1 
ErbB2ANLS
pEGFP-N 1 
ErbB2ANLS 
(ErbB2 with 
deletion of the 
Nuclear 
Localisation 
Signal)
pEGFP-N 1 ErbB2ANLS
Prof. Hung 
(MD Anderson 
cancer center, 
USA)
Table 2.1 -  Transfected cell lines and corresponding plasmids.
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Cell line Origin Culture condition Supplier
MCF-7
Human Caucasian 
breast 
adenocarcinoma
RPMI 1640
Cancer Research 
UK, London 
Research Institute
SK-BR-3
Human Caucasian 
breast 
adenocarcinoma
McCoy’s 5A 
modified
Cancer Research 
UK, London 
Research Institute
MDA-MB-453
Human Caucasian 
breast metastatic 
carcinoma
Dulbecco’s 
Minimal Essential 
Medium (DMEM)
Cancer Research 
UK, London 
Research Institute
MDA-MB-468
Human Black 
breast metastatic 
carcinoma
Dulbecco’s 
Minimal Essential 
Medium (DMEM)
Cancer Research 
UK, London 
Research Institute
Table 2.2 -  Summary of the cell lines used.
2.2 Tissue culture
2.2.1 Cell lines maintenance
All cell lines were grown in 75cm flasks (T75), in humidity-saturated (95%) 
incubators (Forma Scientific, UK), at 37°C with 5% CO2. All procedures were carried 
out in Class II MDH biological safety cabinet (Intermed MDH, UK) using aseptic 
techniques (cabinet was cleaned with 70% industrial methylated spirit -  IMS -  as 
well as the equipment used inside the cabinet). Cells were routinely passage twice a 
week, at 80-90% confluence. As all cell lines were adherent, media was removed and 
cells were washed with 3ml of sterile 0.01M phosphate-buffered saline solution (PBS, 
Sigma-Aldrich, UK) to remove the residual serum. Cells were subsequently detached 
using 5ml of lxTrypsin/EDTA (Autogen Bioclear, UK) at 37°C. 5ml of complete 
medium was then added to inactivate the trypsin and cells were pelleted by 
centrifugation at 1500rpm for 5 minutes at room temperature. The supernatant was 
discarded and cells were resuspended in 10ml of complete medium. Cells were finally 
seeded into new flasks at a ratio of 1/2 to 1/5 according to the cell line. All cell lines 
were passaged to a maximum of 30 times, after which point fresh cells were retrieved 
from the liquid nitrogen stock.
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2.2.2 Storage and retrieval from liquid nitrogen
In order to store cell lines, frozen cell stocks were prepared. Cells were grown in 
175cm2 flasks (T175) to 80% confluence. Cells were trypsinised and resuspended to a 
concentration of lx l06cells/ml in freezing medium (FCS containing 10% 
dimethylsulphoxide -  DMSO -  Sigma-Aldrich, UK). The cell suspension was 
aliquoted in 1ml cryotubes and frozen at -80°C for one day. Tubes were then 
transferred to a liquid nitrogen tank. Cells were recovered from liquid nitrogen by 
thawing the cryotubes rapidly in a 37°C water bath. The cell solution was added to a 
25cm flask (T25) containing 9ml of complete growth medium. Flasks were 
incubated at 37°C with 5% CO2. The medium was changed after 24 hours (once cells 
have re-attached to the bottom of the flask) to avoid toxicity due to the DMSO from 
the freezing mixture.
2.2.3 Cell count
Cells were counted, once resuspended in 10ml of complete growth medium (see cell 
line maintenance), using a haemocytometer. A haemocytometer has two chambers 
and each chamber has a microscopic grid etched on the glass surface (central 
counting area formed of 25 squares). The chambers are overlaid with a glass coverslip 
that rests on pillars exactly 0.1mm above the chamber floor. 60pl of cell suspension 
was mixed with 60pl of trypan blue (Sigma-Aldrich, UK) in order to exclude dead 
cells (1 in 2 dilution). Some of this solution was loaded into both chambers. The 
number of cells was determined for each central counting of the two chambers (each
•y ->
counting area has a surface of 1mm and a volume of 0.1mm or 0.1 pi), since a 1 in 2 
dilution was made. The total number of cells obtained was multiplied by lx l0 4, 
giving the number of cells per ml of suspension.
2.2.4 Cell doubling time
Cells were seeded in 6 well plates at a concentration of 5xl04cells/ml with complete 
growth medium, each single well was used for one time point. Cells were counted (as 
in 2.2.3) and the concentration was determined. Cell concentration was determined 
every 24 hours until confluence. The doubling time was determined by plotting the 
cell concentration against the number of hours.
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2.3 Chemotherapeutic drugs and other reagents
Clinical grade Gefitinib (Iressa, ZD 1839) was kindly provided by AstraZeneca 
(Macclesfield, UK). Etoposide, Melphalan, Doxorubicin, Paclitaxel were purchased 
from Sigma-Aldrich (Dorset, UK). Wheat germ agglutinin (Lectin from Triticum 
vulgaris) was purchased from Merck Biosciences (Nottingham, UK). Cisplatin (DBL, 
Warwick, UK) and trastuzumab (Herceptin® -  Roche, Welwyn Garden City, UK) 
were obtained from The Middlesex Hospital (UCL Hospital, London, UK). Details of 
the compounds used for this study are described in Table 2.3. Stock solutions were 
either prepared in advance or fresh prior to experiments according to stability of each 
compound. Stock solution concentrations were adjusted according to the cytotoxicity 
of each drug. Trastuzumab and cisplatin were obtained pre-diluted at the indicated 
concentrations from the hospital.
Compounds Type of drug Structure Dilutionsolvent
Stock
solution
Gefitinib
Quinazoline 
derivative 
inhibiting 
EGFR (ErbBl) 
tyrosine kinase 
activity (small 
molecule)
1 \ 
/ 
o 
o
p
o
DMSO lOmM
Etoposide
Topoisomerase 
inhibitor 
(inhibitor of 
chromatin 
function)
on
°----
'Y 9M2 ; h 
o. — o o
h NN on /
OH
DMSO lOmM
Melphalan
Bifunctional 
alkylating 
agent - 
nitrogen 
mustard based 
(covalent 
DNA-binding 
drug)
CIH5CH5C /--y Nn?\ / \  1N—(\ ^-CHj—CH—COOH
CIHjCHjC '--y
Ethanol 
with 1% 
HC1
lOmM
Doxorubicin
DNA 
intercalating 
agent(non 
covalent DNA 
binding drug)
0 OH 0
^0 0 OH 0. ^ 
NH2
Sterile
Water ImM
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Compounds Type of drug Structure Dilutionsolvent
Stock
solution
Paclitaxel
Microtubule 
inhibitor 
(inhibitor of 
chromatin 
function) V
DMSO ImM
Cisplatin
Alkylating 
agent -  
platinum 
compound 
(covalent 
DNA binding 
drug)
H3N ^ n h 3
/ Rx
Cl Cl
Sterile
water 3.3mM
Trastuzumab
Monoclonal 
antibody 
inhibiting 
ErbB2 tyrosine 
kinase activity w w w . 3 d c h e m . c o m
Sterile
Water 21 mg/ml
Wheat germ 
agglutinin 
(WGA)
Lectin from 
Triticum 
vulgaris 
inhibiting 
nuclear import
w w w . b m b . u e a . e d u
Sterile
PBS 5mg/ml
Table 2.3 -  Compounds used in the BRCA1 and ErbB2 studies.
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METHODS
2.4 In vitro cytotoxicity assay
Cytotoxicity of drugs was assessed using the colorimetric assay Sulphorhodamine B 
(SRB) in 96-well microtiter plates. The SRB allows sensitive measure of drug- 
induced cytotoxicity comparable to the MTT or clonogenic assays. It is based on the 
ability of the protein dye sulforhodamine B to bind on protein basic amino acid 
residues of trichloroacetic acid-fixed cells. Under mild acidic conditions it binds to 
the cells and is easily extracted and solubilised for measurement (Voigt W., 2005). 
The SRB assay gives results which are linear with the number of cells and more 
sensitive than the Lowry and Bradford assays and twenty other visible dyes (Skehan 
et al., 1990).
This assay was used to determine the effect of drugs and drug combinations on cell 
proliferation. Cells were seeded (200pl per well), according to their doubling time 
(MCF-7 wild type, MCF-7 3.23 and MCF-7 scrambled at lx l04cells/ml, SK-BR-3 at 
2xl04cells/ml, MDA-MB-453 at 5xl04cells/ml and MDA-MB-468 wild type and 
transfected MDA-MB-468 cell lines at 2xl04cells/ml) into 96-well microtitre plates 
(Nunclon, VWR, UK) and incubated for 24 hours at 37°C with 5% CO2, prior to drug 
treatment.
2.4.1 Single agent cytotoxicity
For single agent assays, drugs were added at a range of concentrations (all drugs were 
used at clinically achievable peak plasma concentrations and adjusted to each cell 
line) to wells in triplicate and left in solution continuously for 5 days or one hour 
followed by 5 days in drug free media. Alternatively, cells were treated for 3 days 
continuously or one hour followed by 3 days in drug free media. Drugs were diluted 
in complete growth medium and 200pl of the appropriate concentration was added to 
the appropriate well. Each experiment included a solvent control lane and a drug-free 
media control lane (100% cell proliferation), treated in the same way with change of 
media at the appropriate time. Plates were incubated in a humid box at 37°C in 5% 
C02.
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2.4.2 Dual agent treatments and synergistic effect
For dual agent treatments (combination assays), drugs were either added 
concomitantly (drug A and B together) for 5 days or added concomitantly for 24 
hours (drug A+B) followed by 4 days of drug-free media (no drug) or media 
containing the drug B. Combination experiments included one control lane (drug-free 
media) and one solvent control lane. Plates were incubated in a humid box at 37°C in 
5% CO2. To determine synergy, drug B was used at a sub-toxic concentration 
(concentration producing 10-20% inhibition of proliferation) and combined with a 
range of concentration of drug A.
2.4.3 SRB assay and data analysis
At the end of the incubation period, cells were fixed by adding IOOjj.1 per well of ice- 
cold 10% w/v trichloroacetic acid for 20 minutes at 4°C, wells were then washed with 
distilled water and stained with 0.4% SRB in 1% v/v acetic acid for 20 minutes at 
room temperature (staining of living cells). Wells were finally washed using 1% 
acetic acid and left to dry at room temperature overnight. Purple crystals formed were 
dissolved in lOOpl of lOmM Tris Base (Sigma-Aldrich, UK) / ImM EDTA (Sigma- 
Aldrich, UK) for 20 minutes at room temperature. The absorbance (OD) of each well 
was read at 540nm using a Spectrafluor Plus plate reader (Tecan, UK). The mean 
absorbance of each drug concentration was expressed as a percentage of the untreated 
control wells absorbance:
% proliferation = OD treated x 100
OD control
Data obtained were the average of three independent experiments, showing standard 
deviations. Dose-response curves obtained were used to determine the IC5 0 . The IC50 
being the drug concentration required to produce 50% growth inhibition.
The Student t-icst (Appendix 1) was used to statistically compare the IC50 obtained 
for two independent treatments. Data were said to be significantly different, at a 95% 
(p=0.05) or 99% (p=0.01) probability {p being the level of significance), if the 
calculated t value (Appendix 1) was superior to the tabulated t value. Each 
independent experiment was repeated in triplicate, so the degree of freedom 
(Appendix 1) used to read the tabulated t value was 4. When studying synergistic
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effect o f drugs producing IC50 individually, data were analysed using the isobologram 
analysis (detailed in section 2.6).
2.5 Radiation survival curve
Assessing the survival of cell after irradiation was achieved in a similar manner to the 
cell proliferation assay described in section 2.4. MCF-7 wild type, MCF-7 3.23 and 
MCF-7 scrambled were diluted at lx l04cells/ml in 15ml falcon tubes (VWR, UK). 
Cells were exposed on ice to a range of radiation doses using the GEC Newton Victor 
X-ray machine at 25kV. As the machine delivers 2.5Gy per minute, time of exposure 
was varied to obtain the desired doses. Control cells were not exposed to any 
radiation. Cells were then plated in 96-well microtitre plates (200pl per well) and 
incubated for 6 days in a humid box at 37°C with 5% CO2. After the incubation 
period, cells were treated as previously described in the SRB assay (fixing, staining 
and reading). Each experiment was repeated in triplicate, results were expressed as in 
section 2.3.
2.6 Isobologram analysis
Isobologram analysis (Tallarida, 2001) has been described in order to identify when 
two drugs that produce antagonistic, additive or synergistic effects. An isobologram 
was used to assess the effect of combination of any given chemotherapeutic agent 
with gefitinib. An example of an isobologram is shown in Figure 2.1. In order to 
analyse the results, a particular effect level is selected, in our case 50% of the 
maximum killing for gefitinib (IC50) and doses of each drug alone that give this 
effect. These values are plotted as axial points in a Cartesian plot (i.e. IC50 for each 
drug - single agent treatment - is plotted on each axis). The straight line connecting 
the two IC50 values (A and B representing the IC50 of the two drugs) is the locus of 
points (isoboles) that produce the additive combination of compounds. Thus, all the 
combinations of IC50 of two drugs, on or close to the line (as defined by the red 
circle), have an additive effect (illustrated by the letter P). Combinations of IC50 
above this line, such as R, have a sub-additive or an antagonistic effect. IC50 values 
such as point Q show a super-additive or a synergistic effect. However, the
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isobologram does not allow a statistical distinction, due to the error inherent in the 
dose-effect data. Hence, points on or close to the line do not provide a conclusive 
distinction. For those points further statistical analysis such as regression analysis 
would be required (these analysis will not be required in our case).
CD
40
20
R *  _
•
Q
*
. . . . « . _ _ 1 - - - - 1
Dose A
Figure 2.1 -  Isobologram analysis. A and B are the IC50 of the two drugs studied in 
combination, R = sub-additive or antagonistic effect. P = additive effect, Q = super-additive 
or synergistic effect. The red circle defines the region giving additive effect. Tallarida R.J., 
Journal of Pharmacology and Experimental Therapeutics, 2001, 298(3):865-72.
2.7 Western blotting analysis
2.7.1 Total protein extraction
Two methods of protein extraction were used according to the protein extracted. The 
freeze-thawr method was used for the BRCA1 study. After treatment, cells were 
pelleted in an eppendorf tube using trypsin, and kept on dry ice. Lysis buffer (450mM 
NaCl, 25% glycerol, 5mM EDTA, 0.5mM DTT, 20mM Hepes pH 7.9 and protease 
inhibitor x l) containing fresh protease inhibitor (Roche, UK) was added to the cell 
pellet. The pellet with added lysis buffer was freeze-thawed five times (freeze for 1-2 
minutes and thaw for 30 seconds at 30°C) and subsequently centrifuged for 10 
minutes at 4°C (13,000rpm) in order to remove insoluble material. The total cell 
lysate (supernatant) was carefully transferred to a fresh eppendorf tube and stored at 
-80°C.
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The RIPA method was used for the ErbB2 study, since ErbB2 is a cell surface 
receptor it can be damaged by trypsin. Treated cells were washed twice with PBS 
(phosphate buffered saline, pH 7.3). RIPA lysis buffer (1% deoxycholic acid, 1% 
Triton X-100, 0.1% SDS, 250mM NaCl, 50mM Tris HC1 and protease inhibitor xl), 
containing fresh protease inhibitor (Roche, UK), was added to the cells (kept on wet 
ice) for five minutes. Then, cells were scraped using cell scrapers (VWR, UK) and 
insoluble material was cleared by centrifugation for 10 minutes at 4°C (13,000rpm). 
The total cell lysate was placed in a fresh eppendorf tube and placed at -80°C.
2.7.2 Nuclear and cytoplasmic protein extraction
Nuclear and cytoplasmic separation was achieved using the Nuclear extract kit from 
Perbio (Cramlington, UK). Cells were grown and treated in 25cm flasks (T25). 
Briefly, cells were washed gently twice with cold PBS and scraped in 2ml of cold 
PBS. Cell solutions obtained were transferred to a pre-chilled 15ml falcon tube 
(VWR, UK) and centrifuged 5 minutes at 500g at 4°C (supernatant was discarded). 
Cell pellets were resuspended in 300pl of cold PBS and transferred to a cold 
eppendorf tube and centrifuged at 500g, 4°C for 5 minutes (supernatant was discarded 
-  all the PBS must be removed). Pellets were finally resuspended in lOOpl of ice cold 
CERI (Cytoplasmic Extraction Reagent I) buffer, containing protease inhibitor, and 
vortexed at high speed for 15 seconds. The cell suspensions were incubated 10 
minutes on ice before adding 5.5pi of CERII (Cytoplasmic Extraction Reagent II) 
buffer. Cell solutions were vortexed for 5 seconds and incubated for 1 minute on ice. 
Solutions were vortexed once more for 5 seconds and centrifuged for 5 minutes at 
16,000g at 4°C. The supernatant corresponds to the cytoplasmic fraction and was 
stored at -80°C (the last few microliters of supernatant were discarded to avoid 
contamination with the nuclear pellet).
The nuclear pellets were resuspended in 50pl of NER (Nuclear Extraction Reagent) 
buffer containing protease inhibitor and vortexed 15 seconds at high speed. Samples 
were vortexed for 15 seconds every 10 minutes for 40 minutes. Lysed nuclei were 
centrifuged for 10 minutes at 16,000g at 4°C and the nuclear fractions (supernatant) 
were stored at -80°C.
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2.7.3 Protein quantification
Once extracted, proteins were quantified using the RC DC protein assay from Bio- 
Rad Laboratories. This assay is based on the Lowry protocol (Lowry et al., 1951), 
using reagents A, S and B. Briefly, 2pl of each lysate was mixed with 18pl of 
distilled water, then lOOpl of the mix of reagent A and S (20pl of reagent S with 1ml 
of reagent A) was added. Finally 800pi of reagent B is added and solutions are 
incubated for 15 minutes at room temperature. Absorbance (OD) was measured, 
against a blank containing only distilled water at 750nm on a Philips 
spectrophotometer (Beam PU8620 Series UV/Vis single) and total protein 
concentration was determined with the following formula:
Concentration in pg/pl = OD*25
Once the concentration was determined, loading dye (250mM Tris HC1, pH 6.8, 
500mM DTT, 10% SDS, 0.5% Bromophenol Blue, 50% glycerol and distilled water 
were used to make a 5 times stock) was added to 50pg of protein (volume 
equivalent). Samples were boiled at 100°C for 4 minutes and then stored at -20°C 
until immunoblotting.
2.7.4 Immunoblotting
Samples prepared as in section 2.7.1 and 2.7.2 were centrifuged for 5 seconds and 
loaded onto 3-8% Tris acetate gels (Novex pre-cast gels, Invitrogen, UK), using the 
XCell SureLock™ Mini-Cell module (Invitrogen, UK) with NuPAGE tri-acetate SDS 
running buffer (60.5g Tris Base, 89.5 Tricine, 10.Og SDS and distilled water added to 
a volume of 1 litre were used to make a 20 times stock) in order to separate proteins 
at 150V, at room temperature. Proteins smaller than 40kDa were separated on 4-12% 
Bis-Tris gels (Novex pre-cast gels, Invitrogen, UK) using the same module as above 
but with MES running buffer (97.6g MES, 60.6g Tris Base, lOg SDS, 3g EDTA and 
distilled water added to a volume of 500ml was used to make a 20 times stock). 
Kaleidoscope marker (Bio-Rad, UK) was used as a size marker.
Proteins were transferred electrophoretically (40V at 4°C for 3 hours) onto activated 
immobilon P membranes (Sigma-Aldrich, UK) (membranes are activated by
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immersion in 100% MeOH for 30 seconds, followed by 2 minute in distilled water 
and 5 minutes in transblot buffer), using the XCell II Blot module (Invitrogen, UK) 
with transblot buffer (100ml of running buffer stock xlO (30.3g Tris Base, 144.1 
Glycine and distilled water to 1 litre -  pH 8.3), 200ml MeOH and distilled water to 2 
litre). Unbound sites on membranes were subsequently blocked using blocking 
buffer: 5% Marvel milk in Tris-Buffered Saline (TBS -  20mM Tris Base, 0.2M NaCl, 
pH 7.5 in distilled water) with 0.1% Tween 20 when probing for non-phosphorylated 
proteins and 5% BSA (Bovine Serum Albumin -  Sigma-Aldrich, UK) in TBS with 
0.1% Tween 20 for phosphorylated proteins. Proteins were probed using the 
appropriate antibody (see dilutions and preparation in Table 2.4). Finally, the primary 
antibody was probed with HRP-conjugated polyclonal antibodies (Mouse or Rabbit -  
1/2000, Abeam -  see Table 2.4) for chemiluminescence detection (ECL system, 
Amersham Biosciences, UK). To this end, blots were dried and incubated 1 minute 
with ECL reagents before covering them with cling film and exposing them to Kodak 
X-OMAT™LS film for various times (2 seconds to 10 minutes).
Membranes were subsequently re-hydrated and stripped of already bound antibodies, 
in order to re-probe for another antibody, using stripping buffer (lOOmM p- 
mercaptoethanol, 2% SDS and 62.5mM Tris HC1 pH 6.8) in a hybridiser (Techne, 
UK) at 50°C for 30 minutes. Finally membranes were washed twice 10 minutes in 
TBS with 0.1% Tween 20, before blocking and re-probing as previously described. 
For all experiments using total protein lysate, a-tubulin was used as a loading control. 
However, for the nuclear and cytoplasmic separation, lamin was used for the nuclear 
fraction and calnexin for the cytoplasmic fraction.
Antibodies Dilutions Dilutionbuffer Supplier
Anti-BRCAl (Ab-1) 1/50 3% milk Oncogene, UK
Anti-EGFR 1/1000 5% BSA Cell Signaling, UK
Anti-ErbB2 1/1000 5% BSA Cell Signaling, UK
Anti-phosphoErbB2 (PY1248) 1/1000 5% BSA Cell Signaling, UK
Anti-ErbB3 1/1000 5% BSA Cell Signaling, UK
Anti-ErbB4 1/1000 5% BSA Cell Signaling, UK
Anti-DNA-PKcs 1/400 5% Milk Abeam,UK
Anti-phosphoDNA-PKcs 1/400 5% BSA Abeam, UK
Anti-ATM 1/1000 5% Milk Abeam, UK
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Antibodies Dilutions Dilutionbuffer Manufacturer
Anti-phosphoATM 1/500 5% BSA Abeam, UK
Anti-ATR 1/500 5% Milk Abeam, UK
Anti-phosphoATR 1/1000 5% BSA Cell signaling, UK
Anti-T0P02a 1/1000 5% Milk Santa Cruz, UK
Anti-Artemis 1/500 5% Milk Abeam, UK
Anti-Ku70 1/500 5% Milk Abeam, UK
Anti-Akt 1/1000 5% BSA Cell Signaling, UK
Anti-phosphoAkt (T308) 1/1000 5% BSA Cell signaling, UK
Anti-phospho Akt (S473) 1/1000 5% BSA Cell signaling, UK
Anti-RAD51 1/200 5% Milk Abeam, UK
Anti-ERCC 1 (clone 8F1) 1/200 5% Milk Neomarker, UK
Anti-MAPK (p42/44) 1/1000 5% BSA Cell signaling, UK
Anti-phosphoMAPK 1/1000 5% BSA Cell signaling, UK
Anti-PARP (also detects 
cleaved PARP) 1/1000 5% Milk Cell signaling, UK
Anti-PTEN 1/1000 5% BSA Cell Signaling, UK
Anti-Calnexin 1/1000 5% BSA Cell Signaling, UK
Anti-LaminA/C 1/1000 5% milk Cell Signaling, UK
Anti-Mouse (ab6728) 1/2000 5% milk Abeam, UK
Anti-Rabbit (ab6721) 1/2000 5% milk Abeam, UK
Anti- a-tubulin (Clone B-5-1- 
2)
1/4000 5% milk Sigma-Aldrich, UK
Table 2.4 -  Antibodies used in the BRCA1 and ErbB2 studies
2.8 Reverse Transcriptase Polymerase Chain Reaction
2.8.1 RNA extraction and quantification
RNA was extracted from cell pellets using the RNeasy minikit (Qiagen, UK). Briefly, 
cells were disrupted using 600pl of buffer RLT containing p-mercaptoethanol and 
samples were homogenised by passing solutions trough a 20-gauge syringe. After 
adding 600pl of 70% ethanol, solutions were filtered using RNeasy mini-columns (15 
seconds at 13,000rpm), 700pl of RWI buffer was then added to the column and 
centrifuged (15 seconds at 13,000rpm). Then, columns were washed twice with 500pl 
of buffer RPE. Finally, 40pl of RNase-free water was added onto the membrane of 
the column to elute the RNA (1 minute at 13,000rpm). RNA was kept at -80°C.
103
RNA was quantified by measuring the absorbance at 260nm (Philips 
spectrophotometer, Beam PU8620 Series UV/Vis single) of a 1 in 500 dilution of the 
RNA, in DEPC water (0.1% DEPC in distilled water, solution was left at room 
temperature overnight in foil and autoclaved): Absorbance26o of 1 = 40pg/ml. Purity 
of the RNA was checked by calculating the ratio at 260nm and 280nm (A260/A280) -  
which should be between 1 and 2.
2.8.2 Synthesis of first strand cDNA
cDNA was synthesised from the RNA extracted, using Superscript II RNase H' 
reverse transcriptase enzyme (Invitrogen, UK). Briefly, 2.5pl of oligo (dT)is 
(500pg/ml, Promega, UK) was mixed with 5pg RNA, 2.5pl of dNTP mix (lOmM 
each -  dTTP, dCTP, dATP and dGTP, Promega, UK) and DEPC water (distilled 
water containing 0.1% DEPC left in the dark overnight and autoclaved) to a volume 
of 30pl. Samples were heated at 65°C for 5 minutes then chilled quickly on ice before 
adding lOpl of 5 times first strand buffer (Invitrogen, UK) and 5pi of 0.1M DTT 
(Invitrogen, UK). Samples were heated for 2 minutes at 42°C and 2.5pl of superscript 
II RNase H‘ reverse transcriptase (200 units per pi, Invitrogen, UK) as well as 2.5pl 
DEPC water was added. Finally, samples were incubated at 42°C for 50 minutes then 
15 minutes at 70°C. cDNA was stored at -20°C.
2.8.3 Reverse Transcriptase PCR amplification
PCR amplification was performed using a PTC-225 thermal cycler (GRI, UK). 
Primers (MWG Biotech, Germany) and annealing temperatures used are shown in 
Table 2.5. BLASTN search (www.ncbi.nlm.nih.gov) was conducted in order to 
confirm the total gene specificity of the nucleotide sequences.
5pl of cDNA previously synthesised was mixed with 4pl of dNTP mix (2.5mM each, 
Promega, UK), 3pl of magnesium chloride at 25mM (Invitrogen, UK), lOpl of 5x 
GoTaq flexi PCR buffer (Promega, UK), 0.3pl of GoTaq polymerase (5 units per pi, 
Promega, UK), 5pl of each primer of interest at lOpM (BRCA1) and 2pl of each 
internal control primer at lOpM (p-actin). DEPC water was added to a volume of 
50pl. p-actin was used as an internal control and sizes of the bands were determined 
using a 50bp DNA ladder (Invitrogen, UK). PCR was achieved on a PTC-225 (MJ
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Research, UK) PCR machine and cycling parameters were as follows: 95°C (1 min -  
denaturation); 59°C (1 min -  annealing); 72°C (1.5 min -  elongation) for 35 cycles. A 
final step at 72°C for 10 minutes was used to allow annealing completion.
At the end of the PCR cycles, electrophoresis of the products on a 2% agarose 
ethidium bromide gel (using lxTAE -  2.5mM EDTA, 40mM Tris Base and 0.1% 
acetic acid) was performed at 100V -  gels were photographed using a dual intensity 
ultraviolet transilluminator coupled with camera (UVP, UK).
Genes Primers Sequences
Amplicons 
size 
(base pair)
Annealing
temperature
BRCA1 BRCA1-forward
5 ’ -TT GC GGG AGG A A A AT G 
GGTAGTTA-3’ 285bp 59°C
BRCA1 BRCA1-reverse
5 ’-TGTGCC AAGGGTGA 
ATGATGAAAG-3 ’
p-actin p-actin-forward
5 ’ -GAGCACAGAGC 
CTCGCCTTTG-3’ 636bp 59°C
P-actin p-actin-reverse
5’-GGATCTTCATGAGG
TAGTCAGTCAGG-3’
Table 2.5 -  Sequences and annealing temperature for each primer set used in the 
BRCA1 study (BRCA1 primer set originated from the paper published by Xian et al., 2003, 
and the P-actin primer set from Kotecha et a l 2003).
2.9 Real Time Polymerase Chain Reaction
2.9.1 Real Time PCR
This type of PCR is different from conventional PCR as it measures the formation of 
the PCR product as it is formed, using fluorescence emitted from the reporter dye on 
the probe (Figure 2.2). For that purpose, probes used are highly specific to the 
sequence amplified with the primer, and labelled with a quencher dye (TAMRA) and 
a reporter dye (6-FAM). Also, PCR products obtained must be of small size (50 to 
150bp). Real Time PCR was performed using the ABI PRISM® 7000 Sequence 
Detection System (Perkin-Elmer Applied Biosystems, UK). Primers and probes 
(MWG Biotech, Germany) used are described in Table 2.6. Sequences were either 
obtained from the literature or designed (Appendix 2) using Primer Express® software 
(Applied Biosystem, UK). BLASTN search (www.ncbi.nlm.nih.gov) was conducted
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in order to confirm the total gene specificity of the nucleotide sequences. 
Housekeeping gene p-glucuronidase (de Kok et al., 2005) was purchased from 
Perkin-Elmer Applied Biosystems (UK) as a ready made mix of primers/probe.
PCR products verification
Primers were initially tested by reverse transcriptase PCR in order to ensure that a 
single product was amplified. This was performed as described previously in section 
2.8 (no internal control, cycling parameters: 94°C 30 seconds, 60°C 30 seconds and 
72°C 15 seconds for 45 cycles) with the primers described in Table 2.6 (annealing 
temperature during the real time PCR being 60°C). Part of the PCR product was 
analysed on a 2% agarose ethidium bromide gel (along with a lOObp DNA ladder) for 
a purity check and another part was used for TOPO TA cloning and sequencing.
As the small size of the PCR fragments did not allow for accurate sequencing,
(Sbfragments had to be cloned into pCR 2.1-TOPO vector and amplified in competent 
cells. Cloning was carried out using TOPO TA cloning kit (Invitrogen, UK). Briefly,
2pl of PCR products were mixed with lpl of salt solution, 2pl of water and lpl of
(£)TOPO vector (TA cloning is possible since Taq polymerase leave a 3’ A overhang -  
no proofreading) to allow TA cloning for 5 minutes at room temperature. 2pi of this 
reaction was added to one vial of One shot® chemically competent (Invitrogen , UK) 
Escherichia coli (E. coli) for 15 minutes on ice. Cells were then heat shocked at 42°C 
for 30 seconds and 250pl of SOC medium was added. 40pl of the cells were plated 
on LB (Luria-Bertani) agar plates (Invitrogen, UK) containing 50pg/ml of ampicillin 
(Sigma-Aldrich, UK) and grown overnight at 37°C. As the sequence of interest was 
inserted in the lactose region of the plasmid, a blue/white selection was performed 
using blue/white select screening reagent (Sigma-Aldrich, UK). Colonies containing 
the plasmid with the insert appeared white. After selection, colonies were picked and 
grown overnight in 10ml of LB broth base (Lennox L Broth Base) medium 
(Invitrogen, UK) containing 50pg/ml of ampicillin (Sigma-Aldrich, UK), in 15ml 
falcon tubes at 37°C. Plasmids were finally extracted using the QIAprep Spin 
Miniprep kit (Qiagen, UK). Briefly, after harvesting the cells, 250pl of buffer PI was 
added to resuspend the cells and 250pl of buffer P2 was added to lyse the cells. Then, 
350pl of buffer N3 was added, creating precipitation, and the supernatant obtained by
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centrifugation was applied onto QIAprep Spin columns and washed with 500pi of 
buffer PB. Finally, columns were washed with 750pl of buffer PE and plasmids were 
eluted in 50pl of DEPC water. Plasmids were sent to the Windeyer Institute of 
Medical Sciences for sequencing of the inserted PCR fragment, using M l3 forward 
and reverse primers.
Real Time PCR
Once the PCR products were shown to match the desired gene sequence, primers 
were used in the real time PCR. To this end, 2.5pi of cDNA (synthesised as described 
in section 2.8.2) was mixed with 12.5pl of Taqman PCR master mix (Perkin-Elmer 
Applied Biosystem, UK), 1.25pi of p-glucuronidase primer/probe mix (Perkin-Elmer 
Applied Biosystem, UK), 0.5pi of probe specific to the gene amplified, 2.5pi of each 
primer (forward and reverse) of the gene of interest and DEPC water was added to a 
volume of 25pi. All reactions were performed in triplicate and included a water 
control reaction and a standard curve using a sample serially diluted (1/2, 1/5, 1/10, 
1/20, 1/50, 1/100 -  see section 2.9.2). Schematic representation of real time PCR is 
shown in figure 2.2. The amplification of the fragment was measured by the release 
of the reporter dye from the quencher (Figure 2.3 - Amplification plot). Cycling 
conditions used were as follows: 50°C 2 minutes (optimal AmpErase UNG enzyme 
activity), 95°C 10 minutes (activation of DNA polymerase), 40 cycles: 95°C for 15 
seconds (strands separation) and 60°C 1 minute (annealing).
107
Genes / 
Accession 
number
Primers
and
probes
Sequences
Amplicons 
size 
(base pair)
Paper
source
BRCA1
U14680
BRCA1
forward
5 ’ -C AGAGG AC AAT 
GGCTTCCATG-3 ’
81bp
Provided by 
Dr. Li 
(CRUK)
BRCA1
reverse
5’-CTACACTGTCCA 
ACACCC ACTCTC-3 ’
BRCA1
probe
5 ’(6-F AM)-C AGGTGCC 
TCACACATCTG 
CCC AATT-(TAMRA)3 ’
ErbB2 
Ml 1730
ErbB2
forward
5’-GGATGTGCGG
CTCGTACAC-3’
74bp Designed
ErbB2
reverse
S’-TAATTTTGACA 
TGGTTGGGACTCTT-3 ’
ErbB2
probe
5 ’ (6-F AM)-CTT GGCC 
GCTCGGAACGT 
GC-(TAMRA)3’
T 0P02a
NM00106
7
T0P02a
forward
5’-ATTGAAGACGCT 
TCGTTATGGG-3 ’
96bp
Obtained 
from Dr. 
Kotecha 
(Oncology 
Dept - 
UCL)
T0P02a
reverse
5 ’ -GAT GG AT A A AAT 
TAATC AGC AAGCCT-3 ’
TOP02a
probe
5’(6-FAM)-CAGATCAGG
ACCAAGATGGTTCCCAC
ATC-(TAMRA)3’
Table 2.6 -  Primers, probes and number of cycles used for Real Time PCR. Primers and 
probe for ErbB2 gene have been designed using Primer Express (Perkin-Elmer Applied 
Biosystems). 6-FAM (6-carboxyfluorescein) being the reporter dye and TAMRA (N, N, N ’, 
N’-tetramethyl-6-carboxyrhodamine) the quencher dye. Details of the design of TaqMan 
probes and primers using Primer Express are in Appendix 2.
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Polym erisation
5’
3 ’
5 ’
Forward
primer
5’
Strand displacem ent 3 ’
5 ’
Cleavage
5 ’
Polym erisation
com pleted
3’
5’
i
t
5’
5’
3 ’
5 ’
Reverse
primer
5 ’
3 ’
5’
3 ’
5’
5’
3 ’
5 ’
5 ’
3 ’
5 ’
R = Reporter 
Q = Quencher
Figure 2.2 -  Real Time PCR reaction: amplification of the fragment. When the target 
sequence is present, the probe anneals downstream from one of the primer sites and is 
cleaved by the 5' nuclease activity of Taq DNA polymerase as this primer is extended. 
Cleavage of the probe separates the reporter dye from quencher dye, increasing the reporter 
dye signal. Cleavage removes the probe, and primer extension continues to the end of the 
template strand. Thus, with fluorescent probes, non-specific amplification due to mis-priming 
or primer-dimer artifact does not generate signal. When two sets of primers / probes are used 
in the same reaction, probes must be labelled with different and distinguishable reporter dyes. 
Hence, amplification of two distinct sequences can be detected in a single PCR reaction (e.g. 
BRCA1 and (3-glucuronidase).
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2.9.2 Optimisation
Optimisation was mainly required to determine if reactions of the target gene and the 
internal control could be run in the same tube (multiplex). Optimisation was required 
for BRCA1 and ErbB2 real time PCR, as the T0P02a had been previously optimised 
by Dr. Kotecha (Oncology Department, UCL, UK). Different criteria had to be 
defined: the primer limiting concentration, the probe concentration and whether the 
reactions (target gene and housekeeping gene) could occur in the same tube without 
interfering with each other.
The primer limiting concentration is designed to determine the primer concentrations 
to use in order to avoid competition between the two primer sets (competition for 
common reagents during amplification). A range of forward and reverse primer 
concentrations were used and primer limiting concentration was reached when a 
plateau phase was formed on the graph charting Ct versus primer concentrations. The 
combination of concentrations giving the low Ct (threshold value -  see figure 2.3) 
value and high fluorescence (ARn) value was used. However, if the limiting 
concentration can not be reached, primers should be redesigned or run in separate 
tubes (singleplex).
The probe concentration was determined using the same principle (range of probe 
concentrations used). In order to obtain accurate results, the concentration giving low 
Ct and high fluorescence was used. Concentrations of primers and probe for the 
internal control p-glucuronidase (enzyme from the lysosome with hydrolase activity) 
did not need optimisation as these were purchased as a primer probe mix.
In order to compare multiplex and separate tube reactions, a relative standard curve 
(dilution of a sample set at a value of 1 -  untreated control -  is used to construct the 
standard curve: 1/2; 1/5; 1/10; 1/20; 1/50 and 1/100) was used. Reactions of the target 
gene and the housekeeping gene were carried out in the same tube if no interference 
occurred (distorsion of the fluorescence curve), and if the difference in efficiencies 
(see section 2.9.3) of the primer sets (for target and housekeeping genes) between the 
two methods (separate and same tube) was minimal (ABI, User Bulletin #2 and #5, 
2001).
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2.9.3 Results Analysis
Each run included a triplicate of the samples and a standard curve. Levels of BRCA1, 
ErbB2 and T 0P02a mRNA were expressed in relation to the reference housekeeping 
gene (gene regulating basic and ubiquitous cellular function and code) P- 
glucuronidase (exoglycosidase in lysosomes) as a ratio of target gene/housekeeping 
gene (all reactions were performed in triplicate). A new mathematical approach for 
quantification in real time PCR has been described by Pfaffl (2001). It is based on the 
relative expression ratio (R) of a target gene (BRCA1, ErbB2 or T0P02a) versus an 
internal control (int. control) gene (P-glucuronidase):
17 ACYj et
__ target (1)
Z7 A C7jnt controi
int. control
Where E = io('1/slope) (2)
and ACt target — Ct target for reference — Ct target for unknown (3)
ACt int. control = Ct int. control for reference. Ct int. control for unknown (4)
For all equations, Ct corresponds to the threshold cycle (see figure 2.3) which is 
defined as the fractional cycle number at which the fluorescence, generated by 
cleavage of the probe, passes a fixed threshold (defined by the user on the exponential 
phase of the fluorescence curve) above baseline (Bieche et al., 1999). Hence, Ct is 
determined where the threshold crosses with the fluorescence curve and is read on the 
x axis (number of cycles). In equations (3) and (4), reference is the sample of 
reference (i.e. wild type or untreated) and unknowns the samples which have an 
increased or decreased level of the target gene. Efficiencies (E) (2) for the target and 
the internal control are defined by the slope of the standard curve of the target and the 
internal control, respectively. For the relative standard curves, serial dilutions of the 
reference sample were used, in our studies: 1; 1/2; 1/5; 1/10; 1/20; 1/50; 1/100 
(triplicate of each point). Hence, the quantification of the amount of target in an 
unknown sample is determined by measuring Ct and using the standard curve.
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Figure 2.3 -  Typical real time PCR amplification plot. Fluorescence signal versus cycle 
number, obtained with the standard curve serial dilutions -  the figure shows the threshold 
cycle (determined by the user, anywhere on the exponential phase of the curves) and the Ct 
values read on the x axis (www.cambio.co.uk).
2.10 Single cell gel electrophoresis Comet assay
The comet assay was first developed as a method to measure DNA strand breaks at a 
single cell level (Ostling and Johanson, 1984). However, a modification of this assay 
has been shown to achieve sensitive detection of interstrand crosslinks (Hartley et al., 
1999; Spanswick et al., 2002).
2.10.1 The Comet assay
Study o f drug concentration on DNA damage level
Cells were plated at 10xl04cells/ml in 25cm2 flasks (Nunclon, VWR, UK) and 
incubated for 24 hours at 37°C in 5% CO2. In order to analyse DNA damage and 
repair, cells were treated with the appropriate chemotherapeutic drug at a range of 
concentrations. Drugs were left in contact with the cells for a short period of time (1 
to 2 hours according to the drug) and left to incubate in drug free media (if 
necessary), for DNA damage to reach its peak (e.g. 9 hours for cisplatin). From this, a 
fixed drug concentration was determined to treat the cell and observe the repair of 
drug-induced DNA damage. For strand breaks agents (such as etoposide), the drug 
concentration producing a tail moment (see section 2.10.2) of 10-12 was used. For
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interstrand crosslink agents (such as melphaian or cisplatin), the drug concentration 
giving 50-70% decrease in tail moment (see section 2.10.2) was used.
DNA damage repair study
Once the concentration was selected, fresh cells were plated at 10xl04cells/ml in T25 
and incubated at 37°C in 5% CO2 for 24 hours. Cells were then treated for the 
appropriate time and the drug was subsequently replaced by drug free media. Cells 
were incubated in drug free media for various period of time in order to measure 
DNA damage repair. Cells were collected by trypsinisation, pelleted and resuspended 
in 1ml of foetal calf serum containing 10% DMSO, before to be stored at -80°C.
Assay methodology
When studying damage caused by a crosslinking agent, cells were thawed and 
resuspended in ice cold media to a concentration of 2.5x104cells/ml. Those cell 
suspensions were divided into two samples, one of which being irradiated (12.5Gy) 
using an X-ray source (GEC Newton Victor X-ray machine 25kV) to deliver a fixed 
number of random DNA strand breaks (procedure carried out on ice), immediately 
before analysis. For strand breaking agents, cells were thawed and diluted to a 
concentration of 2.5x104cells/ml without any irradiation.
In both cases, the following methodology was the same. All procedures were carried 
out on ice and in subdued light. Cells were embedded in 1% type VII agarose (Sigma- 
Aldrich, UK) (1ml of agarose + 0.5ml of cell suspension) on duplicate 1% type 1A 
agarose (Sigma-Aldrich, UK) pre-coated microscope slides. Cells were lysed, in the 
dark on ice, for one hour in ice cold lysis buffer (lOOmM disodium EDTA, 2.5M 
NaCl, lOmM Tris-HCl pH 10.5) containing 1% Triton X-100 (Sigma-Aldrich, UK) 
added fresh. Slides were subsequently washed every 15 minutes in ice cold distilled 
water for 1 hour. Slides were then incubated in ice cold alkali buffer (50mM NaOH, 
ImM disodium EDTA, pH 12.5) for 45minutes followed by electrophoresis in the 
same buffer for 25 minutes at 18 V (0.6V/cm), 250mA. The slides were finally rinsed 
in neutralising buffer (0.5M Tris-HCl, pH 7.5) then saline (PBS). Slides left to dry 
overnight were re-hydrated for 20 minutes with distilled water and stained with
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propidium iodide (2.5pg/mL) for 30 minutes (in the dark) then rinsed in distilled 
water. Finally, slides were left to dry in a drying oven and stored.
2.10.2 Data analysis
Images (illustrated in figure 2.4) were visualised using a NIKON inverted microscope 
with high-pressure mercury light source, 510-560nm excitation filter and 590nm 
barrier filter at x20 magnification. Images were captured using an on-line charge- 
couple device (CCD) camera and analysed using Komet Analysis software (Kinetic 
Imaging, Liverpool, U.K.). For each duplicate slide 25 individual cells were analysed. 
Tail moment for each cell was calculated using the Komet Analysis software as the 
product of the percentage DNA in the comet tail and the distance between the means 
of the head and tail distributions, based on the definition of Olive et al. (2002).
Figure 2.4 -  Screen display of Komet analysis software. The figures shows untreated 
irradiated cells. Red arrows are showing the head and the tail of comet. The background is 
also taken into consideration by the software for calculation of the tail moment.
For strand breaks, tail moment data were analysed as a function of time post­
incubation or drug concentration. Figure 2.5 illustrates the effect of etoposide after 
drug incubation. Data shown were the result of three independent experiments and 
included corresponding standard error bars.
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Figure 2.5 -  Repair of DNA damage caused by etoposide treatment. Comet tail appears to 
be reduced as DNA strand breaks, caused by etoposide treatment, are repaired.
For crosslinking agents, results were expressed as percentage decrease in tail moment 
compared to untreated controls calculated by the following formula (tail moment was 
calculated from the same software as previously described):
[ /  TMdi - TMcu \  “|1 - I -------------------  1  I x 1 0 0y  TMci - TMcu J
where TMdi = tail moment of drug-treated irradiated sample 
TMcu = tail moment of untreated, unirradiated control 
TMci = tail moment of untreated, irradiated control
Percentage decrease in tail moment data were the result of three independent 
experiments, with corresponding standard error bars. Figure 2.6 represents DNA 
damage repair profile of irradiated cell treated with cisplatin. The short comet tail 
after 9 hours is due to the presence of interstrand crosslinks, delaying the DNA 
migration. Hence, as crosslinks are unhooked (repaired), the comet tail in irradiated 
cells is restored. For cisplatin the peak of crosslinking is observed after 9 hours post­
incubation (for melphalan it is 16 hours).
Time post­
treatment 
(hours)
Figure 2.6 -  DNA damage repair profile of irradiated cells treated with cisplatin. Cells 
were treated with cisplatin for 1 hour and subsequently incubated in drug-free media for 
various times. After 9 hours crosslinking reached its maximum (60-70% crosslinks) as the tail 
appears much shorter (crosslinks are causing the delay in DNA migration). At 24 and 48 
hours, the unhooking (repair) of cisplatin crosslinks causes the comet tail to re-elongate.
2.11 Cisplatin intrastrand crosslink assay
Cisplatin intrastrand adducts represent 90% of cisplatin DNA damage. In order to 
determine the level of these adducts, competitive Enzyme-Linked ImmunoSorbant 
Assay (ELISA) method was used. This assay was developed by Tilby et al. (1987, 
1991).
2.11.1 M ethodology  
DNA extraction
Prior to the assay 10ml of cells were plated in T25 at a concentration of 
lx l0 5cells/ml. After drug treatment cells were pelleted and DNA was extracted using 
the DNeasy blood & tissue kit (Qiagen, UK). Briefly, cells were pelleted for 5 
minutes at 300g at room temperature and cells were resuspended in 200pl of PBS and 
20pl of proteinase K. 200pl of lysis buffer (AL) was added to the solution and 
vortexed for 10 seconds. The solution was incubated at 56°C for 10 minutes and 
200pl of 100% ethanol was added before vortexing the solution for 10 seconds. The 
mixture was added onto a DNeasy mini spin column and centrifuge at 8,000rpm for 1 
minute (supernatant was discarded). The column was then washed with 500pl of 
washing buffer (AW1) followed by a wash with 500pi of washing buffer (AW2) by 
centrifugation for 3 minutes at 14,000rpm. Finally, DNA was eluted with 200pl of 
AE buffer at 8,000rpm for 1 minute. DNA was quantified at 260nm using a 
NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop, UK). DNA was stored 
at -20°C.
Competitive ELISA
High bind ELISA plates (Greiner, UK) were coated with 50pl of platinated DNA 
(denatured calf thymus DNA treated with cisplatin to give an adduct level of 
25.5pmoles/g of DNA, kindly provided by M.J. Tilby, University of Newcastle) 
diluted 1 in 2,000 in high salt coating buffer (1M NaCl, 50mM sodium phosphate, pH 
7.0). Plates were placed in a sealable box at 37°C, overnight.
On the following day ELISA wells were blocked with 150pl of blocking buffer (1% 
BSA in PBS w/v) for at least 30 minutes at room temperature. Samples were diluted 
in DB buffer (50mM NaCl, 50mM sodium phosphate, pH7.0), starting concentration
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was determined by trial and error as it varies according to the level of cisplatin 
adducts. Samples and standards (one standard containing 801fmol of adduct/ml and 
another standard with 797fmol of adduct/ml, kindly provided by Dr. Tilby, University 
of Newcastle) were incubated for 5 minutes in boiling water to increase 
immunoreactivity, cooled on iced water and spun briefly. Samples and standard were 
serially diluted (one row = one sample) in a 96 well plate (Nunclon , VWR, UK) in 
DB buffer. The monoclonal antibody CP9/19 (kindly provided by Dr. Tilby, 
University of Newcastle) was diluted 1 in 60,000 in PBS containing 0.2%BSA, 
90mM sodium chloride, 0.2% Tween 20 and 0.2mg/ml phenol red. 55pl of this 
solution was mixed (30 minutes at 37°C) with 5 5 pi of the serially diluted samples and 
standards to allow binding to intrastrand adducts. A low concentration of antibody is 
used in order to maximise the sensitivity of the assay. Each plate included four wells 
with no DNA (sample or standard) and no antibody for background measurement and 
wells with antibody but no DNA (100% fluorescence). ELISA plates were washed 
twice with PBS containing 0.1% tween 20 (PBS-Tween) and 50gl of the mix 
solutions were subsequently transferred into ELISA plates in duplicate wells and 
incubated for 1 hour at 37°C. Following five washes with PBS-Tween, 50pl of 
biotinylated anti-rat solution (biotinylated goat anti-rat -  Sigma-Aldrich, UK -  
diluted at 1 in 2500 in 1% BSA, 0.2% Tween 20 and PBS) was added for 30 minutes 
at 37°C. Plates were washed three times with PBS-Tween and 50pl of p- 
galactosidase-streptavidin conjugate (Boehringer, UK) solution (P-galactosidase- 
streptavidin conjugate diluted at 1 in 10,000 in 1% BSA, 0.1% Tween 20, lOmM 
MgCE and 2pl and PBS). Finally, after 30 minutes incubation at 37°C plates were 
washed seven times (PBS-Tween) and 50pl of substrate solution (PBS containing 
80pg/ml 4-methyl-umbelliferyl-p-D-galactoside -  Sigma-Aldrich, UK -  and lOmM 
MgCE) was added to each well. Plates were placed in a sealable box, in the dark at 
room temperature, overnight.
2.11.2 Data analysis
Cleavage of 4-methyl-umbelliferyl-p-D-galactoside by P-galactosidase caused the 
release of fluorescent molecule 4-methylumbelliferone. Fluorescence was measured 
at 360nm excitation and 465nm emission, using a Spectrafluor Plus plate reader
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(Tecan, UK). The mean background was substracted from all reading and the 
percentage of fluorescence (%FV) was calculated for each serial dilution (compared 
to the 100% fluorescence value). Data obtained were fitted to the logistic equation 
(FV=MxCs/(Cs+Ks))) as described by Tilby et al. (1987), and the 50% inhibition (K 
value) was determined using GraphPad Prism 4 software. A typical fitting curve, 
obtained with GraphPad Prism, is illustrated in Figure 2.7. The figure is showing the 
decrease of the fluorescence intensity as the concentration of adduct increases, a 
similar profile is obtained for the samples (reduction of fluorescence as DNA 
concentration increases). The choice of the initial DNA concentration in the samples 
is important as points on the curve must span the 50% inhibitory level so as to 
maximise the accuracy of the curve fitting to estimate the concentration of samples 
giving 50% inhibition.
Once the K values were calculated, the level of adduct was determined for each 
samples. In the case of the standards the K value corresponds to the level of adduct 
necessary to cause 50% reduction of assay signal this is then in femtomol (fmol) of 
cisplatin adduct per well (fmol Pt/well) as the concentration of cisplatin adducts is 
known. In the case of samples of DNA extracted from cells, these are the quantities of 
DNA per well (ng/well). Since reduction in assay signal is due only to cisplatin 
adducts (except at very high DNA concentrations, i.e. > 5 pg/well), the quantity of 
sample DNA that causes 50% reduction in signal must carry the same number of 
adducts that causes 50 % reduction of the signal in the standards. Results are 
expressed in moles of adducts per grams of DNA. E.g. If K value for samples = 50ng 
DNA per well and K value for standard = 2fmol Pt adduct per well, 50ng of DNA 
carries 2fmol of adduct. Thus 1 g DNA carries 40nmoles of adduct (40nmoles 
adduct/g DNA).
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Figure 2.7 -  Typical curve fitting for two standards obtained with GraphPad Prism 4.
Points appear to span the 50% inhibitory level shown by the horizontal doted line. As the 
concentration in cisplatin adducts increases the fluorescence decreases (as adduct 
concentration increases the free antibody in solution is reduced).
2.12 Cell cycle analysis
Effect of drug treatment on cell cycle was studied using cytofluorimetry analysis.
2.12.1 Methodology
2 ml of cells were plated at a concentration of 1 0 x l0 4cells/ml in six well plates 
(Nunclon®, VWR, UK) and incubated at 37°C in 5 %CC>2 for 24 or 48 hours prior to 
treatment. After treatment, media was collected in 5ml tubes and cells were washed 
with 0.5ml of cold PBS with 0.02% sodium azide (also collected). Cells were 
subsequently trypsinised (0.5ml of trypsin for 5 minutes at 37°C) and collected in the 
same tube. Each well was finally washed with 0.5ml of cold PBS azide (collected in 
the FACS tube). Cells were pelleted at 2,000rpm for 15 minutes at 4°C and 
supernatant was discarded. Cells were washed with PBS azide and spun at 2,000rpm 
for 5 minutes at 4°C. Supernatant was discarded and cells were fixed with 0.75ml of
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cold 70% ethanol overnight. Samples were kept for up to a week at -20°C before 
staining.
Once collected and fixed, samples were spun at 2,000rpm for 5 minutes at 4°C. 
Supernatant was removed and cells were washed twice with 1ml of PBS with 0.01% 
azide. Cells were resuspended in 400pl of propidium iodide (PI) staining solution 
(0.05mg/ml of propidium iodide mixed with 0.5mg/ml of RNAse A and PBS azide to 
a volume of 35ml). Samples were incubated for 30 minutes at room temperature in 
the dark and placed on ice and analysed immediately.
2.12.2 Data analysis
Red fluorescence from PI staining was analysed with a Becton Dickinson FACscan 
(UK) cytofluorometer on the channel FL3. Gates were draw in order to only observe 
individual cells and eliminate clumped cells.
Data were analysed using WinMDI 2.8 and Cylchred software in order to quantify the 
number of cells in each phase of the cell cycle. Figure 2.8 represent a typical profile 
of normally cycling cells, with sub-Gl, Gl, S and G2 phases. Samples were taken at 
different time points to observe the evolution of the cell cycle with time (Figure 2.9).
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Figure 2.8 -  Histogram profile showing the number of events in each phase versus DNA 
quantity. Arrows are pointing to the different phase of the cell cycle: Sub-Gl is in blue (on 
the left), G1 is the first peak in red, the S phase is represented in green and the last peak in red 
corresponds to the G2 phase. This figure was obtained from a screenshot of the Cylchred 
software.
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Figure 2.9 -  Histogram profile obtained with WinMDI software. Untreated cells were 
collected every 24 hours. One event = one cell.
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2.13 Topoisomerase II activity assay
Topoisomerase II activity was assayed using the TopoII assay kit from Topogen 
(Florida, USA). This assay was performed on untreated, exponentially growing cells 
(10ml of 5xl04cells/ml in a T25 flask incubated for 48 hours at 37°C in 5% CO2, 
before the assay). All the steps of this procedure were carried out on ice as enzymes 
inactivate readily in vitro and are easily proteolysed.
Cells were gently scraped in media and pelleted in a pre-chilled 15ml falcon tube, at 
800g for 3 minutes at 4°C. Supernatant was discarded and cells were resuspended in 4 
ml of ice cold TEMP buffer (lOmM Tris-HCl, pH 7.5, ImM EDTA, 4mM MgC12, 
0.5mM PMSF) by pipetting. Cells were centrifuged as before and resuspended in 3 
ml of TEMP. Samples were incubated on ice for 10 minutes and dounced in tight 
fitting homogeniser with eight strokes. Nuclei were pelleted at 1500g for 10 minutes 
at 4°C and subsequently resuspended in 1ml of ice cold TEMP buffer. Suspensions 
were transferred in an eppendorf tube and centrifuge at 4,000rpm for 2 minutes at 
4°C. Supernatant was completely removed and pellets were resuspended in a small 
volume (no more than four pellet volumes) of TEP buffer (same as TEMP but lacking 
MgCE). An equal volume of 1M NaCl was added and solutions were vortexed for 5 
seconds and incubated on ice for 45 minutes. Finally, suspensions were centrifuge at 
15,000g for 15 minutes (at 4°C). The supernatant contains topo I and II activities. 
However, the kit used is specific of topisomerase II activity.
lpl of each sample was mixed with 10 times complete assay buffer (Topogen, 
Florida, USA), 2pl of kinetoplast DNA (kDNA) and distilled water to 20pl. Solutions 
were incubated for 45 minutes at 37°C. Since the extract contains high salt (0.5M) 
care was taken not to poison the reaction with excessive amounts of the extract 
(different volumes of extract were used to define the least toxic volume giving the 
best results). Reactions were stopped by adding 4pl of loading dye (5 times buffer is 
5% sorkosyl, 0.125% bromophenol blue and 25% glycerol) and loaded, along with 
decatenated kDNA control and linearised kDNA control, onto a 1% agarose ethidium 
bromide gel (using lxTAE -  2.5mM EDTA, 40mM Tris Base and 0.1% acetic acid). 
The gel was electrophoresed at 100V and photographed using a dual intensity 
ultraviolet transilluminator coupled with camera (UVP, UK).
122
2.14 Immunofluorescence
Exponentially growing cells were seeded in Labtek™ II chamber slides (Nunclon™, 
VWR, UK) at 2xl04cell/well (0.5ml per well). Cells were incubated in a humid box 
for 24 hours at 37°C in 5% CO2, prior to treatment. At the end of the treatment, media 
was removed and wells were washed twice with cold PBS (0.5ml/well). Cells were 
fixed using cold 50% methanol/50% acetone solution (0.5ml/well) at 4°C for 8 
minutes. Wells were then washed with cold PBS and 0.5ml of permeabilisation (0.5% 
Triton X-100 -  Sigma-Aldrich, UK -  in PBS) buffer was added for 5 minutes at room 
temperature. Wells were subsequently washed and 0.5ml of blocking buffer (0.2% 
skimmed dry milk, 0.1% Triton X-100 in PBS) was added overnight at 4°C. Three 
washes were performed with cold PBS. 200pl of the desired antibody (see Table 2.7) 
was added to each well, left overnight at 4°C, then washed three times with 0.1% 
Triton X-100 in PBS for 15 minutes. 200pl of FITC-labelled secondary antibody 
(Alexa fluor® 488 goat anti-rabbit IgG -  see Table 2.7) was added for one hour in the 
dark. As before slides were washed three times for 15 minutes and counter-stained 
with 2pg/ml propidium iodide (PI) for 3 minutes. Slides were destained with distilled 
water for 20 minutes, mounted using VECTASHIELD® Mounting Medium H-1000 
(Vector Labs, UK) and photographed using a LSM510 Axioplan 2 (Zeiss, UK) 
confocal microscope. Excitation wavelengths used were 488nm for the Alexa fluoro® 
and 543nm for PI.
Antibody
Colour under 
microscope and 
on pictures
Dilution Supplier
Anti-ErbBl (15F8) Green 1/64 Cell Signaling, UK
Anti-ErbB2 (29D8) Green 1/64 Cell Signaling, UK
Alexa fluor® 488 
goat anti-rabbit IgG Red 1 /1 0 0 0 Invitrogen, UK
Table 2.7 -  Antibodies used for immunofluorescence experiments.
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2.15 Small interfering RNA (siRNA) transfection
Small interfering RNA transfection was used in order to reduce the level of 
expression of the ErbB2 gene. siRNA sequences were obtained from the literature 
and synthesised by MWG Biotech. (Germany). The sequences are detailed in Table 
2.8, and were transfected using RNAifect (Qiagen, UK) transfection reagent. Briefly, 
cells were plated out in 2ml (MCF-7 lxlO5 cells/well, SK-BR-3 2xl05 cells/well and 
MD-MB-453 5x105 cells/well) in 6 -well plates (Nunclon™, VWR, UK) 24 hours 
before transfection (time to reach 50% confluence). 5pg of siRNA was diluted in EC- 
R buffer (Qiagen, UK) to a volume of lOOpl, then 15 pi of RNAifect transfectant 
reagent was added to the diluted siRNA. The solutions were incubated for 15 minutes 
at room temperature. Media from the cells was removed and replaced by 1.9ml of 
complete media with no antibiotics, and the siRNA mix (115pl) was added dropwise. 
Cells were then incubated at 37°C in 5% CO2. All siRNAs are 19-bp double stranded 
sequences with symmetric 3' overhangs of two deoxythymidines. Scrambled 
sequences have been determined using the siRNA design tool from Promega 
(www.promega.com). Total specificity of the siRNA sequences was confirmed by a 
BLASTN search (www.ncbi.nlm.nih.gov).
Transfected cells were collected every 24 hours over a period of 120 hours and cells 
were analysed by western blotting and real time PCR in order to observe the effect of 
siRNAs on protein and gene expression level.
Genes / 
Accession 
number
siRNA
names Coding Strands
Position on 
the gene
Paper
source
ErbB2 
Ml 1730
ErbB2 5’-GGGGCUGGCUCCGAUGUAUTT-3’ 3388 - 3406
Faltus T. 
et al., 
2004ErbB2
scrambled
5’-GCGCGUCGGGUGG
UUACUATT-3’
Random 
sequence 
non specific 
of a gene
Table 2.8 -  ErbB2 siRNA sequences. Only the coding strand is shown (RNAi ordered as 
double stranded RNA sequences).
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2.16 Stable transfection
2.16.1 Stable transfection of ErbB2 plasmids
Plasmids were obtained from Dr. Segatto (Regina Elena Cancer Institute, Italy) and 
Prof. Hung (MD Anderson Cancer Center, USA) as mentioned in section 2.1. In order 
to proceed to the transfection, plasmids were transformed and amplified in 
Escherishia coli (E. coli). The pcDNA3 plasmid (Invitrogen, UK) contains the 
ampicillin resistant gene and the pEGFP-Nl plasmid (Clontech, UK) the kanamycin 
resistant gene (illustrated in Figures 2.10 and 2.11), to assist selection after 
transformation.
Plasmids transformation and amplification
In order to transform the plasmids into E. coli, lOOpl of TOPI OF chemically 
competent E. coli (Invitrogen, UK) was mixed with 5 pi of plasmid and incubated for 
15 minutes on ice. Cells were heat shocked for 90 seconds at 42°C before incubation 
for 2 minutes on ice. 800pl of SOC medium was added and cells were pelleted for 6.5 
minutes at 4,000rpm, at room temperature. Finally, 750pl of the supernatant was 
removed and the pellet was resuspended in the rest of the supernatant. Each 
transformed plasmid was plated on a pre-warmed LB (Luria-Bertani) agar plate 
(Invitrogen, UK), containing either 50pg/ml of ampicillin (Sigma-Aldrich, UK) or 
30pg/ml of kanamycin (Sigma-Aldrich, UK) selective agent. Plates were incubated 
overnight at 37°C. After selection, colonies were picked and grown overnight in 10ml 
of LB broth base (Lennox L Broth Base) medium (Invitrogen, UK) containing 
50pg/ml of ampicillin (Sigma-Aldrich, UK) or 30pg/ml of kanamycin (Sigma- 
Aldrich, UK), in an incubator shaker (37°C, 300rpm). Cells were harvested and 
plasmids were extracted (as previously described in section 2.9.1) using the QIAprep 
Spin Miniprep kit (Qiagen, UK) and quantified at 260nm using a NanoDrop® ND- 
1000 UV-Vis.Spectrophotometer (NanoDrop, UK).
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B sm l
Figure 2.10 -  pcDNA3 plasmid map. This plasmid carries the resistance gene ampicillin 
and neomycin. Unique restriction sites are indicated on the plasmid, (www.invitrogen.com).
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Figure 2.11 -  pEGFP-Nl plasmid map. This plasmid carries the resistance gene 
kanamycin/neomycin. Unique restriction site are indicated on the plasmid and in the detailed 
MCS (Multiple Coning Site) sequence, shown below the plasmid map. (www.clontech.com').
Plasmids verification
After extraction, integrity and purity of the plasmids was checked. As plasmids have 
been previously described in the literature, restriction enzymes were used to confirm 
the inserts. pcDNA3-ErbB2 has been described by Tzahar et al. (1996) and pEGFP- 
Nl-ErbB2 wild type and ErbB2ANLS were described by Giri et al. (2005). For the 
restriction reactions, 2pl of plasmids was incubated with 0.5pl of the appropriate 
enzyme (see Table 2.9), 1.5pl of the corresponding lOx buffer (supplied with the 
enzyme), lpl of RNAse A at 30.3mg/ml (Sigma-Aldrich, UK) and distilled water to 
15pi. Reactions were incubated for 2 hours at 37°C and run on a 1% agarose ethidium 
bromide gel. The gel was electrophoresed at 100V and photographed using a dual 
intensity ultraviolet transilluminator coupled with camera (UVP, UK). A 1Kb DNA 
ladder was used to determine the size of each fragment obtained. The expected sizes 
were as follow: ErbB2 ~ 4.4Kb; pcDNA3 ~ 5.4Kb; pEGFP-Nl ~ 4.7Kb; ErbB2ANLS 
~ 3.7Kb; N-terminal part of ErbB2ANLS ~ 2.0Kb and C-terminal part of ErbB2ANLS 
~ 1.7Kb.
Plasmid Enzyme Supplier
pcDNA3 Xhol and Xbal New England Biolabs, UK
pcDNA3-ErbB2 Xhol and Xbal New England Biolabs, UK
pEGFP-N 1 Nhel, Agel and Hindlll
New England Biolabs, 
UK
pEGFP-N 1 ErbB2 wild type Nhel, Agel and Hindlll
New England Biolabs, 
UK
pEGFP-N 1 ErbB2ANLS Nhel, Agel and Hindlll
New England Biolabs, 
UK
Table 2.9 -  List of enzymes used for plasmids restriction. Enzymes were chosen according 
to the position of the insert on the plasmid.
Plasmids transfection
Transfection was achieved using GeneJuice® transfection reagent (Novagen® EMD 
Biosciences Darmstadt, Germany). Exponentially growing MDA-MB-468 cells were 
plated in 6  well plates (Nunclon™, VWR, UK) at a concentration of 2xl05cells/ml 
(2ml per well), without any antibiotics and incubated for 24 hours at 37°C (5% CO2). 
3pi was vortexed with lOOpl of DMEM FCS free and incubated for 5 minutes in an
127
eppendorf. lpg of plasmid was added to the solution and incubated at room 
temperature for 15 minutes. Media from the plates was removed and replaced by 
fresh complete media with no antibiotics. Each plasmid/Gene Juice mixture was added 
dropwise to one well. Cells were incubated at 37°C (5% CO2) until confluence. Cells 
were subsequently trypsinised (0.5ml of trypsin) and pelleted before being plated in 
T25 flasks with media containing antibiotics and selective agent G418 (Sigma- 
Aldrich, UK). Transfected cells were incubated for 3 to 4 weeks to allow clones to 
grow (media was regularly changed to keep selective pressure). All the clones used 
were grown as stable transfected cell lines, maintaining selective pressure in the 
media.
2.16.2 Plasmids encoding specific human BRCA1 siRNA
DNA-directed RNA interference was used to reduce expression of BRCA1 gene. To 
this end, the MCF-7 cell line was stably transfected with a plasmid encoding specific 
human BRCA1 siRNA provided by Dr. C. Lord from the Institute of Cancer Research 
(UK). MCF-7 3.23 cells were transfected with a pSUPER-eCFP plasmid expressing 
siRNA directed against BRCA1 (BRCA1 siRNA sequence: 5’-
GGAACCTGTCTCCACAAAG-3’) and MCF-7 scrambled was transfected with the 
same plasmid but expressing a control sequence (Control siRNA sequence: 5’- 
CATGCCTGATCCGCTAGTC-3’) which does not recognise any human gene. In 
order to maintain selective pressure, for stable transfection, cells were grown with 
media containing blasticidin (Invivogen, UK). Stably transfected cell lines were 
subsequently analysed to assess the effect of the siRNA on protein and gene 
expression.
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2.17 Drug treatments
Prior to drug treatment, cells were seeded in flasks, 96 or 6  well plates and incubated 
at 37°C in 5% CO2 for 24 to 48 hours. Cells were then treated at a range of 
concentrations and lengths of exposure (Table 2.10). Concentrations varied according 
to the sensitivity of the cell lines. Appropriate schedules were used for the different 
experiments, as outlined in the methods detailed previously.
Compounds Lengths of exposure Range of concentrations
Gefitinib 24 hours or continuously 0 -  50pM
Etoposide
2 hours for Comet assays 
and continuously for SRB 
assay
0 -  250pM
Melphalan
1 hour for Comet assay 
and continuously for SRB 
assay
0 -  250pM
Doxorubicin Continuously for SRB assay 0 - lp M
Paclitaxel Continuously for SRB assay O-lOOnM
Cisplatin
Continuously for SRB 
assay and 1 hour for all 
other assays
0 -  250p.M
Trastuzumab
1 to 72 hours to determine 
the effect on ErbB2 level 
(western Blot) and 
continuously for all other 
assays
0  -  lOOpg/ml
Wheat germ agglutinin 
(WGA)
Continuously for SRB 
assay and 1.5hours for all 
other assays
0  -  lOOpg/ml
Table 2.10 -  Range of concentrations and lengths of exposure for drugs used in the 
different experiments. The ranges of concentration indicated in the table reflect the 
minimum and maximum concentrations used.
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Chapter 3
Modulation of the repair of drug- 
induced DNA damage by ErbB2
inhibition
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INTRODUCTION
Overexpression of ErbB2 tyrosine kinase receptor occurs in approximately one third 
of breast cancer cases and has been shown to be important in the development of this 
disease (Harari and Yarden, 2000). There has been an increasing interest in studying 
its function in breast cancer development and its role and interactions within the EGF 
receptor family (EGFR; ErbB2; ErbB3; ErbB4). Furthermore, ErbB2 overexpression 
has been related to poor prognosis in cancer patients due to factors including 
increased proliferation rate (Harari and Yarden, 2000).
3.1 Trastuzumab and ErbB2 protein expression
Currently, trastuzumab (Herceptin®) is the only approved therapy specifically 
targeting ErbB2. Trastuzumab is a monoclonal antibody which has been reported to 
have successful therapeutic effects on malignant cell lines and xenografts with 
overexpressed ErbB2 levels. Its therapeutic effects involve receptor phosphorylation 
(Yarden, 1990), receptor internalisation (Yarden, 2001b), inhibition of ectodomain 
cleavage (Molina et al., 2001), decrease in heterodimerisation (Emens and Davidson, 
2004) and in some cases down-regulation of receptor expression (Guan et al., 2005). 
Nevertheless, some conflicting studies have shown no cell surface ErbB2 down- 
regulation in tumour cells (Lane et al., 2000; Nahta et al., 2004). These events result 
in decreased cell proliferation.
Furthermore, by causing ErbB2 degradation, trastuzumab has been shown to lead to 
inhibition of the downstream PI3K and MAPK signalling cascades (Sliwkowski et 
al, 1999; Lane et al., 2000), G1 arrest through modulation of p27kipl (Sliwkowski et 
al., 1999), induction of apoptosis and inhibition of angiogenesis (Izumi et al., 2002). 
Trastuzumab monotherapy also proved successful clinically, as several studies 
(Baselga et al., 1996 and 2005; Cobleigh et al., 1999) have shown that it is well 
tolerated and clinically active in ErbB2 overexpressing metastatic breast cancer and 
causes tumour regression.
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3.2 Trastuzumab and chemotherapeutic agents
Trastuzumab has also been studied, in vitro and in vivo, in combination with 
chemotherapeutic agents, in ErbB2 overexpressing cells. Hancock et al. (1991) and 
Pietras et al. (1994) demonstrated that anti-ErbB2 antibodies were able to potentiate 
the cytotoxicity of cisplatin by altering the DNA repair activity of the cells. In 
addition, Pietras et al. (1994) also established that the interaction between cisplatin 
and an anti-ErbB2 antibody (4D5), causing the inhibition of ErbB2 overexpressing 
cells, was synergistic. More recently, several studies (Pegram and Slamon, 1999; 
Pegram et al., 2004a; Naruse et al., 2002) have reported the synergistic effect 
between anti-ErbB2 antibodies, such as trastuzumab, and carboplatin, cisplatin, 
docetaxel or vinorelbine. Pegram et al. (2004a) also obtained synergistic or additive 
effects, in xenografts, between anti-ErbB2 antibody and chemotherapeutic agents, 
such as alkylating agents, platinum analogs and topoisomerase II inhibitors, 
demonstrating rational combinations for human clinical trials. Furthermore, in this 
study they also established that synergistic effect was obtained using a three-drug 
combination of trastuzumab, carboplatin and docetaxel together, at very low dose. 
This finding was further confirmed by a clinical trial (Pegram et al., 2004b) showing 
that the three-drug combination leads to a higher response rate and a slower 
progression of the disease. Other clinical trials have also been carried out, 
investigating the combination of trastuzumab with paclitaxel (Seidman et al., 2001; 
Slamon et al., 2001) or docetaxel (Esteva et al., 2002), demonstrating an increased 
response rate and a reduced progression of the disease compared to the monotherapy. 
However, many patients develop trastuzumab resistance after initial response. 
Therefore, in order to improve patient survival a better understanding of the 
molecular mechanisms of action and resistance of trastuzumab, as well as identifying 
more effective combinations, is necessary.
3.3 Trastuzumab and DNA damage repair
Although enhancement of the cytotoxicity of chemotherapeutic agents was suggested 
to be due to an inhibition of DNA damage repair, only a few studies have investigated 
the effect of trastuzumab on the kinetics of DNA damage formation and repair. 
Studies by Pietras et al. (1994 and 1999) have established that trastuzumab caused a
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reduction of the DNA repair ability of tumour cells, by measuring unscheduled DNA 
synthesis. Those studies have shown that combining the anti-ErbB2 antibody with 
radiation or cisplatin, led to a decrease in unscheduled DNA synthesis compared to 
the treatments with cisplatin or radiation alone.
However, unscheduled DNA synthesis analysis, based on the replication of DNA 
during the excision repair of certain types of DNA lesions, as demonstrated by the 
incorporation of tritiated thymidine into the DNA repair sites, requires the use of 
radioactivity, has a limited sensitivity and is a non-specific assay. In contrast, single 
cell gel electrophoresis, used in this study, is a very sensitive method to detect low 
levels of DNA damage, requires a small number of cells, can be used in vitro and in 
vivo and requires a short time period to complete the experiment (Tice et al., 2000). 
Therefore, a more extensive investigation of the modulation of the repair of drug- 
induced DNA damage by ErbB2 inhibition was required, using the comet assay.
3.4 Aims
This chapter investigated the effect of ErbB2 inhibition on drug sensitivity and repair 
of DNA damage. Three breast cancer cell lines having been described in the literature 
as having different level of ErbB2 protein (Moasser et al., 2001), were used: MCF-7, 
MDA-MB-453 and SK-BR-3 cells. In order to study the effect of ErbB2 expression 
on drug-induced DNA damage response, the following questions have been 
addressed:
• How does trastuzumab affect ErbB2 protein expression and cell proliferation?
• Does trastuzumab enhance the cytotoxic effect of chemotherapeutic drugs?
• Does trastuzumab modulate the kinetics of formation and repair of drug- 
induced DNA damage?
However, as a starting point for this investigation, the normal protein expression level 
of each EGF receptor was identified for each cell line studied.
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RESULTS
3.5 EGF receptor protein expression
The level of expression of EGFR (ErbBl), ErbB2, ErbB3 and ErbB4 was determined 
by western blotting from total protein lysate of exponentially growing cells. Figure
3.1 shows that ErbB2 is overexpressed in SK-BR-3 and MDA-MB-453 cell lines, 
whereas ErbB2 is detectable but not overexpressed in MCF-7 cells.
EGFR (185kDa)
ErbB2 (185kDa)
ErbB3 (185kDa)
ErbB4 (185kDa)
Tubulin (50kDa)
MCF-7 SK-BR-3 MDA-MB-453
Figure 3.1 -  Western blotting of each EGF receptor in MCF-7, SK-BR-3 and MDA-MB- 
453 cell lines, a-tubulin was used as a loading control.
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3.6 Effects of trastuzumab treatment
In order to investigate the effect of ErbB2 inhibition on DNA damage repair, effects 
of trastuzumab on the ErbB2 protein level and on cell proliferation were assessed.
3.6.1 Down-regulation of ErbB2 by trastuzumab
ErbB2 expression was assessed by immunoblotting after treating the cells 
continuously with a range of trastuzumab concentrations (0-30pg/ml). Figures 3.2, 
3.3 and 3.4 represent the immunoblots obtained after 1 hour, 16 hours and 24 hours, 
respectively, of trastuzumab treatment for all three cell lines. Blots were also probed 
for the phosphorylated form of ErbB2 (pErbB2).
Immunoblots obtained show a reduction of ErbB2 protein expression after 16 hours at 
trastuzumab concentrations above 0.3pg/ml, for MCF-7 and MDA-MB-453 cells 
(Figure 3.3 A and C). For SK-BR-3, a reduction of ErbB2 protein level was seen after 
16 hours (Figure 3.3 B) with 3|ig/ml of trastuzumab. However, the fall is more 
noticeable after 24hours (Figure 3.4 B), with 0.3pg/ml of trastuzumab. To detect the 
decrease in protein level, in SK-BR-3 cells, short exposures were required, as the 
level in ErbB2 protein in extremely high. Hence, in all three cell lines, trastuzumab 
causes reduction of ErbB2 protein level. However, trastuzumab did not affect the 
level of phosphorylated ErbB2 protein.
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(A) MCF-7 
ErbB2 (185kDa) 
PErbB2 (185kDa) 
a-tubulin (50kDa)
0.03 0.3 30 pg/ml trastuzumab
(B) SK-BR-3 
ErbB2 (185kDa) 
pErbB2 (185kDa) 
a-tubulin (50kDa)
m  « h « p h  i #
« A » m m m —
0.03 0.3 30 pg/ml trastuzumab
(C) MDA-MB-453 
ErbB2 (185kDa) 
pErbB2 (185kDa) 
a-tubulin (50kDa)
0 0.03 0.3 3 30 pg/ml trastuzumab
Figure 3.2 -  Immunoblots of ErbB2 and pErbB2 in MCF-7, SK-BR-3 and MDA-MB- 
453 cell lines treated with trastuzumab for 1 hour. MCF-7 (A), SK-BR-3 (B) and MDA- 
MB-453 (C) cells were exposed to a range of trastuzumab concentrations (0-30pg/ml) for 1 
hour, a-tubulin was used as a loading control.
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(A) MCF-7 
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PErbB2 (185kDa) 
a-tubulin (50kDa)
0.03 0.3 30 pg/ml trastuzumab
(B) SK-BR-3 
ErbB2(185kDa) 
PErbB2 (185kDa) 
a-tubulin (50kDa)
0.03 0.3 30 pg/ml trastuzumab
(C) MDA-MB-453 
ErbB2 (185kDa)
PErbB2 (185kDa) 
a-tubulin (50kDa)
0 0.03 0.3 3 30 pg/ml trastuzumab
Figure 3.3 -  Immunoblots of ErbB2 and pErbB2 in MCF-7, SK-BR-3 and MDA-MB- 
453 cell lines treated with trastuzumab for 16 hours. MCF-7 (A), SK-BR-3 (B) and MDA- 
MB-453 (C) cells were exposed to a range of trastuzumab concentrations (0-30pg/ml) for 16 
hours, a-tubulin was used as a loading control.
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(B) SK-BR-3 
ErbB2 (185kDa) 
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(C) MDA-MB-453 
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Figure 3.4 -  Immunoblots of ErbB2 and pErbB2 in MCF-7, SK-BR-3 and MDA-MB- 
453 cell lines treated with trastuzumab for 24 hours. MCF-7 (A), SK-BR-3 (B) and MDA- 
MB-453 (C) cells were exposed to a range of trastuzumab concentrations (0-30pg/ml) for 24 
hours, a-tubulin was used as a loading control.
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3.6.2 Inhibition of cell proliferation by trastuzumab
Having shown the reduction of total ErbB2 protein level after continuous exposure to 
trastuzumab. its effects on cell proliferation was studied using the SRB assay. Figure 
3.5 represents the effect of trastuzumab on cell proliferation. Proliferation of MCF-7 
cells (expressing the lowest level of ErbB2 protein — Figure 3.1) is not affected, 
whereas SK-BR-3 cells proliferation is reduced by 40%, with concentrations as low 
as O.lpg/ml. MDA-MB-453 cells proliferation is reduced by 20%, with 
concentrations as low as O.lpg/ml. The figure below also shows that >50% inhibition 
of proliferation was not achieved with high trastuzumab concentrations (lOOpg/ml), 
so no IC50 could be determined.
120.00
100.00 -
c
0s 80.00
05L_
£ 60.00 -
0
Q. 40.00
s?
20.00 -]
0.00 -
0.1 1 10
Trastuzum ab (Mg/ml)
100
■ MCF-7
■ SK-BR-3
□ MDA-MB-453
Figure 3.5 -  Inhibition of cell proliferation by trastuzum ab in MCF7, SK-BR-3 and 
MDA-MB-453 cells. MCF-7 (red), SK-BR-3 (blue) and MDA-MB-453 (yellow) cells were 
treated continuously for 5 days with a range of trastuzumab concentrations. This result is the 
average of triplicate experiments (standard deviation indicated on the figure).
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3.7 Trastuzumab and chemotherapeutic treatments
3.7.1 Determination of IC50 of common chemotherapeutics
Several studies have reported an enhanced activity, in vitro and in xenograft models, 
of chemotherapeutic drugs when used in combination with trastuzumab (Pegram et 
al, 2004a; Baselga et al., 1998). Using the SRB assay, the effects of cisplatin, 
etoposide, melphalan, doxorubicin and paclitaxel were investigated as single agents. 
All cells were incubated for 5 days with the drugs, at a range of concentrations, in 
triplicate wells. To assure accuracy and reproducibility, all assays were repeated in 
triplicate. Inhibition of proliferation caused by each drug is represented in Figure 3.6 
and results for the 50% growth inhibition (IC50) are presented in Table 3.1. IC50 
values in Table 3.1 show that SK-BR-3 cells are the most sensitive to all 
chemotherapeutic drugs used (except for paclitaxel) compared to the other cell lines. 
Therefore, the ErbB2 protein expression level could not be associated with an 
increased chemoresistance.
Drug MCF-7 SK-BR-3 MDA-MB-453
Cisplatin 1.00±0.16pM 0.25±0.05pM 2.50±1.01pM
Etoposide 0.70±0.02pM 0.15±0.05pM 5.20±1.07pM
Melphalan 8.00±1.76pM 5.00±1.42pM 15.00±1.53pM
Paclitaxel 1.80±0.42nM 2.90±0.30nM 5.00±0.91nM
Doxorubicin 32.0±8.0nM 15.00±2.08nM 75.00±11.02nM
Table 3.1 -  IC50±SD results after single agent treatment in MCF-7, SK-BR-3 and MDA- 
MB-453 cells. Cells were treated continuously for 5 consecutive days.
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Figure 3.6 -  Inhibition of MCF-7, SK-BR-3 and MDA-MB-453 cell proliferation after 
single agent treatment. MCF-7 (♦), SK-BR-3 (■) and MDA-MB-453 ( ) cells were treated 
for 5 consecutive days with cisplatin (A), etoposide (B) melphalan (C), paclitaxel (D) or 
doxorubicin (E). Experiments have been repeated in triplicate.
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3.7.2 Combination of trastuzumab with chemotherapeutic agents
All drugs were used in combination with trastuzumab, using a range of concentrations 
of the chemotherapeutic drugs and trastuzumab at 3 and 20pg/ml. For all 
experiments, cells were incubated with the combination of drugs for 5 days, in 
triplicate wells. To ensure accuracy and reproducibility, all assays were repeated three 
times. Inhibition of proliferation caused by each drug is represented in Figures 3.7, 
3.8 and 3.9 for MCF-7, SK-BR-3 and MDA-MB-453 cells, respectively. Results for 
the 50% growth inhibition (IC50) are presented in Tables 3.2, 3.3 and 3.4. For ease of 
comparison, IC50 of the single agent treatments have been added to the tables.
Using the student /-test, IC50 of the combination treatments were compared to their 
respective IC50 for the single agent treatment, with a degree of freedom of 4 and a 
significance levelp  = 0.05 (95% probability). In Tables 3.2 to 3.4, IC50 highlighted in 
red were significantly different to their respective IC50 for the single agent treatment. 
Combining trastuzumab with chemotherapeutic drugs only increased the 
chemosensitivity of MCF-7 cells to some agents, with high trastuzumab 
concentrations (20fig/ml), whereas for SK-BR-3 cells (expressing high level of 
ErbB2) combining any of the chemotherapeutic drugs studied with trastuzumab, 
increased significantly their chemosensitivity, by up to 50 times for doxorubicin. In 
MDA-MB-453 cells, the combination of drugs also increased their chemosensitivity 
to all chemotherapeutic agents used, with 20pg/ml of trastuzumab. Hence, inhibition 
of ErbB2 protein level, by trastuzumab, sensitised cells overexpressing ErbB2 to 
chemotherapeutic drugs.
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Drug IC50 (single agent)
IC50 (combination 
with trastuzumab 
3pg/ml)
IC50 (combination 
with trastuzumab 
2 0  pg/ml)
Cisplatin 1.00±0.16pM 1.10±0.67pM 1.40±0.35pM
Etoposide 0.70±0.02pM 0.70±0.15pM 0.41±0.19fiM
Melphalan 8.00±1.76pM 7.00±2.08pM 4.00±1.32pM
Paclitaxel 1.80±0.42nM 1.10±0.38nM 0.90±0.15nM
Doxorubicin 32.00±8.00nM 24.00±6.66nM 21.00±7.00nM
Table 3.2 -  IC50±SD results for MCF-7 cells after single agent treatment and 
combination treatments. Cells were treated with the combination of drugs for 5 consecutive 
days. IC50 highlighted in red were significantly different to their respective IC50 for the single 
agent treatment (Student /-test, degree of freedom = 4 and significance level p  = 0.05).
Drug I C 50 (single agent)
I C 50 (combination 
with trastuzumab 
3pg/ml)
I C 50 (combination 
with trastuzumab 
2 0  pg/ml)
Cisplatin 0.25±0.05pM 0.02±0.01pM 0.02±0.01pM
Etoposide 0.15±0.05pM 0.02±0.01pM 0.02±0.01pM
Melphalan 5.00±1.42pM 1.10±0.70pM 0.07±0.04pM
Paclitaxel 2.90±0.30nM 0.90±0.46nM 0.46±0.09nM
Doxorubicin 15.00±2.08nM 0.30±0.06nM 0.85±0.20nM
Table 3.3 -  IC5o±SD results for SK-BR-3 cells after single agent treatment and 
combination treatments. Cells were treated with the combination of drugs for 5 consecutive 
days. IC50 highlighted in red were significantly different to their respective IC50 for the single 
agent treatment (Student /-test, degree of freedom = 4 and significance level p  = 0.05).
Drug I C 50 (single agent)
I C 50 (combination 
with trastuzumab 
3pg/ml)
I C 50 (combination 
with trastuzumab 
2 0  pg/ml)
Cisplatin 2.50±1.01|iiM 1.80±1.23pM 0.40±0.15pM
Etoposide 5.20±1.07pM 1.90±1.1 lpM 0.08±0.01pM
Melphalan 15.00±1.53pM 13.00±3.51pM 2.50±0.47pM
Paclitaxel 5.00±0.91nM 1.00±0.90nM 1.00±0.21nM
Doxorubicin 75.00±11.02nM 12.00±2.00nM 11.0±1.00nM •
Table 3.4 -  IC5o±SD results for MDA-MB-453 cells after single agent treatment and 
combination treatments. Cells were treated with the combination of drugs for 5 consecutive 
days. IC50 highlighted in red were significantly different to their respective IC50 for the single 
agent treatment (Student /-test, degree of freedom = 4 and significance level p  = 0.05).
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Figure 3.7 -  Inhibition of MCF-7 cells proliferation after continuous treatment with
trastuzumab combined with chemotherapeutic drugs. Cells were treated for 5 days with 
cisplatin (A), etoposide (B), melphalan (C), paclitaxel (D) or doxorubicin (E), alone (♦) and 
in combination with trastuzumab 3pg/ml ( ) and 20pg/ml (■). Error bars correspond to the 
standard deviation obtained from three independent experiments.
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Figure 3.8 -  Inhibition of SK-BR-3 cells proliferation after continuous treatment with 
trastuzumab combined with chemotherapeutic drugs. Cells were treated for 5 days with 
cisplatin (A), etoposide (B), melphalan (C), paclitaxel (D) or doxorubicin (E), alone (♦) and 
in combination with trastuzumab 3pg/ml ( ) and 20pg/ml (■). Error bars correspond to the 
standard deviation obtained from three independent experiments.
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Figure 3.9 -  Inhibition of MDA-MB-453 cells proliferation after continuous treatment
with trastuzumab combined with chemotherapeutic drugs. Cells were treated for 5 days 
with cisplatin (A), etoposide (B), melphalan (C), paclitaxel (D) or doxorubicin (E), alone (♦) 
and in combination with trastuzumab 3pg/ml ( ) and 20pg/ml (■). Error bars correspond to 
the standard deviation obtained from three independent experiments.
146
3.8 Modulation of DNA damage repair by ErbB2 inhibition
In the previous section, sensitisation of cells overexpressing ErbB2 to 
chemotherapeutic drugs by trastuzumab was observed. Therefore, the kinetics of 
DNA damage and repair following some of the combination treatments were 
investigated. Using the alkaline single-cell gel electrophoresis (comet) assay, 
formation and repair of DNA strand breaks or interstrand crosslinks (ICLs), induced 
by cisplatin, melphalan and etoposide, were studied. Prior to this investigation, the 
optimal dose of each chemotherapeutic agent to be used was determined for each cell 
line.
3.8.1 Measurement of DNA damage
Measurement of cisplatin and melphalan-induced DNA
interstrand crosslinks formation
DNA ICLs are one of the most toxic forms of DNA damage and have been 
demonstrated to be critical in the cellular effects of cisplatin (Zwelling et al., 1981) 
and melphalan (Hansson et al., 1987; Spanswick et al., 2002). Interstrand crosslinks 
represent only a small fraction of adducts formed but are considered to be critical 
lesions responsible for the cytotoxicity due to their inhibition of DNA strand 
separation and, therefore, of DNA replication, transcription, and segregation. Indeed, 
only 5-10% of adducts formed by cisplatin are ICLs, taking a few hours to form 
(Malinge et al., 1994). Similarly, melphalan, a member of the nitrogen mustard class 
of chemotherapeutic agents, also form ICLs which make up only 5% of the total 
adducts. In order to study DNA damage repair, the dose giving 50% to 70% 
crosslinks or decrease in tail moment (at peak of crosslinking) was determined by a 
dose response curve for each drug in all three cell lines.
For cisplatin treatments, cells were treated for 1 hour at a range of concentrations and 
incubated in drug free media for 9 hours, the time of the peak of crosslinking for 
cisplatin (Zwelling et al., 1979). For melphalan treatments, cells were treated for 1 
hour at a range of concentrations and incubated in drug free media for 16 hours, the 
time of the peak of crosslinking for melphalan (Spanswick et al., 2002). Results 
obtained for cisplatin and melphalan treatments are represented in Figures 3.10, 3.11 
and 3.12, for MCF-7, SK-BR-3 and MDA-MB-453, respectively. All three figures
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show that 150pM of cisplatin and 200pM of melphalan are required to produce ~50% 
interstrand crosslinks in each cell line, except for SK-BR-3 where 150pM of cisplatin 
caused ~45% interstrand crosslinks.
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Figure 3.10 -  DNA interstrand crosslinks in MCF-7 after cisplatin and melphalan 
treatment. Cells were treated with a range of concentrations of cisplatin (♦) and melphalan 
( A )  -  measurements at the peak of cross linking, 9 hours and 16 hours post-treatment, 
respectively. Data presented are the results of three independent experiments, as shown by the 
standard error.
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Figure 3.11 -  DNA interstrand crosslinks in SK-BR-3 after cisplatin and melphalan 
treatment. Cells were treated with a range of concentrations of cisplatin (♦) and melphalan 
( A )  -  measurements at the peak of crosslinking, 9 hours and 16 hours post-treatment, 
respectively. Data presented are the results of three independent experiments, as shown by the 
standard error.
—♦— Cisplatin 
—A — Melphalan
100.0 n
80.0 -
2!
60.0 -4->c05
E
o
E 40.0 J
&
20.0 -
0.0
0 50 100 150 200 250
D r u g  c o n c e n t r a t i o n  ( p M )
Figure 3.12 -  DNA interstrand crosslinks in MDA-MB-453 after cisplatin and 
melphalan treatment. Cells were treated with a range of concentrations of cisplatin (♦) and 
melphalan ( A )  -  measurements at the peak of crosslinking, 9 hours and 16 hours post­
treatment, respectively. Data presented are the results of three independent experiments, as 
shown by the standard error.
149
Measurement o f etoposide-induced DNA strand breaks
Etoposide is a topoisomerase II poison and forms a ternary complex with DNA. It 
causes protein-associated DNA strand breaks (single or double) by impairing the 
DNA strand rejoining function of the enzyme (Godard et al., 1999). DNA strand 
breaks are measured directly and are proportional to the tail moment of the comet. 
Cells are treated for 2 hours at a range of concentrations of etoposide, as strand breaks 
form rapidly. The peak of strand breaks (tail moment between 10 and 12) occurs 
quickly and is measured directly after incubation, as strand breaks are repaired 
quickly after removal of the drug (Long et al., 1985).
Figure 3.13 shows that 150pM of etoposide is required to produce a tail moment of 
11 in MCF-7, whereas 250pM of etoposide is needed to produce a tail moment of 10 
in SK-BR-3 and MDA-MB-453. Both cisplatin and melphalan did not produce any 
detectable strand breaks (data not shown).
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Figure 3.13 -  DNA strand breaks in MCF-7, SK-BR-3 and MDA-MB-453 cells after 
etoposide treatment. MCF-7 (♦), SK-BR-3 (■) and MDA-MB-453 ( ) cells were treated 
with a range of concentrations of etoposide -  measurements of strand breaks directly after the 
2 hours treatment. Data presented are the results of three independent experiments, as shown 
by the standard error.
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3.8.2 Effect of trastuzumab on the repair of drug-induced DNA 
damage
Effect o f trastuzumab on cisplatin-induced interstrand 
crosslinks repair
Using 20|ig/ml of trastuzumab, a clinically achievable dose (Baselga et al., 2005), 
and 150pM of cisplatin (determined as previously described), cells were either treated 
with cisplatin alone or a combination of both drugs for 1 hour. Cells were 
subsequently incubated in drug free media or media containing trastuzumab and 
repair of DNA damage was measured over 72 hours post-incubation. Results are 
presented in Figures 3.14, 3.15 and 3.16 for MCF-7, SK-BR-3 and MDA-MB-453 
cell lines, respectively. In all three cell lines, trastuzumab did not affect the level of 
cisplatin-induced ICLs. However, compared to cells treated with cisplatin alone, 
trastuzumab caused a clear delay in DNA ICLs repair when combined with cisplatin. 
The most significant inhibition in DNA repair was in SK-BR-3 cells (Figure 3.15). 
After 24 hours, 36.6±1.2% of ICLs were present in cells treated with cisplatin alone 
whereas in combination with trastuzumab 61.7±4.4% of ICLs were present. In all 
three cell lines, after 24 or 48 hours, a higher level of residual ICL remains when the 
cells were treated with a combination of cisplatin and trastuzumab than when treated 
with cisplatin alone. All three cell lines show a complete repair of ICLs after 72 
hours.
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Figure 3.14 -  Cisplatin-induced DNA interstrand crosslinks in MCF-7 cells. Cells treated 
with trastuzumab alone ( ), cisplatin alone (♦) or a combination of cisplatin with trastuzumab 
( A ) .Data presented are the results of three independent experiments, as shown by the 
standard error.
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Figure 3.15 -  Cisplatin-induced DNA interstrand crosslinks in SK-BR-3 cells. Cells 
treated with trastuzumab alone ( ), cisplatin alone (♦) or a combination of cisplatin with 
trastuzumab ( A ) .Data presented are the results of three independent experiments, as shown 
by the standard error.
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Figure 3.16 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-453 cells. Cells 
treated with trastuzumab alone ( ), cisplatin alone (♦) or a combination of cisplatin with 
trastuzumab (A).Data presented are the results of three independent experiments, as shown 
by the standard error.
Effect o f trastuzumab on the repair o f melphalan-induced
interstrand crosslinks
Similarly to the study with cisplatin, cells were treated with the previously 
determined dose of melphalan and 20pg/ml of trastuzumab. Results are presented in 
Figures 3.17, 3.18 and 3.19 for MCF-7, SK-BR-3 and MDA-MB-453 cell lines, 
respectively. As with cisplatin-induced ICLs, the peak of ICLs for melphalan was not 
modified by trastuzumab. However, while trastuzumab affected the repair of 
cisplatin-induced interstrand crosslinks, melphalan-induced interstrand crosslinks 
were not affected by the presence of trastuzumab. For example, in SK-BR-3 (Figure 
3.19), the level of ICLs after 24 hours is 43.5±5.1% for cells treated with melphalan 
alone and 46.3±2.7% when cells were co-treated with trastuzumab.
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Figure 3.17 -  Melphalan-induced DNA interstrand crosslinks in MCF-7 cells. Cells 
treated with melphalan alone (♦) or a combination of melphalan with trastuzumab (A) .  Data 
presented are the results of three independent experiments, as shown by the standard error.
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Figure 3.18 — Melphalan-induced DNA interstrand crosslinks in SK-BR-3 cells. Cells 
treated with melphalan alone (♦) or a combination of melphalan with trastuzumab (A) .  Data 
presented are the results of three independent experiments, as shown by the standard error.
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Figure 3.19 -  Melphalan-induced DNA interstrand crosslinks in MDA-MB-453 cells.
Cells treated with melphalan alone (♦) or a combination of melphalan with trastuzumab (A) .  
Data presented are the results of three independent experiments, as shown by the standard 
error.
Effect o f trastuzumab on the repair o f etoposide-induced
strand breaks
As previously described, cells were treated with etoposide (at the appropriate dose) 
alone or a combination of etoposide and trastuzumab (20pg/ml). Cells were incubated 
for 2 hours and media was replaced by drug free media or media containing 
trastuzumab only. Repair of strand breaks was observed over 72 hours post­
incubation. Figures 3.20 to 3.22 show the formation and repair strand breaks in all 
three cell lines. Trastuzumab alone did not alter the level of strand breaks produced 
following two hours incubation. For example, in MCF-7 at the end of the 2 hours 
treatment, etoposide produces a tail moment of 11.7±0.5 and in combination with 
trastuzumab 12.1 ±0.4. Strand break repair was detectable within the first 30 minutes 
and almost complete repair after 6 hours in all three cell lines. Combining 
trastuzumab with etoposide did not affect the repair of the strand breaks. For 
example, in MDA-MB-453 cells, after 1 hour post-incubation, the tail moment of 
cells treated with etoposide alone was 4.7±0.1 and the combination treatment gave a 
tail moment of 4.4±0.1. In all cell lines a small level of damage persisted after 72
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hours (tail moment of 2), which may be due to apoptotic cells present in solution, as a 
small level of damage was also detected in the untreated control cells. Therefore not 
all repair pathways for DNA damage induced by chemotherapeutic agents are 
modulated by trastuzumab.
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Figure 3.20 -  Etoposide-induced DNA strand breaks in MCF-7 cells. Cells treated with 
trastuzumab alone ( ), etoposide alone (♦) or a combination of etoposide with trastuzumab 
(A) .  Data presented are the results of three independent experiments, as shown by the 
standard error.
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Figure 3.21 -  Etoposide-induced DNA strand breaks in SK-BR-3 cells. Cells treated with 
trastuzumab alone ( ), etoposide alone (♦) or a combination of etoposide with trastuzumab 
(A) .  Data presented are the results of three independent experiments, as shown by the 
standard error.
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Figure 3.22 -  Etoposide-induced DNA strand breaks in MDA-MB-453 cells. Cells treated 
with trastuzumab alone ( ), etoposide alone (♦) or a combination of etoposide with 
trastuzumab (A) .  Data presented are the results of three independent experiments, as shown 
by the standard error.
157
3.8.3 Effect of trastuzumab dosage and drug treatment schedule
Having demonstrated that trastuzumab was able to modulate cisplatin-induced DNA 
interstrand crosslinks repair on the three breast cancer cell lines studied, the MDA- 
MB-453 cell line was used to study the effect of the dosage and drug scheduling on 
cisplatin-induced DNA damage repair.
Inhibition of DNA repair in a dose dependent manner
MDA-MB-453 cells were treated as previously described, with cisplatin and a range 
of trastuzumab doses. Figure 3.23 shows that trastuzumab caused inhibition of the 
repair of cisplatin-induced DNA interstrand crosslinks in a dose dependent manner. 
After 48 hours post-treatment with cisplatin alone, only 16.9±2.8% of the crosslinks 
remain, whereas combining cisplatin with trastuzumab (20pg/ml) 23.1 ±7.7% remain 
and 48.1 ±3.1% of crosslinks persist if trastuzumab is used at 40pg/ml. Using a high 
trastuzumab concentration (100pg/ml), 55.5±0.5% of crosslinks remain unhooked 
after 48 hours. 300pg/ml of trastuzumab is a much higher dose than can be achieved 
clinically. However, at this dose of trastuzumab DNA repair can be almost 
completely inhibited, with only 26.3±3.0% of the damage being repaired after 72 
hours.
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Figure 3.23 -  Trastuzumab dose dependent repair of cisplatin-induced DNA damage in 
MDA-MB-453 cells. Cisplatin-induced DNA interstrand crosslinks were measured following 
treatment using a range of trastuzumab doses, on MDA-MB-453 cells. Data presented are the 
results of three independent experiments, as shown by the standard error.
159
Modulation of drug scheduling and inhibition of DNA repair
Trastuzumab has been shown to inhibit DNA repair in a dose dependent manner, but 
drug scheduling may also affect this as in the case of EGFR with gefitinib 
(Friedmann et al., 2004). Firstly, prior to cisplatin treatment, MDA-MB-453 cells 
were pre-treated with 20pg/ml of trastuzumab for 24 hours. However, as shown in 
Figure 3.24, inhibition of DNA damage repair was not increased. After 24 hours, 
50.1±1.2% of the ICLs persisted in cells pre-treated with trastuzumab and 51.4±2.5% 
were not repaired in non pre-treated cells. The second modification was the time of 
pre-incubation before treatment of the cells. Previously, all cells were plated and 
incubated, in drug free media, for 24 hours prior treatment. Figure 3.25 shows the 
DNA repair kinetics of cells treated after 24 hours and 48 hours pre-incubation. For 
cells pre-incubated for 24 hours and treated with cisplatin alone, 16.2±7% of ICLs 
persisted after 48 hours in cells, whereas 20.6±4.6% remained in cells pre-incubated 
for 48 hours. In the combined treatment with trastuzumab at 40pg/ml no difference 
was seen, 48.1 ±3.1% of ICLs were still present after 48 hours in cells pre-incubated 
for 24 hours and 47.9±2.4% in cells pre-incubated for 48 hours. Hence, pre-treating 
the cells with trastuzumab for 24 hours (prior cisplatin treatment) or increasing the 
time of incubation in drug free media (prior cisplatin treatment) does not affect the 
DNA repair kinetics of MDA-MB-453 cells.
Furthermore, the pre-incubation time did not affect the IC50 of cisplatin alone or in 
combination with trastuzumab, for MDA-MB-453 cells, as measured by the SRB 
assay. Results are presented in Table 3.5 and Figure 3.26, IC50 of the combination 
treatments have been statistically compared to the IC50 of cisplatin single agent 
treatment, using the student /-test (degree of freedom = 4 and p = 0.05). Data for the 
24 hours pre-incubation are the same as the one presented in section 3.4.2. Similarly 
to section 3.4.2, IC50 of cisplatin combined with trastuzumab (20pg/ml) were 
significantly different to the IC50 of the cisplatin alone with a 95% probability (data 
highlighted in red). In addition, comparing the data obtained with 24 hours and 48 
hours pre-incubation did not show any significant difference. Thus, pre-incubation 
time, in drug free media, does not alter the cytotoxic effect cisplatin and trastuzumab. 
Although the effect of drug scheduling has not been studied extensively, these data 
demonstrated that drug scheduling does not alter the DNA repair kinetics, in vitro.
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Cisplatin 150pM
100.0 Cisplatin 150pM + 
trastuzumab 20pg/ml
80.0 -
Cisplatin 150pM + 
trastuzumab 20pg/ml 
pre-treatment60.0 h
40.0 -
20.0 -
0.0
-2 0 .0  J
I n c u b a t i o n  t i m e  ( H o u r s )
Figure 3.24 -  Effect of trastuzumab pre-treatment on cisplatin-induced DNA ICLs in 
MDA-MB-453 cells. Cells were treated with cisplatin (♦) or cisplatin and trastuzumab, with 
( ) or without ( A )  trastuzumab pre-treatment. Data presented are the results of three 
independent experiments, as shown by the standard error.
Cisplatin alone 150pM- 48 hours 
pre-incubation
Cisplatin 150pM + trastuzumab 
40pg/ml - 48 hours pre-incubation100.0 -
Cisplatin alone 150pM- 24 hours 
pre-incubation80.0 -
60.0 - Cisplatin 150pM + trastuzumab 
40pg/ml - 24 hours pre-incubation
40.0 -
20.0
0.0
-2 0 .0  J
T i m e  ( H o u r s )
Figure 3.25 -  Effect of drug free media pre-incubation on cisplatin-induced DNA ICLs 
repair kinetics in MDA-MB-453 cells. Cells were pre-incubated in drug free media for 24 
hours or 48 hours. Data presented are the results of three independent experiments, as shown 
by the standard error.
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P r e - i n c u b a t i o n  
t i m e  in  d r u g  
f r e e  m e d i a
C i s p l a t i n
C i s p l a t i n  +  
t r a s t u z u m a b  
3 j i g / m l
C i s p l a t i n  +  
t r a s t u z u m a b  
2 0 n g / m l
2 4  h o u r s 2 . 5 0 ± 1 . 0 1 p M 1 . 8 0 ± 1 . 2 3 p M 0 . 4 0 ± 0 . 1 5 p M
4 8  h o u r s 2 . 9 0 ± 0 . 8 5 p M 1 . 8 0 ± 0 . 5 0 p M 0 . 8 0 ± 0 . 4 1 j i M
Table 3.5 -  ICso±SD of cisplatin single agent and combined with trastuzum ab, in MDA- 
MB-453 cells pre-incubated in drug-free media for 24 hours or 48 hours. Results have 
been statistically analysed using the student /-test and IC5o highlighted in red are significantly 
different to the IC50 of the cisplatin alone with a 95% probability (degree of freedom = 4 and 
p  = 0.05).
-♦—  Cisplatin
-■—  Cisplatin +
trastuzum ab 20pg/ml
Cisplatin + 
trastuzum ab100.0
O 80.0
60.0
oL.
CL
40.0
20.0
0.0
10.0 100.00.0 0.1 1.0
C i s p l a t i n  c o n c e n t r a t i o n  ( p M )
Figure 3.26 -  Inhibition of MDA-MB-453 cells proliferation after 48 hours of pre­
incubation in drug free media. Following 48 hours pre-incubation, cells were treated with 
cisplatin alone (♦), cisplatin combined with trastuzumab 3pg/ml ( ) and cisplatin combined 
with trastuzumab 20pg/ml (■).
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DISCUSSION
Results presented in this chapter described the effect of trastuzumab on ErbB2, its 
effect on sensitivity to chemotherapeutic agents and the modulation of DNA damage 
repair in breast cancer cells MCF-7, SK-BR-3 and MDA-MB-453. The DNA 
damaging agents used for this study are widely used clinically and their mechanism 
of action is well understood. Although conflicting studies exist on the exact 
mechanism of action of trastuzumab, several investigations have shown the 
therapeutic benefits in breast cancer of trastuzumab alone (Vogel et al., 2002; Mass et 
al., 2005) and in combination of chemotherapeutic agents (Slamon et al., 2001; 
Burstein et al., 2003). Results demonstrated that trastuzumab inhibited ErbB2 
expression and enhanced the anti-proliferative effects of cisplatin, melphalan, 
etoposide, paclitaxel and doxorubicin, in ErbB2 overexpressing cells. Furthermore, 
trastuzumab was shown to cause a delay in cisplatin-induced DNA damage repair.
3.9 Trastuzumab affects ErbB2 overexpressing cells
This investigation was carried out in three breast cancer cell lines, expressing 
different level of ErbB2 protein, ranging from low for MCF-7 cells to overexpressed 
for MDA-MB-453 and SK-BR-3 cells. It was previously reported that interaction of 
trastuzumab with ErbB2 caused an increase in phosphorylation, down-regulation of 
ErbB2, internalisation of the antibody-receptor complex and a decrease in ErbB2 
heterodimerisation (Yarden, 1990; Park et al., 1992; Maier et al., 1991; Klapper et 
al., 1997).
In this study, trastuzumab was shown to down-regulate ErbB2 in all three cell lines 
when treated for at least 16 hours with 0.3pg/ml of trastuzumab. Although many 
studies have reported a reduction of ErbB2 level in cells overexpressing ErbB2 
(Cuello et al., 2001; Guan et al., 2005; Lee et al., 2002b), there are conflicting results 
(Lane et al., 2000; Nahta et al., 2004). This may be explained by the time of exposure 
to trastuzumab, since ErbB2 protein level in SK-BR-3 cells was not affected before 
24 hours of treatment. Another effect of trastuzumab is the inhibition of cell 
proliferation, as reported by Longva et al. (2005), where SK-BR-3 cells proliferation 
was inhibited after treatment with trastuzumab at 15pg/ml. In addition, Pegram et al.
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(1999) demonstrated that anti-ErbB2 antibody led to an inhibition of tumour 
progression in xenografts. The results obtained there established that trastuzumab 
caused inhibition of cell proliferation of ErbB2 overexpressing cells, SK-BR-3 and 
MDA-MB-453, with concentration as low as O.lpg/ml.
Trastuzumab causing ErbB2 down-regulation in all cell lines but inhibition of cell 
proliferation only in ErbB2 overexpressing cells, its anti-proliferative effect was 
therefore not directly associated with ErbB2 down-regulation.
3.10 Trastuzumab enhances chemotherapeutic cytotoxicity
Different studies (Pegram and Slamon, 1999; Pegram et al., 2004a; Naruse et al., 
2 0 0 2 ) have reported increased cytotoxic effect or synergistic effect of the monoclonal 
antibody (at relevant concentration -  Arteaga, 2003) when used in combination with 
cisplatin, in vitro and in xenografts. Additive effects have also been reported with 
doxorubicin and paclitaxel (Pegram et al., 2004a). A study by Hancock et al. (1991), 
using a monoclonal antibody specific to ErbB2 (TAb250), also demonstrated the 
inhibition of cell proliferation in a dose dependent manner and an enhance 
cytotoxicity of cisplatin when combined with this antibody. In vivo, Slamon et al. 
(2 0 0 1 ) also established that trastuzumab increased the clinical benefit of first-line 
chemotherapy, such as paclitaxel and doxorubicin, in metastatic breast cancer 
overexpressing ErbB2. In the data presented, using chemotherapeutic drugs as single 
agents or in combination with trastuzumab (at clinically achievable concentrations), 
cells overexpressing ErbB2 (SK-BR-3 and MDA-MB-453 cells) were sensitised in 
the presence of the monoclonal antibody. In addition, this result was most significant 
in SK-BR-3, as with 3pg/ml trastuzumab sensitivity of the cells increased with all 
chemotherapeutic drugs used. The increased sensitivity observed in combination 
treatments was also related to the inhibition of proliferation caused by trastuzumab. 
Doses of 3pg/ml and 20pg/ml of trastuzumab produced growth inhibition of 20% to 
40% in those two cell lines but did not affect MCF-7 cells which have a low level of 
ErbB2 proteins.
Comparing dose response curves of ErbB2 transfected cells with their parent cell 
lines, Pegram et al. (1997) established that the association between ErbB2 expression
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and chemoresistance, to agents such as cisplatin, doxorubicin, paclitaxel or etoposide, 
was cell line specific. In addition, in vivo results for parent/daughter xenografts, 
differing only by their ErbB2 expression level, demonstrated that ErbB2 
overexpression did not cause increased chemoresistance. Nevertheless, they showed 
that ErbB2 overexpressing xenografts had a more rapid re-growth in response to 
chemotherapeutic agents. Similarly, in vitro results obtained for single agent 
treatments showed that a higher level of ErbB2 did not correlate with an increased 
chemoresistance, as the SK-BR-3 cell line, with a high level of ErbB2, was the most 
sensitive to the chemotherapeutic agents studied. However, MDA-MB-453 cells, with 
a high ErbB2 protein level, were more chemoresistant than MCF-7 cells. Nonetheless, 
as cell lines used are derived from different sources, they may inherently differ in 
characteristics other than the ErbB2 expression level, which could have an impact on 
drug sensitivity.
Thus, it is difficult to compare the chemoresistance of different cell lines based solely 
on their ErbB2 protein level since chemoresistance is controlled by several genes 
which can be more or less amplified in different cell lines. Furthermore enhancement 
of cytotoxicity effect of chemotherapeutic agents by trastuzumab was less significant 
than the one described in published data. This may be explained by the use of the 
SRB assay as clonogenic assay or xenograft studies have been proved to be more 
sensitive. Nevertheless, as synergistic effects between trastuzumab and 
chemotherapeutic agents have been extensively described in published studies, the 
SRB assay will be sufficient to confirm enhancement of chemotherapeutic 
cytotoxicity.
3.11 Trastuzumab modulates DNA damage repair
Although synergistic mechanisms of trastuzumab with chemotherapeutic agents are 
not fully understood, it has been suggested that these mechanisms are due to the 
inhibition of repair by trastuzumab. Hancock et al. (1991) suggested that the 
enhancement of cisplatin cytotoxicity, by an ErbB2 inhibitor, could be explained by 
an inhibition of DNA repair. In addition, studies by Pietras et al. (1994 and 1998), 
demonstrated that trastuzumab was able to inhibit partially the repair of DNA damage 
induced by cisplatin and radiation, by blocking unscheduled DNA synthesis (UDS).
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Nonetheless, the use of UDS analysis is limited as it does not measure specifically 
one type of repair but overall genome repair. Furthermore, in their study trastuzumab 
was used at 2 0 0 pg/ml which is much higher than the clinically achievable doses 
described in the study by Baselga et al. (2005).
Cisplatin and melphalan-induced DNA ICLs -  Using clinically achievable doses 
of trastuzumab and the more sensitive comet assay, results obtained here established 
that trastuzumab did not affect the peak of crosslinking of cisplatin or melphalan. 
Nonetheless, whilst the repair of melphalan-induced DNA ICLs was not affected by 
trastuzumab, a clear delay in cisplatin-induced DNA ICLs repair was observed. This 
delay persisted for more than 48 hours after drug treatment, in all three cell lines. In 
addition, trastuzumab was shown to induce DNA repair inhibition in a dose 
dependent manner, when using a range of trastuzumab doses, in MDA-MB-453 cells. 
Thus, trastuzumab affects the downstream pathway responsible for the repair of 
interstrand crosslinks induced by cisplatin. These results are similar to those obtained 
by Friedmann et al. (2004) in this laboratory, when they demonstrated that inhibition 
of EGFR tyrosine kinase inhibited cisplatin-induced DNA damage but not melphalan- 
induced DNA damage.
Although both melphalan and cisplatin caused the formation of ICLs, the repair 
mechanisms of those damages are affected differently by the inhibition of ErbB2. 
This could be explained by the type and frequency of ICLs that differ between 
cisplatin and melphalan. Indeed, De Silva et al. (2002) demonstrated that repair of 
cisplatin ICLs does not involve the formation of double strand breaks, in contrast to 
other conventional crosslinking agents, such as melphalan. Several studies have 
identified the importance of the XPF-ERCC1 heterodimer component of nucleotide 
excision repair (De Silva et al., 2000; Mu et al., 2000; Kuraoka et al., 2000) for the 
unhooking of cisplatin ICLs. Nevertheless, De Silva et al. (2002) suggested that 
homologous recombination was initiated prior to excision of cisplatin ICLs since they 
found that XRCC2 and XRCC3 HR mutants were defective in the unhooking step of 
cisplatin ICLs. For melphalan, Clingen et al. (2005) demonstrated that the repair of 
DNA ICLs was dependent on the XPF-ERCC1 heterodimer component of the 
nucleotide excision repair pathway. Therefore, inhibition of the mechanisms of repair 
of melphalan and cisplatin-induced ICLs requires further investigation.
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Furthermore, the molecular mechanisms by which trastuzumab blocks DNA repair is 
thought to involve the inhibition of p21WAF1. Indeed, Pietras et al. (1999) reported 
that combining radiation therapy with trastuzumab caused inhibition of p2 1 WAF1 
induction, leading to cell cycle progression and accumulation of unrepaired DNA 
damage. Thus, further investigation of the modulation of the cell cycle induced by 
trastuzumab after cisplatin-induced DNA damage will be required.
Etoposide-induced DNA strand breaks -  Investigating the effect of trastuzumab on 
etoposide-induced DNA strand breaks did not show any increase of strand breaks by 
trastuzumab, in any of the cell line studied, as had been reported previously by 
Mayfield et al. (2001). In their study, they demonstrated that treating ErbB2 
overexpressing cells, such as SK-BR-3 cells, with trastuzumab at lOpg/ml caused an 
increase in DNA strand breaks. Furthermore, results obtained established that 
trastuzumab did not alter the repair of etoposide-induced DNA strand breaks. 
Although no study has investigated the repair of etoposide-induced strand breaks 
following trastuzumab treatment, a study by Pietras et al. (1999) investigated the 
effect of ErbB2 on ionising radiation-induced DNA damage repair, using 
unscheduled DNA synthesis analysis. Their results demonstrated that trastuzumab 
caused a decrease in radiation-induced DNA strand break repair and highlighted that 
signal transduction pathways provided by ErbB2 were essential to the repair of this 
type of DNA damage. Therefore, further investigation of the effect of ErbB2 
inhibition, by trastuzumab, on DNA strand break repair is needed using the more 
sensitive comet assay.
3.12 Conclusion
These results demonstrated that the inhibition of ErbB2 protein expression has an 
effect on cells sensitivity to chemotherapeutic drugs, suggesting a biological role for 
ErbB2 in the resistance to chemotherapy. These experiments have also proved that a 
clear inhibition of cisplatin-induced DNA ICLs repair was obtained by ErbB2 
inhibition. Moreover, this delay in DNA repair was not seen after strand break 
damage and was specific to ICLs caused by cisplatin, as the repair of melphalan- 
induced DNA ICL was not affected.
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Therefore, it is reasonable to conclude that enhancement of cisplatin cytotoxicity, by 
inhibition of ErbB2, is caused, at least in part, by an alteration of DNA repair 
mechanisms.
Further understanding of the mechanisms, involved in the interaction between ErbB2 
and DNA damage repair, will be essential in order to improve the clinical 
management of breast cancer. To this end, the next chapter will discuss the effects of 
ErbB2 inhibition on cell cycle and downstream proteins.
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Chapter 4
DNA repair modulation and cell 
cycle regulation
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INTRODUCTION
In the previous chapter, enhancement of the cytotoxicity of chemotherapeutic agents 
in combination with trastuzumab, an inhibitor of ErbB2 protein, was seen in cells 
overexpressing ErbB2. It was also demonstrated that the inhibition of ErbB2 led to 
the inhibition of the repair of cisplatin-induced DNA interstrand crosslink. Thus, the 
effects of ErbB2 inhibition might be due primarily to cell cycle arrest. Therefore, the 
influence of the DNA repair modulation, by trastuzumab, on cell cycle regulation, 
apoptosis and the expression level of key DNA repair and downstream proteins 
involved in ErbB2 signalling pathways was investigated.
4.1 Effects of trastuzumab on the cell cycle
During cell division, genetic integrity is maintained through the proper execution of 
the cell cycle mechanism. Upon trastuzumab treatment, some studies have shown 
cells undergo cell cycle arrest in the G1 phase (Sliwkowski et al., 1999). In addition, 
several studies (Marches and Uhr, 2004; Lane et al., 2000; Le et al., 2003) suggested 
that this cell cycle arrest in G1 was due to a reduction of proteins responsible for the 
cyclin-dependent kinase (cdk) inhibitor p27kipl sequestration, causing its 
accumulation. Sliwkowski et al. (1999) reported that an anti-ErbB2 antibody led to an 
increase in p27kipl in reducing the number of cells entering the S phase of the cell 
cycle. This cdk was shown to bind to cyclinE/cdk2 complexes, causing their 
inhibition (Lane et al., 2001) and subsequent cell cycle arrest. However, increased 
Akt was shown to cause down-regulation of p27kipl (Di Cristofano et al., 2001) or 
phosphorylation of p27k,pl causing its cytoplasmic retention (Yakes et al., 2002).
In other studies, anti-ErbB2 antibodies also caused a reduction in p21WAF1 level in 
cells overexpressing ErbB2. p21WAF1 is another cyclin-dependent kinase which was 
shown to lead to cell cycle arrest upon nuclear localisation and activation (El-Deiry et 
al., 1993; Xiong et al., 1993; Waga et al., 1994). However, studies have demonstrated 
that the inhibition of cell cycle progression, by p2 1 WAF1, was not due to the reduction 
in cyclin Dl (Pietras et al., 1998 and 1999) but a dramatic diminution in cyclins D2 
and D3 (Lane et al., 2000; Neve et al., 2000). In addition, in response to DNA 
damage, p2 1 WAF1 was shown to be activated and caused cell cycle arrest upon
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cyclin/cdk binding (El-Deiry et a l, 1993; Chen et a l, 1994). Using trastuzumab in 
combination with radiation, Pietras et al (1999) established that the monoclonal 
antibody was able to inhibit p21WAF1. Hence, this reduction in p21WAF1 caused cell 
cycle progression and accumulation of unrepaired DNA damage, leading to an 
enhanced cell killing. Therefore, the study of trastuzumab effects on the cell cycle 
may potentially explain the modulation in DNA damage repair.
4.2 Effect of trastuzumab on apoptosis
In Chapter 3, single agent trastuzumab was shown to reduce cell proliferation of 
ErbB2 overexpressing cells. However, conflicting results have been obtained on the 
effect of trastuzumab on the induction of apoptosis. As demonstrated by the clinical 
data from Mohsin et al (2005), trastuzumab induced a significant increase in 
apoptotic cell death in ErbB2 overexpressing breast cancer patients receiving 
trastuzumab as a single agent followed by trastuzumab in combination with 
docetaxel. On the contrary, in a similar study, Gennari et al (2004) did not find any 
decrease in proliferation in patients with ErbB2 overexpressing operable breast cancer 
treated with single agent trastuzumab. Nevertheless, the latter was carried out in a 
small number of patients and over a short period of time. Therefore, apoptosis and a 
decrease in breast cancer proliferation need to be observed over a longer period.
Thus, more research is required to characterise the cytotoxic effect of trastuzumab, 
since induction of apoptosis by trastuzumab could explain the increase in 
chemosensitivity reported in Chapter 3.
4.3 ErbB2 signalling cascade and topoisomerase Hot
In order to investigate the observed delay in DNA damage repair, modulation of the 
level of proteins involved in DNA damage repair will be studied. Additionally, other 
important proteins need to be considered, such as Akt involved in the ErbB2 
signalling cascade and topoisomerase Hoc expression, which is dependent on the cell 
cycle phase.
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4.3.1 Role of Akt in ErbB2 signalling cascade
As described previously, alteration of the cell cycle by trastuzumab has been shown 
to be mediated through the PI3K/Akt signalling pathway (Le et al., 2005). In 
addition, several studies (Normanno et al., 2002; Yakes et al., 2002) have 
demonstrated that inhibition of PI3K and its target Akt was required to obtain 
trastuzumab anti-tumour activity. Akt is a downstream component of the PI3K 
signalling pathway, which is activated upon phosphorylation of receptor tyrosine 
kinases such as EGFR and ErbB2. This protein has been shown to be important in 
regulation of metabolism, cell survival motility, transcription and cell cycle regulation 
(Figure 4.1).
Upon activation of the PI3K signalling pathway, Akt is phosphorylated at threonine 
308 for Akt activation and serine 473 for maximal activity (Fayard et al., 2005). 
Activated Akt has been shown to have anti-apoptotic effects by inactivating pro- 
apoptotic factors BAD and pro-caspase 9. Moreover, Akt was shown to prevent the 
release of cytochrome c from mitochondria, inactivating forkhead transcription 
factors and expression of pro-apoptotic factors (Datta et al., 1999). Activation of Akt 
was also previously described to cause degradation of p27k,pl leading to stability of 
cyclin D and cell cycle progression (Collado et al., 2000). In addition, Akt also 
inhibits the function of cell cycle suppressor p21WAF1 and p27klpl through their 
phosphorylation and subsequent cytoplasmic retention (Zhou et al., 2001b; Motti et 
al., 2005). Cytoplasmic p21WAF1 will then bind ASK1, inhibiting apoptosis (Zhou et 
al., 2001b). Finally, activated Akt also phosphorylates MDM2, causing an increase in 
nuclear localisation and inhibition of its interaction with pl9ARF. In the absence of 
interaction with pl9ARF, MDM2 associates with the tumour suppressor, p53, causing 
its cytoplasmic translocation and degradation (Zhou et al., 2001a).
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Figure 4.1 -  Effect of Akt activation. Testa J.R. et al., Proceedings of the National 
Academy of Sciences, 2001, 98(20): 10983-10985.
4 .3 .2  T o p o is o m e r a s e  I l a  a n d  c e ll  c y c le
Topoisomerase II is an enzyme responsible for relaxation of DNA supercoils, DNA 
decatenation of circular double stranded DNA and is involved in chromatin 
remodelling during mitosis (Nitiss, 1998). There are two homologous forms, a  and p. 
The gene coding for topoisomerase Ila is adjacent to the ErbB2 oncogene at the 
chromosome location 17ql2-q21 (Jarvinen and Liu, 2006). In addition, the a  form is 
regulated with the cell cycle and becomes detectable in late G1 phase with an 
increasing level up to G2/M phase (Woessner et al., 1991). Topoisomerase Ila 
activity is increased by phosphorylation through casein kinase II. A recent study 
suggested the involvement of MAPK-regulated kinase pathway (Shapiro et al., 1999). 
Furthermore, topoisomerase II has been shown to be influenced by p53 and 
retinoblastoma susceptibility gene product (Rb). p53 down-regulates topoisomerase 
Ila expression by transcriptional regulation (Wang et al., 1997). Conversely, several 
studies (Carrier et al., 1999; Hochhauser et al., 1999) have shown that p53 was able 
to stimulate topoisomerase Ila. Similarly to p53, Rb has been shown to inhibit the 
activity of this enzyme (Bhat et al., 1999). Moreover, a protein of the 14-3-3 family, 
responsible for cell cycle control, apoptosis and stress response, has recently been 
shown to inhibit the DNA binding capacity of topoisomerase Ila (Van Hemert et al., 
2001; Kurz et al., 2000).
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Therefore, topoisomerase Ila activity plays an important role in tumour progression. 
Several studies also demonstrated that T0P02a amplification was associated with 
ErbB2 gene amplification in breast cancer and non-small cell lung cancer (Keith et 
al., 1992; Smith et al., 1993). Furthermore, since both genes are located on the 
chromosome 17, amplification of one gene locus may affect the other, explaining the 
concurrent overexpression of ErbB2 and T0P02a in breast cancer (Jarvinen et al., 
1996).
4.4 Aims
In this chapter, possible mechanisms responsible for the delay in the repair of 
cisplatin-induced DNA ICLs, described in Chapter 3, will be investigated. Using the 
MDA-MB-453 cell line overexpressing ErbB2, the following questions will be 
addressed:
• How do the combinations in the doses used in this study affect the cell cycle?
• Does trastuzumab induce apoptosis?
• How are proteins involved in DNA damage repair and ErbB2 signalling 
cascade affected by trastuzumab?
• Is topoisomerase Ila expression altered by trastuzumab in these cell lines?
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RESULTS
4.5 Influence of DNA repair modulation on cell cycle
regulation
Inhibition of ErbB2 has been shown to modulate the repair of cisplatin-induced DNA 
damage and it is possible that this effect might be due to cell cycle modulation. 
Therefore, to investigate this, the cell cycle of MDA-MB-453 cells was studied using 
flow cytometry (FACS analysis). Cells were treated with cisplatin alone (150pM) for 
one hour or cisplatin in combination with trastuzumab (40pg/ml) for one hour. Cells 
were subsequently incubated in drug-free media or media containing trastuzumab 
(40pg/ml). Two controls were included, cells treated continuously with trastuzumab 
alone and untreated cells. Cells were then collected at different time points over 72 
hours (post-treatment). The percentages of cells in each phase of the cell cycle are 
presented in Tables 4.1 to 4.4 and with each table the appropriate histogram profile of 
the cells, from representative experiments, was associated (Figures 4.2 to 4.5).
Trastuzumab alone (Figure 4.3 and Table 4.2) caused the cells to accumulate in the 
G1 phase by 14 hours, resulting in a reduction in the cells entering the S phase, 
compared to untreated cells (Figure 4.2). 32.9±4.3% of the cells were in S phase after 
4 hours of trastuzumab treatment whereas 16.5±1.7% were in S phase after 48 hours 
of treatment. In contrast, 24.1 ±1.0% of untreated cells were in S-phase after 48 hours. 
It is also noted that, compared to untreated cells, trastuzumab treatment did not cause 
a significant increase in sub-Gl, characteristic of apoptotic cells.
Cells treated for 1 hour with cisplatin (Figure 4.4 and Table 4.3) accumulated in G2 
phase by 48 hours. After cisplatin treatment (0 hour), 16.8±2.7% of cells were in G2 
phase, whereas 34.4±0.3% of cells were in G2 after 72 hours. This accumulation in 
G2 stopped the cells from entering the G1 phase, as 48.7±2.0% of cells were in G1 
after treatment and only 13.8±1.4% after 72 hours. Furthermore, cisplatin caused an 
increase of cells in sub-Gl, as 2.4±0.4% of cells were in sub-Gl after treatment and 
14.8+1.2% after 72 hours. Nevertheless, it is noted that at the peak of ICLs (9 hours), 
no change in the cell cycle was observed.
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Combining trastuzumab with cisplatin (Figure 4.5 and Table 4.4) caused a smaller 
reduction in cells undergoing G2 arrest. After 72 hours, 22.9±3.5% of cells were in 
arrested in G2 whereas 34.4±0.3% of cells treated with cisplatin alone were arrested 
in G2. There was also an increase in cells entering sub-Gl, as 14.8±1.2% of cells 
were in sub-Gl 72 hours after cisplatin treatment whereas 22.7±2.4% were in sub-Gl 
72 hours after the combination treatment. It was also noted that cisplatin alone or in 
combination with trastuzumab caused an increase in sub-Gl after 14 to 19 hours, 
which may be due to cells arrested in G2 entering apoptosis.
Therefore, the delay in the repair of cisplatin-induced DNA ICLs caused by 
trastuzumab may be due to the progression of the cells through the G2 arrest, induced 
by cisplatin. It is also noted that the increase in cell sensitivity observed in the 
previous chapter (section 3.4.2) with the combination treatment is reflected in an 
increase in apoptotic cells (sub-Gl).
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Figure 4.2 -  Histogram profile of MDA-MB-453 untreated cells. Cells have been 
collected every 24 hours. One event = one cell. Histogram from a representative experiment.
C o n t r o l S u b G l G 1 S G 2
0 1.4±0.4 47.1±3.8 31.513.1 2 0 .0 1 0 .6
2 4 4.1±1.0 57.8±2.0 21.312.5 16.811.0
4 8 5.2±1.0 61.4±2.1 24.111.0 9.311.7
7 2 4.3±0.4 59.9±1.3 26.110.8 9.811.4
Table 4.1 -  Percentage of untreated MDA-MB-453 cells in each phase of the cell cycle.
These values are an average of three independent experiments. Data presented are the average 
of three independent experiments as shown by the standard error.
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Figure 4.3 -  Histogram profile of MDA-MB-453 cells treated with trastuzumab. Cells 
were treated with trastuzumab (40pg/ml) continuously. Cells have been collected at different 
time point. One event = one cell. Histogram from a representative experiment.
T r a s t u z u m a b
4 0 j ig /m l
S u b G l G 1 S G 2
0 2.1±0.3 49.911.4 34.412.1 13.611.0
4 2.4±0.5 48.214.7 32.914.3 16.510.5
9 4.0±1.3 45.114.5 29.114.7 21.811.5
14 4.9±1.0 64.610.7 14.811.2 15.710.3
19 5.8±1.8 62.411.1 13.011.4 18.810.4
2 4 6.911.3 60.312.6 20.711.8 12.412.0
4 8 7.110.3 66.111.3 16.511.7 10.310.3
7 2 6.210.9 59.110.5 22.110.5 12.710.1
Table 4.2 -  Percentage of MDA-MB-453 cells treated with trastuzumab in each phase of 
the cell cycle. Cells were treated with trastuzumab (40pg/ml) continuously. These values are 
an average of three independent experiments. Data presented are the average of three 
independent experiments as shown by the standard error.
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Figure 4.4 -  Histogram profile of MDA-MB-453 cells treated with cisplatin. Cells were 
treated with cisplatin (150pM) for one hour. Cells have been collected at different time point 
after the 1 hour treatment. One event = one cell. Histogram from a representative experiment.
C is p la t in
1 5 0 p M
S u b G l G 1 S G 2
0 2.410.4 48.7±2.0 32.113.0 16.812.7
4 2.5±0.9 50.313.4 32.513.8 14.711.3
9 2.8±0.2 45.413.9 39.014.0 12.710.3
14 16.3±2.1 41.812.1 32.311.0 9.611.0
19 16.7±1.5 40.210.7 31.511.1 11.511.3
2 4 4.9±0.7 40.811.4 41.911.3 12.410.2
4 8 11.3±0.4 23.210.9 41.211.3 24.310.6
72 14.8±1.2 13.811.4 37.010.7 34.410.3
Table 4.3 -  Percentage of MDA-MB-453 cells treated with cisplatin in each phase of the 
cell cycle. Cells were treated with cisplatin (150pM) for one hour (±standard error). These 
values are an average of three independent experiments. Data presented are the average of 
three independent experiments as shown by the standard error.
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Figure 4.5 -  Histogram profile of MDA-MB-453 cells treated with a combination of 
cisplatin and trastuzumab. Cells were treated with cisplatin (150pM) for one hour and 
trastuzumab (40pg/ml) continuously. Cells have been collected at different time point after 
the 1 hour treatment with both drugs. One event = one cell. Histogram from a representative 
experiment.
T r a s t u z u m a b  
4 0 p ,g /m l +  
C is p la t in  150 |n M
S u b G l G 1 S G 2
0 2.0±0.4 51.2±2.9 33.9±4.3 13.011.9
4 2.6±0.3 51.7±4.0 33.9±3.8 11.810.9
9 4.1±0.4 44.5±2.0 36.9±5.2 14.413.3
14 21.0±1.9 38.5±2.2 29.6±1.6 10.911.9
19 26.0±3.9 35.3±1.4 28.3±1.7 10.311.4
2 4 9.0±0.6 38.5±0.7 38.812.9 13.711.9
4 8 18.1±1.8 28.8±1.2 35.710.4 17.311.9
72 22.7±2.4 15.9±1.5 38.513.0 22.913.5
Table 4.4 -  Percentage of MDA-MB-453 cells treated with cisplatin and trastuzumab in 
each phase of the cell cycle. Cells were treated with a combination of cisplatin (150pM) for 
one hour and trastuzumab (40pg/ml) continuously. Data presented are the average of three 
independent experiments as shown by the standard error.
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4.6 Influence of DNA repair modulation on apoptosis
In the previous section, a reduction of the cisplatin-induced G2 arrest was observed in 
presence of trastuzumab. In addition, in the combination treatment, trastuzumab 
increased the proportion of cells entering apoptosis (sub-Gl). In order to investigate 
the influence of trastuzumab on apoptosis, protein expression level of Poly (ADP- 
ribose) polymerase (PARP), in MDA-MB-453 cells, was evaluated by western 
blotting. PARP (113kDa) is a protein cleaved by caspase-3 during apoptosis 
(Boulares et al., 1999), giving two fragments of 89kDa and 24kDa. Thus, apoptotic 
cells are often detected by monitoring PARP cleavage (Soldani and Scovassi, 2002). 
Cells were treated as previously described in the cell cycle analysis.
Figures 4.6A and 4.6B represent the results obtained for untreated cells (control) and 
cells treated with trastuzumab alone (continuously), respectively. These figures show 
that trastuzumab alone did not induce apoptosis as a similar level of cleaved PARP 
was observed in untreated cells and trastuzumab cells, after 48 hours. Figure 4.6C 
represents the level of PARP and cleaved PARP obtained in cells treated with 
cisplatin alone for 1 hour. A marked increase of cleaved PARP is seen at the peak of 
crosslinking (9 hours), increasing steadily up to 48 hours, demonstrating that cisplatin 
induces apoptosis. Nonetheless, the level of cleaved PARP is inferior to the level of 
total PARP, as no variation of PARP expression level can be noticed. When 
combining cisplatin with trastuzumab (Figure 4.6D), a similar level of cleaved PARP 
was observed after 9 hours, increasing steadily up to 48 hours, similarly to cells 
treated with cisplatin alone.
Consequently, measurement of PARP cleavage did not demonstrate that trastuzumab 
induced apoptosis. Nonetheless, trastuzumab may induce apoptosis after a longer 
period of time. Therefore, the results of the experiment on cisplatin/trastuzumab 
combinations were not due to induction of apoptosis.
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(A)
PARP (113kDa)
Cleaved PARP (89kDa)
a-tubulin (50kDa)
Time post-treatment (hours) 14 19 24 48 72
(B)
PARP (113kDa)
Cleaved PARP (89kDa)
a-tubulin (50kDa)
Time post-treatment (hours) 14 19 24 48 72
(C)
PARP (113kDa)
Cleaved PARP (89kDa)
a-tubulin (50kDa)
Time post-treatment (hours) 14 19 24 48 72
(D)
PARP (113kDa)
Cleaved PARP (89kDa)
a-tubulin (50kDa)
Time post-treatment (hours) 14 19 24 48 72
Figure 4.6 -  Western blot analysis of PARP and cleaved PARP protein in MDA-MB-453 
cells. MDA-MB-453 cells untreated (A), cells treated continuously with trastuzumab 
(40pg/ml) -  B. cells treated for one hour with cisplatin (150pM) -  C, and cells treated for one 
hour with cisplatin (150pM) and continuously with trastuzumab (40pg/ml) -  D. Cleaved 
PARP is an indicator of apoptosis. a-tubulin was used as a loading control.
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4.7 Identification of proteins involved in the modulation of
DNA repair caused by ErbB2 inhibition
Having shown that the delay in the repair of DNA damage may be due to a 
progression of the cells through cell cycle arrest, proteins involved in DNA repair and 
in the ErbB2 signalling pathways were investigated.
4.7.1 Influence of DNA damage repair delay on the level of 
proteins involved in DNA damage repair and ErbB2 signalling 
pathways
Using MDA-MB-453 and SK-BR-3 cells, the effect of trastuzumab in combination 
with cisplatin was investigated on different proteins involved in different DNA repair 
pathways (DNA-PK, ATM, ATR, Ku70, BRCA1, Artemis, RAD51 and ERCC1) and 
ErbB2 downstream signalling pathway, such as Akt, by immunoblotting. Cells were 
treated as previously described in the cell cycle analysis.
Modulation o f proteins level in MDA-MB-453 cells
Protein expression levels in MDA-MB-453 cells are shown in Figures 4.7 to 4.10. 
Proteins involved in DNA repair pathways were not affected by trastuzumab, since 
the levels of proteins in untreated cells (Figure 4.7) did not differ from the proteins 
level observed in trastuzumab treated cells (Figure 4.8). Furthermore, the presence of 
cisplatin, alone (Figure 4.9) or in combination with trastuzumab (Figure 4.10), did not 
cause any changes in the expression level of the DNA repair proteins studied.
T0P02a protein level was evaluated, as Jarvinen and Liu (2006) reported that ErbB2 
amplification was often associated with T 0P02a amplification which had an impact 
on the therapeutic response in patients. T 0P02a levels were shown to decrease with 
time in untreated cells and cells treated with trastuzumab alone, in a similar fashion. 
Therefore ErbB2 inhibition by trastuzumab did not cause any alteration of T0P02a 
expression. This reduction after 49 hours can be explained by the cells reaching 
confluence and not being able to grow exponentially. In cells treated with cisplatin 
alone (Figure 4.9), T 0P02a protein level was reduced after treatment (1 hour) but
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quickly increased after 10 hours to reach a level higher than untreated cells. This 
reduction was explained by the accumulation of cells in G2 due to the formation of 
cisplatin-induced interstrand crosslinks, reaching a peak 9 hours post-treatment. 
These ICLs were then repaired allowing the cells to cycle normally. In combination 
with trastuzumab the reduction of T 0P02a was not present (Figure 4.10) but the 
protein level of T 0P02a increased steadily up to 73 hours.
As expected, ErbB2 was down-regulated in the presence of trastuzumab alone or in 
combination with cisplatin (Figures 4.8 and 4.10). This downregulation is noticeable 
after 10 hours of treatment. EGFR (which forms heterodimers with ErbB2 causing its 
activation) protein level is not affected by any of the treatments.
Akt protein level was not affected by any of the treatments but a major change in its 
phosphorylated form (pAkt Serine 473 -  S473) was noticed in presence of 
trastuzumab (Figures 4.8 and 4.10). pAkt was not detectable in untreated MDA-MB- 
453 cells or in cells treated with cisplatin alone, however, in presence of trastuzumab 
for 1 hour, Akt became phosphorylated (pAkt S473). Activated Akt was then down- 
regulated when cells were treated with trastuzumab alone. Whereas, pAkt was not 
reduced in cells treated with cisplatin and trastuzumab. Therefore, cisplatin treatment 
maintained the phosphorylation state of Akt (pAkt S473), after activation by 
trastuzumab.
In conclusion, proteins levels investigated were not affected dramatically by 
trastuzumab, except for the phosphorylated form of Akt (S473) which was activated 
by trastuzumab. As a result, the phosphorylated forms of other proteins were 
investigated.
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DNA-PK (470kDa) 
ATM (350kDa) 
ATR (305kDa) 
BRCA1 (220kDa) 
EGFR (185kDa) 
ErbB2 (185kDa) 
T 0P02a (170kDa) 
Artemis (78kDa) 
Ku70 (73kDa) 
pAkt S473 (60kDa) 
Akt (60kDa) 
a-tubulin (50kDa) 
RAD51 (37kDa) 
ERCC1 (32kDa)
Time (Hours) Control 1 10 25 49 73
Figure 4.7 -  Immunoblots of MDA-MB-453 untreated cells. Immunoblots were probed for 
DNA repair proteins and proteins involved in ErbB2 signalling pathways, a-tubulin was used 
as a loading control.
184
DNA-PK (470kDa)
ATM (350kDa)
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Figure 4.8 -  Immunoblots of MDA-MB-453 cells treated with trastuzumab. Cells were 
treated with trastuzumab alone (40pg/ml) continuously and immunoblots were probed for 
DNA repair proteins and proteins involved in ErbB2 signalling pathways, a-tubulin was used 
as a loading control.
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Figure 4.9 -  Immunoblots of MDA-MB-453 cells treated with cisplatin. Cells were 
treated with cisplatin alone (150pM) for one hour then incubated in drug-free media. 
Immunoblots were probed for DNA repair proteins and proteins involved in ErbB2 signalling 
pathways, a-tubulin was used as a loading control.
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Figure 4.10 -  Immunoblots of MDA-MB-453 cells treated with cisplatin and 
trastuzumab. Cells were treated with cisplatin (150pM) + trastuzumab (40pg/ml) for one 
hour then incubated in media containing trastuzumab alone (40pg/ml). Immunoblots were 
probed for DNA repair proteins and proteins involved in ErbB2 signalling pathways, a- 
tubulin was used as a loading control.
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Modulation of proteins level and their phosphorylated forms
in MDA-MB-453 and SK-BR-3 cells
MDA-MB-453 and SK-BR-3 cell lines were used to examine the effect of 
trastuzumab on the phosphorylated forms of some of the proteins investigated 
previously. SK-BR-3 cells were also used to determine if any observed effects were 
specific to MDA-MB-453 cells. Comparing both cell lines (Figures 4.11 to 4.14), 
proteins levels of DNA-PK, ATM, ATR, ErbB2, Ku70 and Akt were unaltered by 
drug treatments and similar to the one presented previously for MDA-MB-453 cells 
(Figures 4.7 to 4.10). In addition, pDNA-PK, pATM, pATR (phosphorylated forms of 
some of the proteins mentioned before) were not altered by any of the treatments and 
their level remained constant.
In MDA-MB-453 cells, cisplatin alone caused a reduction in T0P02a protein level 
up to 10 hours, followed by an increase in the protein level by 25 hours (Figure 4.11). 
Whereas in cells treated with the combination of cisplatin and trastuzumab the 
T0P02a protein level increased steadily up to 49 hours (Figure 4.12). Furthermore, 
pAkt S473 (Serine 473) and pAkt T308 (Threonine 308) proteins level behaved in a 
similar manner. The phosphorylated forms of Akt were not detectable in untreated 
cells (data not shown) or in cells treated with cisplatin alone (Figure 4.11). However, 
pAkt S473 and T308 were both activated after one hour of treatment with 
trastuzumab (data not shown) and their level slowly decreased with time. When 
combined with cisplatin (Figure 4.12), trastuzumab also activated both forms of pAkt 
but their level was maintained with time. Therefore, these results confirmed the 
changes in proteins level described previously.
For SK-BR-3 cells, immunoblots showed that cells treated with trastuzumab, alone or 
in combination with cisplatin, had their ErbB2 protein level reduced. Similarly to 
MDA-MB-453 cells, phosphorylated forms of Akt (pAkt S473 and T308) were not 
detectable in SK-BR-3 cells untreated (data not shown) or treated with cisplatin 
(Figure 4.13), but trastuzumab alone (data not shown) or in combination with 
cisplatin (Figure 4.14) caused phosphorylation of Akt (pAkt S473 and T308) after 1 
hour. In addition, activated Akt was only reduced in cells treated with trastuzumab 
alone, similarly to MDA-MB-453 cells. Finally, in SK-BR-3 cells, cisplatin (Figure 
4.13) also caused a reduction in T 0P02a protein expression level up to 10 hours (not
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as detectable as in MDA-MB-453 cells) followed by an increase in protein level by 
25 hours. Cells treated with a combination of trastuzumab and cisplatin (Figure 4.14) 
had no reduction in TOP02a protein but a steady increase.
Therefore, results from SK-BR-3 cells confirmed those obtained with MDA-MB-453 
cells; trastuzumab in combination with cisplatin modulates protein expression level of 
T0P02a and alone, or in combination with cisplatin, modulates activation of Akt.
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a-tubulin (50kDa)
Time (Hours) Control 1 10 25 49
Figure 4.11 -  Immunoblots of MD-MB-453 cells treated with cisplatin. Cells were treated 
with cisplatin alone (150pM) for one hour then incubated in drug-free media. Immunoblots 
were probed for DNA repair proteins and proteins involved in ErbB2 signalling pathways, a- 
tubulin was used as a loading control.
189
DNA-PK (470kDa) 
pDNA-PK (470kDa)
ATM (350kDa) 
pATM (350kDa)
ATR (305kDa) 
pATR (300kDa)
ErbB2 (185kDa)
T0P02a (170kDa)
Ku70 (73kDa) 
pAkt-S473 (60kDa) 
pAkt-T308 (60kDa)
Akt (60kDa) 
a-tubulin (50kDa)
Time (Hours) Control 1 10 25 49
Figure 4.12 -  Immunoblots of MDA-MB-453 cells treated with cisplatin and 
trastuzumab. Cells were treated with cisplatin (150pM) + trastuzumab (40pg/ml) for one 
hour then incubated in media containing trastuzumab alone (40gg/ml). Immunoblots were 
probed for DNA repair proteins and proteins involved in ErbB2 signalling pathways, a- 
tubulin was used as a loading control.
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Figure 4.13 -  Immunoblots of SK-BR-3 cells treated with cisplatin. Cells were treated 
with cisplatin alone (150pM) for one hour then incubated in drug-free media. Immunoblots 
were probed for DNA repair proteins and proteins involved in ErbB2 signalling pathways, a- 
tubulin was used as a loading control.
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Figure 4.14 -  Immunoblots of SK-BR-3 cells treated with cisplatin and trastuzumab.
Cells were treated with cisplatin (150pM) + trastuzumab (40pg/ml) for one hour then 
incubated in media containing trastuzumab alone (40pg/ml). Immunoblots were probed for 
DNA repair proteins and proteins involved in ErbB2 signalling pathways, a-tubulin was used 
as a loading control.
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Effect o f trastuzumab treatment o f Akt protein level
Having demonstrated that trastuzumab has a striking effect on the phosphorylation of 
Akt after 1 hour, the effect was further investigated within the first hour of 
trastuzumab treatment. MDA-MB-453 cells were treated with trastuzumab and 
proteins were extracted every 10 minutes for 1 hour. As shown by Figure 4.15, 
trastuzumab caused phosphorylation of Akt (pAkt S473 and T308) within the first 10 
minutes with a peak of phosphorylation at 30 minutes.
Akt (60kDa) 
pAkt S473 (60kDa) 
pAkt T308 (60kDa) 
a-tubulin (50kDa) 
Time (minutes) 0 10 20 30 40 50 60
Figure 4.15 -  Akt and pAkt protein expression in MDA-MB-453 cells treated with 
trastuzumab. Cells were treated with trastuzumab alone (40pg/ml) continuously and 
immunoblots were probed for Akt and the two phosphorylated forms of Akt (S473 and 
T308). Samples were taken every 10 minutes after addition of trastuzumab to the cells, a- 
tubulin was used as a loading control.
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4.7.2 Influence of ErbB2 inhibition on T 0 P 0 2 a  mRNA level
It was shown that almost 90% of primary breast tumours with ErbB2 amplification 
have the simultaneous up-regulation of T0P02a (Jarvinen and Liu, 2006; Jarvinen et 
al., 2000). Furthermore, TOP02a has been shown to be involved in important 
processes of cell cycle regulation. In section 4.7.1, trastuzumab was shown to block 
the decrease in TOP02a protein level observed in cells treated with cisplatin alone. 
Therefore, it is important to consider the effect of ErbB2 inhibition, by trastuzumab, 
on TOP02a mRNA expression level. In order to examine the effect of trastuzumab 
on TOP02a amplification, MDA-MB-453 cells were treated with cisplatin and 
trastuzumab, and TOP02a mRNA level was measured by real time PCR. As PCR 
conditions and primers had already been optimised, no optimisation was carried out. 
Figure 4.16 represent the level of TOP02a mRNA post-treatment, with the values in 
Table 4.5. Each control is set at a value of 1 and mRNA level of treated samples are 
calculated in comparison to their control.
In untreated cells and cells treated with trastuzumab alone, the mRNA level increased 
up to 9 hours then decreased rapidly, this decrease was caused by the cells reaching 
confluence with time. In both treatments containing cisplatin, topoisomerase Ila 
mRNA level decreased up to 9 hours then increased up to 48 hours. The decrease 
observed can be attributed to the accumulation of cells in the G2 phase caused by 
cisplatin, thus arresting cell cycle progression to allow the repair of DNA damage. 
mRNA level increased up to 3 fold in cells treated with the combination of cisplatin 
and trastuzumab.
Therefore, these data are in accordance with the results obtained at the protein level 
(Figures 4.11 and 4.12), and demonstrate that inhibiting ErbB2 in cisplatin-induced 
DNA damaged cells increases topoisomerase Ila mRNA level, suggesting a 
progression of the cells through cell cycle arrest.
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Time post­
treatment (Hours) Control
Trastuzumab
(40pg/ml)
Cisplatin
(150pM)
Cisplatin 
(150pM) + 
trastuzumab 
(40p£/ml)
Control 1.0010.00 1.0010.00 1.0010.00 1.0010.00
9 2.1010.05 1.9010.19 0.6010.10 0.5010.02
24 0.9010.05 1.2010.22 0.7010.22 1.5010.04
48 0.5010.04 0.6010.01 1.2010.17 3.1010.40
Table 4.5 -  T 0 P 0 2 a  mRNA expression in MDA-MB-453 cells. T0P02a mRNA 
expression ratio in treated MDA-MB-453 cells compared to untreated cells. For each 
treatment one untreated control was used, set at a value of 1. Data presented are the average 
of three independent experiments as shown by the standard error.
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Figure 4.16 -  T 0 P 0 2 a  mRNA level in MDA-MB-453 cells. Expression ratio in untreated 
MDA-MB-453 cells (dark blue), trastuzumab treated cells (red), cisplatin treated cells (light 
blue) and trastuzumab + cisplatin treated cells (yellow). Data presented are the average of 
three independent experiments as shown by the standard error.
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DISCUSSION
In this chapter the effect of DNA repair modulation by trastuzumab, on the cell cycle, 
the induction of apoptosis and the expression level of proteins involved in DNA 
repair and ErbB2 signalling were investigated. Results established that the delay in 
the repair of cisplatin-induced DNA damage, caused by trastuzumab, may be 
explained by a progression of the cells through cell cycle arrest. Inhibition of ErbB2 
was also shown to modulate Akt activation and topoisomerase Ila mRNA and protein 
expression.
4.8 Cell cycle and apoptosis
The study of the effects of DNA repair modulation, on the cell cycle, was carried out 
on MDA-MB-453 cells and showing a delay in the repair of cisplatin-induced DNA 
ICLs following treatment with trastuzumab. Sliwkowski et al. (1999) and Gong et al.
(2004) demonstrated that trastuzumab alone caused a reduction of cells undergoing S 
phase and an accumulation of cells in the G1 phase. Furthermore, studies by Le et al.
(2005) and Yakes et al. (2002) also demonstrated that trastuzumab led to an increase 
of p27kipl in the nucleus through down-regulation of PI3K/Akt pathway and 
especially reduced phosphorylation of Akt, causing inhibition of cell growth in Gl. 
Results obtained here showed that trastuzumab reduced the number of cells 
undergoing S phase causing an accumulation of cells in Gl.
Sekiguchi et al. (1996) reported that cisplatin alone was shown to cause accumulation 
of cells in the G2 phase. Flow cytometry results presented here confirmed the 
accumulation of cells in G2 caused by cisplatin. This effect was also observed in the 
combined treatment of cisplatin and trastuzumab. Nonetheless, in combination with 
trastuzumab the G2 cell cycle arrest observed with cisplatin alone was altered, as the 
proportion of cells arrested in G2 was reduced and more cells were entering 
apoptosis, suggesting that the cells were progressing through cell cycle arrest. 
Sliwkowski et al. (1999) reported that combining trastuzumab with chemotherapeutic 
agents results in increased anti-tumour activity than either agent given alone. 
However, study of the effect of trastuzumab on apoptosis has so far produced 
conflicting results (Mohsin et al., 2005; Gennari et al., 2004). The increase in sub-Gl
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observed is a marker of apoptosis and the increase in chemosensitivity (Chapter 3) is 
related to the increase in sub-Gl. Nevertheless, the increase in apoptotic cells was not 
confirmed by measurement of PARP cleavage.
Therefore, the delay in the repair of cisplatin-induced DNA damage reported in 
Chapter 3 can be explained by the progression of the cells through cell cycle arrest 
caused by cisplatin. Further experiments need to be carried out to determine the effect 
of cisplatin/trastuzumab combination on apoptosis as results from flow cytometry and 
PARP cleavage were conflicting.
4.9 Modulation of proteins level by trastuzumab
4.9.1 Akt and cytoplasmic localisation of p21WAF1
p2 1 WAF1 is a cyclin-dependent kinase which was shown to be activated by the tumour 
suppressor p53 following DNA damage, leading to cell cycle arrest (El-Deiry et al., 
1993; Xiong et al., 1993; Waga et al., 1994). In addition, p21WAF1 was also shown to 
be induced by MAPK (Bottazzi et al., 1999; Liu et al., 1996) and PI3K (Zhou et al., 
2001b) signalling pathways. Zhou et al. (2001b) suggested that ErbB2 overexpressing 
cell lines promoted cell growth through activation of Akt and subsequent 
phosphorylation of p21WAF1 at threonine 145, resulting in its cytoplasmic localisation 
and cell cycle progression. Furthermore, Yakes et al. (2002) demonstrated that 
trastuzumab caused a down-regulation of phosphorylated Akt, but no up regulation 
was noted within the first hour. A study by Pietras et al. (1999) also established that 
combining radiation with trastuzumab (lOOpg/ml) caused a delay in DNA repair and 
inhibition of p21WAF1. They demonstrated that in presence of trastuzumab cells were 
able to escape cell cycle arrest, by inhibition of p2 1 WAF1, which did not allow enough 
time for DNA damage repair and caused an accumulation of unrepaired DNA 
damage. In addition, the study by McDonald et al. (1996) established that following 
DNA damage, caused by UV irradiation or cisplatin, p21WAF1 deficient cells had a 
prominent defect in DNA repair compared to p21WAF1 +/+ cells. Finally, Yu et al. 
(1998b) demonstrated that p21WAF1 up-regulation, causing cell cycle arrest allowing 
DNA damage repair, was associated with chemoresistance in ErbB2 overexpressing 
cells.
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Results obtained for MDA-MB-453 and SK-BR-3 cells demonstrated that after 
activation of Akt by trastuzumab (within the first 10 minutes -  Figure 4.17), pAkt 
was down-regulated in the presence of trastuzumab alone but not in combination with 
cisplatin. These results, taken together with published data, demonstrate that 
trastuzumab leads to a G1 arrest and a reduction of cells undergoing S phase, due to 
decreased Akt activation and subsequent p21WAF1 nuclear localisation. In contrast, in 
combination with cisplatin, pAkt level was maintained causing an increase in p2 1 WAF1 
cytoplasmic localisation and inhibition of cell cycle arrest. In addition, Kandel et al. 
(2002) suggested that activation of Akt can overcome the p5 3-dependent G2/M cell 
cycle arrest and apoptosis induced by DNA damage. Thus, combining trastuzumab 
and cisplatin reduces the number of cells arresting in G2 and causes accumulation of 
unrepaired DNA damage, leading to apoptosis.
Although expression level of p21WAF1 was not studied, results suggest that the delay 
in the repair of cisplatin-induced DNA damage by trastuzumab was due to a 
modulation of p21WAF1. Nevertheless, other signal transduction pathways may be 
involved in the escape of cells from cell cycle arrest.
4.9.2 Akt and inhibition of p27kipl function
Another important protein involved in cell cycle regulation is the cdk inhibitor 
p27kipl. Previous studies (Sliwkowski et al., 1999; Marches and Uhr, 2004; Lane et 
al., 2000; Le et al., 2003) have shown that the anti-proliferative effect of trastuzumab 
was associated with cell cycle arrest in Gl, by inhibition of proteins responsible for 
p27kipl sequestration. p27kipl has also been shown to be degraded following up- 
regulation of MAPK and PI3K pathways (Busse et al., 2000; Lenferink et al., 2001). 
Lenferink et al. (2001) suggested that blocking ErbB2 caused inhibition of MAPK 
and its mediated phosphorylation of p27kipl, causing its stability. This study also 
demonstrated that the PI3K/Akt signalling pathway was inhibited, through inhibition 
of phosphorylated Akt, causing downregulation of cyclin Dl. In addition, p27kipl was 
also shown to be transcriptionally activated through PI3K/Akt signalling pathway 
inhibition (Medema et al., 2000). Therefore, these data taken together with the results 
obtained here for Akt activation, suggest that trastuzumab alone causes a Gl arrest by 
down-regulation of activated Akt and p27kipl activation. In combination with 
cisplatin, however, activated Akt is not reduced and leads to an escape from cell cycle
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arrest, through continued activation of the PI3K/Akt pathway and progression of the 
cell cycle by p27kipl degradation or cytoplasmic retention (Medema et a l, 2000; 
Motti et a l, 2005).
Consequently, the decrease in the number of cells arrested in G2 when trastuzumab 
was combined with cisplatin, compared to cells treated with cisplatin alone, is 
explained by the cells escaping cell cycle arrest due to a degradation of p27kipl as well 
as a cytoplasmic localisation of p27kipl and p21WAF1. Furthermore, progression of the 
cells through cell cycle arrest results in accumulation of unrepaired DNA damage as 
shown by the delay in DNA repair (Chapter3), and sensitisation of ErbB2 
overexpressing cells to chemotherapeutic agents, by trastuzumab (Chapter 3). 
Nevertheless, further analysis of proteins involved in the escape of cells from cell 
cycle arrest is required, as Crowder et al (2004) have reported that PTEN was also 
involved in PI3K/Akt signalling and may confer resistance to trastuzumab.
4.10 Trastuzumab and topoisomerase Hoc
Topoisomerase Ila is a protein regulated by the cell cycle and involved in many cell 
cycle regulation processes. Jarvinen and Liu (2003) reported that TOP02a 
amplification was often associated with ErbB2 gene co-amplification in breast cancer. 
Although trastuzumab alone was not shown to affect the expression levels of 
TOP02a, cisplatin caused a decrease in TOP02a mRNA and protein levels. This 
decrease was associated with the DNA damage caused by cisplatin at 9 hours post­
treatment, which corresponds to the peak of cisplatin crosslinks. As reported by Wang 
et al (1997), p53 can down-regulate topoisomerase Ila expression by transcriptional 
regulation to stop the replication after DNA damage. The level of TOP02a slowly 
increased again as DNA ICLs were repaired, as shown by the comet assay in Chapter 
3. However, combining trastuzumab with cisplatin caused a decrease in TOP02a 
mRNA level but not in the protein level, and the increase was much more dramatic 
than with cells treated with cisplatin alone. This would suggest that fewer cells 
undergo cell cycle arrest, as TOP02a protein level is not reduced, and that there is 
cell cycle progression as topoisomerase Ila increased. Furthermore, Akt activation
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was shown to cause p53 degradation, through MDM2 degradation (Zhou et al., 
2001a), blocking p53-induced topoisomerase Ila  down-regulation.
Therefore, this observation supports the idea that cells treated with the combination of 
cisplatin and trastuzumab escaped cell cycle arrest due to activation of Akt and 
subsequent p53 degradation.
4.11 Conclusion
These results established that the delay in the repair of cisplatin-induced DNA ICLs 
observed in Chapter 3 could be attributed to a progression of the cells through cell 
cycle arrest. Furthermore, trastuzumab alone was shown to cause a reduction in cells 
undergoing S phase associated with an increase in Gl, similarly to previous published 
studies. In addition, in combination with cisplatin, trastuzumab was shown to induce 
apoptosis. Although results were not confirmed by the PARP cleavage, further 
investigation need to be carried out. Results obtained also established that in 
combination with cisplatin, trastuzumab caused continuous activation of Akt and 
subsequent escape of cells from cell cycle arrest, through p21WAF1 and p27k,pl 
degradation or cytoplasmic retention. Furthermore, p53 degradation is also thought to 
be involved in the inhibition of induction of apoptosis.
Therefore, considering those results with other published studies on the effect of 
trastuzumab, it is reasonable to suggest that the delay in DNA damage repair is 
caused by an escape of the cells from cell cycle arrest. However, further analysis of 
the effect of trastuzumab on proteins involved in MAPK and PI3K/Akt signalling 
pathways is required to confirm this finding.
As the molecular mechanism of trastuzumab within the cells remains unclear, further 
understanding of the role of ErbB2 in DNA damage repair is required. To this end, 
the next chapter will discuss the specific role of ErbB2 on DNA damage repair using 
ErbB2 negative MDA-MB-468 cells, stably transfected with a plasmid containing 
ErbB2.
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Chapter 5
Modulation of the repair of drug- 
induced DNA damage and ErbB2
expression
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INTRODUCTION
In Chapter 4 it was suggested that the observed delay caused by ErbB2 inhibition of 
the repair of cisplatin-induced DNA ICLs was caused by an escape of cells from cell 
cycle arrest. Therefore, it is important to investigate further the specific role of ErbB2 
overexpression in the repair of drug-induced DNA damage. In order to study the 
specific role of ErbB2, two approaches were considered: the use of ErbB2 siRNA in 
ErbB2 positive cell lines and the transfection of ErbB2 in ErbB2 negative cells. Using 
the most suitable approach, the effect on the repair of cisplatin-induced DNA damage 
will be studied further.
5.1 ErbB2 overexpression
In breast cancer, ErbB2 overexpression has been previously associated with increased 
cell proliferation and poor patient prognosis. Nevertheless, the role of ErbB2 
overexpression in chemotherapeutic response remains unclear. Indeed, conflicting 
results have been published, clinical studies by Allred et al. (1992) and Wright et al. 
(1992) demonstrated that ErbB2 overexpression in patients was associated with 
increased resistance to chemotherapeutic treatments such as cyclophosphamide and 
carboplatin. Whereas Muss et al. (1994) reported that ErbB2 overexpression 
increased the response to doxorubicin. Furthermore, in vitro studies have also 
produced conflicting results showing that ErbB2 could be associated with increased 
resistance to cisplatin and paclitaxel whereas no difference was seen with doxorubicin 
and fluorouracil (Benz et al., 1992). Nonetheless, Pegram et al. (1997) reported that 
chemosensitivity associated with ErbB2, in vitro, was cell line specific, and that in 
vivo ErbB2 overexpression did not alter the chemosensitivity but caused a more rapid 
re-growth.
5.2 Cisplatin-induced DNA damage
Cisplatin or cz's-Diamminedichloroplatinum (II) is a widely used chemotherapeutic 
agent, its cytotoxic effects are due to the formation of two main types of adducts, the 
1,2-intrastrand crosslinks forming up to 90% of the platinum-DNA adducts and the
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interstrand crosslinks adducts (Jakupec, 2003). Although DNA interstrand crosslinks 
represent only 1 0 % of the lesions caused by cisplatin, they have been described as 
being critical cytotoxic lesions in diving cells (Dronkert and Kanaar, 2001; Lawley 
and Phillips, 1996). Intrastrand crosslinks have been shown to be repaired by 
nucleotide excision repair (Zamble et al., 1996). The mechanism of repair of 
cisplatin-induced interstrand crosslinks adducts remains unclear. Nevertheless, many 
studies have suggested that repair of cisplatin ICLs relies upon XPF-ERCC1 for the 
unhooking of the crosslink (De Silva et al., 2000; Mu et al., 2000; Kuraoka et al., 
2000). De Silva et al. (2002) also described that homologous recombination played 
an important role in the repair of cisplatin induced DNA ICLs repair, as they 
demonstrated the importance of XRCC2 and XRCC3 proteins in this repair pathway. 
Having shown that inhibition of ErbB2, by trastuzumab, led to a delay in the repair of 
cisplatin-induced DNA interstrand crosslinks, it is important to consider its effect on 
the repair of each of those two types of adducts.
Therefore, when studying the repair of cisplatin-induced DNA damage it is important 
to consider both types of adducts, as different protein are involved. As previously 
described in Chapter 3, DNA interstrand crosslinks formation and repair was studied 
using the comet assay. However, formation and repair of cisplatin-induced DNA 
intrastrand crosslinks can be measured using the competitive ELISA assay (described 
in Chapter 2), as developed by Tilby et al. (1987; 1991). This method is based on the 
use of an antibody that recognise cisplatin 1,2 -intrastrand adducts.
5.3 Cell cycle modulation
Chapter 4 suggested that Akt and topoisomerase Ila were involved in the escape of 
cells from cell cycle arrest, following combination treatment with cisplatin and 
trastuzumab. Nevertheless, other proteins have been shown to be involved.
5.3.1 Mitogen-Activated Protein Kinase (MAPK)
In addition to the PI3K pathway, ErbB2 overexpression was shown to prolong and 
enhance signalling from the MAPK pathway (Karunagaran et al, 1996; Waterman et 
al., 1999). Activation of the Ras/MAPK pathway causes degradation of p27kipl and
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inhibits its ability to bind cdk2, increasing cyclin D1 expression and cell cycle 
progression (Kawada et al., 1997; Rivard et al., 1999). Furthermore, Lenferink et al. 
(2001) established that ErbB2 was able to modulate p27kipl and cyclin D1 protein 
levels through modulation of Ras/MAPK and PI3K/Akt signalling pathways. In 
addition, they demonstrated that inhibition of MAPK led to p27kipl stability and Gl 
cell cycle arrest. Moreover, MAPK was shown to induce p21WAF1 (Bottazzi et al., 
1999; Liu et a l, 1996), leading to cell cycle arrest in Gl phase.
5.3.2 Phosphatase and Tensin homolog (PTEN)
PTEN is as a tumour suppressor gene causing inhibition of the PI3K pathway through 
inhibition of Akt activity. Indeed, upon ErbB2 phosphorylation, tyrosine kinase 
residues of the receptor recruit intracellular signalling molecules to the intracellular 
domain, including the non-receptor tyrosine kinase Src. Phosphorylated Src becomes 
activated and phosphorylates PTEN preventing its translocation to the plasma 
membrane and the dephosphorylation of PIP3, generated by PI3K (Crowder et al., 
2004). In addition, Nagata et al. (2004) reported that ErbB2 overexpression caused 
inhibition of PTEN through its phosphorylation, potentiating the activation of PI3K. 
Nevertheless, they showed that in presence of trastuzumab, PTEN becomes activated 
through dephosphorylation and inhibits the PI3K/Akt signalling pathway, leading to 
inhibition of tumour progression. However, loss of PTEN function from PTEN 
mutations has been shown to increase trastuzumab resistance in vitro and in vivo, as 
PTEN cannot be activated and inhibit PI3K/Akt pathway. Thereby, causing 
tumourigenesis and trastuzumab resistance. Fujita et al. (2006) further confirmed that 
PTEN could be used a predictive marker for trastuzumab resistance. Therefore, it is 
important to consider the expression of PTEN in cell cycle regulation and the 
response to combination treatments with trastuzumab.
5.3.3 Topoisomerase II activity
The study by Pu and Bezwoda (1999) reported that elevated topoisomerase Ila level 
as well as increase of topoisomerase II activity was associated with an increase 
resistance to alkylating agents. Furthermore, Harris et al. (2001) demonstrated that 
ErbB2 signalling activation caused an increase of topoisomerase II protein and 
enzymatic activity, leading to chemoresistance to the alkylating agent
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cyclophosphamide. In addition, the study by Pietras et al. (1994) reported that 
modulation of ErbB2 expression by trastuzumab led to a reduction of the repair of 
cisplatin-induced DNA damage. Therefore, it is possible that topoisomerase II is 
involved in the modulation of repair activity causing modulation of chemosensitivity.
5.4 Aims
ErbB2 expression was modulated using siRNA and ErbB2 plasmid transfection. 
Nevertheless, only one of these two models was used to evaluate the effect of ErbB2 
expression on the repair of cisplatin-induced DNA damage. To this end, the following 
questions were addressed:
• How does ErbB2 protein expression affect sensitivity to cisplatin and 
trastuzumab?
• Does ErbB2 overexpression affect the repair of cisplatin and melphalan- 
induced DNA interstrand crosslinks?
• Is the repair of cisplatin-induced DNA intrastrand crosslinks also affected?
• How is expression of proteins involved in DNA damage repair and ErbB2 
signalling pathway modified by ErbB2 expression and drug treatment?
• Is topoisomerase II activity affected by ErbB2 overexpression?
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RESULTS
5.5 D ow n-regulation o f  E rbB 2 expression  by siR N A
In order to study the specific role of ErbB2, its expression level needed to be altered. 
To this end, specific ErbB2 siRNA, from Faltus et al. (2004), was used to cause 
down-regulation of ErbB2. RNA interference (RNAi or siRNA) regulates endogenous 
gene expression, the siRNA technique using the introduction of small double stranded 
RNA with a sequence specific to the gene being silenced. As siRNA does not always 
have the same efficiency in each cell line, all three breast cancer cell lines previously 
studied (MCF-7, SK-BR-3 and MDA-MB-453 cells) were used.
5.5.1 Determination of ErbB2 mRNA down-regulation by real 
time PCR
In order to determine the efficiency of the siRNA, down-regulation caused by specific 
human ErbB2 siRNA was measured by real time PCR. However, initially PCR 
conditions needed to be optimised.
PCR product verification and optimisation o f the conditions
Prior to analysis, the purity of the product formed, using the designed primers, was 
checked by reverse transcriptase PCR (result not shown) and PCR samples were 
sequenced. The sequence below represents the sequence amplified during PCR 
(forward primer in red and reverse primer in blue):
5’-GGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGC 
T GGTC A AG AGT C CC AACC AT GTC A A A ATT A-3 ’
Conditions for the PCR were optimised by determining the primer limiting 
concentration, the probe concentration and the conditions of the PCR (internal control 
and ErbB2 reactions in the same tube or separate tube). All optimisation experiments 
were carried out with cDNA from untreated cells.
The primer limiting concentration was defined by using a range of concentrations, 
which were: forward primer (pM): 0.1; 0.4; 0.7; 1.0 and 1.4, and reverse primer 
(pM): 0.1; 0.4; 0.7; 1.0 and 1.4. No plateau phase could be observed, the absence of 
plateau phase indicated that the primer limiting concentration could not be reached.
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Therefore, each set of primer needed to be run in separate wells. Primers 
concentrations were then determined using separate tubes for each experiment (results 
not shown). The concentrations of forward and reverse primers that yield the lowest 
Ct and the highest ARn values were 1.3pM of forward primer and 0.7pM of reverse 
primer. The probe concentration was determined using the same criteria (low Ct and 
high ARn) and 350nM of the probe was found to be enough to achieve a low Ct value 
and a high ARn.
Having determined the optimum concentrations, standard curves for p-glucuronidase 
(internal control) and ErbB2 were obtained using serial dilutions of the wild type 
cDNA. Reactions of the internal control and the ErbB2 gene were run in separate 
tubes and in the same tubes, in order to compare efficiencies. Results (not shown) 
indicated that interference occurred between the primer sets since efficiencies were 
affected if both reactions were run in the same tube. Furthermore, low correlation 
coefficients were obtained for the standard curves. Hence, reactions needed to be 
carried out in separate tubes.
Modulation of ErbB2 mRNA level
MCF-7, SK-BR-3 and MDA-MB-453 cells were transfected (as detailed in Chapter 2, 
section 2.15) with the siRNA and samples were analysed every 24 hours. Results 
obtained using the previously defined conditions are presented in Tables 5.1 to 5.3 
and Figures 5.1 to 5.3. For each time point, untransfected cells were used as the 
control set at a value of 100% expression (or 1). A scrambled siRNA, which did not 
recognise any specific gene, was also used as a negative control.
Results showed that ErbB2 siRNA down-regulated the ErbB2 mRNA level in all cell 
lines. However,- efficiency of the siRNA varied between cell lines. MCF-7 cells 
(Figure 5.1 and Table 5.1) had the ErbB2 mRNA level reduced to greater extent than 
the SK-BR-3 (Figure 5.2 and Table 5.2) and MDA-MB-453 cells (Figure 5.3 and 
Table 5.3) cells. In MCF-7 cells, transfected with ErbB2 siRNA, the mRNA level was 
reduced by 76% at the maximum effect, after 72 hours, and then increased from 96 
hours. Similarly, in MDA-MB-453 cells the maximum mRNA reduction (55%) was 
seen after 72 hours and increased from 96 hours. In SK-BR-3 cells ErbB2 mRNA 
level was not affected before 96 hours, reaching a maximum effect after 120 hours,
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with 62% reduction. It was also noted that ErbB2 mRNA level of MCF-7 and SK- 
BR3 cells transfected with scrambled siRNA was up regulated. This could possibly 
be explained by the effect of the transfection itself. However, in MDA-MB-453 cells 
transfected with scrambled siRNA the level of ErbB2 mRNA remained constant up to 
96 hours.
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Figure 5.1 -  Effect of ErbB2 siRNA on ErbB2 mRNA level in MCF-7 cell line.
Time
(Hours)
Control
untransfected Scrambled siRNA ErbB2 siRNA
0 1 .0 0 1 .0 0 1 .0 0
24 1 .0 0 1.25 0.49
48 1 .0 0 1.64 0.51
72 1 .0 0 1.57 0.24
96 1 .0 0 1.17 0.32
1 2 0 1 .0 0 1.08 0.46
Table 5.1 -  ErbB2 mRNA level in MCF-7 cells. Cells were transfected with scrambled 
siRNA and ErbB2 specific siRNA. Time indicated was post-transfection.
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Figure 5.2 -  Effect of ErbB2 siRNA on ErbB2 mRNA level in SK-BR-3 cell line.
Time
(Hours)
Control
untransfected Scrambled siRNA ErbB2 siRNA
0 1 .0 0 1 .0 0 1 .0 0
24 1 .0 0 1.31 0.99
48 1 .0 0 1.92 0.84
72 1 .0 0 1.55 0 .8 8
96 1 .0 0 1.71 0.58
1 2 0 1 .0 0 1.29 0.38
Table 5.2 -  ErbB2 mRNA level in SK-BR-3 cells. Cells were transfected with scrambled 
siRNA and ErbB2 specific siRNA. Time indicated was post-transfection.
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Figure 5.3 -  Effect of ErbB2 siRNA on ErbB2 mRNA level in MDA-MB-453 cell line.
Time
(Hours) Control Scrambled siRNA ErbB2 siRNA
0 1.00 1.00 1.00
24 1.00 1.08 0.79
48 1.00 0.95 0.77
72 1.00 1.13 0.45
96 1.00 1.08 0.61
1 2 0 1.00 1.21 0.91
Table 5.3 -  ErbB2 mRNA level in MDA-MB-453 cells. Cells were transfected with 
scrambled siRNA and ErbB2 specific siRNA. Time indicated was post-transfection.
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5.5.2 Effect of ErbB2 siRNA on ErbB2 protein expression level
As the level of ErbB2 mRNA was shown to be reduced in all three cell lines, levels of 
ErbB2 proteins were evaluated by western blotting. Figures 5.4 to 5.6 represent the 
immunoblots obtained for cells transfected with ErbB2 siRNA, in all three cell lines 
studied. All cells untransfected and transfected with scrambled siRNA did not show 
variation of the ErbB2 expression level (data not shown). MCF-7 cells transfected 
with ErbB2 specific human siRNA (Figure 5.4) had a large reduction in ErbB2 
protein expression after 48 hours, with the lowest expression level reached after 72 
hours. This result demonstrated that the reduction in ErbB2 mRNA coincided with 
the ErbB2 protein expression level. ErbB2 protein expression level in SK-BR-3 cells 
(Figure 5.5) was slowly decreasing up to 96 hours, but a significant reduction was 
observed after 120 hours. For MDA-MB-453 cells, ErbB2 protein level was reduced 
up to 96 hours with ErbB2 siRNA (Figure 5.6) and increased after 120 hours. This 
may be explained by the effect of the transient transfection of ErbB2 siRNA.
All those observations concur with the effect of the siRNA on the mRNA level 
detailed previously. It also demonstrates that ErbB2 siRNA reduces ErbB2 protein in 
all the cell lines studied. Furthermore, the main reduction in protein level was seen in 
MCF-7 cells, expressing the lowest level of ErbB2 protein. Therefore, more 
optimisation work, on the amount of siRNA to be used and the conditions of 
transfection, would be required before using this siRNA in ErbB2 overexpressing 
cells for the study of ErbB2 modulation.
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ErbB2 (185kDa)
a-tubulin (50kDa) 
Time (Hours) 24 48 72 96 120
Figure 5.4 -  ErbB2 protein level in MCF-7 cells transfected with ErbB2 siRNA. Cells 
were transfected for 120 hours (sample taken every 24 hours), a-tubulin was used as a 
loading control.
ErbB2 (185kDa)
a-tubulin (50kDa)
Time (Hours) 24 48 72 96 120
Figure 5.5 -  ErbB2 protein level in SK-BR-3 cells transfected with ErbB2 siRNA. Cells 
were transfected for 120 hours (sample taken every 24 hours), a-tubulin was used as a 
loading control.
ErbB2 (185kDa)
a-tubulin (50kDa)
Time (Hours) 24 48 72 96 120
Figure 5.6 -  ErbB2 protein level in MDA-MB-453 cells transfected with ErbB2 siRNA.
Cells were transfected for 120 hours (sample taken every 24 hours), a-tubulin was used as a 
loading control.
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5.6 Transfection of ErbB2 in ErbB2 negative cell line
The second approach developed in parallel of the ErbB2 siRNA, was the use of an 
ErbB2 negative cell line, MDA-MB-468 (Moasser et al., 2001), transfected with a 
plasmid encoding ErbB2. This plasmid has been described by Tzahar et al. (1996), 
showing very good ErbB2 expression level in CHO cells. The plasmids pcDNA3 and 
pcDNA3-ErbB2 were a kind gift from Dr O. Segatto (Regina Elena Cancer Institute, 
Italy).
ErbB2 negative cell line, MDA-MB-468, was stably transfected with pcDNA3 and 
pcDNA3-ErbB2 in order to create a MDA-MB-468 cell line expressing ErbB2 and a 
MDA-MB-468 cell line used as a vector control. Stable transfection was carried out 
as described in Chapter 2 (section 2.16). Pooled transfection was carried out to 
minimise interclonal variation and selective pressure was maintained using G418 
(0.75|ug/ml). Once the two cell lines were growing exponentially, expression of 
ErbB2 was measured by western blotting and immunofluorescence. Figure 5.7 shows 
that ErbB2 was not expressed in MDA-MB-468 and shows that ErbB2 was only 
expressed in MDA-MB-468 cells transfected with pcDNA3-ErbB2. Furthermore, 
transfection did not affect the expression level of the other receptors of the ErbB 
family. Immunofluorescence confirmed that ErbB2 (green) was only expressed in 
MDA-MB-468 cells transfected with pcDNA3-ErbB2 (Figure 5.8 C), in the 
cytoplasm and the nucleus (stained red). In addition, MDA-MB-468 wild type cells 
(Figure 5.8 A) and MDA-MB-468 pcDNA3 (vector control -  Figure 5.8 B) did not 
express ErbB2. It is also noted that the level of ErbB2 expression was comparable to 
the one observed in MDA-MB-453 cells as shown in Figure 5.8 D. Another 
characteristic of those cell lines is that EGFR was largely overexpressed.
As no further optimisation work was required for these stably transfected cell lines, 
this model was easier to use than the siRNA transfected cells. Thus, ErbB2 
transfected cells were used for the investigation of the effect of ErbB2 expression in 
the repair of cisplatin-induced DNA damage.
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Figure 5.7 -  Protein expression of each ErbB receptor in MDA-MB-468, MDA-MB-468 
pcDNA3 (vector control) and MDA-MB-468 pcDNA3-ErbB2 cells, a-tubulin was used as 
a loading control.
Figure 5.8 — ErbB2 immunofluorescence of MDA-MB-453 and MDA-MB-468 cells.
MDA-MB-468 wild type cells (A), MDA-MB-468 cells transfected with pcDNA3 (B), 
MDA-MB-468 cells transfected with pcDNA3-ErbB2 (C) and MDA-MB-453 cells (D) were 
stained with anti-ErbB2 (green) and counter-stained with propidium iodide (red).
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5.7 Effect of trastuzumab on MDA-MB-468 cells
overexpressing ErbB2
5.7.1 Effect of trastuzumab on ErbB2 protein level
MDA-MB-468 pcDNA3-ErbB2 cells were treated with a range of trastuzumab 
concentrations, for different periods of exposure. Expression of ErbB2 and the 
phosphorylated form of Erb2 were measured by western blotting. Figure 5.9 
demonstrates expression of ErbB2 obtained by immunoblotting after 1, 16, 24 and 72 
hours of exposure to a range of trastuzumab concentrations. ErbB2 protein expression 
level was reduced after 16 hours of exposure to trastuzumab at 0 04pg/ml (Figure 5.9 
B). After 1 hour of exposure, no reduction was observed. Similarly to the experiment 
in Chapter 3 (section 3.3), trastuzumab did not affect the level of phosphorylated 
ErbB2.
Down-regulation of ErbB2 by trastuzumab was also confirmed by 
immunofluorescence (Figure 5.10 A and B). After 24 hours with 40pg/ml of 
trastuzumab (Figure 5.10 B) ErbB2 protein level was reduced. This concentration of 
trastuzumab was used for the study of DNA interstrand crosslinks in the next section.
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Figure 5.9 -  ErbB2 and pErbB2 protein expression in MDA-MB-468 pcDNA3-ErbB2 
cells treated with trastuzumab. Cells were treated with a range of trastuzumab 
concentrations for 1 hour (A), 16 hours (B), 24 hours (C) and 72 hours (D). a-tubulin was 
used as a loading control.
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Figure 5.10 -  ErbB2 immunofluorescence in MDA-MB-468 pcDNA3-ErbB2 cells before 
and after trastuzumab treatment. ErbB2 was measured in untreated cells (A) and cells 
treated for 24 hours with 40|ig/ml of trastuzumab (B).
5.7.2 Effect of trastuzumab on cell proliferation
Having shown the reduction of total ErbB2 protein level after continuous exposure to 
trastuzumab, effects on cell proliferation were investigated using the SRB assay. 
MDA-MB-468 wild type cells and the two stably transfected cell lines were exposed 
to a range of trastuzumab concentrations for 5 consecutive days. Figure 5.11 
demonstrates that MDA-MB-468 wild type and MDA-MB-468 pcDNA3 vector 
control cells proliferation were not affected by trastuzumab. In addition, cells 
overexpressing ErbB2 were only affected by high doses of trastuzumab (lOOpg/ml), 
causing 10-20% inhibition of proliferation.
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□  M D A -M B -468 pcD N A 3-  
ErbB2
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T r a s t u z u m a b  c o n c e n t r a t i o n  (M g/ml)
Figure 5.11 -  Inhibition of MDA-MB-468 cells proliferation by trastuzumab. MDA-MB- 
468 wild type cells (red), MDA-MB-468 pcDNA3 vector control cells (blue) and MDA-MB- 
468 pcDNA3-ErbB2 cells (yellow) were treated with a range of trastuzumab concentrations. 
Data presented are the result of three independent experiments, as shown by the standard 
deviation.
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5.8 Trastuzumab and cisplatin treatment
As demonstrated in Chapter 3 (section 3.4), trastuzumab was capable of enhancing 
the anti-tumour activity of chemotherapeutic drugs (Pegram et al., 2004a). In Chapter 
3, trastuzumab was shown to enhance cisplatin anti-tumour activity but also to delay 
the repair of cisplatin-induced DNA ICL. Therefore, the effect of cisplatin in 
combination with trastuzumab was studied on MDA-MB-468 wild type cells and the 
transfected cell lines.
5.8.1 Effect of combination treatment after continuous exposure
Cells were treated with trastuzumab at 4pg/ml or 40}ig/ml and a range of cisplatin 
concentrations, for 5 consecutive days. To ensure accuracy and reproducibility, all 
assays were performed in triplicate. Proliferation curves are presented in Figure 5.12 
A, B and C for MDA-MB-468 pcDNA3-ErbB2, MDA-MB-468 pcDNA3 (vector 
control) and MDA-MB-468 wild type cells, respectively. IC5o results are presented in 
Table 5.4, for cisplatin alone and the combination treatments. IC50 were statistically 
analysed using the student t-test (see Appendix 1) with a degree of freedom of 4 and a 
significance level of p  = 0.05 (95% probability). Results highlighted in red 
demonstrate that MDA-MB-468 cells overexpressing ErbB2 were significantly more 
resistant (1.5 fold) to cisplatin than the ErbB2 negative cells and the vector control 
cells. However, combining trastuzumab with cisplatin did not sensitise any of the cell 
lines to cisplatin, since the IC50 between the single agent and the combination 
treatments were not significantly different. For the cell line overexpressing ErbB2 it 
would be expected to see a sensitisation to cisplatin when combined with 
trastuzumab, as described in Chapter 3. However, optimisation of the drug scheduling 
may be required to observe sensitisation by trastuzumab.
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C e l l  l in e
I C 50
( c i s p la t in
a lo n e )
I C 50 ( c i s p la t in  
w it h  t r a s t u z u m a b  
4 * ig /m l)
I C 50 ( c is p la t in  
w it h  t r a s t u z u m a b  
4 0 |u g /m l)
MDA-MB-468
pcDNA3-ErbB2 0 .2 8 ± 0 .0 5 p M 0 .2 8 ± 0 .0 4 p M 0 .3 1 ± 0 .0 3 p M
MDA-MB-468 
pcDNA3 vector 
control
0.21±0.04pM 0.15±0.0.04pM 0.22±0.07pM
MDA-MB-468 
wild type 0.20±0.02|uM 0.15±0.06pM 0.20±0.06pM
Table 5.4 -  IC50±SD results for MDA-MB-468 cells after cisplatin single agent treatment 
and combination with trastuzumab. MDA-MB-468 wild type, MDA-MB-468 pcDNA3- 
ErbB2 and MDA-MB-468 pcDNA3 vector control cells were treated for five consecutive 
days. IC50 were statistically compared to the IC50 of the wild type cells, using the student t- 
test, n = 4 and p = 0.05. Results highlighted in red are significantly different to the 
corresponding IC50 in the wild type cells.
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Figure 5.12 -  Inhibition of MDA-MB-468 cells proliferation by cisplatin alone and in 
combination with trastuzumab for 5 days. MDA-MB-468 pcDNA3-ErbB2 (A), MDA- 
MB-468 pcDNA3 (B) and MDA-MB-468 wild type cells (C) were treated by cisplatin alone 
(♦) and cisplatin in combination with trastuzumab 4pg/ml (■) and 40pg/ml ( ) for 5 
consecutive days. Data presented are the result of three independent experiments, as shown 
by the standard deviation.
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5.8.2 Effect of combination treatment after short exposure
MDA-MB-468 cells overexpressing ErbB2 were shown to be more resistant to 
cisplatin than the wild type cells, after continuous exposure. However, cells were not 
sensitised to cisplatin in presence of trastuzumab. In order to determined cell 
sensitivity to combination treatment, under similar conditions to the comet assay, 
cells were treated with cisplatin alone or cisplatin with trastuzumab for 1 hour, then 
incubated in drug free media or media containing trastuzumab (for combination 
treatments) for 5 days. Inhibition of proliferation curves are presented in Figure 5.13 
A, B and C. IC50 values (Table 5.5) have been statistically analysed using the student 
/-test with a degree of freedom n = 4 and a significance level p  = 0.05 (probability 
95%). Similarly to the continuous treatments, ErbB2 positive cells were more 
resistant to cisplatin than the wild type cells (IC50 highlighted in red), when treated 
with cisplatin alone or in combination with trastuzumab at 4pg/ml. With a higher 
concentration of trastuzumab (40pg/ml), MDA-MB-468 pcDNA3-ErbB2 cells were 
not significantly more resistant or sensitive to cisplatin, than the ErbB2 negative cells. 
Nevertheless, ErbB2 positive cells were shown to be more sensitive to cisplatin (IC50 
highlighted in bold blue) when treated in combination with trastuzumab (40|ug/ml) 
than to cisplatin alone. In addition, it is noted that trastuzumab alone, at 40pg/ml, did 
not cause a large inhibition of cell proliferation. Therefore, trastuzumab sensitised 
ErbB2 overexpressing cells to cisplatin.
C e ll  l in e
I C 50 ( c i s p la t in  
a lo n e )
I C 50 ( c i s p la t in  
w it h  t r a s t u z u m a b  
4 p g /m l )
I C 50 ( c is p la t in  
w it h  t r a s t u z u m a b  
4 0 p g /m l )
MDA-MB-468
pcDNA3-ErbB2 18.00±3.21pM 17.00±2.75(iM 1 2 .0 0 ± 3 .4 0 p M
MDA-MB-468 
pcDNA3 vector 
control
9.50±3.11pM 9.50±3.62pM 8.50±3.04pM
MDA-MB-468 
wild type 10.00±3.00pM 8.50±3.79pM
8.50±3.88pM
Table 5.5 -  IC50±SD results for MDA-MB-468 after cisplatin single agent treatm ent and 
combination with trastuzum ab, for 1 hour. Cells were treated for 1 hour followed by 5 
days in drug free media or media containing trastuzumab alone. Results were statistically 
analysed with the student /-test, n = 4 and p = 0.05. MDA-MB-468 pcDNA3-ErbB2 cells 
were more resistant to cisplatin than ErbB2 negative cells (IC50 highlighted in red). IC50 in 
blue shows that trastuzumab (40pg/ml) sensitised ErbB2 overexpressing cells to cisplatin.
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Figure 5.13 -  Inhibition of MDA-MB-468 cells proliferation by cisplatin alone and in 
combination with trastuzumab for 1 hour. MDA-MB-468 pcDNA3-ErbB2 (A), MDA- 
MB-468 pcDNA3 (B) and MDA-MB-468 wild type (C) cells were treated with cisplatin 
alone (♦) or cisplatin with trastuzumab 4pg/ml (■) and 40pg/ml ( ) for 1 hour, then 
incubated in drug free media or media containing trastuzumab (for combination treatments) 
for 5 days. Data presented are the result of three independent experiments, as shown by the 
standard deviation.
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5.9 Modulation of ErbB2 expression and DNA interstrand
crosslink repair
In the previous section, sensitisation of cells overexpressing ErbB2 to cisplatin, by 
trastuzumab, was demonstrated. Therefore, to investigate if ErbB2 inhibition was 
responsible for the delay in the repair of cisplatin-induced interstrand crosslinks, the 
kinetics of DNA damage repair following combination treatment of cisplatin with 
trastuzumab was studied in the transfected cell lines, using the comet assay. 
Furthermore, the kinetics of DNA damage repair of melphalan was also investigated. 
However, prior to this investigation, the optimal dose of each chemotherapeutic agent 
to be used was determined.
5.9.1 Kinetics of cisplatin DNA damage and repair
Measurement of cisplatin-induced DNA interstrand 
crosslinks
In order to study the repair of DNA damage produced by cisplatin, the dose resulting 
in 50-70% ICL at the peak time of crosslinking (9 hours post-treatment) was 
determined using a range of cisplatin concentrations. Cells were treated for 1 hour 
and incubated in drug free media for 9 hours. The dose used was defined for MDA- 
MB-468 wild type cells, and the same dose was then used for all three cell line for 
comparison purposes. The dose response curve presented in Figure 5.14 showed that 
lOOpM cisplatin was required to produce ~60% ICL in MDA-MB-468 wild type 
cells.
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Figure 5.14 -  DNA interstrand crosslinks in MDA-MB-468 wild type cells after cisplatin 
treatment. Cells were treated with a range of cisplatin concentrations, for 1 hour. 
Measurements at the peak of crosslinking, 9 hours post-incubation. Data presented are the 
result of three independent experiments, as shown by the standard error.
Effect o f ErbB2 modulation on the kinetics of formation and
repair o f cisplatin-induced DNA interstrand crosslinks
Using trastuzumab at 40|ug/ml and cisplatin at lOOpM, as defined previously, MDA- 
MB-468 wild type, MDA-MB-468 pcDNA3 and MDA-MB-468 pcDNA3-ErbB2 
cells were treated with either cisplatin alone or cisplatin in combination with 
trastuzumab for 1 hour, followed by incubation in drug free media or media 
containing trastuzumab (for combination treatment). ICLs were measured at different 
time points, post-treatment.
Trastuzumab did not alter the kinetics of repair of cisplatin-induced DNA damage in 
MDA-MB-468 wild type (Figure 5.15) and MDA-MB-468 pcDNA3 (Figure 5.16) 
cells, non expressing ErbB2. For example, in the wild type cell line, after 48 hours, 
36.1±3.0% of ICLs remained in cells treated with cisplatin alone, and 32.0±3.9% 
were unrepaired in cells treated with the combined drugs. Inhibition of ErbB2 by 
trastuzumab, in MDA-MB-468 pcDNA3-ErbB2 (Figure 5.17) caused a delay in the
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repair of cisplatin-induced DNA ICL. After 48 hours 24.2±3.8% of ICLs remained in 
cells treated with cisplatin alone, whereas 55.7±3.6% was unrepaired in cells treated 
with cisplatin in combination with trastuzumab. Therefore, these results concur with 
the data obtained in Chapter 3 on the effect of trastuzumab in the repair of cisplatin- 
induced DNA damage.
Furthermore, Figure 5.18 demonstrates that ErbB2 plays a direct role in the repair of 
cisplatin-induced DNA damage, since ErbB2 overexpressing cells treated with 
cisplatin alone repaired cisplatin ICLs faster (24.2±3.8% after 48 hours) than ErbB2 
negative cells (36.1±3.0% after 48 hours). It is also noted that the transfection of 
ErbB2 did not affect the level of formation of crosslinks, as 61.7±3.6% of crosslinks 
were formed after 9 hours post-treatment in MDA-MB-468 wild type cells and 
66.8±2.1% in ErbB2 overexpressing cells. The cells transfected with the vector 
control having 70.4±1.8% of crosslinks formed, after 9 hours.
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Figure 5.15 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 wild type 
cells. Cells were treated with trastuzumab alone ( ), trastuzumab in combination with 
cisplatin ( A )  or cisplatin alone (♦). Data presented are the result of three independent 
experiments, as shown by the standard error.
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Figure 5.16 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 pcDNA3 
vector control cells. Cells were treated with trastuzumab alone ( ), trastuzumab in 
combination with cisplatin (▲) or cisplatin alone (♦). Data presented are the result of three 
independent experiments, as shown by the standard error.
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Figure 5.17 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 pcDNA3- 
ErbB2 cells. Cells were treated with trastuzumab alone ( ), trastuzumab in combination with 
cisplatin ( A )  or cisplatin alone (♦). Data presented are the result of three independent 
experiments, as shown by the standard error.
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Figure 5.18 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 cells.
MDA-MB-468 wild type (♦), MDA-MB-468 pcDNA3 ( ) and MDA-MB-468 pcDNA3- 
ErbB2 (▲) cells were treated with cisplatin alone. Data presented are the result of three 
independent experiments, as shown by the standard error.
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5.9.2 Kinetics of melphalan-induced DNA damage and repair
Although melphalan-induced DNA interstrand crosslinks were shown to be 
unaffected by the inhibition of ErbB2 (see Chapter 3), it was interesting to consider 
the effect of ErbB2 overexpression on the kinetics of melphalan-induced DNA 
damage and repair.
Measurement of melphalan-induced DNA interstrand 
crosslinks
Similarly to the experiment with cisplatin, cells were treated for 1 hour with a range 
of melphalan concentrations and crosslinks were measured after 16 hours (peak of 
ICL for melphalan). The dose used was defined for MDA-MB-468 wild type cells 
and the same dose was then used for all three cell lines for comparison purposes. The 
dose response curve presented in Figure 5.19 showed that 150pM of melphalan was 
required to produce 50-60% ICL in MDA-MB-468 wild type cells.
100.0 n
0>
0)(0
£
80.0
o
©T3
C©Eo
E
60.0 -
40.0 -
(0l-
20.0
0.0
100.0 150.0 200.00.0 50.0 75.0
Melphalan concentration (pM)
Figure 5.19 -  DNA interstrand crosslinks in MDA-MB-468 wild type cells after 
melphalan treatment. Cells were treated with a range of melphalan concentrations, for 1 
hour. Measurements at the peak of crosslinking, 16 hours post-incubation. Data presented are 
the result of three independent experiments, as shown by the standard error.
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Effect of ErbB2 modulation on the kinetics of formation and
repair of melphalan-induced DNA interstrand crosslinks
Using trastuzumab at 40pg/ml and melphalan at the previously defined dose of 
150pM, MDA-MB-468 wild type, MDA-MB-468 pcDNA3 and MDA-MB-468 
pcDNA3-ErbB2 cells were treated with either melphalan alone or melphalan in 
combination with trastuzumab for 1 hour, followed by incubation in drug free media 
or media containing trastuzumab alone (for combination treatment). ICLs were 
measured at different time points, post-treatment.
The repair kinetics of melphalan-induced DNA ICL remained unaffected by the 
presence of trastuzumab, in MDA-MB-468 cells (Figure 5.20) and MDA-MB-468 
pcDNA3 vector control cells (Figure 5.21). Those results were comparable to the one 
obtained for MDA-MB-453 cells in Chapter 3. As shown in Figure 5.22, inhibition of 
ErbB2 (MDA-MB-468 pcDNA3-ErbB2), by trastuzumab, did not cause any delay in 
the repair of melphalan interstrand crosslinks. After 24 hours, 45.7% of crosslinks 
remained unrepaired in cells treated with cisplatin alone and 47.3% in cells treated 
with the combination of both drugs.
Furthermore, Figure 5.23 shows that overexpression of ErB2 alone did not alter the 
kinetics of melphalan-induced DNA ICL damage and repair. After 24 hours 
40.5±3.7% of ICLs remained in MDA-MB-468 wild type cells and 45.7±1.1% were 
still unrepaired in MDA-MB-468 cells overexpressing ErbB2. Similarly to the result 
obtained with cisplatin, transfection of ErbB2 did not affect the peak of crosslinking, 
since 58.1±1.3% of ICLs were formed after 16 hours post-treatment in the wild type 
cells and 59.7±1.4% in the ErbB2 transfected cell line. In the same way, melphalan 
treatment of cells transfected with the empty vector produced 58.3±4.8% of ICLs 
after 16 hours.
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Figure 5.20 -  Melphalan-induced DNA interstrand crosslinks in MDA-MB-468 wild 
type cells. Cells were treated with trastuzumab in combination with cisplatin ( A )  or cisplatin 
alone (♦). Data presented are the result of three independent experiments, as shown by the 
standard error.
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Figure 5.21 -  Melphalan-induced DNA interstrand crosslinks in MDA-MB-468 pcDNA3 
vector control cells. Cells were treated with trastuzumab in combination with cisplatin ( A )  
or cisplatin alone (♦). Data presented are the result of three independent experiments, as 
shown by the standard error.
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Figure 5.22 -  Melphalan-induced DNA interstrand crosslinks in MDA-MB-468 
pcDNA3-ErbB2 cells. Cells were treated with trastuzumab in combination with cisplatin ( A )  
or cisplatin alone (♦).Data presented are the result of three independent experiments, as 
shown by the standard error.
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Figure 5.23 -  Melphalan-induced DNA interstrand crosslinks in MDA-MB-468 cells.
MDA-MB-468 wild type (♦), MDA-MB-468 pcDNA3 ( ) and MDA-MB-468 pcDNA3- 
ErbB2 ( A )  cells were treated with melphalan alone. Data presented are the result of three 
independent experiments, as shown by the standard error.
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5.10 Modulation of ErbB2 expression and DNA intrastrand
crosslinks repair
Cisplatin-induced DNA intrastrand crosslinks form up to 90% of the platinum-DNA 
adducts (Jakupec, 2003). Therefore, having shown the effect of ErbB2 expression on 
the repair of cisplatin-induced DNA ICLs, it was important to study the formation 
and repair of intrastrand crosslinks. In order to carry out this investigation, a 
competitive ELISA assay, established by Tilby et al. (1987 and 1991), was used. 
Cisplatin-induced intrastrand adducts are formed quickly when cells are in contact 
with cisplatin and the peak of intrastrand crosslinks (i.e. formation of adducts post­
treatment) has been previously observed within a few hours (De Silva et a l, 2002). 
Nevertheless, this peak of intrastrand crosslinks may be cell line dependent and a 
number of factors need to taken into consideration. Firstly, the intracellular drug 
concentration will vary between cells and residual cisplatin in the cells after removal 
of extra-cellular drug will continue to react with DNA, react with other molecules 
and/or be exported. The balance between these factors will determine how many 
more adducts are formed post-drug removal. Secondly, levels of adducts on DNA 
being reduced by repair and/or dilution through continued DNA synthesis, the 
balance between rates of continued adduct formation and rate of adduct level 
reduction will determine the detailed shape of the adduct level curve. Finally, 
monofunctional adducts on the DNA will be converting to 1,2-crosslinks, therefore 
adducts present on the DNA at the time of cell harvesting and DNA extraction may 
convert to the cross-links during the time of the extraction and the assay procedures.
Therefore, cisplatin intrastrand crosslinks were measured shortly after incubation at 
different time intervals. In order to compare the effect of ErbB2 expression on the 
kinetics of this type of damage, the same cisplatin concentration as in the single gel 
electrophoresis assay, was used. However, a preliminary experiment was carried out 
to demonstrate that lOOpM cisplatin caused enough DNA intrastrand crosslinks to 
study their repair accurately.
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5.10.1 Measurement of cisplatin-induced intrastrand crosslinks
As the vector control cell line did not show any differences with MDA-MB-468 cells, 
only the wild type and ErbB2 transfected cells have been studied in this experiment. 
Cells were treated for 1 hour with a range of cisplatin concentrations and samples 
were analysed at the end of the drug treatment. As shown in Figure 5.24, lOOpM of 
cisplatin caused the formation of 430nmol of adduct/ g of DNA. Therefore, the 
transfection of ErbB2 did not affect the formation of 1,2-intrastrand crosslinks.
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Figure 5.24 -  Cisplatin-induced intrastrand crosslinks in MDA-MB-468 cells. MDA- 
MB-468 wild type (♦) and MDA-MB-468 pcDNA3-ErbB2 (■) cells were treated with a range 
of cisplatin concentrations, for 1 hour. Measurements were made at the end of the 1 hour 
treatment. Data presented are the result of three independent experiments, as shown by the 
standard error.
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5.10.2 Effect of ErbB2 modulation on the kinetics of formation
and repair of cisplatin-induced intrastrand crosslinks
Cells were treated with cisplatin alone or with a combination of cisplatin and 
trastuzumab, as detailed in the study of interstrand crosslinks. As shown in Figure 
5.25, formation of cisplatin-induced intrastrand crosslinks was not affected by ErbB2 
overexpression. In these two cell lines the peak of intrastrand adduct formation was 
observed immediately after the 1 hour treatment, and was not modified by ErbB2 
overexpression. Furthermore, adducts were rapidly repaired within the first 5 hours 
post-treatment. After 24 hours, 162.0±8.4nmol of intrastrand adducts/g of DNA 
remained in wild type cells and 160.5±9.7nmol of intrastrand adducts/g of DNA was 
present in cells overexpressing ErbB2. Furthermore, inhibition of ErbB2 by 
trastuzumab did not affect the kinetics of DNA intrastrand crosslink formation or 
repair. In cells overexpressing ErbB2, after 9 hours, 222.3±9.1nmol of intrastrand 
adducts/g of DNA was present in cells treated with cisplatin alone and 238.5±9.0nmol 
of intrastrand adducts/g of DNA in cells treated with a combination of cisplatin and 
trastuzumab.
Figure 5.26 demonstrates that repair of intrastrand crosslinks was not altered by 
modulation (overexpression or inhibition) of ErbB2. After 9 hours, MDA-MB-468 
wild type cells had 49.7±6.4% of adducts repaired and MDA-MB-468 pcDNA3- 
ErbB2 cells had 37.7±4.3% of adducts repaired. The difference obtained there is not 
considered significant due to the standard errors obtained. It is also noted that repair 
of intrastrand adducts was not complete, since the repair of adducts reached a plateau 
at -60% after 48 hours post-treatment. This was explained by the high level of 
adducts obtained with 100pM of cisplatin, resulting in incomplete repair. Using the 
same technique, incomplete repair of cisplatin intrastrand adducts was also observed 
in the study by De Silva et al. (2002).
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Figure 5.25 -  Cisplatin-induced DNA intrastrand crosslinks in MDA-MB-468 cells.
MDA-MB-468 wild type (♦ and ) and MDA-MB-468 pcDNA3-ErbB2 (▲ and x) cells (with 
standard error), after treatment with cisplatin alone or cisplatin and trastuzumab. Data 
presented are the result of three independent experiments, as shown by the standard error.
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Figure 5.26 -  Repair of cisplatin-induced DNA intrastrand crosslinks in MDA-MB-468 
cells. MDA-MB-468 wild type (♦ and ) and MDA-MB-468 pcDNA3-ErbB2 ( A  and x) cells 
(with standard error), after treatment with cisplatin alone or cisplatin and trastuzumab. Data 
presented are the result of three independent experiments, as shown by the standard error.
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5.11 Modulation of expression of DNA repair proteins and
proteins of the ErbB2 signalling pathway
Having shown that cisplatin-induced DNA interstrand crosslink repair was affected 
by the modulation of ErbB2 protein expression, and that Akt was involved in the 
delay of DNA damage repair observed in MDA-MB-453 and SK-BR-3 cells (Chapter 
4), the expression level of different proteins involved in the ErbB2 signalling pathway 
and DNA damage response have been investigated in MDA-MB-468 cells 
overexpressing ErbB2 and the two ErbB2 negative cell lines.
The expression level of DNA-PK, Akt and their phosphorylated forms has been 
investigated. In addition to those proteins, MAPK, pMAPK (phosphorylated form of 
MAPK) and PTEN protein expression levels were examined. Although DNA-PK 
expression was not shown to be altered by the inhibition of ErbB2 (Chapter 4, section 
4.4), it remains an important protein as it was shown to physically interact with 
EGFR, another member of the epidermal growth factor family, following the 
inhibition of the tyrosine kinase activity of EGFR (Friedmann B. et al., 2004). Akt 
and MAPK have been studied due to their involvement in the ErbB2 signalling 
pathway and their effect on p27kipl and p21WAF1, as described in Chapter 4. Finally, 
PTEN was studied due to its interaction with the PI3K/Akt pathway (Nagata et al., 
2004; Fujita et al., 2006). Cells were treated as described in the study of DNA ICL 
repair and immunoblots obtained are presented in Figures 5.27 to 5.30 for MDA-MB- 
468 wild type cells and Figures 5.31 to 5.34 for MDA-MB-468 pcDNA3-ErbB2 cells. 
Results for MDA-MB-468 pcDNA3 cells are not presented as they were similar to 
those obtained for the wild type cells.
Results obtained showed that protein levels of DNA-PK and its phosphorylated form 
(pDNA-PK) were not affected by any of the treatments in the three cell lines. ErbB2, 
only expressed in MDA-MB-468 pcDNA3-ErbB2 cells, was down-regulated in the 
presence of trastuzumab alone (Figure 5.34) or in combination with cisplatin (Figure 
5.34). In untreated MDA-MB-468 pcDNA3-ErbB2 cells (Figure 5.31) or cells treated 
with cisplatin alone (Figure 5.33), ErbB2 protein level remained unaltered.
As shown in Chapter 4, the protein level of Akt was not affected by trastuzumab or 
cisplatin, and Akt phosphorylated at serine 473 (pAkt S473) was not detectable in
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untreated cells (Figures 5.27 and 5.31) or cells treated with cisplatin alone (Figures 
5.29 and 5.33). However, a low level of Akt phosphorylated at threonine 308 (pAkt 
T308) was present in all three untreated cell lines (the strength of the pAkt band may 
differ between the immunoblots presented due to the length of exposure of the films). 
In addition, level of pAkt T308 was higher in cells overexpressing ErbB2 (Figure 
5.31) than in ErbB2 negative cells (Figures 5.27). Moreover, pAkt T308 and pAkt 
S473 increased in presence of trastuzumab alone for 1 hour (Figures 5.28, 5.32). This 
level reduced slowly with time in ErbB2 negative cells whereas the reduction in 
ErbB2 positive cells was much more rapid. It was also noted that pAkt S473 reduced 
dramatically in ErbB2 positive cells after 10 hours (Figure 5.32). In combination with 
cisplatin (Figure 5.30 and 5.34), trastuzumab also caused phosphorylation of Akt 
after 1 hour but there was no reduction of pAkt (S473 and T308) with time in ErbB2 
negative cells, while in MDA-MB-468 pcDNA3-ErbB2 cells, only pAkt T308 level 
was maintained.
Therefore, trastuzumab caused similar effects in ErbB2 positive and negative cells, 
identical to the one described in Chapter 4. However, overexpression of ErbB2 
caused an increase in phosphorylation of Akt (pAkt T308) compared to ErbB2 
negative cells. Moreover, ErbB2 overexpression caused a rapid reduction of pAkt 
S473, after activation by trastuzumab.
MAPK was present in all cell lines but its expression was not affected by any of the 
treatments. However, MAPK became phosphorylated (pMAPK) after treatment with 
cisplatin alone or in combination, and its phosphorylated state was maintained with 
time. In addition, trastuzumab or ErbB2 overexpression did not alter its 
phosphorylation level.
PTEN was not detectable in any of the three untreated cell lines. However, after 1 
hour of treatment with trastuzumab alone it was present in all three cell lines with a 
level reducing quickly with time. In combination with cisplatin, trastuzumab caused 
activation of PTEN with its level reducing slowly with time. Therefore similarly to 
pAkt cisplatin maintained the activated level of PTEN caused by trastuzumab.
238
DNA-PK (470kDa) 
pDNA-PK (470kDa) 
pAkt-S473 (60kDa) 
pAkt-T308 (60kDa) 
Akt (60kDa)
PTEN (54kDa) 
a-tubulin (50kDa) 
pMAPK (42/44kDa) 
MAPK (42/44kDa) 
Time (Hours)
ft I
Ct 1 10 25 49
Figure 5.27 -  Immunoblots of untreated MDA-MB-468 wild type cells. Immunoblots 
were probed for DNA repair proteins and proteins involved in ErbB2 signalling pathways, a- 
tubulin was used as a loading control.
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Figure 5.28 -  Immunoblots of MDA-MB-468 wild type cells treated with trastuzumab.
Cells were treated with trastuzumab (40pg/ml) and immunoblots were probed for DNA repair 
proteins and proteins involved in ErbB2 signalling pathways, a-tubulin was used as a loading 
control.
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Figure 5.29 — Immunoblots of MDA-MB-468 wild type cells treated with cisplatin. Cells 
were treated with cisplatin (lOOpM) for 1 hour and immunoblots were probed for DNA repair 
proteins and proteins involved in ErbB2 signalling pathways, a-tubulin was used as a loading 
control.
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Figure 5.30 -  Immunoblots of MDA-MB-468 wild type cells treated with cisplatin and 
trastuzumab. Cells were treated with cisplatin (lOOpM) and trastuzumab (40pg/ml) for 1 
hour then incubated in media containing trastuzumab alone (40pg/ml), immunoblots were 
probed for DNA repair proteins and proteins involved in ErbB2 signalling pathways, a- 
tubulin was used as a loading control.
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Figure 5.31 -  Immunoblots of untreated MDA-MB-468 pcDNA3-ErbB2 cells.
Immunoblots were probed for DNA repair proteins and proteins involved in ErbB2 signalling 
pathways, a-tubulin was used as a loading control.
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Figure 5.32 -  Immunoblots of MDA-MB-468 pcDNA3-ErbB2 cells treated with 
trastuzumab (40pg/ml). Immunoblots were probed for DNA repair proteins and proteins 
involved in ErbB2 signalling pathways, a-tubulin was used as a loading control.
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Figure 5.33 -  Immunoblots of MDA-MB-468 pcDNA3-ErbB2 cells treated with cisplatin
(lOOpM). Cells were treated for 1 hour and immunoblots probed for DNA repair proteins and 
proteins involved in ErbB2 signalling pathways, a-tubulin was used as a loading control.
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Figure 5.34 -  Immunoblots of MDA-MB-468 pcDNA3-ErbB2 cells treated with cisplatin
(lOOpM) and trastuzumab (40fig/ml). Cells were treated for 1 hour then incubated in media 
containing trastuzumab alone (40pg/ml) and immunoblots probed for DNA repair proteins 
and proteins involved in ErbB2 signalling pathways, a-tubulin was used as a loading control.
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5.12 ErbB2 overexpression and topoisomerase II activity
Harris et al. (2001) demonstrated that ErbB2 signalling led to an increase in 
topoisomerase Hoc protein and topoisomerase II activity, causing increased resistance 
to the alkylating agent cyclophosphamide. Therefore, having shown that ErbB2 
overexpressing cells were more resistant to cisplatin treatment, it was important to 
consider the modulation of topoisomerase II activity due to ErbB2 overexpression.
Using catenated kinetoplast DNA (kDNA), DNA decatenation activity was studied in 
the three untreated cell lines described in section 5.6. Nuclear extract was incubated 
for 30 minutes at 37°C with kDNA before being separated on a 1% agarose gel 
(Figure 5.35). Results demonstrated that overexpression of ErbB2 (lane 4) increased 
the activity of topoisomerase II, as more decatenated kDNA was formed compared to 
the wild type MDA-MB-468 cells (lane 2) or the vector control cells (lane 3). It is 
also noted that the increase in decatenated kDNA was associated with a decrease in 
catenated kDNA.
Catenated kDNA
jNicked decatenated kDNA
Circular decatenated kDNA
1 2  3 4
Figure 5.35 -  Topoisomerase Ila  activity assay in MDA-MB-468 cells. Topoisomerase Ila 
activity was assessed in MDA-MB-468 wild type (2), MDA-MB-468 pcDNA3 (3) and 
MDA-MB-468 pcDNA3-ErbB2 (4) cell lines, using kinetoplast DNA (kDNA). Decatenated 
kDNA (1) was used as a positive control. Reactions were stopped after 30 minutes. Increase 
in decatenated kDNA was observed in cells overexpressing ErbB2 (4).
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DISCUSSION
In this chapter, the specific role of ErbB2 in the repair of cisplatin-induced DNA 
damage was investigated. To this end two approaches were considered. The first one 
was the use of siRNA to down-regulate ErbB2 expression in a breast cancer cell line 
overexpressing ErbB2. Although successful results were obtained with the siRNA, 
only partial down-regulation was achieved in cell lines overexpressing ErbB2 such as 
MDA-MB-453 cells. Therefore, the second approach using MDA-MB-468 cells, 
ErbB2 negative, stably transfected with a plasmid coding ErbB2 expression, was 
chosen. Results demonstrated that overexpression of ErbB2 was obtained and that 
ErbB2 was present in the cytoplasm and in the nucleus (immunofluorescence data). 
Using the same plasmid, Tzahar et al. (1996) obtained similar results as they showed 
overexpression of ErbB2 in CHO cells, negative for ErbB2. In addition, ErbB2 
overexpression was shown to increase resistance to cisplatin and subsequent 
inhibition by trastuzumab caused an increase in sensitivity. Furthermore, modulation 
of ErbB2 expression caused a modulation of the kinetics of repair of cisplatin-induced 
DNA ICL but not repair of DNA intrastrand crosslinks. Finally, results demonstrated 
that modulation of Akt and PTEN activation was independient of the ErbB2 status. In 
addition, DNA decatenation activity by topoisomerase II was shown to be up- 
regulated by ErbB2 overexpression.
5.13 ErbB2 expression and drug sensitivity
Trastuzumab was shown to reduce the ErbB2 protein level similarly to the results 
obtained in MDA-MB-453 cells. However, growth inhibition of MDA-MB-468 
ErbB2 positive cells was only observed at high trastuzumab doses (>100pg/ml). This 
result differs from the results in Chapter 3, which showed that increased ErbB2 
expression was associated with increased sensitivity to trastuzumab. Nevertheless, 
Gong et al. (2004) demonstrated that trastuzumab single agent treatment did not 
always reduce cell proliferation of ErbB2 overexpressing cells.
In Chapter 3, breast cancer cells overexpressing ErbB2 (e.g. SK-BR-3) were not 
shown to be more resistant to chemotherapeutic agents than cells with a lower level of 
ErbB2 protein (e.g. MCF-7 and SK-BR-3 cells). As reported by Pegram et al. (1997)
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resistance to chemotherapeutic agents is not only associated with the ErbB2 
expression and is often cell line specific. Nevertheless, results from Benz et al. (1992) 
demonstrated that ErbB2 overexpression in transfected MCF-7 cells caused a 2-4 fold 
increase in resistance to cisplatin. Similarly, clinical trial studies (Allred et al., 1992; 
Wright et al., 1992) have also suggested the association of ErbB2 overexpression 
with increased resistance to chemotherapeutic agents. Results obtained here 
demonstrated that ErbB2 transfection in MDA-MB-468 wild type cells caused an 
increase in resistance to cisplatin, by 1.5 fold after continuous exposure and by almost 
2 fold after short exposure (1 hour).
Studies by Pegram et al. (1997) and Orr et al. (2000) demonstrated that ErbB2 
overexpression is not always sufficient to account for increased resistance to 
chemotherapeutic agents. Conversely, Hancock et al. (1991) also reported that ErbB2 
negative cells sensitivity to cisplatin was not affected by trastuzumab. Furthermore, 
the study by Pegram and Slamon (1999) established that combining trastuzumab with 
cisplatin enhances chemosensitivity of ErbB2 overexpressing cells. Naruse et al. 
(2002) also confirmed that trastuzumab was able to enhance the cytotoxic effect of 
cisplatin. The results obtained in the present study demonstrated that combining 
trastuzumab with cisplatin did not increase the chemosensitivity of ErbB2 negative 
cells. They also showed that trastuzumab was able to sensitise ErbB2 overexpressing 
cells to cisplatin, as an increase of 1.5 folds in sensitivity to cisplatin was observed 
when cells were treated with trastuzumab and cisplatin. Therefore, a direct 
association can be made between ErbB2 overexpression and cisplatin 
chemoresistance.
It was also demonstrated that drug scheduling played an important role, as 
sensitisation of ErbB2 positive cells to cisplatin, by trastuzumab, was only seen after 
short exposure to cisplatin. Thus, there is an important need to define the optimal 
schedule of administration of anticancer drugs with trastuzumab. A study of 
trastuzumab in combination with paclitaxel and carboplatin in metastatic breast 
cancer reported that drug scheduling played an important role in determining toxicity 
and efficacy of the treatment in vivo (Perez, 2004). Similarly, studies have shown that 
drug scheduling was important to consider in order to obtain synergistic effect 
between gefitinib, an EGFR tyrosine kinase inhibitor, and chemotherapeutic agents, 
such as cisplatin (Friedmann et al., 2004; Xu et al., 2003).
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5.14 ErbB2 expression modulates repair of drug-induced
DNA damage
Studying the repair of cisplatin-induced interstrand crosslink established that ErbB2 
overexpression caused an increase in DNA ICL repair efficiency, compared to the 
ErbB2 negative cells. Moreover, subsequent inhibition of ErbB2, by trastuzumab, 
caused a significant delay in DNA ICL repair, similarly to the results obtained for 
MDA-MB-453 cells in Chapter 3. Pietras et al (1994) reported that inhibition of 
ErbB2 led to a decrease in the rate of unscheduled DNA synthesis, used as a measure 
of DNA damage repair, after cisplatin treatment. Therefore, overexpression of ErbB2 
in MDA-MB-468 cells caused an increased resistance to cisplatin due to a more 
efficient repair of DNA ICLs, and combination of trastuzumab with cisplatin 
increased significantly the sensitivity to cisplatin, due to ErbB2 inhibition, and caused 
a delay in the repair of cisplatin-induced DNA interstrand crosslinks. It was also 
demonstrated that melphalan-induced DNA interstrand crosslinks were not affected 
by the modulation of ErbB2 expression. This difference from cisplatin can be 
explained by the type and frequency of ICLs formed, as De Silva et al (2002) 
demonstrated that repair of cisplatin ICLs did not involve the formation of double 
strand breaks, in contrast to other conventional crosslinking agents, such as 
melphalan.
In contrast to interstrand crosslinks, the kinetics of formation and repair of intrastrand 
crosslinks formed by cisplatin was not altered by ErbB2 overexpression or 
subsequent down-regulation by trastuzumab. However, Arteaga et al (1994) 
demonstrated that cisplatin-induced DNA intrastrand crosslinks were affected by 
ErbB2 inhibition. Using a competitive cisplatin-DNA ELISA, they showed that 
inhibition of ErbB2, using the anti-ErbB2 antibody Tab250, caused an increase in the 
formation of DNA intrastrand adducts and a delay in the repair of this type of 
adducts.
Therefore, according to the results obtained modulation of ErbB2 protein expression 
affects specifically the repair of cisplatin-induced DNA interstrand crosslinks. This 
specificity relies on the difference in the repair pathway involved for each type 
cisplatin adduct formed (De Silva et a l, 2002). As described previously, Zamble et
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al. (1996) established that cisplatin-induced intrastrand crosslinks were repaired by 
nucleotide excision repair. Whereas the repair of interstrand crosslinks adducts, which 
represent only 10% of the lesions caused by cisplatin, has been shown to involve the 
XPF-ERCC1 heterodimer component of nucleotide excision repair (De Silva et al., 
2000; Mu et al., 2000; Kuraoka et al., 2000) and XRCC2 and XRCC3 proteins of the 
homologous recombination repair pathway (De Silva et al., 2002). Although DNA 
interstrand crosslinks represent only 10% of cisplatin-DNA adducts, they have been 
described as being critical cytotoxic lesions in diving cells (Dronkert and Kanaar, 
2001; Lawley and Phillips, 1996).
Consequently, it is logical that ErbB2 transfected cells, repairing cisplatin ICLs more 
efficiently than ErbB2 negative cells, are more resistant to cisplatin than the ErbB2 
negative wild type cells. Hence, ErbB2 plays a role in the repair of cisplatin-induced 
ICLs and cisplatin chemoresistance.
5.15 Modulation of cell cycle progression
Proteins investigated in order to establish a possible explanation for the delay in DNA 
damage repair demonstrated that Akt, PTEN and pMAPK were affected by 
trastuzumab and the combination with cisplatin.
5.15.1 Role of Akt in the modulation of cell cycle
Results obtained were similar to those described in Chapter 4, with an activation of 
Akt (pAkt S473 and T308) by trastuzumab. Interestingly, trastuzumab had similar 
effects on pAkt in ErbB2 positive and negative cells, suggesting that escape of cells 
from the cell cycle, through inhibition of p21WAF1 and p27k,pl activity (Zhou et al., 
2001b; Medema et al., 2000), also occurred in MDA-MB-468 wild type cells. This 
may be explained by the presence of undetectable level of ErbB2 protein in MDA- 
MB468 wild type cells. However, overexpression of ErbB2 caused an increase of 
pAkt T308 level in untreated cells compared to ErbB2 negative cells. In addition, in 
ErbB2 positive cells, trastuzumab alone caused a more rapid decrease in pAkt 
following its activation. Yakes et al. (2002) also reported that inhibition of pAkt was 
only observed in cell lines with the highest ErbB2 protein expression. This finding
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could explain why inhibition of pAkt is faster in MDA-MB-468 cells positive for 
ErbB2 than in ErbB2 negative cells, leading to an increase in G1 arrest (discussed in 
Chapter 4). Furthermore, in ErbB2 positive cells, reduction of pAkt S473 was more 
rapid than reduction of pAkt T308 after activation by trastuzumab. A similar effect 
was observed with trastuzumab in combination with cisplatin, since only pAkt T308 
level was maintained with time. Thus, ErbB2 expression modulates differently 
phosphorylation of Akt at S473 and T308. This can be explained by the difference in 
phosphorylation mechanism, since threonine 308 has been shown to be 
phosphorylated by the kinase PDK1 (Alessi et al., 1997) whereas phosphorylation at 
serine 473 remains controversial (Toker and Newton, 2000).
Consequently, trastuzumab alone caused cell cycle arrest through inhibition of Akt 
activation, but in combination with cisplatin cells escaped cell cycle arrest due to the 
continuous activation of Akt. Furthermore, increased pAkt in ErbB2 cells may 
account for the increased resistance to cisplatin as Akt activation causes cell cycle 
progression and inhibition of apoptosis.
5.15.2 Role of MAPK in the modulation of cell cycle
Although ErbB2 overexpression was previously described to enhance MAPK 
signalling, results presented here did not show increased MAPK or pMAPK protein 
levels. However, in the presence of cisplatin, MAPK was shown to be activated. This 
concurs with the study by Wang et al. (2000a) which demonstrated that cisplatin 
caused activation of MAPK signalling and that it played a major role in mediating 
cisplatin-induced apoptosis. Contrary to the study by Yakes et al. (2002), in 
combination with cisplatin, trastuzumab did not cause inhibition of pMAPK in ErbB2 
overexpressing cells.
Therefore, cisplatin activates the MAPK signalling pathway and contributes to cell 
cycle arrest through modulation of p27kipl and cyclin D1 (Lenferink et al., 2001).
5.15.3 PTEN and PI3K/Akt signalling
Studies by Nagata et al. (2004) and Fujita et al. (2006) have previously established 
that trastuzumab caused activation o f  PTEN through its dephosphorylation. 
Furthermore, they reported that activation of PTEN led to an inhibition of the
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PI3K/Akt pathway. Results obtained here demonstrated that PTEN was rapidly 
activated by trastuzumab. Therefore, in the presence of trastuzumab alone, reduction 
of activated Akt and G1 arrest was mediated through PTEN activation. However, in 
combination with cisplatin, trastuzumab activated PTEN continuously but no down- 
regulation of pAkt was observed, suggesting that PTEN activation is not sufficient to 
cause inhibition of the PI3K pathway and cell growth inhibition.
Therefore, further investigation is required to determine the role of PTEN when 
combining trastuzumab with chemotherapeutic drugs and proteins regulating the 
PI3K/Akt signalling pathway.
5.16 ErbB2 overexpression increases topoisomerase II activity
A study by Harris et al. (2001) demonstrated that activation of ErbB2 led to an 
increase in topoisomerase II protein and activity, conferring increased resistance to 
cyclophosphamide, an alkylating agent. In addition, they also showed that inhibition 
of ErbB2, by trastuzumab, led to the reversal of this effect. Although no decrease in 
topoisomerase Ila  protein level was observed in Chapter 4, after combination of 
trastuzumab with cisplatin, an increase in sensitivity to cisplatin was reported. As 
demonstrated by several studies (Larsen et al., 1998; Pu and Bezwoda, 1999; Eder et 
al., 1995), the increase of topoisomerase II activity and protein level contribute, in 
some cell lines, to resistance to DNA crosslinking agent, cisplatin. Furthermore, 
topoisomerase II was also suggested to play a role in DNA repair through modulation 
of the chromatin structure. Investigating the DNA decatenation ability of stably 
transfected ErbB2 positive and negative cells, demonstrated that ErbB2 
overexpression caused an increase in topoisomerase II activity.
Therefore, together with published data, results suggest that ErbB2 overexpression 
increased topoisomerase II activity leading to a modulation of DNA repair activity 
and resistance to cisplatin. It is also suggested that combining cisplatin with 
trastuzumab causes a reduction in topoisomerase II activity. Nevertheless, further 
understanding of the molecular mechanism involved here is required.
ik,.
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5.17 Conclusion
The results presented in this chapter demonstrated that ErbB2 overexpression 
increased the repair of cisplatin-induced DNA interstrand crosslinks and subsequent 
down-regulation of ErbB2 by trastuzumab led to a delay in the repair of this type of 
cisplatin-DNA adduct. In addition, results also established that cisplatin-induced 
intrastrand crosslinks were not affected by ErbB2 expression modulation. 
Furthermore, ErbB2 overexpression was shown to increase resistance to cisplatin 
which was associated with the increased DNA ICLs repair efficiency, pAkt protein 
level and topoisomerase II activity. Trastuzumab was also shown to enhance the 
sensitivity of ErbB2 overexpressing cells to cisplatin and cause a delay in the repair 
of cisplatin-induced DNA ICLs. Finally, studying the expression of proteins involved 
in DNA damage repair and ErbB2 signalling pathway confirmed the results obtained 
in Chapter 4, however, PTEN activation did not cause inhibition of pAkt in the 
combination treatment, contrary to some published studies. Cisplatin was also 
suggested to induce cell cycle arrest and apoptosis through activation of the MAPK 
signalling pathway.
Therefore, considering those results it is reasonable to conclude that ErbB2 
expression can alter the repair of cisplatin-induced DNA ICLs. In addition, the delay 
in the repair of DNA damage was also suggested to be caused by an escape of the 
cells from cell cycle arrest.
ErbB2 having been shown to localise in the cytoplasm and the nucleus and since 
DNA repair occurs in the nucleus, its nuclear localisation may play an important role 
in the repair of cisplatin-induced DNA damage. In order to determine the effect of 
ErbB2 nuclear localisation, MDA-MB-468 cells, ErbB2 negative, will be used and 
stably transfected with a plasmid encoding a mutated form of ErbB2, with a deletion 
of the nuclear localisation signal (NLS).
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Chapter 6
Role of ErbB2 nuclear localisation 
in the repair of cisplatin-induced
DNA ICL
251
INTRODUCTION
The previous chapter demonstrated that ErbB2 overexpression caused an increase in 
efficiency in the repair of cisplatin-induced DNA interstrand crosslink. In addition, 
ErbB2 protein inhibition, by trastuzumab, led to a delay in the repair of DNA ICLs 
induced by cisplatin. Finally, it was demonstrated that ErbB2 overexpression induced 
an increased in DNA decatenation activity. Since ErbB2 was shown, in certain cancer 
cell lines, to be expressed in the cytoplasm and the nucleus, it is important to consider 
the potential role of ErbB2 nuclear localisation in the repair of cisplatin-induced DNA 
interstrand crosslink.
6.1 Nuclear localisation of EGFR family members
The epidermal growth factor receptor family of receptor tyrosine kinases, including 
EGFR, ErbB2, ErbB3 and ErbB4, are expressed at the cell surface. Binding of these 
receptors to their respective ligands causes heterodimerisation and homodimerisation 
leading to activation of the tyrosine kinase activities (Schlessinger, 2002). This will 
subsequently relay information from the cell surface to the nucleus through a network 
of downstream signalling pathways, such as the MAPK and PI3K pathways, 
regulating cellular proliferation, differentiation and programmed cell death (Olayioye 
et al., 2000). However, recent studies have shown that EGFR family members are 
able to translocate to the nucleus (Massie and Mills, 2006). Nuclear localisation has 
been shown to be mediated by a nuclear localisation signal sequence (NLS -  
Pemberton L.F. and Paschal B.M., 2005), and transported to the nucleus through the 
formation of a complex with importin a/p (Hu and Jans, 1999) or importin p alone 
(Truant and Cullen, 1999).
Similarly, Chen et al. (2005) recently identified a NLS (KRRQQKIRKYTMRR) that 
is responsible for ErbB2 nuclear localisation. This sequence may provide an 
explanation for the mechanism underlying ErbB2 nuclear function. Although the 
mechanism responsible for nuclear translocation of ErbB2 remains unclear, Giri et al. 
(2005) established a mechanism, involving importin p 1 as a driver, for ErbB2 nuclear 
translocation from the cell surface. It is also suggested that this translocation route 
may serve as a general mechanism for other receptor tyrosine kinases. Hsu and Hung
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(2007) recently characterised a tripartite nuclear localisation sequence formed of 13 
amino acids, which is conserved among the EGFR family members and responsible 
for their nuclear translocation. Conflicting results have also shown that this tripartite 
NLS is required for receptor dimerisation (Aifa et a l, 2005). Conversely, Giri et al. 
(2005) demonstrated that deletion of the ErbB2 tripartite NLS did not affect its 
membrane localisation and its ability to activate MAPK signalling pathway. 
Therefore, association between dimerisation of EGFR and nuclear localisation needs 
to be investigated further. Although nuclear translocation of the four members of the 
EGFR family has been shown, it was reported that they were translocated into the 
nucleus under different forms.
For EGFR (Lin et al., 2001), the complete full ligand length receptor complex is 
translocated into the nucleus, for ErbB2 and ErbB3 the full length protein is 
translocated (Wang et al., 2004; Offterdinger et al., 2002), whereas for ErbB4 only 
the intracellular domain is translocated into the nucleus (Lee et al., 2002a). Detection 
of nuclear EGFR was first reported by Kamio et al. (1990). Although nuclear EGFR 
lacks DNA binding domain/function, Lin et al. (2001) established that nuclear EGFR 
acts as a transcriptional activator through binding to adenine/thymidine-rich DNA 
sequences. In their study they showed that EGFR was able to activate cyclin D1 
through binding to the promoter region. In a different study (Lo et al., 2005), nuclear 
EGFR was shown to associate with the signal transducers and activators of 
transcription 3 (STAT3) leading to activation of inducible nitric oxide synthase 
(iNOS) and subsequent tumour growth and angiogenesis (Cianchi et al., 2003; 
Vakkala et a l, 2000). A recent study by Hanada et al. (2006) suggested that nuclear 
function of EGFR can be phosphorylation dependent, since nuclear EGFR was able to 
phosphorylate E2F1 which is responsible for the activation of B-Myb, a transcription 
factor. Upon cell irradiation, EGFR has also been shown to translocate, together with 
Ku70/80, into the nucleus for regulation of DNA-PK (Dittmann et al., 2005). 
Therefore, nuclear EGFR is not only used as a transcriptional activator but can serve 
to trigger DNA repair. Although nuclear EGFR has been more widely studied, 
unidentified transcriptional targets may exist. Clark et al. (2005) also demonstrated 
that nuclear ErbB4 was able to act as a transcriptional activator through 
phosphorylation of the serine of STAT5a transcription factor and subsequent 
activation of the p-casein gene (Williams et al., 2004). Nuclear ErbB2 was also
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shown to associate with a specific DNA sequence, HER-2 associated sequence (HAS) 
in the cyclooxygenase enzyme COX-2 promoter (Wang et al., 2004), a protein 
associated with tumour progression (Turini and Dubois, 2002). Indeed, Wang et al. 
(2004) demonstrated that nuclear ErbB2 was used as a transcriptional regulator by 
forming a complex with the COX-2 promoter. In addition, they also identified a HAS 
in the Fanconi Anemia Complementation group C (FANCC) promoter, suggesting 
that nuclear ErbB2 acts as a transcriptional regulator of the FANCC protein, involved 
in the repair of DNA damage generated from oxidative stress.
Together, these observations suggest that nuclear localisation of ErbB2 may also 
affect other nuclear events since it contains intrinsic ability to enhance gene 
transcription, through transcription co-factors with DNA binding ability. In addition, 
ErbB2 nuclear localisation may have other functions such as DNA damage repair.
6.2 Wheat germ agglutinin and nuclear translocation
Nuclear translocation of large molecules depends on the nuclear localisation signal, as 
previously described. This nuclear import is divided into two steps, binding in or near 
the nuclear pore and translocation through it (Newmeyer and Forbes, 1988). The 
translocation step is energy dependent and can be inhibited by the lectin wheat germ 
agglutinin (WGA -  Yoneda et al., 1987; Newmeyer and Forbes, 1988; Wolff et al., 
1988) which binds specifically to the glycoconjugates of the nuclear pore complex 
(Davis and Blobel, 1987; Finlay et al., 1987). Therefore, WGA does not physically 
block the pore and does not affect the signal sequence-dependent binding step. This 
inhibition has been shown to be reversed by addition of competing sugars (Finlay et 
al., 1987).
Therefore, WGA can be used as a pharmacological method to block nuclear 
translocation. As Dittmann et al. (2005) reported, radiation-induced nuclear 
translocation of EGFR was blocked after treating the cells with lOOpg/ml of WGA 
for 30 minutes, prior to irradiation. Although WGA can be used to block nuclear 
translocation of EGFR, it is not specific for this protein and effects observed may be 
due to the inhibition of nuclear translocation of other proteins. Furthermore, after 
removal of WGA, nuclear translocation inhibition will gradually decrease. WGA may
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therefore be used for the inhibition of ErbB2 nuclear translocation, in order to study 
the effect on the repair of cisplatin-induced DNA interstrand crosslinks.
6.3 Aim s
To investigate the role of ErbB2 nuclear localisation in the repair of drug-induced 
DNA damage, using MDA-MB-468 wild type cells stably transfected with a plasmid 
encoding ErbB2 with a deletion of the nuclear localisation signal (as described by 
Giri et a l, 2005), the following questions will be addressed:
• Is ErbB2 nuclear localisation blocked by the deletion of the NLSs?
• Does ErbB2 nuclear localisation affect the sensitivity to trastuzumab and 
cisplatin?
• Does inhibition of ErbB2 nuclear translocation affect the repair of cisplatin- 
induced DNA interstrand crosslinks?
• How does the modulation of the repair of cisplatin-induced DNA ICL 
correlate with EGFR and ErbB2 nuclear localisation?
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RESULTS
6.4 Expression of mutated ErbB2 with a deletion of the NLS 
sequence
The plasmid encoding the mutated form of ErbB2 containing a deletion of the NLSs 
(amino acids 676-KRRQQKIRKYTMRR-689) was described by Giri et al. (2005) 
and was a kind gift from Prof. M.C. Hung (MD Anderson Cancer Center, USA). 
Similarly to Chapter 5, MDA-MB-468 cells were used for stable transfection, in order 
to express the mutated form of ErbB2.
6.4.1 ErbB2 protein expression by immunoblotting
The ErbB2 negative cell line, MDA-MB-468, was stably transfected with the three 
plasmids as previously described. Cells were pooled transfected and selective 
pressure was maintained using G418. After four to five weeks, the three new cell 
lines (MDA-MB-468 vector control, MDA-MB-468 ErbB2 and MDA-MB-468 
ErbB2ANLS) were exponentially growing. It is noted that MDA-MB-468 vector 
control and ErbB2 are different from the one described in Chapter 5 as the vector 
used is pEGFP-Nl. Figure 6.1 shows that ErbB2 is overexpressed in MDA-MB-468 
ErbB2 cells and in MDA-MB-468 ErbB2ANLS cells. Other ErbB receptors protein 
expression levels are not affected by the transfection. Furthermore, results presented 
in Figure 6.2 revealed that ErbB2 is not present in the nucleus of MDA-MB-468 
ErbB2ANLS cells (Figure 6.2 B) but is present in both the nucleus and the cytoplasm 
of MDA-MB-468 ErbB2 cells (Figure 6.2 A).
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r i t x i
EGFR (185kDa) 
ErbB2 (185kDa) 
ErbB3 (185kDa) 
ErbB4 (185kDa) 
a-tubulin (50kDa)
Figure 6.1 -  Protein expression of each ErbB receptor in MDA-MB-468 wild type (1), 
vector control (2), ErbB2 (3) and ErbB2ANLS (4) cells, a-tubulin was used as a loading 
control.
ErbB2 (185kDa)
Calnexin (90kDa)
Lamin A/C (67kDa)
Figure 6.2 -  ErbB2 protein expression in MDA-MB-468 ErbB2 (A) and MDA-MB-468 
ErbB2ANLS (B) cells. Calnexin is used as a loading control for the cytoplasmic fraction (C) 
and Lamin A/C as a loading control for the nuclear fraction (N).
A -  ErbB2 B -  ErbB2ANLS
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6.4.2 ErbB2 protein expression by immunofluorescence
Immunofluorescence confirmed that ErbB2 was present in the nucleus of MDA-MB- 
468 ErbB2 cells (red arrow Figure 6.3 C), but not in the nucleus of MDA-MB-468 
ErbB2ANLS cells (Figure 6.3 D). Therefore, the stably transfected MDA-MB-468 
cells expressing a mutated form of ErbB2 was used to investigate the role of ErbB2 
nuclear localisation in the repair of cisplatin-induced DNA damage.
Figure 6.3 -  Immunofluorescence ErbB2 protein expression in MDA-MB-468 cells.
MDA-MB-468 wild type (A), MDA-MB-468 pEGFP-Nl vector control (B), MDA-MB-468 
ErbB2 (C) and MDA-MB-468 ErbB2ANLS (D) cells were stained with anti-ErbB2 (green) 
and counter stained with propidium iodide (red). The red arrow indicates that ErbB2 is 
expressed in the nucleus.
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6.5 Effect of trastuzumab and cisplatin on transfected cell 
lines
6.5.1 Effect of trastuzumab on MDA-MB-468 cell lines
Trastuzumab and ErbB2 protein expression
MDA-MB-468 ErbB2 and ErbB2ANLS cell lines were treated with trastuzumab at 
40(i g/ml for 24 hours. ErbB2 protein expression was measured by 
immunofluorescence and western blotting (total protein level). Trastuzumab caused a 
reduction of the total ErbB2 protein level after treatment for 24 hours in MDA-MB- 
468 ErbB2 cells (Figure 6.4 B and C) compared to the untreated cells (Figure 6.4 A). 
It is also noted that nuclear ErbB2 is reduced by trastuzumab in MDA-MB-468 
ErbB2 cells (Figure 6.4 D). Indeed, although trastuzumab does not affect nuclear 
ErbB2 directly, it is suggested that less membrane bound ErbB2 (cytoplasmic 
fraction) was available for nuclear translocation, thus reducing nuclear ErbB2. A 
similar result was obtained for MDA-MB-468 ErbB2ANLS cells (Figure 6.5 B and C) 
but no ErbB2 protein was present in the nucleus.
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cErbB2
a-tubulin
Control Trastuzumab 
40pg/ml
D
Cytoplasmic fraction Nuclear fraction
ErbB2
Lamin A/C as a t
Calnexin
Control Trastuzumab Control Trastuzumab 
40pg/ml 40|ig/ml
Figure 6.4 -  Nuclear and cytoplasmic ErbB2 protein expression in MDA-MB-468 
ErbB2 cells. ErbB2 protein expression was measured in untreated cells (A) and cells treated 
for 24 hours with 40pg/ml of trastuzumab (B) by immunofluorescence. Total ErbB2 protein 
expression was measured by western blotting (C). ErbB2 protein level was also measured 
separately in the nuclear fraction and cytoplasmic fraction (D).
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Figure 6.5 — ErbB2 protein expression in MDA-MB-468 ErbB2ANLS cells. ErbB2 
protein expression was measured in untreated cells (A) and cells treated for 24 hours with 
40pg/ml of trastuzumab (B) by immunofluorescence. Reduction of total ErbB2 protein 
expression was also shown by western blotting (C).
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Effect o f  trastuzumab on cell proliferation
Having shown that trastuzumab caused the down-regulation of ErbB2 protein level in 
both cell lines expressing ErbB2 (mutated and non-mutated), its effect was observed 
on the proliferation of cells. All four cell lines were exposed to a range of 
trastuzumab concentrations for 5 consecutive days, experiment were repeated in 
triplicate. The inhibition of proliferation assay revealed that cell proliferation was not 
affected by trastuzumab with concentrations up to lOOpg/ml (Figure 6.6). Therefore, 
ErbB2 overexpression and inhibition of its nuclear localisation did not alter inhibition 
of proliferation by trastuzumab.
MDA-IVB-468 w ild type
1 4 0 ::
120.00  -
o  100.00 \
80.00
60 00 -
40.00 -
20 00
0.1 1.0 10.0 
Trastuzumab concentration (pg/ml)
100.0
■ IVDA-IVB-468 pEGFP-N1 
vector control
□ MDA-IVB-468 ErbB2
□ MDA-MB-468 BrbB2 NLS 
mutant
Figure 6.6 -  Inhibition of MDA-MB-468 cells proliferation by trastuzumab. MDA-MB- 
468 wild type (dark blue), MDA-MB-468 vector control (red), MDA-MB-468 ErbB2 
(yellow) and MDA-MB-468 ErbB2ANLS (light blue) cells were treated with a range of 
trastuzumab concentrations. Data presented are the result of three independent experiments, 
as shown by the standard deviation.
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6.5.2 Sensitivity to cisplatin treatment
Cells were exposed to a range of cisplatin concentrations for 1 hour and incubated in 
drug free media for 3 days. For accuracy and repeatability all experiments have been 
repeated in triplicate. Results of the inhibition of proliferation assay are presented in 
Figure 6.7 and IC50 obtained in Table 6.1. IC50 were statistically analysed using the 
student Mest with a degree of freedom n = 4 and a significance level p  = 0.01 (99% 
probability). Result obtained for the cell line overexpressing the normal form of 
ErbB2 was comparable to the result obtained in Chapter 5. As shown in Table 6.1, 
overexpression of the non-mutated ErbB2 protein caused an increase in resistance 
(1.5 fold) to cisplatin (result in red) whereas deletion of the nuclear localisation signal 
sequence caused an increase in sensitivity (3 fold -  result in bold blue). Sensitivity of 
the NLS mutant increased by 3 fold compared to ErbB2 negative cells and by 5 fold 
compared to the cells that could translocate ErbB2 into the nucleus. Consequently, 
these results suggest that ErbB2 nuclear translocation plays an important role in the 
response to cisplatin-induced DNA damage.
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Cisplatin
IC50
MDA-MB- 
468 wild type
MDA-MB-468 
pEGFP-Nl 
vector control
MDA-MB-468
ErbB2
MDA-MB-468
ErbB2ANLS
9.00±0.75pM 9.10±1.01pM 15.00±1.53pM 3.10±0.25pM
Table 6.1 -  IC50±SD results for MDA-MB-468 cells treated with cisplatin alone. MDA- 
MB-468 wild type, MDA-MB-468 vector control, MDA-MB-468 ErbB2 and MDA-MB-468 
ErbB2ANLS cells were treated with cisplatin for one hour, followed by 3 days in drug free 
media. Results were statistically compared to the wild type cells, using the student Mest with 
n = 4 and p  = 0.01 (99% probability). Cells overexpressing the normal form of ErbB2 were 
more resistant (result in red) to cisplatin but with the deletion of the NLS sequence cells 
became more sensitive (result in bold blue).
—♦— MDA-MB-468 wild type
MDA-MB-468 pEGFP-N1 vector control 
MDA-MB-468 ErbB2
100.00 MDA-MB-468 ErbB2 NLS mutant
c 80.00 - O
cck.
i 60.00 -
Q.
3* 40.00 -
20.00 -
0.00
1000.001.00 10.00 100.000.00 0.01 0.10
Cisplatin concentration (pM)
Figure 6.7 -  Inhibition of MDA-MB-468 cells proliferation by cisplatin. MDA-MB-468 
wild type (♦), MDA-MB-468 vector control (■), MDA-MB-468 ErbB2 ( ) and MDA-MB- 
468 ErbB2ANLS (x) cells were incubated 1 hour with a range of cisplatin concentration 
followed by 3 days in drug free media. Data presented are the result of three independent 
experiments, as shown by the standard deviation.
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6.6 Modulation of DNA damage repair by inhibition of
ErbB2 nuclear translocation
The importance of ErbB2 nuclear translocation in the response to cisplatin-induced 
DNA damage was shown in the previous section. However, to determine whether 
nuclear translocation plays a role in the repair of cisplatin-induced DNA interstrand 
crosslink, kinetics of formation and repair of cisplatin-induced DNA ICLs was 
studied using the same cisplatin dose defined in Chapter 5.
6.6.1 Modulation of the repair of cisplatin-induced DNA
interstrand crosslinks
In order to study the role of nuclear translocation, the cell line expressing the mutated 
form of ErbB2 as well as WGA were used. MDA-MB-468 wild type, MDA-MB-468 
pEGFP-Nl vector control, MDA-MB-468 ErbB2 and MDA-MB-468 ErbB2ANLS 
were treated with lOOpM of cisplatin for 1 hour followed by incubation in drug free 
media. Cells were also incubated with WGA and trastuzumab in combination with 
cisplatin. All experiments were repeated in duplicate. WGA was used at 50pg/ml 
(lOOpg/ml was too toxic for MDA-MB-468 cells) for 30 minutes before cisplatin 
treatment and 1 hour in combination with cisplatin.
Results showed that transfection of the empty vector did not affect the kinetics of 
cisplatin-induced DNA ICLs formation and repair (Figures 6 .8  and 6.9). As ErbB2 is 
not present in the wild type and vector control cell line, trastuzumab did not alter 
DNA damage repair. In addition, inhibition of protein nuclear translocation by WGA 
did not change the kinetics of DNA repair. However, ErbB2 overexpression caused 
an increase in DNA ICL repair efficiency Figure 6.12), with 41.7±0.1% of ICLs 
unrepaired after 24 hours compared to the wild type which had 57.6±3.6% of ICLs 
unrepaired after 24 hours. Subsequent inhibition of ErbB2, by trastuzumab, led to a 
delay in the kinetics of repair of cisplatin-induced DNA ICLs (Figure 6.10) causing 
66.5±0.3% unrepaired ICLs after 24 hours. The effect of trastuzumab is comparable 
to the effect of WGA, which caused 67.2±3.6% of interstrand crosslinks to be 
unrepaired after 24 hours. Down-regulating ErbB2 by trastuzumab and blocking its 
nuclear translocation increased the delay in DNA damage repair only after 72 hours.
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This result, together with the data from the ErbB2 negative cells lines, demonstrates 
that ErbB2 nuclear translocation plays a major role in the repair of cisplatin-induced 
DNA ICLs.
Deletion of the ErbB2 NLS sequence caused a delay in DNA ICLs repair (Figure 
6.12), since after 24 hours 66.8±2.0% of ICLs are unrepaired compared to 57.6±3.6% 
in the wild type cells and 41.7±0.1% in cells overexpressing the normal form of 
ErbB2. Trastuzumab and WGA did not change the kinetics of DNA ICLs formation 
and repair of MDA-MB-468 ErbB2ANLS cells (Figure 6.11). After 24 hours 
66.8±2.0% of ICLs remained unrepaired in cells treated with cisplatin alone and 
68.9±0.1% were unrepaired in cells treated with a combination of cisplatin and 
trastuzumab. Nevertheless,
Therefore, ErbB2 overexpression was confirmed to cause an increase in DNA ICLs 
repair efficiency whereas blocking its nuclear translocation led to a decrease of the 
effectiveness of this repair. Furthermore, using WGA demonstrated that nuclear
ErbB2 has a role in repair of ICLs induced by cisplatin.
Cisplatin alone 100pM
Cisplatin 100pM + trastuzum ab 40pg/rri
Cisplatin 10OpM + WGA 50pg/ml
100.0
Cisplatin 100pM + WGA 50pg/ni + 
trastuzum ab 40pg/ml
8 0 .0
6 0 .0
4 0 .0
20.0
0.0
7 22 4 3 6 4 8
- 20.0
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Figure 6.8 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 wild type 
cells. Cells were treated with cisplatin alone (lOOpM) for one hour followed by incubation in 
drug free media (♦), cisplatin (lOOpM) with trastuzumab (40|ig/ml) for one hour followed by 
incubation in media containing trastuzumab alone ( A ) ,  WGA (50pg/ml) for 30 minutes 
followed by cisplatin (lOOpM) with WGA for l hour then incubated in drug free media (x), 
or WGA (50pg/ml) and trastuzumab (40jig/ml) for 30 minutes then cisplatin (lOOpM) was 
added for 1 hour and cells were incubated in media containing trastuzumab alone ( ). Data 
presented are the result of three independent experiments, as shown by the standard deviation.
266
Cisplatin alone 100pM
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Figure 6.9 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 pEGFP-Nl 
vector control cells. Cells were treated as MDA-MB-468 wild type cells. Cells were treated 
as MDA-MB-468 wild type cells: with cisplatin alone (100pM) (♦), cisplatin (lOOfiM) with 
trastuzumab (40pg/ml) ( A ) ,  WGA (50pg/ml) and cisplatin (100pM) (x) or WGA (50pg/ml), 
trastuzumab (40pg/ml) and cisplatin (lOOpM) ( ). Data presented are the result of three 
independent experiments, as shown by the standard deviation.
—♦—  Cisplatin alone 10OpM
—A— Cisplatin 100pM + trastuzumab 40pg/ml
—x— Cisplatin 100pM + WGA 50pg/ml
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Figure 6.10 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 ErbB2 
cells. Cells were treated as MDA-MB-468 wild type cells. Cells were treated as MDA-MB- 
468 wild type cells: with cisplatin alone (lOOpM) (♦), cisplatin (lOOpM) with trastuzumab 
(40pg/ml) ( A ) ,  WGA (50pg/ml) and cisplatin (lOOpM) (x) or WGA (50pg/ml), trastuzumab 
(40pg/ml) and cisplatin (lOOpM) ( ). Data presented are the result of three independent 
experiments, as shown by the standard deviation.
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Figure 6.11 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 
ErbB2ANLS cells. Cells were treated as MDA-MB-468 wild type cells. Cells were treated as 
MDA-MB-468 wild type cells: with cisplatin alone (lOOpM) (♦), cisplatin (lOOpM) with 
trastuzumab (40pg/ml) ( A ) ,  WGA (50pg/ml) and cisplatin (lOOpM) (x) or WGA (50pg/ml), 
trastuzumab (40pg/ml) and cisplatin (lOOpM) ( ). Data presented are the result of three 
independent experiments, as shown by the standard deviation.
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Figure 6.12 -  Cisplatin-induced DNA interstrand crosslinks in MDA-MB-468 cells 
treated with cisplatin. MDA-MB-468 wild type (♦), vector control (A) ,  ErbB2 ( ) and 
ErbB2ANLS (x) cells were treated cisplatin alone (IOOjiM) for one hour then incubated in 
drug-free media. Data presented are the result of three independent experiments, as shown by 
the standard deviation.
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6.6.2 EGFR and ErbB2 nuclear localisation
Previous studies have shown that EGFR and ErbB2 were able to translocate into the 
nucleus to activate the transcription of several genes (Lo et al., 2005; Hanada et al., 
2006) and trigger DNA repair (Dittmann et al., 2005). Consequently, studying their 
nuclear translocation, by immunofluorescence, may explain some of the modulation 
of the repair of cisplatin-induced DNA ICLs observed previously. MDA-MB-468 
wild type, MDA-MB-468 ErbB2 and MDA-MB-468 ErbB2ANLS cells were treated 
as previously described and analysed after 24 hours.
Section 6.4 established that wild type cells do not express ErbB2 and that MDA-MB- 
468 cells expressing the mutated form of ErbB2 do not have translocation of ErbB2 
into their nucleus contrary to cells expressing the normal form of ErbB2. Upon 
cisplatin treatment, an increase in ErbB2 nuclear translocation was observed in cells 
transfected with full length ErbB2 (Figure 6.13 B). However, in the presence of 
trastuzumab ErbB2 present in the cytoplasm and the nucleus was reduced (Figure 
6.13 C). WGA in combination with cisplatin caused a complete inhibition of ErbB2 
nuclear translocation (Figure 6.13 D and E).
EGFR, which was shown to be overexpressed in MDA-MB-468 cells, was mainly 
present in the cytoplasm but after cisplatin treatment nuclear translocation occurred in 
MDA-MB-468 wild type cells (Figure 6.14 A and B). It is also noted that 
trastuzumab did not alter EGFR nuclear translocation in ErbB2 negative cells. 
Nevertheless, ErbB2 overexpression (full length or mutated) was shown to reduce 
EGFR nuclear translocation after cisplatin treatment (Figure 6.15 A and B for 
mutated form of ErbB2, result not shown for full length ErbB2). In addition, presence 
of trastuzumab caused an increase in EGFR nuclear translocation in the two cell lines 
expressing ErbB2 (Figures 6.15 C, result not shown for MDA-MB-468 ErbB2) 
compared to ErbB2 positive cells treated with cisplatin alone. These results suggest 
that ErbB2 overexpression in the cytoplasm reduces nuclear translocation of EGFR.
In the presence of WGA, EGFR was localised in the cytoplasm of MDA-MB-468 
ErbB2 cells (result not shown) and MDA-MB-468 ErbB2ANLS cells (Figure 6.15 D 
and E). Nevertheless, in MDA-MB-468 wild type cells (Figure 6.14 D and E), after 
24 hours, some EGFR was seen re-entering into the nucleus.
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Therefore, these results demonstrate that, by overexpressing ErbB2 (full length or 
with a deletion o f the NLSs) in MDA-MB-468 cells, EGFR nuclear translocation is 
limited, possibly caused by the formation of ErbB2-EGFR heterodimers.
Figure 6.13 -  ErbB2 immunofluorescence of MDA-MB-468 ErbB2. ErbB2 was measured 
in untreated cells (A), cells treated with cisplatin alone lOOgM (B), cisplatin lOOpM and 
trastuzumab 40pg/ml (C), cisplatin lOOpM and WGA 50pg/ml (D), cisplatin lOOpM, WGA 
50pg/ml and trastuzumab 40pg/ml (E). Cells were analysed 24 hours post-treatment.
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Figure 6.14 -  EGFR immunofluorescence of MDA-MB-468 wild type cells. EGFR was 
measured in untreated cells (A), cells treated with cisplatin alone lOOpM (B), cisplatin 
lOOpM and trastuzumab 40pg/ml (C), cisplatin lOOpM and WGA 50pg/ml (D), cisplatin 
lOOpM, WGA 50pg/ml and trastuzumab 40pg/ml (E). Cells were analysed 24 hours post­
treatment.
Figure 6.15 -  EGFR immunofluorescence of MDA-MB-468 ErbB2ANLS cells. EGFR 
was measured in untreated cells (A), cells treated with cisplatin alone lOOpM (B), cisplatin 
lOOpM and trastuzumab 40pg/ml (C), cisplatin lOOpM and WGA 50pg/ml (D), cisplatin 
lOOpM, WGA 50pg/ml and trastuzumab 40pg/ml (E). Cells were analysed 24 hours post­
treatment.
DISCUSSION
These results demonstrate the role of ErbB2 nuclear localisation in the repair of 
cisplatin-induced DNA interstrand crosslinks, using MDA-MB-468 cells transfected 
with a plasmid encoding ErbB2 with a deletion of the nuclear localisation signal 
sequence. Results have confirmed that ErbB2 overexpression caused an increase in 
cisplatin resistance and an increase in repair efficiency of cisplatin-induced DNA 
ICLs. However, blocking ErbB2 translocation to the nucleus increased significantly 
the sensitivity of the cells to cisplatin and delays DNA ICLs repair. Finally, 
overexpression of ErbB2 was shown to reduce EGFR nuclear translocation.
6.7 Trastuzumab and ErbB2 nuclear translocation
Although ErbB2 nuclear translocation has only recently been investigated (Giri et al., 
2005), nuclear ErbB2 has been shown to act as a transcriptional activator (Wang et 
al., 2004). Nevertheless, its role within the nucleus has not yet been extensively 
studied and potential unidentified nuclear targets may exist. Based on the nuclear 
function of EGFR during DNA repair, the potential role of nuclear ErbB2 in cisplatin- 
induced DNA interstrand crosslinks was investigated. Similarly to Giri et al. (2005), 
expression of nuclear ErbB2 in MDA-MB-468 ErbB2ANLS cells was not visible, as 
shown by western blotting and confocal microscopy. Furthermore, cells 
overexpressing full length ErbB2 clearly showed that ErbB2 was present in the 
nucleus. Having shown that ErbB2 was present in the nucleus, it was interesting to 
consider the effect of trastuzumab as an anti-ErbB2 monoclonal antibody shown to 
cause receptor internalisation and degradation (Yarden, 2001b) as well as down- 
regulation of the receptor (Guan et al., 2005). Dittmann et al. (2005) demonstrated 
that the anti-EGFR monoclonal antibody C225 (Cetuximab) blocked the nuclear 
import of EGFR and radiation-induced activation of DNA-PK, leading to an increase 
in radio-sensitivity. In the results presented here, trastuzumab was shown to reduce 
ErbB2 present in the cytoplasmic membrane but also in the nucleus. This is explained 
by the effect of trastuzumab causing degradation of the receptor, thus limiting ErbB2 
nuclear translocation and reducing nuclear ErbB2. Furthermore, although trastuzumab 
was previously shown to reduce cell proliferation of ErbB2 overexpressing cells, such
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as MDA-MB-453 or SK-BR-3 cells, no effect was observed on cells overexpressing 
ErbB2 and ErbB2ANLS. A study by Gong et al. (2004) also reported the absence of 
growth inhibition by trastuzumab alone in ErbB2 overexpressing gastric cancer cells. 
In this study, they demonstrated that this phenomenon did not affect the ability of 
trastuzumab to increase the cytotoxicity of chemotherapeutic drugs when used in 
combination.
6.8 Cisplatin sensitivity
Unpublished data obtained in our laboratory demonstrated that radiation treatment 
caused EGFR nuclear translocation which was blocked upon gefitinib and cetuximab 
treatment. In addition, Dittmann et al. (2005) established that inhibition of EGFR 
nuclear translocation caused inhibition of DNA repair and increased radiosensitivity 
of cells. In this study, full length ErbB2 overexpression was confirmed to cause 
increased cellular resistance to cisplatin. However, cells overexpressing ErbB2ANLS 
showed increased sensitivity to cisplatin compared to cells overexpressing ErbB2. 
Therefore, trastuzumab causing a reduction in membrane bound ErbB2 protein level 
and ErbB2 nuclear translocation explains the increase in sensitivity to cisplatin, 
caused by trastuzumab, previously described. These data taken together reinforce the 
idea that nuclear ErbB2 plays a role in DNA repair processes. Furthermore, 
overexpressing ErbB2ANLS also caused in increase in sensitivity to cisplatin 
compared to ErbB2 negative cells. This suggests that deletion of the ErbB2 nuclear 
localisation signal sequence inhibited the effect of ErbB2 and also altered the normal 
response to cisplatin-induced DNA damage present in ErbB2 negative cell line. In the 
same way, Aifa et al. (2005) demonstrated that the tripartite NLS sequence was 
required for EGFR receptor dimerisation and phosphorylation. However, Giri et al.
(2005) demonstrated that deletion of the ErbB2 tripartite NLS did not affect its 
membrane localisation and its ability to activate MAPK signalling pathway. 
Consequently, these results taken together demonstrate that ErbB2 nuclear 
translocation plays an important role in the response to cisplatin-induced DNA 
damage and that deletion of the nuclear localisation signal sequence causes a 
sensitisation of the cells to chemotherapeutic drugs, such as cisplatin.
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6.9 Modulation of DNA damage repair
So far, there has been little study of the implication of a nuclear ErbB family member 
during DNA repair processes. Studies by Dittmann et al. (2005) and Friedmann et al.
(2006) have demonstrated the implication of EGFR nuclear translocation and its 
association with the DNA repair protein, DNA-PK. Therefore, having shown that 
overexpression of full length ErbB2 increased dramatically the repair efficiency of 
cisplatin-induced DNA ICLs, in the previous chapter, the importance of nuclear 
ErbB2 remained to be determined. Deletion of the ErbB2 NLSs resulted in a 
significant inhibition of the repair of cisplatin-induced DNA ICLs compared to cells 
overexpressing full length ErbB2. This result was confirmed using WGA in cells 
overexpressing full length ErbB2. Indeed, wheat germ agglutinin which caused 
inhibition of ErbB2 nuclear translocation, also resulted in a delay in the repair of 
cisplatin-induced DNA interstrand crosslinks, compared to cells treated with cisplatin 
alone. In addition, a similar delay in DNA repair was obtained with trastuzumab, 
suggesting that trastuzumab causes a delay in DNA damage repair through reduction 
of nuclear ErbB2. These results indicate that nuclear ErbB2 has role in DNA repair 
processes. Furthermore, the novel link between ErbB2 and DNA repair may partly 
explains the association between ErbB2 overexpression and chemoresistance (Benz et 
al., 1992; Allred et al., 1992; Wright et al., 1992). Moreover, inhibition of ErbB2 
nuclear translocation, by WGA or deletion of ErbB2 NLSs, did not restore the 
kinetics of repair of cisplatin-induced DNA ICLs observed in ErbB2 negative cells. In 
fact, inhibition of ErbB2 nuclear translocation led to a large decrease in DNA repair 
efficiency compared to the wild type cells.
Having shown, by immunofluorescence, that overexpression of ErbB2 caused a 
reduction in EGFR nuclear translocation, it is possible that overexpression of ErbB2 
leads to a dimerisation of the two receptors causing an increase in DNA repair 
efficiency. Whereas overexpression of ErbB2ANLS inhibits the DNA repair function 
of nuclear ErbB2, it is suggested to form non-functional EGFR-ErbB2 heterodimers 
that sequester EGFR in the cytoplasmic membrane and are unable to trigger the DNA 
repair signalling cascade. Furthermore, deletion of the NLS may also lead to a 
disruption of the normal ErbB2 signalling cascade thereby further reducing the 
capacity of the cells to repair cisplatin-induced DNA ICLs. Similar results were
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obtained using WGA in cells overexpressing full length ErbB2, since WGA also 
inhibits EGFR translocation and translocation of proteins involved in the DNA repair 
signalling cascades.
In this study, only EGFR was considered as it is overexpressed in MDA-MB-468 
cells and its ability to translocate to the nucleus and activate DNA repair processes 
has already been shown (Dittmann et al., 2005). Nevertheless, dimerisation with other 
ErbB family members needs to be considered.
A novel link between ErbB2 nuclear localisation and DNA repair has been 
established and it is suggested that ErbB2 overexpression affects EGFR nuclear 
localisation and deletion of ErbB2 NLSs alters the DNA repair signalling cascade.
6.10 Conclusion
This chapter confirmed that ErbB2 overexpression increased resistance to cisplatin 
and increased the repair efficiency of cisplatin-induced DNA ICLs. In addition, 
deletion of ErbB2 NLS inhibits ErbB2 nuclear translocation and was shown to 
increase cell sensitivity to cisplatin. Furthermore, ErbB2 nuclear translocation was 
shown to play an important role in the repair of cisplatin-induced DNA interstrand 
crosslinks. Finally, ErbB2 overexpression reduced EGFR nuclear translocation and it 
was suggested that deletion of the ErbB2 tripartite NLSs impairs DNA repair 
signalling cascade and EGFR functional activity.
Considering those results, it is reasonable to conclude that a novel function for 
nuclear ErbB2 has been established in the repair of cisplatin-induced DNA ICLs. It is 
also suggested that increase in sensitivity to chemotherapeutic drugs, caused by 
trastuzumab, was partially due to the reduction in nuclear ErbB2. However, potential 
targets for nuclear ErbB2 need to be identified in order to establish a molecular 
mechanism for the modulation of DNA repair. In addition, further investigation is 
required to determine the effects of NLSs deletion on ErbB2 and EGFR dimerisation 
and the proteins involved in the DNA repair signalling cascade.
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Chapter 7
Effect of the modulation of 
BRCA1 expression on cellular 
response to chemotherapeutic
agents
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INTRODUCTION
In the previous chapters, the importance of ErbB2 in the repair of drug-induced DNA 
damage has been demonstrated in breast cancer cells. BRCA1 is another important 
protein in breast cancer, since loss-of-function mutations have been reported to cause 
an 82% risk of developing breast cancer and a 54% risk to develop ovarian cancer. 
However, germline mutations in BRCA1 account for only 5% of breast and ovarian 
cancers (King et al., 2003).
Furthermore, several studies have shown that BRCA1 is involved in fundamental 
processes such as DNA repair (homologous recombination), cell cycle checkpoint 
and transcription (Venkitaraman, 2002; Yoshida and Miki, 2004; Turner et al., 2005). 
Thus, it is an important protein for the maintenance of genomic integrity (Powell and 
Kachnic, 2003). A study by Wang et al. (2000b) also reported that BRCA1 was 
associated with a large number of proteins, named the BRCA1-associated genome 
super-complex (or BASC super-complex), which plays an important role in DNA 
damage recognition and repair, conferring BRCA1 with an important biological role 
within the cell.
7.1 BRCA1 and chemotherapeutic response
Chemotherapeutic drugs commonly used in breast and ovarian cancer cause DNA 
double strand breaks either directly or indirectly (Kennedy et al., 2004). BRCA1 is a 
protein involved in DNA damage repair through association with proteins involved in 
DNA double strand break repair by homologous recombination and non homologous 
end-joining (Scully et al., 1997c; Zhong et al., 1999). In addition, Wang et al. 
(2000b) reported that BRCA1 was associated with the BASC super-complex formed 
of proteins involved in nucleotide excision repair (NER), which can be sub-divided 
into transcription-coupled repair and genomic repair pathways.
Therefore, BRCA1 has a critical role in promoting cell survival and preventing 
apoptosis after DNA damage (Bernstein et al., 2002; MacLachlan et al., 2002). As 
shown by Tassone et al. (2003) BRCA1 expression is critical in the response to 
chemotherapeutic treatment and can modulate the chemosensitivity of cells.
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Consequently, BRCA1 can be used as a useful predictive marker for the response to 
chemotherapeutic treatment. Nevertheless, in addition to its role in DNA repair 
pathways and cell cycle regulation, the importance of BRCA1 in the response to 
DNA damaging agents has also been shown to be due to its association with Fanconi 
anemia proteins. Indeed, Folias et al. (2002) reported that BRCA1 associated with 
different Fanconi anemia proteins in order to detect the arrest of the replication fork 
after DNA damage and was implicated in the repair of DNA crosslinks through 
homologous recombination (Pichierri and Rosselli, 2004; Howlett et al., 2002; Tutt et 
al., 2001). Furthermore, Taniguchi et al. (2003) demonstrated that disruption of the 
Fanconi anemia-BRCA pathway, through reduced expression of the Fanconi anemia 
F protein, led to an increase in sensitivity to cisplatin in ovarian cancer. Therefore, 
BRCA1 is an important protein participating in genome integrity via regulation of 
cell cycle checkpoint and DNA damage repair.
7.2 Mutations and loss of BRCA1 function
7.2.1 BRCA1 expression and chemotherapy
The loss of BRCA1 function has been associated with increased sensitivity to DNA- 
damaging agents (Kennedy et al., 2004), such as cisplatin (Bhattacharyya et al., 
2000), and mitomycin C (Moynahan et al., 2001). Tassone et al. (2003) demonstrated 
that inhibition of BRCA1 expression led to an increase in chemosensitivity following 
cisplatin-induced DNA damage, similarly to the studies by Lafarge et al. (2001) and 
Husain et al. (1998). However, they also showed that BRCA1 expression caused an 
increased sensitivity to doxorubicin and paclitaxel. Nevertheless, conflicting results 
exist as Brodie et al. (2001) demonstrated that BRCA1 inactivation led to an 
increased sensitivity to doxorubicin.
Furthermore, Quinn et al. (2003) established that BRCA1 is a modulator of apoptosis 
according to the nature of the damaging agent. They showed that absence of BRCA1 
increased the resistance to some spindle poisons, paclitaxel and vinorelbine, and 
increased sensitivity to agents causing double strand breaks such as etoposide, 
indicating that BRCA1 functions as a differential regulator of chemotherapy-induced
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apoptosis. Therefore, the nature of the agent used in the treatment of breast cancer 
will need to be considered according to the BRCA1 expression status.
7.3.2 BRCA1 expression and radiotherapy
Several studies have also investigated the effect of BRCA1 mutations on DNA 
double strand breaks caused by ionizing radiation. Conflicting results have been 
obtained on the importance of BRCA1 in ionising radiation-induced DNA strand 
break repair. Indeed, Scully et al. (1999) demonstrated that wild type BRCA1 
reduced sensitivity to ionizing radiation and increased the efficiency of double strand 
break repair, compared to BRCA1-/- cells. Conversely, Wang et al. (2001) reported 
that BRCA1 did not play a role in the rejoining of DNA double strand breaks induced 
by ionising radiation. They demonstrated that cells with a mutant BRCA1 status were 
able to repair radiation-induced DNA double strand breaks, through the DNA-PK- 
dependent non homologous end joining pathway, as efficiently as the cells expressing 
wild type BRCA1. Therefore, the role of BRCA1 in radiation-induced DNA double 
strand breaks repair remains unclear.
7.3 BRCA1 and topoisomerase II activity
In addition to its role in DNA damage repair described previously, BRCA1 has also 
been shown to maintain chromosome integrity through its involvement in DNA 
decatenation. Deming et al. (2001) established that BRCA1 was involved in the 
decatenation G2 checkpoint. Furthermore, Lou et al. (2005) have recently 
demonstrated that BRCA1 deficient cells had a defect in DNA decatenation and 
chromosome segregation. In addition, they showed that BRCA1 co-localised with 
topoisomerase Ila  in the S phase and that BRCA1 deficient cells had a lower 
decatenation activity. Therefore, these findings establish a further role for BRCA1 
and reinforce its role in the maintenance of chromosome integrity.
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7.4 Aims
This chapter will discuss the effect of modulation of BRCA1 expression on DNA 
damage repair, using MCF-7, a breast cancer cell line, transfected with a plasmid 
encoding specific human BRCA1 siRNA. Moreover, similarly to the study by 
Friedmann et al. (2004) which demonstrated that inhibition of EGFR tyrosine kinase 
activity sensitised MCF-7 cells to cisplatin, the effect of BRCA1 down-regulation 
will be investigated. To this end, the following question will be addressed:
• Does BRCA1 expression modulate sensitivity to gefitinib and 
chemotherapeutic agents?
• Does BRCA1 down-regulation enhance the effect of gefitinib and cisplatin in 
combination?
• DoesBRCAl expression modulate radiosensitivity?
• Is topoisomerase II activity affected by BRCA1 down-regulation?
2 8 1
RESULTS
7.5 Modulation of BRCA1 mRNA level
Using the MCF-7 cell line, stably transfected with a plasmid encoding specific human 
BRCA1 siRNA, modulation of BRCA1 was studied. Three breast cancer cell lines 
were kindly provided by Prof. A. Ashworth and Dr. C Lord (Institute of Cancer 
Research): MCF-7 wild type, MCF-7 scrambled (MCF-7 transfected with a vector 
encoding a scrambled siRNA sequence) and MCF-7 3.23 (MCF-7 transfected with a 
plasmid encoding human specific BRCA1 siRNA) cells. The level of BRCA1 mRNA 
was measured by RT-PCR and real time PCR for quantification.
7.5.1 Determination of BRCA1 mRNA level by RT-PCR
BRCA1 mRNA level was evaluated in MCF-7 wild type, MCF-7 scrambled and 
MCF-7 3.23 cells using reverse transcriptase PCR, in order to demonstrate the 
efficacy of the siRNA. Figure 7.1 shows a large reduction of BRCA1 mRNA level in 
the BRCA1 siRNA transfected cell line compared to the wild type and the scrambled 
cell line. The level of BRCA1 mRNA in the scrambled cell line was also slightly 
reduced. However, standard reverse transcription PCR only detected the amount of 
final amplified product at the end of the reaction and was not appropriate for accurate 
quantification. Real time PCR is a more specific and sensitive technique as it 
quantifies the initial amount of the template and monitors the progress of the PCR as 
it occurs. Therefore, this technique was required to quantify the level of BRCA1 
mRNA.
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(3-Actin (636bp)
BRCA1 (285bp)
Primers
Figure 7.1 -  Reverse Transcriptase PCR analysis of MCF-7 wild type, MCF-7 
scrambled and MCF-7 3.23 cells. (3-actin was used as an internal control.
MCF-750bp Water MCF-7 MCF-7
marker control scrambled 3.23type
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7.5.2 Quantification of BRCA1 mRNA level
Having determined that BRCA1 mRNA was reduced in MCF-7 3.23 cell line, the 
reduction o f mRNA was quantified by real time PCR. However, prior to analysis 
PCR conditions were optimised.
Optimisation o f the real time PCR conditions
Primers sequences provided by Fiona Li (CRUK) were analysed by reverse 
transcriptase PCR to confirm that the correct product was formed (result not shown). 
PCR products were also checked by sequencing analysis, as explained in Chapter 2, 
section 2.9.1. Each PCR product sequenced matched the sequence o f interest (8 lbp) 
detailed below (forward prim er in red and reverse prim er in blue):
5’-CAGAGGACAATGGCTTCCATGCAATTGGGCAGATGTGTGAGGCAC
CTGTGGTGACCCGAGAGTGGGTGTTGGACAGTGTAG-3’
Subsequently, real time PCR conditions were optimised (as indicated in Chapter 2, 
section 2.9) to obtain accurate and reliable results. All optimisation steps were carried 
out using cDNA from M CF-7 wild type. Optim isation was achieved by determining 
the primer limiting concentration, the probe concentration and the conditions o f the 
PCR (internal control and BRCA1 reactions run in the same tube or separate tube). 
The primer limiting concentration was defined by using a range o f concentrations, 
which were as follow: forward prim er (|iM ): 0.5; 0.7; 0.9; 1.1 and 1.5, and reverse 
primer (gM): 0.1; 0.2; 0.3; 0.4 and 0.5. Results obtained indicated that the 
concentrations o f  forward and reverse primers yielding the lowest Ct and the highest 
ARn values were 0.9pM  o f  forward prim er and 0.3pM  o f reverse primer. The probe 
concentration used was 200nM  and was determined using the same criteria (low Ct 
and high ARn). Finally, (3-glucuronidase (internal control) and BRCA1 primer sets 
were shown to be detected in a multiplex reaction without causing interference as the 
difference in efficiency between the standard curves was small and correlation 
coefficients were high (above 0.95).
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Quantification of BRCA1 mRNA level
Using the PCR conditions defined previously, results obtained for BRCA1 mRNA 
levels are presented in Table 7.1 and Figure 7.2 (each cell line was compared to the 
wild type set at a value of 100%). Efficiencies obtained for the standard curve were 
2.29 for BRCA1 and 2.16 for p-glucuronidase. Compared to the MCF-7 wild type 
cells, the level of BRCA1 in MCF-7 3.23 cells was reduced by 77%, nevertheless the 
scrambled cell line BRCA1 mRNA level was also reduced by 28%. Therefore, the 
real reduction in BRCA1 mRNA level compared to MCF-7 scrambled cells was 68%.
Samples CtfiRCAl Ctp_giucur0nidase ACtRRCAl ACtp_giucuronidase R
MCF-7 
wild type 24.69 23.17
0.00 0.00 1.00
MCF-7 
wild type 24.94 22.85
MCF-7 
wild type 24.97 23.05
Average 24.87 23.02
MCF-7
scrambled 25.56 23.34
-0.72 -0.36 0.72
MCF-7
scrambled 25.83 23.54
MCF-7
scrambled 25.38 23.26
Average 25.59 23.38
MCF-7
3.23 26.42 22.61
-1.56 0.22 0.23
MCF-7
3.23 26.54 23.22
MCF-7
3.23 26.33 22.59
Average 26.43 22.81
Table 7.1 — Quantification of BRCA1 mRNA level in MCF-7 cell lines. R is the
expression ratio for BRCA1 in each cell line compared to M CF-7 wild type cell line (set at a 
value of 100% or 1).
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Figure 7.2 -  BRCA1 mRNA level in MCF-7 cell lines. MCF-7 wild type was used as 
reference to determine the BRCA1 mRNA level in MCF-7 scrambled and MCF-7 3.23 cell 
lines.
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7.6 Modulation of BRCA1 protein expression level
As the level of BRCA1 mRNA in MCF-7 3.23 was shown to be reduced by 68% 
compared to MCF-7 scrambled, BRCA1 protein expression level was detected by 
western blotting. Figure 7.3 indicates that the level of BRCA1 protein was reduced in 
the MCF-7 3.23 cell line. This result correlated with the results obtained by reverse 
transcriptase PCR and real time PCR. However, the BRCA1 protein level of MCF-7 
scrambled, which had a 28% reduction in BRCA1 mRNA level, was not affected. 
Hence, transfection of the scrambled siRNA did not affect BRCA1 protein 
expression. Furthermore, the level of EGFR protein remained similar in all three cell 
lines.
EGFR (185kDa)
BRCA1 (220kDa)
a-tubulin (50kDa)
Figure 7.3 -  EGFR and BRCA1 protein expression in MCF-7 cell lines. Protein levels 
were measured by immunoblotting in MCF-7 wild type, MCF-7 scrambled and MCF-7 3 23 
cell lines, a-tubulin was used as internal control.
» " "  **
i
mm mmmm
MCF-7 
wild type
MCF-7
scrambled MCF-7 3.23
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7.7 Effects of gefitinib and chemotherapeutic treatments
Having confirmed that the transfected MCF-7 (3.23) cell line had a reduced 
expression of BRCA1 protein, effects of gefitinib and common chemotherapeutic 
agents were investigated. Several studies having reported synergistic interactions 
between chemotherapeutic drugs and gefitinib (Ciardiello et a l, 2001; Sirotnak et a l,
2 0 0 0 ), the effects of gefitinib, cisplatin, etoposide and melphalan were investigated as 
single agents, using the SRB assay.
7.7.1 IC50 for single agent treatments
For the single agent treatments, all drugs were incubated for 5 days with the cells, at a 
range of concentrations, in sextuplet wells. To assure accuracy and reproducibility, all 
sets of assays were repeated in triplicate. Results for the 50% growth inhibition (IC50) 
are presented in Table 7.2 and Figure 7.4. IC50 obtained for MCF-7 scrambled and 
3.23 were statistically compared to the IC50 for MCF-7 wild type, using the student t- 
test, with a degree of freedom of 4 and a significance level p  = 0.01 (99% 
probability). The IC50 for cisplatin in MCF-7 3.23 (highlighted in red) was 
significantly higher than the IC50 obtained in MCF-7 with 99% confidence. 
Therefore, inhibition of BRCA1 protein expression caused increased resistance to 
cisplatin. It was also noted that with a 95% probability (p = 0.05) MCF-7 3.23 was 
significantly more resistant to etoposide than MCF-7 wild type. The IC50 found for 
gefitinib in MCF-7 wild type was similar to the one described by Friedmann et al.
(2004).
Drug IC50 in MCF-7 wild type
IC50 in MCF-7 
scrambled
IC50 in MCF-7 
3.23
Gefitinib 16.0 ± 2.4pM 10.0 ± 0.5pM 18.0± l.OpM
Cisplatin 0.9 ± 0.1 pM 1.2 ± 0.3pM 2.5 ± 0.6pM
Etoposide 1.1 ±0.2pM 0.8 ± O.lpM 2.1 ± 0.7pM
Melphalan 2.9 ± 1.5pM 2.5 ± 1.3pM 2.5 ± 1.5pM
Table 7.2 -  IC50 (±SD) results for single agent treatments of MCF-7 cell lines. MCF-7 
wild type, MCF-7 scrambled and MCF-7 BRCA1 cell lines were treated for 5 consecutive 
days with gefitinib, cisplatin, etoposide or melphalan. Data have been statistically analysed 
with the student r-test with n = 4 and p  = 0 .0 1 , comparing IC50 of the wild type cell line with 
IC50 of the transfected cell lines.
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Figure 7.4 -  Inhibition of MCF-7 cells proliferation by single agent treatment. MCF-7 
wild type, MCF-7 scrambled and MCF-7 3.23 cell lines were treated with cisplatin (A), 
gefitinib (B), etoposide (C) or melphalan (D) for 5 consecutive days. Data presented are the 
result of three independent experiments, as shown by the standard deviation.
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7.7.2 Combination of cisplatin with gefitinib
Cisplatin being the only drug to show a significant difference between MCF-7 wild 
type and 3.23, it was studied in combination with gefitinib. Furthermore, Friedmann 
et al. (2004) demonstrated that gefitinib was able to synergise with cisplatin, in MCF- 
7 wild type cells. Gefitinib was used at concentrations yielding 10% inhibition of 
proliferation (4pM for all cell lines) and 20% inhibition of proliferation (10pM for 
MCF-7 3.23 and 6pM for MCF-7 scrambled and wild type), as determined previously 
by the single agent treatment assay. Similarly to Friedmann et al. (2004) different 
drug scheduling were used. Cells were incubated either with cisplatin and gefitinib 
for 24 hours followed by gefitinib alone for 4 days, or with cisplatin and gefitinib for 
5 days, in sextuplet wells. To assure accuracy and reproducibility, all sets of assays 
were repeated in triplicate.
Results for combination treatments are presented in Figures 7.5, 7.6 and 7.7, and IC50 
obtained in Table 7.3. However, in order to determine if drug combinations caused a 
synergistic effect, results were analysed with isobologram analysis at IC50, as defined 
in Chapter 2 (section 2.6). Figure 7.8 represents the isobologram analysis of the data 
for combination treatments using gefitinib at a concentration producing 10% 
inhibition of proliferation, for all three cell lines. Similarly, Figure 7.9 represents the 
isobologram analysis of the data for combination treatments using gefitinib at a 
concentration producing 20% inhibition of proliferation. For each isobologram 
analysis the area where combinations of IC50 of the two drugs have an additive effect 
has been circled. Synergy was obtained when points were situated below this area.
Conversely to the observation by Friedmann et al. (2004), combination of gefitinib 
with cisplatin, in MCF-7 wild type cells, did not produce a synergistic effect. 
Surprisingly, with MCF-7 scrambled a synergistic effect was obtained when cells 
were treated with a combination of cisplatin and gefitinib (10%) for 24 hours (Figure 
7.8 B). Therefore, no conclusion can be drawn from this result since the wild type and 
the scrambled cell line gave different results. Nevertheless, when cells were treated 
for 5 consecutive days with cisplatin and gefitinib (20%) a synergistic effect was only 
observed in MCF-7 3.23 cell line (Figure 7.9 C). This effect was not seen in the two 
other cell lines with the same conditions.
290
Therefore, BRCA1 down-regulation sensitised the cells to the combination treatment, 
suggesting a role of BRCA1 in EGFR signalling pathway in response to cisplatin- 
induced DNA damage.
Cell line
IC50
cisplatin
continuous
exposure
IC50 (combination 5 days) IC50 (combination 24hrs then gefitinib alone)
With 
gefitinib 
causing 
1 0 % 
inhibition of 
proliferation
With 
gefitinib 
causing 
2 0 % 
inhibition of 
proliferation
With 
gefitinib 
causing 
1 0 % 
inhibition of 
proliferation
With 
gefitinib 
causing 
2 0 % 
inhibition of 
proliferation
MCF-7 
wild type 0.9 ± 0.1 pM 0.9 ± 0.3pM 0.8 ± 0.5pM 0.6 ± O.lpM 0.7 ± 0.2pM
MCF-7
scrambled 1.2 ± 0.3pM 1.0 ± 0.4pM 0.9 ± 0.3pM 0.3 ± 0.2pM 0.3 ± 0.1 pM
MCF-7
3.23 2.5 ± 0.6pM 1.4 ± 0.4pM 0.4 ± 0.3pM 1.3±0.4pM 0.8 ± 0.3pM
Table 7.3 -  IC5o (±SD) results for cisplatin/gefitinib combination treatments in MCF-7 
cell lines. MCF-7 wild type, MCF-7 scrambled and MCF-7 3.23 cells were treated with a 
combination of cisplatin and gefitinib.
Cisplatin
Cisplatin +gefitinib 10% 
Cisplatin +gefitinib 20%
120.0
100.0
o 80.0
60.0
Q- 40.0
20.0
0.0
Cisplatin (^M)
Cisplatin
Cisplatin +gefitinib 10% 
Cisplatin +gefitinib 20%
120.0
100.0  ^
.2 80.0 ^
Ia>H- 60.0
2
a. 40.0
20.0
0.0
0 1001 10
Cisplatin (pM) g
Figure 7.5 -  Inhibition of MCF-7 wild type cells proliferation by cisplatin/gefitinib 
combination treatment. Cells were treated with cisplatin and gefitinib for 5 consecutive 
days (A) or with cisplatin and gefitinib for 24 hours followed by 4 days in drug media or 
media containing gefitinib alone (B). Gefitinib was used at doses giving 10% or 20% 
inhibition of proliferation. Data presented are the result of three independent experiments, as 
shown by the standard deviation.
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Figure 7.6 -  Inhibition of MCF-7 scrambled cells proliferation by cisplatin/gefitinib 
combination treatment. Cells were treated with cisplatin and gefitinib for 5 consecutive 
days (A) or with cisplatin and gefitinib for 24 hours followed by 4 days in drug media or 
media containing gefitinib alone (B). Gefitinib was used at doses giving 10% or 20% 
inhibition of proliferation. Data presented are the result of three independent experiments, as 
shown by the standard deviation.
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Figure 7.7 -  Inhibition of MCF-7 3.23 cells proliferation by cisplatin/gefitinib 
combination treatment. Cells were treated with cisplatin and gefitinib for 5 consecutive 
days (A) or with cisplatin and gefitinib for 24 hours followed by 4 days in drug media or 
media containing gefitinib alone (B). Gefitinib was used at doses giving 10% or 20% 
inhibition of proliferation. Data presented are the result of three independent experiments, as 
shown by the standard deviation.
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Figure 7.8 -  Isobologram analysis at IC50 of cisplatin/gefitinib combination treatment 
using gefitinib 10%. Gefitinib was used at a concentration giving 10% inhibition of 
proliferation combined with a range of cisplatin concentrations, on MCF-7 wild type (A), 
MCF-7 scrambled (B) and MCF-7 3.23 (C) cell lines. The circled area defines the 
combinations of IC50 of cisplatin and gefitinib that have an additive effect.
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Figure 7.9 -  Isobologram analysis at IC5o of cisplatin/gefitinib combination treatment 
using gefitinib 20%. Gefitinib was used at a concentration giving 20% inhibition of 
proliferation combined with a range of cisplatin concentrations, on MCF-7 wild type (A), 
MCF-7 scrambled (B) and MCF-7 3.23 (C) cell lines. The circled area defines the 
combinations of IC50 of cisplatin and gefitinib that have an additive effect.
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7.8 Effects of X-ray irradiation
Previous studies have reported conflicting results on the effect of BRCA1 loss of 
function on radiosensitivity. Therefore, it was interesting to consider the effect of 
radiation-induced DNA damage on MCF-7 3.23 cells compared to MCF-7 wild type 
cells, using X-ray irradiation. Results of the proliferation assay and IC50 values are 
presented in Figure 7.10 and Table 7.4, respectively. IC50 have been statistically 
analysed using the student t-test with a degree of freedom n = 4 and a confidence 
interval p  = 0.05 (95% probability). This analysis highlighted (in red) that MCF-7 
cells with a down-regulated BRCA1 protein expression level were more resistant to 
irradiation than MCF-7 wild type cells.
M CF-7
M C F-7 scram bled
100.00 M C F-7 3.23
10.00
1.00
0.0 2.5 5.0
IR(Gy)
Figure 7.10 -  Inhibition of MCF-7 cells proliferation after X-ray irradiation. MCF-7 
wild type, MCF-7 scrambled and MCF-7 3.23 cells were exposed to a range of X-ray doses 
(Gy). Data presented are the result of three independent experiments, as shown by the 
standard deviation.
Cell lines X-ray IC50
MCF-7 wild type 2.0 ±0.1 Gy
MCF-7 scrambled 2.1 ±0.2Gy
MCF-7 3.23 2.5 ± 0.3Gy
Table 7.4 -  IC50 (±SD) results after X-ray irradiation of MCF-7 cell lines. MCF-7 wild 
type, MCF-7 scrambled and MCF-7 3.23 were exposed to a range of X-ray doses. Data 
obtained from the proliferation assay and analysed with the student t-test with n = 4 and p = 
0.05, comparing IC50 of the wild type cell line with IC50 of the transfected cell lines.
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7.9 Topoisomerase II activity
The study by Lou et al. (2005) suggested that BRCA1 interacted with topoisomerase 
Ila and was able to modulate DNA decatenation. Therefore, topoisomerase II activity 
was measured in all three cell lines. Topoisomerase II activity was measured by 
assessing the efficiency of DNA decatenation using catenated kintoplast DNA 
(kDNA). Upon efficient decatenation, topoisomerase Ila formed nicked decatenated 
kDNA and circular decatenated kDNA. Results presented in Figure 7.11 show that 
there was no difference in decatenation efficiency between the three cell lines, since 
there was no alteration of the level of decatenated kDNA. Therefore, BRCA1 down- 
regulation in MCF-7 3.23 cells (lane 6 ) did not modify the DNA decatenation 
efficiency of the cells.
Catenated kDNA
Nicked decatenated kDNA
Circular decatenated kDNA 
1 2 3 4 5 6
Figure 7.11 -  Topoisomerase Ila  activity assay in MCF-7 cell lines. Topoisomerase Ila 
activity was assessed in MCF-7 wild type (4), MCF-7 scrambled (5) and MCF-7 3.23 (6) cell 
lines using kintoplast DNA (kDNA). Decatenated kDNA (2) and linearised kDNA (1) were 
used as positive control and kDNA as negative control (3). Reactions were stopped after 30 
minutes.
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DISCUSSION
Using MCF-7 cells stably transfected, with a plasmid containing BRCA1 siRNA, this 
chapter investigated the effect of BRCA1 down-regulation on cell sensitivity to 
gefitinib, an inhibitor of EGFR tyrosine kinase activity, and common 
chemotherapeutic agents, cisplatin, melphalan and etoposide. BRCA1 is a protein 
involved in several DNA repair pathways which has been shown to be mutated in 
some hereditary forms of breast and ovarian cancers. Loss-of-function mutations in 
BRCA1 have been reported to confer up to an 82% risk of developing breast cancer 
(King et al., 2003). Using the plasmid encoding human specific BRCA1 siRNA 
transfected in MCF-7 cells, a 68% down-regulation in BRCA1 mRNA was achieved 
and a similar reduction of the protein level was also observed. Reduction in BRCA1 
expression caused increased resistance to the anti-proliferative effect of cisplatin and 
etoposide single agents. In addition, BRCA1 down-regulation was shown to cause 
increased radioresistance. Furthermore, combining cisplatin with gefitinib 
demonstrated that a synergistic effect between the agents could be obtained in 
BRCA1 deficient cells. Finally, reduction of BRCA1 expression was not shown to 
affect DNA decatenation activity.
7.10 Chemosensitivity of BRCA1 deficient cells
7.10.1 BRCA1 expression modulates chemosensitivity
Sensitivities of the transfected cells were evaluated and showed that the reduction in 
BRCA1 expression caused a significant increase in resistance to cisplatin. However, 
this result was in contradiction with published data, since BRCA1 has been shown in 
several studies as being involved in recombinational repair of double strand break, 
through association with several proteins such as RAD51 and proteins forming the 
BASC complex, BRCA1-associated genome surveillance complex (Scully et al., 
1997c; Moynahan et al., 1999; Snouwaert et al., 1999; Wang et al., 2000b). 
Furthermore, BRCA1 has also been shown to promote cell survival after DNA 
damage by preventing apoptosis and activating DNA damage repair (Bernstein et al., 
2002). Bhattacharyya et al. (2000) demonstrated that the loss of BRCA1 function was
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associated with an increased sensitivity to cisplatin, in BRCA1-/- isogenic mouse 
embryonic stem cell lines. In a separate study, the increased sensitivity to cisplatin by 
inhibition of BRCA1 using antisense RNAs was also shown to be associated with a 
decrease in DNA repair efficiency (Husain et ah, 1998). Nonetheless, conflicting 
results have been obtained on the effect of BRCA1 expression on the sensitivity to 
topoisomerase II inhibitors. The studies by Lafarge et al. (2001) and Quinn et al. 
(2003) established that a reduction in BRCA1 expression caused an increase in 
sensitivity to etoposide, whereas Tassone et al. (2003) reported that BRCA1 
deficiency increased resistance to doxorubicin that like etoposide is a topoisomerase 
II inhibitor like etoposide. The results obtained in the present study demonstrated 
that, similarly to cisplatin, reduction of BRCA1 expression also conferred resistance 
to etoposide (results compared to the wild type are significantly different with a lower 
probability).
Therefore, results obtained demonstrate that BRCA1 down-regulation caused an 
increase in resistance to chemotherapeutic agents, cisplatin and etoposide. The 
difference with published data suggests that the down-regulation of BRCA1 
expression is not sufficient to inhibit BRCA1 activity. However, the reason for the 
increased chemoresistance remains unclear.
7.10.2 BRCA1 expression and EGFR signalling pathway
Friedmann et al. (2004) demonstrated that gefitinib, an inhibitor of EGFR tyrosine 
kinase, in combination with cisplatin, enhanced the anti-proliferative effect of 
cisplatin, resulting in a synergistic effect, in MCF-7 cells. In this study, they reported 
that synergistic effects were drug scheduling dependent. In order to investigate further 
the result obtained here with cisplatin, cells were treated with a combination of 
gefitinib (using concentrations producing 10% and 20% inhibition of proliferation), 
an EGFR inhibitor of tyrosine kinase, and cisplatin. Although synergistic effects 
between gefitinib and a variety of anticancer agents, including chemotherapeutic 
agents and radiation, have been reported in cell lines and xenografts (Friedmann et 
al., 2004; Huang et al., 2002), no such effect was observed in MCF-7 wild type cells. 
However, using gefitinib at a concentration causing 20% inhibition of proliferation, a 
synergistic effect was observed in BRCA1 deficient MCF-7 cells when treated with 
the drug combination for 24 hours.
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Therefore, synergistic effect between cisplatin and gefitinib was dependent on the 
drug scheduling. Moreover, since synergy was only obtained in the cell line with a 
down-regulated BRCA1 level, it suggests that both EGFR signalling pathway and 
BRCA1 are involved in the repair of cisplatin-induced DNA damage.
7.11 Radiosensitivity of BRCA1 deficient cells
Regarding the role of BRCA1 in radiation-induced DNA damage response, published 
results have been more conflicting than with chemotherapeutic agents. The result 
obtained here suggests that the partial loss o f BRCA1 function increased the 
resistance to ionizing radiation. However, results obtained by Scully et al. (1999) 
suggested that BRCA1 confer radioresistance to cells and is required to efficient 
repair of radiation-induced DNA double strand breaks. Hypersensitivity, to ionizing 
radiation, of BRCA1 deficient cell line was also demonstrated by Scully et al. (1999). 
This finding was contradicted by Wang et al. (2001) showing that BRCA1 did not 
play a major role in the modulation of radio sensitivity. Furthermore, several studies 
demonstrated that heterozigosity of BRCA1 did not account for radiation 
hypersensitivity (Nieuwenhuis et al., 2002). The study by Trenz et al. (2005) reported 
the absence of radiosensitivity of lymphoblastoid cell lines with a heterozygous 
BRCA1 mutation. However, conflicting results have been obtained as DNA end 
joining was shown to be reduced in other lymphoblastoid cell lines with a 
heterozygous BRCA1 mutation (Baldeyron et al., 2002).
Although published results suggest that BRCA1 mutant cell lines have an increased 
radiosensitivity, the direct role of BRCA1 in the repair of radiation-induced DNA 
double strand breaks remains unclear. Taken together with previous studies, the 
results obtained with MCF-7 cells, deficient in BRCA1, show that reduction of 
BRCA1 protein expression does not induce radiosensitivity but that modulation of 
radiosensitivity may rely on the deficiency in the non-homologous repair pathway, 
used to repair radiation-induced double strand breaks (Jeggo, 1998; Wang et al.,
2001). Nevertheless, similarly to the effect on chemosensitivity, the reason for the 
increased radioresistance remains unclear.
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7.12 Role of BRCA1 in DNA decatenation
Lou et al. (2005) have established that BRCA1 plays an important role in DNA 
decatenation, by causing topoisomerase Ila  ubiquitination affecting topoisomerase 
Ila distribution and DNA decatenation activity. Indeed, they demonstrated that 
BRCA1 and topoisomerase Ila  co-localised during the S-phase and that BRCA1 
deficiency resulted in lower DNA decatenation activity and defect in chromosome 
segregation. Conversely, the results obtained in the present study failed to show the 
effect of BRCA1 down-regulation on topoisomerase II activity and DNA 
decatenation activity. However, Lou et al. (2005) used BRCA1 siRNA causing 
complete inhibition of BRCA1 protein expression.
Therefore, the reduction in BRCA1 protein expression level achieved may not be 
sufficient to inhibit completely BRCA1 activity and observe an effect on DNA 
decatenation activity.
7.13 Conclusion
These results obtained demonstrate that partial inhibition of BRCA1 protein 
expression could be obtained using siRNA. However, BRCA1 down-regulation 
caused an increase in resistance to chemotherapeutic agents and ionising radiation, 
contrary to the results reported in published studies. Furthermore, reduction of 
decatenation activity was not demonstrated in cells deficient in BRCA1. 
Nevertheless, a synergistic effect obtained between gefitinib and cisplatin in BRCA1 
deficient cells.
Therefore, it is reasonable to conclude that down-regulation of BRCA1 protein level 
achieved was not sufficient to inhibit BRCA1 activity. Nonetheless, results suggest a 
role of BRCA1 and EGFR signalling pathway in the repair of cisplatin-induced DNA 
damage. Thus, it would be interesting to investigate further the interaction between 
BRCA1 and EGFR signalling pathway. In order to study further the role of BRCA1 
in drug-induced DNA damage, a more efficient plasmid encoding BRCA1 siRNA 
need to be designed, to achieve a significant reduction in BRCA1 activity.
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Chapter 8 
Conclusions and future work
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This study investigated the role of ErbB2 and BRCA1 in repair of drug-induced DNA 
damage. ErbB2 is overexpressed in 20-30% of breast cancer and has been shown to 
correlate with increased tumour chemoresistance and poor patient prognosis. 
Although many published studies have investigated the function of ErbB2 and the 
effect of the anti-ErbB2 monoclonal antibody, trastuzumab, its role in the repair of 
drug-induced DNA damage remains unclear. Firstly, effects of ErbB2 down- 
regulation, on chemotherapeutic response, were studied using trastuzumab. An 
increase in sensitivity caused by trastuzumab was identified in cells overexpressing 
ErbB2, for cisplatin and other chemotherapeutic drugs (Chapter 3). Furthermore, 
overexpression of ErbB2 demonstrated that ErbB2 caused an increase in 
topoisomerase activity and an increased chemoresistance to cisplatin. Combination of 
the chemotherapeutic agent with trastuzumab led to a sensitisation of the cells to 
cisplatin (Chapter 5). In addition, results obtained revealed that inhibition of ErbB2 
nuclear translocation led to an increase in cisplatin sensitivity (Chapter 6). Secondly, 
effects of ErbB2 overexpression and down-regulation by trastuzumab in the repair of 
drug-induced DNA damage was investigated using the comet assay. Modulation of 
ErbB2 expression was shown to affect the repair of cisplatin-induced DNA damage, 
but not the kinetics of damage and repair of melphalan and etoposide-induced DNA 
damage (Chapter 3). More specifically, ErbB2 was shown to only alter the repair of 
cisplatin-induced DNA interstrand crosslink and not cisplatin-DNA intrastrand 
adducts (Chapter 5). Furthermore, in Chapter 6, results obtained demonstrated that 
ErbB2 nuclear localisation was essential to the repair of cisplatin-induced DNA 
interstrand crosslinks. It was also demonstrated that abolishing ErbB2 nuclear 
translocation reduced the normal DNA repair activity of the cells, similarly to the 
effect observed with trastuzumab on ErbB2 overexpressing cells. Therefore, this 
suggests that trastuzumab modulates the repair of cisplatin-induced DNA ICLs by 
reducing ErbB2 nuclear translocation. In addition, ErbB2 overexpression was shown 
to reduce EGFR nuclear localisation, possibly through the formation of EGFR/ErbB2 
heterodimers, suggesting that ErbB2 and its NLSs have an impact on EGFR nuclear 
translocation. Chapter 4 revealed that the delay of the repair of cisplatin-induced 
DNA interstrand crosslinks, by down-regulation of ErbB2 expression, was due to a 
progression of the cell through cell cycle arrest. Investigating the effects of 
trastuzumab on the expression of proteins involved in DNA damage repair and ErbB2 
downstream signalling pathways revealed that trastuzumab caused activation of Akt
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followed by its downregulation. Moreover, in combination with cisplatin, 
trastuzumab caused an escape of cells from cell cycle arrest, associated with 
activation of Akt and increase in topoisomerase Ila  expression. Therefore the delay in 
the repair of cisplatin-induced DNA damage, of ErbB2 overexpressing cells, could 
not be attributed to this effect. In addition, further investigation is required to 
elucidate the molecular mechanism behind the delay in the repair of cisplatin-induced 
DNA damage.
BRCA1 is a protein involved in different cellular pathways and germline mutations 
have been associated with an increased risk of breast and ovarian cancer and account 
for 50% of hereditary breast cancer. Therefore, it is important to fully understand its 
role in the repair of drug-induced DNA damage. Chapter 7 demonstrated that BRCA1 
down-regulation caused an increase in resistance to cisplatin, etoposide and ionizing 
radiation. In addition, BRCA1 down-regulation did not alter DNA decatenation 
activity as previously suggested. Nevertheless, BRCA1 and EGFR signalling 
pathways were shown to play a role in the repair of cisplatin-induced DNA damage, 
as shown by the synergistic effect obtained between cisplatin and gefitinib in cells 
with BRCA1 down-regulated.
These experiments have opened new questions which will be the work of future 
investigations.
8.1 ErbB2 protein expression and sensitivity to trastuzumab 
and chemotherapeutic agents
8.1.1 ErbB2 protein expression and trastuzumab sensitivity
Studying the effect of trastuzumab on cells overexpressing ErbB2, identified its 
ability to inhibit cell proliferation in some cell lines, since trastuzumab did not alter 
the MDA-MB-468 ErbB2 cell proliferation. As reported by Gong et al. (2004) and 
Kasprzyk et al. (1992), trastuzumab does not always alter cell proliferation regardless 
of the ErbB2 expression level. Furthermore, Esteva et al. (2002; 2005) reported that 
response to trastuzumab was predictable in part by the presence of elevated serum 
ErbB2 extracellular domain (ECD - causing increased kinase activity and increased
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metastasis) levels prior treatment. Therefore, the effect of trastuzumab may be cell 
line dependent but future work will need to consider levels of ECD in culture media 
as a way to predict the response to trastuzumab.
8.1.2 ErbB2 protein expression and chemotherapeutic response
Studying the chemosensitivity of different breast cancer cell lines, expressing 
different ErbB2 protein level, did not show any correlation between ErbB2 
overexpression and chemosensitivity to common chemotherapeutics. In addition, 
ErbB2 overexpression was shown to increase the activity of topoisomerase II. 
Published data have shown that increase in topoisomerase II activity causes an 
increased resistance to alkylators but an increased sensitivity to topoisomerase II 
inhibitors (Larsen et al., 1998; Pu and Bezwoda, 1999). Therefore, it would be 
interesting to investigate the effect of ErbB2 expression on the response to different 
classes of damaging agents, as a better understanding of the relationship between a 
given molecular lesion and the chemotherapeutic response will help designing new 
drug combinations for therapeutic use.
Using clinically achievable doses of trastuzumab, ErbB2 overexpressing cells were 
sensitised to chemotherapeutic agents. This effect was shown to be more significant 
in cells overexpressing ErbB2 and with increasing doses of trastuzumab. Therefore, it 
would be interesting to study further enhancement of cytotoxicity caused by 
trastuzumab as altering drug scheduling may change effect on cell proliferation. In 
addition, similarly to the study by Nahta et al. (2004) combining trastuzumab with 
other ErbB inhibitors/anti-ErbB antibodies may highlight new drug combination 
beneficial for therapeutic use. Indeed, using pertuzumab (Nahta et al., 2004), 
sterically blocking ErbB2 dimerisation with other ErbB receptors and blocking 
ligand-activated signalling from ErbB2/EGFR and ErbB2/ErbB3 heterodimers, or 
lapatinib (Xia et al., 2005), an inhibitor of the tyrosine kinase of EGFR and ErbB2, in 
combination with trastuzumab have been shown to be more effective than 
monotherapy. Finally, three drug combinations will need to be considered using a 
combination of ErbB inhibitors/anti-ErbB antibodies with a chemotherapeutic agent. 
Thus, future development in drug combination will help overcome drug resistance 
and cell signalling redundancy.
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8.1.3 Nuclear ErbB2 and chemotherapeutic treatments
Inhibiting ErbB2 nuclear translocation caused an increase in cisplatin sensitivity 
compared to cells overexpressing full length ErbB2 and ErbB2 negative cells. These 
results suggested that nuclear ErbB2 plays a significant role in the response to 
cisplatin-induced DNA damage and that deletion of ErbB2 nuclear localisation signal 
sequence caused a sensitisation of the cells to cisplatin. Furthermore, as trastuzumab 
was shown to reduce membrane bound ErbB2 protein level and ErbB2 nuclear 
translocation, it is suggested that the increase in sensitivity to chemotherapeutic 
agents, caused by trastuzumab, was due to a reduction in nuclear ErbB2. However, 
further analysis is required to determine the molecular mechanism by which 
trastuzumab sensitises cells to chemotherapeutic drugs. In addition, further 
investigation will be required to identify new molecular targets of nuclear ErbB2 as 
the potential nuclear activity of ErbB family members has only been recently 
considered.
8.2 ErbB2 expression and repair of drug-induced DNA 
damage
8.2.1 ErbB2 expression and repair of drug-induced DNA strand 
break
ErbB2 overexpression or subsequent inhibition by trastuzumab did not affect the 
kinetics of formation and repair of etoposide-induced DNA strand breaks. However, 
its cytotoxicity was shown to be enhanced by the presence of trastuzumab. Studies by 
Mayfield et al. (2001) and Pietras et al. (1999) suggesting that trastuzumab was able 
to alter the formation and repair of DNA strand breaks. Moreover, by inhibiting 
EGFR tyrosine kinase activity, Friedmann et al. (2004) showed that the repair of 
etoposide-induced DNA strand break activity was reduced. Therefore, ErbB2-EGFR 
heterodimerisation will need to be considered for further investigation of the role of 
ErbB2 in the repair of etoposide-induced DNA strand breaks.
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8.2.2 ErbB2 expression and repair of drug-induced DNA 
interstrand crosslink
Effects of ErbB2 down-regulation by trastuzumab on the repair of drug-induced DNA 
ICL were also investigated after melphalan and cisplatin-induced DNA damage. 
Similarly to etoposide, the kinetic of formation and repair of melphalan-induced DNA 
ICL was not affected, although trastuzumab was shown to increase its cytotoxic 
effect. In contrast, trastuzumab and ErbB2 overexpression modulated the kinetic of 
repair of cisplatin-induced DNA ICLs. De Silva et al. (2002) and Clingen et al. 
(2005) demonstrated that increased cytotoxicity of cisplatin and melphalan-induced 
ICLs was associated with defects in ERCC1-XPF heterodimers of the NER pathway 
and in XRCC2 and XRCC3 of the homologous recombination pathway. In addition, 
contrary to cisplatin, melphalan was shown to induce the formation of double strand 
breaks. Thus, for further investigation, the effects of trastuzumab should be studied 
on mutant cell lines defective in these pathways.
8.2.3 Nuclear ErbB2 and repair of cisplatin-induced DNA 
interstrand crosslinks
Studying the role of nuclear ErbB2 revealed a novel link between ErbB2 nuclear 
localisation and the repair of cisplatin-induced DNA ICLs. Results obtained 
established that ErbB2 nuclear translocation has a key role in the repair of cisplatin- 
induced DNA ICLs. In addition, results obtained showed that deletion of ErbB2 
nuclear localisation signal sequence caused an increased delay in the repair of 
cisplatin-induced DNA ICL, suggesting a role of the NLSs in ErbB2 dimerisation or 
DNA repair signalling cascade. Since the role of nuclear ErbB2 has not yet been 
extensively studied, further experiments will need to be carried out to identify 
molecular targets, for nuclear ErbB2, involved in DNA damage repair. Furthermore, 
it will be interesting to investigate the role of ErbB2 tripartite NLS in ErbB2 
dimerisation and signalling cascade.
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8.3 ErbB2 and EGFR nuclear localisation
Immunofluorescence revealed that overexpression of ErbB2 or ErbB2ANLS led to a 
reduction of EGFR nuclear translocation. Therefore, it is suggested that ErbB2 
dimerises with EGFR, blocking EGFR nuclear translocation. In addition, 
overexpressing full length ErbB2 causes an amplification of DNA repair efficiency 
whereas overexpressing ErbB2ANLS may lead to the formation of non-functional 
EGFR-ErbB2 heterodimers that sequestrate EGFR in the cytoplasmic membrane and 
are unable to trigger the DNA repair signalling cascade, causing a delay in DNA 
repair. For future investigation it will be interesting to determine the effects of ErbB2 
overexpression and its NLS on the EGFR-ErbB2 heterodimers formation and its 
signalling cascade. In addition, dimerisation with other ErbB family members will 
need to be considered.
8.4 ErbB2 expression and DNA repair proteins
Results of the effect of the trastuzumab/cisplatin combination on the cell cycle and 
proteins involved in the ErbB2 downstream signaling cascade suggested that cells 
progressed through cell cycle arrest, leading to accumulation of unrepaired DNA 
damage and a delay of the repair kinetics of cisplatin-induced DNA damage. 
Therefore, a robust molecular mechanism needs to be established to explain the 
effects of trastuzumab within the cell. Future investigations will study the 
transcriptional changes associated with ErbB2 expression in cells overexpressing full 
length ErbB2 and ErbB2ANLS, treated with cisplatin and cisplatin/trastuzumab 
combination. To this end, cDNA microarray analysis will be used, similarly to 
Mackay et al. (2003), to highlight modulation of gene amplification. The data will be 
statistically analysed and significant results will be confirmed by investigating 
changes in protein levels. In addition, since topoisomerase II activity was shown to be 
increased by ErbB2 overexpression and topoisomerase I la  was suggested to be 
involved in DNA damage repair, it will be interesting to examine further the role of 
topoisomerase Ila in the repair of DNA damage in ErbB2 overexpressing cells.
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8.5 Role of BRCA1 in drug-induced DNA damage
Using a plasmid encoding specific siRNA, BRCA1 protein expression level was 
reduced, however, results obtained for the chemosensitivity and radio sensitivity 
conflicted with published data, as the study showed that BRCA1 downregulation 
caused an increase in resistance. Synergistic effect obtained with cisplatin and 
gefitinib suggested an interaction between BRCA1 and EGFR signalling pathway in 
the repair of cisplatin-induced DNA damage. Therefore, for future investigation, a 
new siRNA sequence will be designed to increase BRCA1 down-regulation 
efficiency. Moreover, it will be interesting to study the effect of BRCA1 down- 
regulation on EGFR signalling pathway, using gefitinib and cisplatin and other 
platinum based compounds, such as carboplatin. In addition, having shown that 
synergistic effect between cisplatin and gefitinib was dependent on the drug 
scheduling, it will be important to consider other classes of DNA damaging agents as 
well as non-DNA damaging agents, as Friedmann et al. (2004) also demonstrated the 
synergistic effect between gefitinib and etoposide, in MCF-7 wild type cells.
8.6 Conclusion
In conclusion, these results have established a novel link between nuclear ErbB2 and 
DNA damage repair, showing the importance of ErbB2 expression. Therefore, future 
work will investigate the nuclear role of ErbB2 and will be extended to other ErbB 
family members. Furthermore, BRCA1 having been shown to induce gene expression 
of ErbB2 interacting protein (Atalay et al., 2002), it will be interesting to examine the 
influence of BRCA1 on ErbB2 expression and activity. Results of this study together 
with further understanding of the molecular mechanisms involved will help in 
designing new targeted therapies and drug combinations.
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Appendices
Appendix 1: Student t-test
The Student t-test was established by William Sealy Gosset. Data (in our case IC50), 
o f two independent treatments to be compared, were listed and the number of 
replicates (ni and treatment was recorded (in our case 3). The mean (x) and the
# ' j
variance ( g  ) were calculated for each treatment. The variance of the difference 
between the two means (cd2) was calculated as follow:
o</ =  Gi2 + g22
ni n2
Using the standard error (SE2 = a  2/n), we obtain:
= SEi2+ SE22 
Hence the t value was finally obtained using:
t -  (xi — x2)/ Dd
With xi > X2
Having determined the degree o f freedom (ni+n2-2) and the level o f significance (p = 
0.01 or 0.05), the tabulated t value is read from the table below (Table I). Hence, if 
the calculated t value is superior to the tabulated value, the IC50 are significantly 
different at 95% or 99% probability. So we can be reasonably confident that the IC50 
differ from one another, but there is still a 5% chance o f being wrong in reaching this 
conclusion.
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Level of significance p
0.1 0.05 0.01 0.005 0.0025 0.001 0.0005
1 3.078 6.314 31.82 63.66 127.3 318.3 636.6
2 1.886 2.92 6.965 9.925 14.09 22.33 31.6
a 3 1.638 2.353 4.541 5.841 7.453 10.21 12.92sox$ 4 1.533 2.132 3.747 4.604 5.598 7.173 8.61
£
Cm
5 1.476 2.015 3.365 4.032 4.773 5.893 6.869
o
4 >$ 6 1.44 1.943 3.143 3.707 4.317 5.208 5.959uf§ 7 1.415 1.895 2.998 3.499 4.029 4.785 5.408
O
8 1.397 1.86 2.896 3.355 3.833 4.501 5.041
9 1.383 1.833 2.821 3.25 3.69 4.297 4.781
10 1.372 1.812 2.764 3.169 3.581 4.144 4.587
Table I -  Tabulated t values. The values are read using a calculated degree of freedom and a 
determined level of significance (www.socr.ucla.edu). Tabulated t values highlighted in bold 
correspond to the values obtained when each independent experiment is done in triplicate, so 
the degree of freedom is 4, and the level of significance p  is 0.01 or 0.05.
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Appendix 2: Design of TaqMan probes and primers using 
Primer Express software
For our studies, probes were all labelled FAM (fluorescent dye) / TAMRA (quencher 
dye). The criteria for primer design are the following (Perkin-Elmer Applied 
Biosystems, UK -  www. appliedbiosy stems .com):
Design o f probes:
- Probes should chosen before the primers
- The Tm (melting point) should be 10°C higher than the primer Tm and kept 
between 68 -  70°C
- GC content should be between 20 -  80%
- Probes should be 9 -  40bp long
- Runs of identical nucleotides should be avoided, especially G’s (no more than 4 
contiguous)
- No G’s at the 5’ end
- It should not have more G ’s than C’s
Design o f the primers:
- Primers should be as close as possible to the probe without overlapping the probe
- GC content should be between 30 -  80%
- Primers should be 9 -  40bp long
- The Tm should be between 58 -  60°C
- Runs o f identical nucleotides should be avoided, especially G ’s (no more than 4 
contiguous)
- The five nucleotides at the 3’ end, of each primer should have no more than two G 
and/or C bases.
- The difference o f Tm between the two primers should be no more than 2%
- Amplicons should be 50 -  150bp long
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